var images_info;if (!images_info) images_info =[]; images_info["54"]={"54001":{"type":"graphic_algorithm","displayName":"Approach to abdominal pain in female of childbearing age","title":"Approach to abdominal pain in female of childbearing age","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Approach to abdominal pain in female of childbearing age</div><div class=\"cntnt\"><img style=\"width:556px; height:547px;\" src=\"images/EM/54001_Abd_pain_female_under_50.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; HCG: human chorionic gonadotropin; OB/Gyn: obstetrics and gynecology; PID: pelvic inflammatory disease; RLQ: right lower quadrant; R/O: rule out; US: ultrasound; UTI: urinary tract infection.<br />* Pelvic examination should NOT be performed in the presence of third-trimester vaginal bleeding.</div><div id=\"graphicVersion\">Graphic 54001 Version 3.0</div></div></div>"},"54002":{"type":"graphic_picture","displayName":"Follicular carcinoma FNA","title":"Fine needle aspirate of the thyroid showing microfollicles and minimal follicle development","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fine needle aspirate of the thyroid showing microfollicles and minimal follicle development</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ENDO/54002_Follicular_carcinoma_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fine needle aspirate of a thyroid nodule showing microfollicles and minimal follicle development. The specimen is cellular, and the cells are crowded, pleomorphic, and clumped. Colloid is scant. This lesion was excised and found to be an invasive follicular cancer.</div><div id=\"graphicVersion\">Graphic 54002 Version 2.0</div></div></div>"},"54003":{"type":"graphic_table","displayName":"Causes postpartum pain","title":"Differential diagnosis of postpartum abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of postpartum abdominal pain</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Gastrointestinal disorders\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bowel obstruction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Postoperative ileus</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute appendicitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute cholecystitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute pancreatitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Peptic ulceration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Gynecologic disorders\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ovarian torsion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ovarian cyst hemorrhage</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ovarian vein thrombosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Uterine fibroid degeneration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Renal disorders\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute pyelonephritis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute urinary retention</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Renal colic</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Urolithiasis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bladder rupture</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Pregnancy-related disorders\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Endometritis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Preeclampsia with liver distension/rupture</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Uterine rupture</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute fatty liver</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Breastfeeding can be associated with painful uterine contractions</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Cardiovascular disorders\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute myocardial infarction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Aortic aneurysm</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mesenteric vascular occlusion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Other\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sickle cell disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Splenic rupture</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 54003 Version 1.0</div></div></div>"},"54004":{"type":"graphic_figure","displayName":"Exercise and CHD PI","title":"Coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronary heart disease</div><div class=\"cntnt\"><img style=\"width:440px; height:314px;\" src=\"images/PI/54004_Exercise_and_CHD_PI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronary events are less frequent among those who exercise. In a study of 5159 men, aged 40 to 49 years, followed for an average of almost 19 years, the age-adjusted coronary heart disease event rate per 1000 person-years is lower in those who perform any physical activity compared to inactive subjects.</div><div class=\"graphic_reference\">Data from: Wannamethee, SG, Shaper, AG, Alberti, KG, Arch Intern Med 2000; 160:2108.</div><div id=\"graphicVersion\">Graphic 54004 Version 1.0</div></div></div>"},"54006":{"type":"graphic_waveform","displayName":"Intermediate case 20","title":"Intermediate case 20","html":"<div class=\"graphic normal\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Intermediate case 20</div><div class=\"cntnt\"><img style=\"width:478px; height:226px;\" src=\"images/CARD/54006_Intermediate_case_20.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54006 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"54009":{"type":"graphic_table","displayName":"Clinical signs trachoma","title":"Simplified World Health Organization trachoma grading system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Simplified&nbsp;World Health Organization&nbsp;trachoma grading system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Clinical signs</td> </tr> <tr> <td>Trachomatous inflammation follicular (TF)</td> <td>Five or more follicles of &#62;0.5 mm on upper tarsal conjunctiva</td> </tr> <tr> <td>Trachomatous inflammation intense (TI)</td> <td>Inflammatory thickening obscuring more than half the normal deep tarsal vessels</td> </tr> <tr> <td>Trachomatous conjunctival scarring (TS)</td> <td>The presence of easily visible scars in the tarsal conjunctiva</td> </tr> <tr> <td>Trachomatous trichiasis (TT)</td> <td>At least one eyelash rubbing on the eyeball or evidence of recent removal of in-turned eyelashes</td> </tr> <tr> <td>Corneal opacity (CO)</td> <td>Corneal opacity blurring part of pupil margin</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54009 Version 2.0</div></div></div>"},"54013":{"type":"graphic_figure","displayName":"MUAP measurements","title":"Motor unit action potential (MUAP) measurements","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Motor unit action potential (MUAP) measurements</div><div class=\"cntnt\"><img style=\"width:518px; height:394px;\" src=\"images/NEURO/54013_MUAP_measurements.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Duration is measured as the time from the initial deflection of the MUAP from baseline to its final return to baseline. It is the parameter that best reflects the number of muscle fibers in the motor unit. Amplitude reflects only muscle fibers very close to the needle and is measured peak to peak. Phases (shaded areas) can be determined by counting the number of baseline crossings and adding 1. MUAPs are generally triphasic. Serrations (also called turns) are changes in direction of the potential that do not cross the baseline. The major spike is the largest positive-to-negative deflection, usually occurring after the first positive peak. Satellite, or linked, potentials occur after the main potential and usually represent early reinnervation of muscle fibers.</div><div class=\"graphic_reference\">Reproduced with permission from: Preston, DC, Shapiro, BE. Electromyography and neuromuscular disorders, Butterworth-Heinemann, Boston 1998. Copyright &#169; 1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 54013 Version 1.0</div></div></div>"},"54017":{"type":"graphic_figure","displayName":"Asthma and fatal and near-fatal reactions","title":"Indicators of severe persistent or uncontrolled asthma in patients experiencing fatal and near-fatal reactions after allergen immunotherapy injections","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Indicators of severe persistent or uncontrolled asthma in patients experiencing fatal and near-fatal reactions after&nbsp;allergen immunotherapy&nbsp;injections</div><div class=\"cntnt\"><img style=\"width:574px; height:372px;\" src=\"images/ALLRG/54017_Asthma_and_FRs_NFRs.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ED: emergency department.</div><div class=\"graphic_reference\">Data from: Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169.</div><div id=\"graphicVersion\">Graphic 54017 Version 4.0</div></div></div>"},"54019":{"type":"graphic_picture","displayName":"Pneumatic compression boots 2","title":"Pneumatic compression boots","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumatic compression boots</div><div class=\"cntnt\"><img style=\"width:382px; height:260px;\" src=\"images/OBGYN/54019_Pneumatic_compression_boo1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(B) Devices may wrap around the entire leg or alternately just the feet.</div><div id=\"graphicVersion\">Graphic 54019 Version 1.0</div></div></div>"},"54020":{"type":"graphic_figure","displayName":"Coronary artery distribution for D-TGA","title":"Coronary artery distribution for D-transposition of the great arteries","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Coronary artery distribution for D-transposition of the great arteries</div><div class=\"cntnt\"><img style=\"width:553px; height:788px;\" src=\"images/PEDS/54020_Coronary_art_distr_DTGA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronary artery distribution in TGA.<br> (Upper panels) Diagnostic projection; diagram of the origin and proximal course as visualized by two-dimensional echocardiography and caudally angulated aortography (see text).<br> (Lower panels) Same coronary artery distribution as viewed anteriorly (surgeon's view, frontal projection). Note that the circumflex coronary artery, or even the entire left coronary artery system, is more likely to pursue a retropulmonary course (dashed lines) when the great arteries are in a side-by-side relationship (shown). An intramural course (shaded) of the proximal coronary artery exists in &lt;3 percent of cases but has been associated with higher risk for transfer during an arterial switch operation. Alternative terminology in brackets is shown as popularized by Quagebeur and Kirklin and the Congenital Heart Surgeons Society.</div><div class=\"graphic_footnotes\">Ant: anterior; Cx: circumflex coronary artery; Inf: inferior; L: left; LAD: left anterior descending coronary artery; Post: posterior; R: right; RCA: right coronary artery; Sup: superior.</div><div class=\"graphic_reference\">Reproduced with permission from: Wernovsky G, Sanders SP. Coronary artery anatomy and transposition of the great arteries. Coron Artery Dis 1993; 4:148. Copyright © 1993 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54020 Version 6.0</div></div></div>"},"54021":{"type":"graphic_figure","displayName":"Placement of injectable soft tissue fillers","title":"Placement of injectable soft tissue fillers","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Placement of injectable soft tissue fillers</div><div class=\"cntnt\"><img style=\"width:519px; height:407px;\" src=\"images/DERM/54021_Soft_tissue_fillers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Soft tissue filler placement in the superficial dermis (A), mid-dermis (B), and subdermal (subcutaneous) layer (C). Soft tissue fillers may also be placed just above the periosteum (D).</div><div id=\"graphicVersion\">Graphic 54021 Version 4.0</div></div></div>"},"54022":{"type":"graphic_picture","displayName":"Lymphomatoid papulosis 3","title":"Lymphomatoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lymphomatoid papulosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/54022_Lymphomatoid_papulosis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphomatoid papulosis nodule with central ulceration.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54022 Version 3.0</div></div></div>"},"54023":{"type":"graphic_picture","displayName":"Immunostaining for CD15 in HL","title":"Immunostaining for CD15 in Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Immunostaining for CD15 in Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:504px; height:756px;\" src=\"images/HEME/54023_ImmunostainingCD15.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunostaining for CD15 demonstrates strong membrane and paranuclear staining of the Hodgkin cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al. Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54023 Version 7.0</div></div></div>"},"54024":{"type":"graphic_waveform","displayName":"Ventricular escape tutorial","title":"Complete heart block: Sinus rhythm with slow junctional or idioventricular escape rhythym","html":"<div class=\"graphic normal\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Complete heart block: Sinus rhythm with slow junctional or idioventricular escape rhythym</div><div class=\"cntnt\"><img style=\"width:501px; height:97px;\" src=\"images/CARD/54024_Ventricular_escape_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple successive QRS complexes appear that are of ventricular origin and occur at a rate which is slower than the underlying sinus rhythm. The presence of P waves that occur independent of the QRS complexes is evidence of atrioventricular dissociation.</div><div id=\"graphicVersion\">Graphic 54024 Version 4.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"54025":{"type":"graphic_figure","displayName":"Cross section head neck","title":"Lateral cross-sectional view of the head and neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral cross-sectional view of the head and neck</div><div class=\"cntnt\"><img style=\"width:432px; height:522px;\" src=\"images/EM/54025_Lat_cross-sect_vw_head_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The epiglottis is located at the base of the tongue and projects cephalad, well above the level of the vocal cords. The epiglottis is attached to the hyoid bone through the hyoepiglottic ligament. The esophagus is a potential space beginning behind the cricoid cartilage and extending caudad behind the trachea.</div><div class=\"graphic_reference\">Reproduced with permission from: Levitan, RM, Kinkle, WC. Chapter 2, Laryngeal anatomy. In: Airway Cam Pocket Guide to Intubation, 2nd ed, Airway Cam Technologies, Wayne, PA 2007. Copyright &#169;2007 Airway Cam Technologies, Inc.</div><div id=\"graphicVersion\">Graphic 54025 Version 2.0</div></div></div>"},"54026":{"type":"graphic_table","displayName":"BTS diving guidelines b","title":"Summary of key points and recommendations (continued)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of key points and recommendations (continued)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Recommendations on specific respiratory conditions</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Lung bullae or cysts increase risk of barotrauma and are contraindications to diving.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Previous\nspontaneous pneumothorax is a contraindication unless treated by\nbilateral surgical pleurectomy and associated with normal lung function\nand thoracic CT scan performed after surgery.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Subjects with asthma should be advised not to dive if they have wheeze precipitated by exercise, cold, or emotion.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"1\">\nSubjects with asthma may be permitted to dive if, with or without\nregular inhaled anti-inflammatory agents (step 2 of the BTS\nguidelines), they:</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Are free of asthma symptoms;</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Have normal spirometry (FEV1&#62;80 percent predicted and FEV1/VC ratio &#62;70 percent predicted); and</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Have a negative exercise test (&#60;15 percent fall in FEV1 after exercise).</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Subjects with\nasthma should monitor their asthma with regular twice daily peak flow\nmeasurement and should refrain from diving if they have:</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Active asthma - that is, symptoms requiring relief medication in the 48 hours preceding the dive;</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">An increased peak flow variability (more than 20 percent diurnal variation).</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">COPD\ncarries a theoretical increased risk of barotrauma and reduced exercise\ntolerance. Subjects will probably be advised against diving on the\nbasis of reduced pulmonary function (FEV1 &#60;80 percent predicted).</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"1\">\nSarcoidosis has been associated with pulmonary barotrauma. Diving is\ncontraindicated in subjects who have active sarcoidosis. Those in whom\nsarcoidosis has resolved should have normal chest radiography and\npulmonary function testing before being advised that they may proceed\nwith diving.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Tuberculosis is a\npotentially transmissible disease that may cause residual impairment of\nlung structure and function. A subject with active tuberculosis should\nnot dive. After curative treatment they may dive if lung function and\nchest radiograph are normal.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Cystic\nfibrosis is often associated with abnormal pulmonary function and\nincreased risk of pneumothorax. Diving is contraindicated in those\npatients who have pulmonary involvement.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Fibrotic lung\ndisease reduces lung compliance and impairs gas transfer. Diving is\ntherefore contraindicated in subjects who have fibrotic lung disease.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Long term effects of diving on the lung</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Divers\ntend to have large lung volumes with proportionately greater increases\nin vital capacity than in FEV1. This may be attributable in part to the\neffects of repeatedly breathing dense gas through increased resistances.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Divers may have reduced expiratory flow rates at low lung volumes, possibly reflecting small airway disease.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Vital capacity of divers may decline with age at an increased rate.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">\nSaturation diving causes a fall in carbon monoxide transfer which, once\nthe dive is completed, gradually returns to pre-dive values.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Sources of specialist advice</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">In the United Kingdom, advice on sports diving\nmay be sought from the medical referees of the British Sub Aqua Club,\nthe Scottish Sub Aqua Club, or the Sub Aqua Association. Information is\navailable on the UK Sport Diving Medical Diving Committee website\n(http://ww.uksdmc.co.uk). The Royal Navy Institute of Naval Medicine is\nalso willing to discuss cases with both divers and physicians.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">The Health and Safety Executive (HSE) is\nresponsible for commercial diving policy and regulation. Individuals\nwho are diving at work require a current HSE certificate of fitness to\ndive following examination by an approved medical examiner of divers.</td>\n\n\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">2/11/2003 perm requested 2/28/2003 perm granted but checking with Tim to see if PC still wants this 3/11/2003 Still wants. Invoice to ajeah 7/14/2003 emailed them about invoice confusion 1/30/2004 renewal requested 2/3/2004 granted 2/2/2005 renewal requested 2/8/2005 granted - they will send invoice 3/9/2005 invoice to susan 5/11/2006 renewal requested 5/19/2006 granted 3/15/2007 - renewal requested.mt 4/3/2007 - BMJ wants to charge over $500/year for these. Asking JG if he still wants to use them.mt 4/24/2007 - yes, he does. putting request through CCC. they will send invoice; put invoice into 16.2 renewals.mt 5/1/2007 - Invoice to Tammy and to 16.2 renewals.mt 4/25/2008--Asked AB to check with her author (JD). 5/22/2008--Renewal granted via Rightslink (JD). 7/15/2008--$264 CD/ $264 Online 5/30/2009--Renewal granted via Rightslink, awaiting formal invoice (JD). 7/6/2009--Formal invoice received, to Catherine for payment (JD). 5/15/2010--Renewal granted via Rightslink, paid on my AMEX (JD). The total fee of $&amp;quot;420.00&amp;quot;was originally charged to BTS_diving_guidelines_a BTS_diving_guidelines_b Assessment_of_potential_divers</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=63426&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>BTS_diving_guidelines_b.htm</title></head></div><div class=\"graphic_reference\">Reproduced from Thorax, British Thoracic Society guidelines on respiratory aspects of fitness for diving, volume 58, pages 3-13, Copyright © 2003, with permission from&nbsp;BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 54026 Version 9.0</div></div></div>"},"54028":{"type":"graphic_table","displayName":"Lung transplant donor management","title":"Cardio-thoracic organ donor management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardio-thoracic organ donor management</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Obtain echocardiogram for all potential donors</td> </tr> <tr> <td>Insert arterial line and two large bore intravenous lines. Consider inserting PAC to monitor patient hemodynamics (placement of PAC is particularly important in patients with an ejection fraction &#60;45 percent or requiring high dose inotropic medication).</td> </tr> <tr> <td>Electrolytes <ul> <li>Maintain serum Na &#62;135 and &#60;150 mEq/dL. </li> <li>Maintain serum K &#62;4 and &#60;6 mEq/dL. </li> <li>Assess serum Mg, Ca, PO<sub>4</sub> and replace as needed. </li> <li>Correct metabolic acidosis with Na bicarbonate and mild hyperventilation. Aim for pH &#8805;7.2 and PaCO<sub>2</sub> 30 to 35 mmHg. </li> </ul> </td> </tr> <tr> <td>Ventilation: Initial set-up <ul> <li>Mode: Volume control (either assist control or SIMV) </li> <li>Tidal volume: 6 to&nbsp;8 mL/kg (use&nbsp;predicted body weight*) </li> <li>Respiratory rate: 8 to 16 breaths/min </li> <li>PEEP: 5 cm H<sub>2</sub>O </li> <li>Initial FiO<sub>2</sub>: 100 percent </li> </ul> Adjustments to initial settings <ul> <li>Adjust rate and tidal volume to maintain mild respiratory alkalosis PaCO<sub>2</sub> 30 to 35 mmHg (4 to 4.67 kPa) </li> <li>Adjust tidal volume, pressure profile, and flow rate to keep peak airway pressure &#60;30 cm H<sub>2</sub>O </li> <li>Titrate FiO<sub>2</sub> to maintain pulse oxygen saturation &#62;95 percent or PaO<sub>2</sub> &#62;90 mmHg (12 kPa) </li> <li>Increase PEEP to 8 to 10 cm H<sub>2</sub>O, as needed to maintain pulse oxygen saturation &#62;95 percent or PaO<sub>2</sub> &#62;90 mmHg (12 kPa) </li> </ul> </td> </tr> <tr> <td>Hormonal resuscitation <ul> <li>Tri-iodothyronine (T3): 4 mcg bolus intravenously; 3 mcg/hour continuous infusion. </li> <li>Arginine vasopressin: 1 unit bolus intravenously, 0.5 to 4 unit/hour continuous infusion, if hypotension or urinary output &#62;1000 mL/hour. Titrate to maintain SVR to 800 to 1200 dyne/sec/cm<sup>5</sup> and urinary output 100 to 200 mL/hour. </li> <li>Methylprednisolone 15 mg/kg intravenous infusion; repeat every 24 hours. </li> <li>Insulin: To achieve a target blood glucose range (120 to 180 mg/dL), avoid the use of glucose-containing intravenous fluids and administer insulin only when necessary. There is no universally accepted insulin regimen. </li> </ul> </td> </tr> <tr> <td>Volume resuscitation: Maintain a mean arterial pressure &#62;60 mmHg, systolic blood pressure &#62;90 mmHg a PCWP of 8 to 12 mmHg or CVP 6 to 8 mmHg, using colloid in preference to crystalloid <ul> <li>Infuse albumin if INR and PTT are normal </li> <li>Infuse fresh frozen plasma if INR or PTT are abnormal (eg, &#8805;1.5 x control) </li> <li>Infuse packed RBC to maintain blood hemoglobin &#8805;10 mg/dL or hematocrit &#8805;30 </li> </ul> </td> </tr> <tr> <td>Pressors: Aim for systolic blood pressure &#62;90 mmHg <ul> <li>See arginine vasopressin above </li> <li>Norepinephrine </li> </ul> </td> </tr> <tr> <td>Repeat echocardiogram when patient has stabilized. An unstable donor has not met two or more of the following criteria: <ul> <li>Mean arterial pressure &#8805;60 mmHg </li> <li>CVP &#8804;12 mmHg </li> <li>PCWP &#8804;12 mmHg </li> <li>SVR 800 to 1200 dynes/sec/cm<sup>5</sup> </li> <li>Left ventricular stroke work index &#62;15 </li> <li>Dopamine dosage &#60;10 mcg/kg/min </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PAC: pulmonary artery catheter; Na: sodium; K: potassium; Mg: magnesium; Ca: calcium; PaCO<SUB>2</SUB>: arterial tension of carbon dioxide; SIMV: synchronized intermittent mandatory ventilation; PEEP: positive end expiratory pressure; FiO<SUB>2</SUB>: inspired oxygen concentration; PaO<SUB>2</SUB>: arterial tension of oxygen; SVR: systemic vascular resistance; PCWP: pulmonary capillary wedge pressure; CVP: central venous pressure; INR: international normalized ratio; PTT: partial thromboplastin time; RBC: red blood cells.<br />* See UpToDate calculator for predicted body weight for men and women.</div><div class=\"graphic_reference\">Adapted from: Critical Pathway for the Organ Donor. UNOS, 2006. Available at: http://www.unos.org/docs/Critical_Pathway.pdf.</div><div id=\"graphicVersion\">Graphic 54028 Version 4.0</div></div></div>"},"54029":{"type":"graphic_figure","displayName":"SF-36 scores post LVRS","title":"SF-36 physical functioning (PF) scale scores from before LVRS (baseline) and after surgery","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">SF-36 physical functioning (PF) scale scores from before LVRS (baseline) and after surgery</div><div class=\"cntnt\"><img style=\"width:475px; height:255px;\" src=\"images/PULM/54029_SF-36_scores_post_LVRS.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Ciccone, AM, Meyers, BF, Guthrie, TJ, et al. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thor Card Surg 2003; 125:513.</div><div id=\"graphicVersion\">Graphic 54029 Version 1.0</div></div></div>"},"54030":{"type":"graphic_table","displayName":"CT studies to detect CVT","title":"Computed tomography studies on detection of cardiac allograft vasculopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Computed tomography studies on detection of cardiac allograft vasculopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Gold standard</td> <td class=\"subtitle1\">Sensitivity</td> <td class=\"subtitle1\">Specificity</td> </tr> <tr> <td>Romeo, 2005<sup>[1]</sup></td> <td>53</td> <td> <p>Angiography</p> &#62;50 percent stenosis</td> <td>0.83</td> <td>0.95</td> </tr> <tr> <td>Iyengar, 2006<sup>[2]</sup></td> <td>20</td> <td> <p>Angiography</p> &#62;50 pecent stenosis</td> <td>1/1 detected</td> <td>&ndash;</td> </tr> <tr> <td>Sigurdsson, 2006<sup>[3]</sup></td> <td>54</td> <td> <p>Angiography</p> &#62;50 percent stenosis</td> <td>0.86</td> <td>0.99</td> </tr> <tr> <td>Gregory, 2006<sup>[4]</sup></td> <td>20</td> <td>IVUS</td> <td>0.70</td> <td>0.92</td> </tr> <tr> <td>Pichler, 2008<sup>[5]</sup></td> <td>66</td> <td> <p>Angiography</p> &#62;70 percent stenosis</td> <td>0.59</td> <td>0.94</td> </tr> <tr> <td>Schepis, 2009<sup>[6]</sup></td> <td>30</td> <td>IVUS</td> <td>0.85</td> <td>0.84</td> </tr> <tr> <td>Mastrobuoni, 2009<sup>[7]</sup></td> <td>30</td> <td>Angiography*</td> <td>&ndash;</td> <td>0.92</td> </tr> <tr> <td>Von Ziegler, 2009<sup>[8]</sup></td> <td>28</td> <td> <p>Angiography</p> &#62;50 percent stenosis</td> <td>0.88</td> <td>0.97</td> </tr> <tr> <td>Von Ziegler, 2012<sup>[9]</sup></td> <td>48</td> <td> <p>Angiography</p> &#62;50 percent stenosis</td> <td>1.00</td> <td>0.86</td> </tr> <tr> <td>Mittal, 2013<sup>[10]</sup></td> <td>138</td> <td> <p>Angiography</p> &#62;50 percent stenosis</td> <td>0.96</td> <td>0.93</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IVUS: intravascular ultrasound; CT: computed tomography.<br />* Only performed when CT is abnormal.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Romeo G, Houyel L, Angel CY, et al. Coronary stenosis detection by 16-slice computed tomography in heart transplant patients: comparison with conventional angiography and impact on clinical management. J Am Coll Cardiol 2005; 45:1826. </li>&#xD;&#xA;    <li>Iyengar S, Feldman DS, Cooke GE, et al. Detection of coronary artery disease in orthotopic heart transplant recipients with 64-detector row computed tomography angiography. J Heart Lung Transplant 2006; 25:1363. </li>&#xD;&#xA;    <li>Sigurdsson G, Carrascosa P, Yamani MH, et al. Detection of transplant coronary artery disease using multidetector computed tomography with adaptative multisegment reconstruction. J Am Coll Cardiol 2006; 48:772. </li>&#xD;&#xA;    <li>Gregory SA, Ferencik M, Achenbach S, et al. Comparison of sixty-four-slice multidetector computed tomographic coronary angiography to coronary angiography with intravascular ultrasound for the detection of transplant vasculopathy. Am J Cardiol 2006; 98:877. </li>&#xD;&#xA;    <li>Pichler P, Loewe C, Roedler S, et al. Detection of high-grade stenoses with multislice computed tomography in heart transplant patients. J Heart Lung Transplant 2008; 27:310. </li>&#xD;&#xA;    <li>Schepis T, Achenbach S, Weyand M, et al. Comparison of dual source computed tomography versus intravascular ultrasound for evaluation of coronary arteries at least one year after cardiac transplantation. Am J Cardiol 2009; 104:1351. </li>&#xD;&#xA;    <li>Mastrobuoni S, Bastarrika G, Ubilla M, et al. Dual-source CT coronary angiogram in heart transplant recipients in comparison with dobutamine stress echocardiography for detection of cardiac allograft vasculopathy. Transplantation 2009; 87:587. </li>&#xD;&#xA;    <li>von Ziegler F, Leber AW, Becker A, et al. Detection of significant coronary artery stenosis with 64-slice computed tomography in heart transplant recipients: a comparative study with conventional coronary angiography. Int J Cardiovasc Imaging 2009; 25:91. </li>&#xD;&#xA;    <li>von Ziegler F, Rummler J, Kaczmarek I, et al. Detection of significant coronary artery stenosis with cardiac dual-source computed tomography angiography in heart transplant recipients. Transpl Int 2012; 25:1065.</li>&#xD;&#xA;    <li>Mittal T, Panicker M, Mitchell A, et al. Cardiac allograft vasculopathy after heart transplantation: electrocardiographically gated CT angiography for assessment. Radiology 2013; 268:374.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Dr. Finn Gustafsson.</div><div id=\"graphicVersion\">Graphic 54030 Version 7.0</div></div></div>"},"54031":{"type":"graphic_table","displayName":"Approaches for ERCP in patients with Roux-en-Y anatomy","title":"Approaches for ERCP in patients with Roux-en-Y anatomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approaches for ERCP in patients with Roux-en-Y anatomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Technique</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> <td class=\"subtitle1\">Best application</td> </tr> <tr> <td>Duodenoscope advanced transorally through anatomic route</td> <td> <ul> <li>Ideal instrument for cannulation and therapy of native papilla </li> <li>Minimally invasive </li> </ul> </td> <td class=\"indent1\">Frequently unsuccessful due to inability to reach target</td> <td>Patients with short Roux limb and native papilla</td> </tr> <tr> <td>Colonoscope/enteroscope advanced transorally through anatomic route</td> <td> <ul> <li>Greater depth of insertion compared to duodenoscope </li> <li>Minimally invasive </li> </ul> </td> <td> <ul> <li>Frequently unsuccessful in patients with long Roux limb </li> <li>Forward view </li> <li>Lack of elevator </li> </ul> </td> <td>Patients with short Roux limb and bilioenteric/ pancreatoenteric anastomosis</td> </tr> <tr> <td>Deep enteroscopy assisted ERCP</td> <td class=\"indent1\">Greater reliability in reaching target, even in patients with long Roux limb</td> <td> <ul> <li>Forward view </li> <li>Lack of elevator </li> <li>Limited availability of accessories and instruments </li> </ul> </td> <td>Patients with long Roux limb and bilioenteric/ pancreatoenteric anastomosis</td> </tr> <tr> <td>Transgastrostomy tract ERCP</td> <td> <ul> <li>Allows use of side viewing duodenoscope and all standard accessories </li> <li>Provides reliable access for repeat procedures </li> </ul> </td> <td class=\"indent1\">More invasive than purely endoscopic techniques</td> <td>RYGB patients with native papilla, or when repeated procedures are anticipated</td> </tr> <tr> <td>Laparoscopy-assisted ERCP</td> <td> <ul> <li>Allows use of side viewing duodenoscope and all standard accessories </li> <li>Ability to diagnosis and treat internal hernias </li> </ul> </td> <td> <ul> <li>More invasive than purely endoscopic techniques </li> <li>Requires significant coordination between surgery and endoscopy teams </li> </ul> </td> <td>RYGB patients with native papilla, particularly when internal hernia is suspected</td> </tr> <tr> <td>Percutaneous approaches via interventional radiology</td> <td class=\"indent1\">Less invasive than surgical approaches</td> <td> <ul> <li>Morbidity (pain, external drains) </li> <li>No access to pancreas </li> </ul> </td> <td>Patients with biliary tract pathology who are poor surgical candidates</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography; RYGB: Roux-en-Y gastric bypass.</div><div class=\"graphic_reference\">Original figure modified for this publication. Lopes TL, Wilcox CM. Endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y anatomy. Gastroenterol Clin North Am 2010; 39:99. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 54031 Version 1.0</div></div></div>"},"54032":{"type":"graphic_picture","displayName":"Pemphigoid vulva","title":"Vulvar pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar pemphigoid</div><div class=\"cntnt\"><img style=\"width:354px; height:396px;\" src=\"images/OBGYN/54032_Pemphigoid_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 54032 Version 3.0</div></div></div>"},"54033":{"type":"graphic_table","displayName":"Ideal char urin reservoir","title":"Ideal characteristics of a urinary reservoir","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ideal characteristics of a urinary reservoir</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Low pressure system</td> <td>Higher internal pressure in the reservoir may overcome the external sphincter mechanisms that maintain continence. </td> </tr> <tr> <td>Stores a functional amount of urine (approximately 500 mL)</td> <td>&nbsp;</td> </tr> <tr> <td>Reliable, complete continence</td> <td>Detubularization of intestinal segments limits the ability to generate a peristaltic pressure wave. These waves can contribute to incontinence.</td> </tr> <tr> <td>Complete voluntary control of voiding</td> <td>&nbsp;</td> </tr> <tr> <td>No absorption of urinary waste products by the reservoir walls</td> <td>Minimizes the likelihood of metabolic complications. </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54033 Version 2.0</div></div></div>"},"54034":{"type":"graphic_table","displayName":"Etiology of headache children","title":"Etiologic classification of headache in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologic classification of headache in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acute</td> </tr> <tr> <td class=\"subtitle2_left\">Localized</td> </tr> <tr> <td class=\"indent1\">Associated with URI (sinusitis, otitis media) or viral infection (influenza)</td> </tr> <tr> <td class=\"indent1\">Post-traumatic</td> </tr> <tr> <td class=\"indent1\">Related to oral cavity (dental abscess, TMJ dysfunction)</td> </tr> <tr> <td class=\"indent1\">Brain abscess</td> </tr> <tr> <td class=\"indent1\">First migraine</td> </tr> <tr> <td class=\"subtitle2_left\">Generalized</td> </tr> <tr> <td class=\"indent1\">Fever</td> </tr> <tr> <td class=\"indent1\">Systemic infection (influenza)</td> </tr> <tr> <td class=\"indent1\">Central nervous system infection (meningitis, viral encephalitis)</td> </tr> <tr> <td class=\"indent1\">Hypertension, hypertensive encephalopathy</td> </tr> <tr> <td class=\"indent1\">Intracranial hemorrhage</td> </tr> <tr> <td class=\"indent1\">Exertional</td> </tr> <tr> <td class=\"indent1\">First migraine headache</td> </tr> <tr> <td class=\"indent1\">Trauma</td> </tr> <tr> <td class=\"indent1\">Toxins (eg, carbon monoxide), medications (eg, amphetamines, oral contraceptives), or illicit substances</td> </tr> <tr> <td class=\"subtitle1_single\">Acute and recurrent</td> </tr> <tr> <td>Migraine headache</td> </tr> <tr> <td>Cluster headache</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic and non-progressive</td> </tr> <tr> <td>Tension-type headache</td> </tr> <tr> <td>Psychiatric (depression, school phobia)</td> </tr> <tr> <td>Post-traumatic, postconcussive</td> </tr> <tr> <td>Medication overuse</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic and progressive</td> </tr> <tr> <td>Idiopathic intracranial hypertension</td> </tr> <tr> <td>Space-occupying lesion (tumor, abscess, hemorrhage, hydrocephalus, vascular malformation)</td> </tr> <tr> <td>Post-traumatic, postconcussive</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">URI: upper respiratory infection; TMJ: temporomandibular joint.</div><div class=\"graphic_reference\">Adapted from:<br> <ol> <li>Morton L. Headache. In: Clinical Handbook of Pediatrics, Schwartz MW (Ed), Williams and Wilkins, Baltimore 1995, p.316. </li> <li>Rothner DA. Headache in adolescence. Adolescent Health Update. 2006; 18:1. </li> <li>Strasburger VC, Brown RT, Braverman PK, et al. Headache. In: Adolescent Medicine A Handbook for Primary Care, Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.25. </li> </ol></div><div id=\"graphicVersion\">Graphic 54034 Version 6.0</div></div></div>"},"54035":{"type":"graphic_figure","displayName":"Patellar apprehension test","title":"Patellar apprehension test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patellar apprehension test</div><div class=\"cntnt\"><img style=\"width:275px; height:462px;\" src=\"images/PEDS/54035_Patellar_apprehension_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with patellar dislocation and/or subluxation have pain in the medial patellar retinacular area and are apprehensive when the examiner tries to push the patella laterally.</div><div id=\"graphicVersion\">Graphic 54035 Version 4.0</div></div></div>"},"54036":{"type":"graphic_diagnosticimage","displayName":"Physiologic bowing radiograph","title":"Physiologic bowing radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Physiologic bowing radiograph</div><div class=\"cntnt\"><img style=\"width:277px; height:396px;\" src=\"images/PEDS/54036_Physiologicbowingxray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standing anteroposterior films of both lower extremities help distinguish physiologic bowing from pathologic causes. Tibial metaphyseal-diaphyseal (MD) angles are typically 11 degrees or less. A similar angle constructed in the distal femur is the same or greater, indicating that the femur and tibia both contribute to the bowing. The ratio of femoral to tibial MD angle is greater than 1.</div><div class=\"graphic_reference\">Reproduced with permission from: Schoenecker PL, Rich MM. The Lower Extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6<SUP>th</SUP> ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54036 Version 15.0</div></div></div>"},"54037":{"type":"graphic_table","displayName":"Behaviors that enhance outcome","title":"Clinical behaviors that enhance the outcomes of medical care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical behaviors that enhance the outcomes of medical care</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Cognitive</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Negotiating priorities and expectations</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Giving an explanation</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Bringing a patient to a crossroads</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Making suggestions</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Educating the patient</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Giving a prognosis</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Affective</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Conveying empathy</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Encouraging emotional expression</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Giving encouragement</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Offering hope</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Touching</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Facilitating self-forgiveness</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Giving reassurance</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Behavioral</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Emphasizing patient's active role</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Praising desired behaviors</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Suggesting alternative behaviors</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Attending to compliance</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Social</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Using family and social supports</td>\n\n\n    </tr>\n    <tr>\n      <td>Using community\nagencies and other health care providers</td>\n    </tr>\n\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Lipkin M, Putnam S, Lazare A. The Medical Interview. Springer-Verlag, New York 1995.</div><div id=\"graphicVersion\">Graphic 54037 Version 2.0</div></div></div>"},"54038":{"type":"graphic_diagnosticimage","displayName":"CPA radiograph and angiogram","title":"Chronic pulmonary aspergillosis","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Chronic pulmonary aspergillosis</div><div class=\"cntnt\"><img style=\"width:516px; height:272px;\" src=\"images/ID/54038_CPA_radiograph_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph showing a large left upper lobe cavity, with some pleural thickening and minor pericavitary infiltrates inferiorly, with no evidence of an aspergilloma. Otherwise, the lung fields are abnormal, with subtle infiltrates most consistent with sarcoidosis. He presented with significant hemoptysis, weight loss, cough, and fatigue over several months.<br />(B) Bronchial artery angiogram in the same patient, showing a extensive network of additional vessels surrounding the empty cavity, which were successfully embolized.</div><div class=\"graphic_reference\">Reproduced with permission from: Denning DW. Chronic aspergillosis. In: Aspergillus fumigatus and aspergillosis, Latge JP, Steinbach WJ (Eds). ASM Press, Washington, DC 2009. Copyright © 2009 ASM Press.</div><div id=\"graphicVersion\">Graphic 54038 Version 6.0</div></div></div>"},"54042":{"type":"graphic_figure","displayName":"Cutaneous peripheral nerve distribution","title":"Pattern of innervation of skin by peripheral nerves","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Pattern of innervation of skin by peripheral nerves</div><div class=\"cntnt\"><img style=\"width:557px; height:553px;\" src=\"images/NEURO/54042_Peripheral_nerve_innervatio.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54042 Version 5.0</div></div></div>"},"54044":{"type":"graphic_picture","displayName":"Keloid ear lobe","title":"Keloid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Keloid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/54044_Keloid_ear_lobe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large keloid of the ear lobe.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54044 Version 3.0</div></div></div>"},"54045":{"type":"graphic_figure","displayName":"Nonsusceptibility invasive pneumococcal isolates children","title":"Rates of antibiotic nonsusceptible pneumococcal disease among children ","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Rates of antibiotic nonsusceptible pneumococcal disease among children </div><div class=\"cntnt\"><img style=\"width:548px; height:410px;\" src=\"images/PEDS/54045_Nnsuscpt_invs_pneumo_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NS: nonsusceptible.<BR>* The old/oral meningitis penicillin breakpoints classify isolates as penicillin nonsusceptible at a MIC &#8805;0.12 mcg/mL.<BR><FONT class=bullet>&#8226;</FONT> Not susceptible to 3 or more of the antibiotic classes tested.<BR>&#916; The new parenteral penicillin breakpoints classify isolates as penicillin nonsusceptible at an MIC &#8805;4 mcg/mL for nonmeningitis disease and &#8805;0.12 mcg/mL for meningitis.</div><div class=\"graphic_reference\">Data from: Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2012; 205:401.</div><div id=\"graphicVersion\">Graphic 54045 Version 2.0</div></div></div>"},"54046":{"type":"graphic_figure","displayName":"Gellhorn pessary","title":"Gellhorn vaginal pessary in situ","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Gellhorn vaginal pessary in situ</div><div class=\"cntnt\"><img style=\"width:477px; height:298px;\" src=\"images/OBGYN/54046_Gellhorn_pessary.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54046 Version 3.0</div></div></div>"},"54047":{"type":"graphic_algorithm","displayName":"Treatment approach ITP","title":"Treatment approach in immune thrombocytopenia (ITP) in adults","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Treatment approach in immune thrombocytopenia (ITP) in adults</div><div class=\"cntnt\"><img style=\"width:494px; height:434px;\" src=\"images/HEME/54047_Treatment_approach_ITP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm represents a <strong>simplified</strong> approach to the treatment of patients with ITP. Threshold platelet counts are presented, but clinical symptoms and patients' concerns must be weighed. The treatment of serious bleeding requires additional therapy including platelet transfusions.<br />NOTE: Only some of the possible treatments for ITP are described in this algorithm. As an example, for first-line therapy, IVIG may be used together with or instead of glucocorticoids when a more rapid increase in platelet count is required; IVIG or anti-D (in appropriate patients) may also be used as first-line or rescue treatment if glucocorticoids are contraindicated or cannot be tolerated. Refer to UpToDate topics on management of ITP for further details regarding management of bleeding, indications for ITP treatment, and choices among available therapies.</div><div class=\"graphic_footnotes\">ITP: immune thrombocytopenia (previously called immune thrombocytopenic purpura; idiopathic thrombocytopenic purpura); IVIG: intravenous immune globulin; TPO: thrombopoietin.<br />* The decision for which management modality to use first, splenectomy or rituximab, is determined by patient and physician preference. If the initial option, splenectomy or rituximab, fails to increase the platelet count to &gt;20,000/microL, then the other modality is appropriate, before TPO receptor agonists or combination therapy is used.</div><div class=\"graphic_reference\">Courtesy of James N George and Donald M Arnold.</div><div id=\"graphicVersion\">Graphic 54047 Version 12.0</div></div></div>"},"54048":{"type":"graphic_figure","displayName":"Variations of aortic arch branching","title":"Variations of aortic arch branching","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Variations of aortic arch branching</div><div class=\"cntnt\"><img style=\"width:591px; height:639px;\" src=\"images/SURG/54048_Aortic_arch_vars.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Variations in the origin of the aortic arch branches. (A) and (B) represent the majority of anomalies found in the general population.<br> (A) Common origin of the left common carotid artery and brachiocephalic artery (bovine arch). Represents 73 percent of all branch variations.<br> (B) Origin of the left common carotid from the mid- to upper brachiocephalic artery. Represents 22 percent of all branch variations.<br> (C) Common carotid trunk giving origin to the left subclavian artery.<br> (D) Common carotid trunk, independent from both subclavian arteries.<br> (E) Left and right brachiocephalic arteries.<br> (F) Single arch vessel (brachiocephalic artery) originates the left common carotid and left subclavian arteries.</div><div class=\"graphic_reference\">Reproduced with permission from: Uflacker R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54048 Version 3.0</div></div></div>"},"54049":{"type":"graphic_figure","displayName":"Incidence of invasive group B streptococcal disease","title":"Incidence of early- and late-onset invasive group B streptococcal (GBS) disease: Active Bacterial Core surveillance areas (1990 to 2015), in relation to publication of guidelines for prevention of GBS disease","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Incidence of early- and late-onset invasive group B streptococcal (GBS) disease: Active Bacterial Core surveillance areas (1990 to 2015),&nbsp;in relation&nbsp;to publication of guidelines for prevention of GBS disease</div><div class=\"cntnt\"><img style=\"width:714px; height:374px;\" src=\"images/PEDS/54049_IncidenceGBS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACOG: American College of Obstetricians and Gynecologists; AAP: American Academy of Pediatrics.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Jordan HT, Farley MM, Craig A, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 2008; 27:1057. </LI>&#xD;&#xA;<LI>Active Bacterial Core Surveillance Report, group B Streptococcus, Centers for Disease Control and Prevention 2008. Available at: <A href=\"http://www.cdc.gov/abcs/reports-findings/survreports/gbs08.html\" target=_blank>www.cdc.gov/abcs/reports-findings/survreports/gbs08.html</A>. Accessed on July 12, 2012.</LI>&#xD;&#xA;<LI>Active Bacterial Core Surveillance Report, group B Streptococcus, Centers for Disease Control and Prevention 2009. Available at: <A href=\"http://www.cdc.gov/abcs/reports-findings/survreports/gbs09.html\" target=_blank>www.cdc.gov/abcs/reports-findings/survreports/gbs09.html</A>. Accessed on July 12, 2012.</LI>&#xD;&#xA;<LI>Active Bacterial Core Surveillance Report, group B Streptococcus, Centers for Disease Control and Prevention 2010. Available at: <A href=\"http://www.cdc.gov/abcs/reports-findings/survreports/gbs10.html\" target=_blank>www.cdc.gov/abcs/reports-findings/survreports/gbs10.html</A>. Accessed on July 12, 2012.</LI>&#xD;&#xA;<LI>Active Bacterial Core Surveillance Report, group B Streptococcus, Centers for Disease Control and Prevention 2011. Available at: <A href=\"http://www.cdc.gov/abcs/reports-findings/survreports/gbs11.html\" target=_blank>www.cdc.gov/abcs/reports-findings/survreports/gbs11.html</A>. Accessed on June 18, 2014.</LI>&#xD;&#xA;<LI>Active Bacterial Core Surveillance Report, group B Streptococcus, Centers for Disease Control and Prevention 2012. Available at: <A spellcheck=true href=\"http://www.cdc.gov/abcs/reports-findings/survreports/gbs12.html\" target=_blank>www.cdc.gov/abcs/reports-findings/survreports/gbs12.html</A>. Accessed on June 18, 2014.</LI>&#xD;&#xA;<LI>Active Bacterial Core Surveillance Report, group B Streptococcus, Centers for Disease Control and Prevention 2013. Available at: <A href=\"http://www.cdc.gov/abcs/reports-findings/survreports/gbs13.html\" target=_blank>www.cdc.gov/abcs/reports-findings/survreports/gbs13.html</A>. Accessed on July 6, 2015.</LI>&#xD;&#xA;<LI>Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Group B Streptococcus, Centers for Disease Control and Prevention 2014. Available at: <A href=\"https://www.cdc.gov/abcs/reports-findings/survreports/gbs14.pdf\" target=_blank>https://www.cdc.gov/abcs/reports-findings/survreports/gbs14.pdf</A>. Accessed on November 7, 2017.</LI>&#xD;&#xA;<LI>Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Group B Streptococcus, Centers for Disease Control and Prevention 2015. Available at: <A href=\"https://www.cdc.gov/abcs/reports-findings/survreports/gbs15.pdf\" target=_blank>https://www.cdc.gov/abcs/reports-findings/survreports/gbs15.pdf</A>. Accessed on November 7, 2017.</LI></OL>Reproduced from: Verani JR, McGee L, Schrag SJ, et al. Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59(RR-10):1.</div><div id=\"graphicVersion\">Graphic 54049 Version 10.0</div></div></div>"},"54050":{"type":"graphic_table","displayName":"Complications of abdominal paracentesis","title":"Complications of abdominal paracentesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of abdominal paracentesis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Leak of ascitic fluid</td> <td>5 percent</td> </tr> <tr> <td>Severe hemorrhage</td> <td>0 to 0.97 percent</td> </tr> <tr> <td>Infection due to paracentesis</td> <td>0.58 to 0.63 percent</td> </tr> <tr> <td>Death associated with paracentesis</td> <td>0 to 0.39 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br> <ol> <li>de Gottardi A, Thevenot T, Spahr L, et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Hep Gastro 2009; 7:906. </li> <li>Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40:484. </li> <li>McVay PA, Toy PTCY. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31:164. </li> <li>Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther 2005; 21:525. </li> <li>Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95:1351. </li> <li>Runyon BA. Paracentesis of ascitic fluid: a safe procedure. Arch Intern Med 1986; 146:2259. </li> </ol></div><div id=\"graphicVersion\">Graphic 54050 Version 2.0</div></div></div>"},"54051":{"type":"graphic_table","displayName":"Treatment of microsporidiosis","title":"Treatment of microsporidiosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of microsporidiosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Pediatric dose</td> </tr> <tr> <td class=\"sublist_other_start\" colspan=\"4\"><strong>Ocular</strong> (<em>Encephalitozoon hellem</em>,&nbsp;<em>Encephalitozoon cuniculi</em>, <em>Vittaforma [Nosema] corneae</em>)</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Drug of choice:</td> <td>Fumagillin (Fumidil B) in saline equivalent to fumagillin 70 mcg/mL eye drops*</td> <td>2 drops every 2 hours for 4 days, then 2 drops 4 times per day</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\"><strong>PLUS for management of systemic infection</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Albendazole<sup>&#182;</sup><sup>&#916;</sup></td> <td>400 mg orally with fatty meal twice per day</td> <td>15 mg/kg per day in 2 divided doses (maximum 400 mg/dose)</td> </tr> <tr> <td class=\"sublist_other_start\" colspan=\"4\"><strong>Intestinal</strong> (<em>Enterocytozoon bieneusi</em>,<em>&nbsp;Encephalitozoon [Septata] intestinalis</em>)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\"><em>E. bieneusi</em></td> </tr> <tr> <td class=\"indent2\">Drug of choice:</td> <td>Fumagillin<sup>&#9674;</sup></td> <td>20 mg orally three times per day for 14 days</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\"><em>E. intestinalis</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Drug of choice:</td> <td>Albendazole<sup>&#182;</sup><sup>&#916;</sup></td> <td>400 mg orally on empty stomach twice per day for 21 days</td> <td>15 mg/kg per day in 2 divided doses (maximum 400 mg/dose)</td> </tr> <tr> <td class=\"sublist_other_start\" colspan=\"4\"><strong>Disseminated</strong> (<em>E. hellem</em>, <em>E. cuniculi</em>, <em>E. intestinalis</em>, <em>Pleistophora </em>spp, <em>Trachipleistophora </em>spp, and <em>Anncaliia [Brachiola] vesicularum</em>)</td> </tr> <tr> <td class=\"indent1\">Drug of choice:<sup>&#167;</sup></td> <td>Albendazole<sup>&#182;</sup><sup>&#916;</sup></td> <td>Immunocompromised: 400 mg orally with fatty meal twice per day for 14 to 28 days. Continue treatment until CD4+ count &#62;200 cells/microL for &#62;6 months after initiation of potent antiretroviral therapy.<br /> Immunocompetent: 400 mg orally with fatty meal twice per day for 7 to 14 days. Symptoms may resolve with no therapy. (Refer to the UpToDate topic on microsporidiosis.)</td> <td>15 mg/kg per day in 2 divided doses (maximum 400 mg/dose)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The mainstay of treatment of microsporidiosis in HIV-infected patients with severe immunosuppression is successful ART for immune restoration of CD4+ counts to greater than 100 cells/microL, which is associated with resolution of symptoms of enteric microsporidiosis, including that caused by <EM>E. bieneusi</EM>.</div><div class=\"graphic_footnotes\">* Available as an investigational agent (non-US Food and Drug Administration [FDA] approved) in the United States from Leiter's Park Avenue Pharmacy (a custom compounding pharmacy), San Jose, CA (8<FONT class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">00-292-6773,</FONT> <A href=\"http://www.leiterrx.com/\" target=_blank>www.leiterrx.com</A>). Ocular lesions due to <EM>E. hellem</EM> in HIV-infected patients have responded to fumagillin eyedrops prepared from Fumidil B (bicyclohexyl ammonium fumagillin) used to control a microsporidial disease of honey bees.<SUP>[1,2]</SUP> For lesions due to <EM>V. corneae</EM>, topical therapy is generally not effective and keratoplasty may be required.<SUP>[3]</SUP><br />¶ Not FDA approved for this indication.<br />Δ For treatment of systemic infection, albendazole must be taken with food; a fatty meal increases oral bioavailability. For treatment of intestinal infection with no systemic involvement, albendazole should be taken on an empty stomach.<br /><FONT class=lozenge>◊</FONT> Oral fumagillin (Flisint, Sanofi-Aventis, France) is not available in the United States. It has been effective in treating <EM>E. bieneusi</EM> in patients with HIV or solid organ transplants<SUP>[4,5]</SUP>&nbsp;but has been associated with thrombocytopenia and neutropenia. Potent antiretroviral therapy may lead to microbiologic and clinical response in HIV-infected patients with microsporidial diarrhea. Octreotide (Sandostatin) has provided symptomatic relief in some patients with large-volume diarrhea.<br />§ There is no established treatment for <EM>Pleistophora</EM>.<SUP>[6]</SUP> For disseminated disease due to <EM>Trachipleistophora</EM> or <EM>Anncallia</EM>, itraconazole 400 mg orally once per day plus albendazole may also be tried.<SUP>[7]</SUP></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Chan CM, Theng JT, Li L, Tan&nbsp;DT. Microsporidial keratoconjunctivitis in healthy individuals: a case series. Ophtalmology 2003; 110:1420.</LI>&#xD;&#xA;<LI>Garvey MJ, Ambrose PG, Ulmer JL.&nbsp;Topical fumagillin in the treatment of microsporidial keratoconjunctivitis in AIDS. Ann Pharmacother 1995; 29:872.</LI>&#xD;&#xA;<LI>Davis RM, Font RL, Keisler MS, Shadduck JA. Corneal microsporidiosis. A case report including ultrastructural observations. Ophthalmology 1990; 97:953.</LI>&#xD;&#xA;<LI>Molina JM, Tourneur M, Sarfati C, et al.&nbsp;Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 2002; 346:1963.</LI>&#xD;&#xA;<LI>Lanternier F, Boutboul D, Menotti J, et al. Microsporidiosis in solid organ transplant recipients: two Enterocytozoon bieneusi cases and review. Transpl Infect Dis 2009; 11:83.</LI>&#xD;&#xA;<LI>Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis 1995; 171:245. </LI>&#xD;&#xA;<LI>Coyle CM, Weiss LM, Rhodes LV 3rd, et al. Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N Engl J Med 2004; 351:42.</LI></OL>Adapted with special permission from: Treatment of microsporidiosis. In: Drugs for parasitic infections, 2nd Ed. New Rochelle, NY: The Medical Letter, Inc; 2010:44-45. www.medicalletter.org.<br />Additional content from: Centers for Disease Control. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009; 58(RR-4):1-207. Available at: <A href=\"http://www.cdc.gov/mmwr/PDF/rr/rr5804.pdf\" target=_blank>http://www.cdc.gov/mmwr/PDF/rr/rr5804.pdf</A>.</div><div id=\"graphicVersion\">Graphic 54051 Version 7.0</div></div></div>"},"54052":{"type":"graphic_figure","displayName":"Autotransplanted kidney in iliac fossa","title":"Autotransplanted kidney in iliac fossa","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Autotransplanted kidney in iliac fossa</div><div class=\"cntnt\"><img style=\"width:512px; height:676px;\" src=\"images/SURG/54052_Autotransplantedkidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure represents an autotransplanted kidney into the iliac fossa secondary to an extensively traumatized proximal ureter. This procedure is not performed when other options are available to repair the proximal ureter.</div><div id=\"graphicVersion\">Graphic 54052 Version 2.0</div></div></div>"},"54053":{"type":"graphic_picture","displayName":"Serum sickness-like reaction 3","title":"Serum sickness-like reaction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum sickness-like reaction</div><div class=\"cntnt\"><img style=\"width:397px; height:391px;\" src=\"images/DERM/54053_Serum_sickness_like_react3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple inflammatory plaques, some with an annular configuration, are present in this child with serum sickness-like reaction. Purpuric lesions are present on the abdomen. Edema is present in the hands.</div><div id=\"graphicVersion\">Graphic 54053 Version 1.0</div></div></div>"},"54054":{"type":"graphic_table","displayName":"Cellular interstitial pneumonia","title":"Causes of nonspecific or nonclassifiable cellular interstitial pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of nonspecific or nonclassifiable cellular interstitial pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Idiopathic</td>\n</tr>\n<tr>\n<td>Connective tissue diseases</td>\n</tr>\n<tr>\n<td>Drug reaction</td>\n</tr>\n<tr>\n<td>Hypersensitivity pneumonitis</td>\n</tr>\n<tr>\n<td>Diffuse alveolar damage</td>\n</tr>\n<tr>\n<td>Infections</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54054 Version 1.0</div></div></div>"},"54055":{"type":"graphic_table","displayName":"Exudative pleural effusions","title":"Causes of exudative pleural effusions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of exudative pleural effusions</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td>Bacterial pneumonia</td> </tr> <tr> <td>Tuberculous pleurisy</td> </tr> <tr> <td>Parasites</td> </tr> <tr> <td>Fungal disease</td> </tr> <tr> <td>Atypical pneumonias (viral, mycoplasma)</td> </tr> <tr> <td>Nocardia, Actinomyces</td> </tr> <tr> <td>Subphrenic abscess</td> </tr> <tr> <td>Hepatic abscess</td> </tr> <tr> <td>Splenic abscess</td> </tr> <tr> <td>Hepatitis</td> </tr> <tr> <td>Spontaneous esophageal rupture</td> </tr> <tr> <td class=\"subtitle1_single\">Iatrogenic</td> </tr> <tr> <td>Central venous catheter misplacement/migration</td> </tr> <tr> <td>Drug-induced</td> </tr> <tr> <td>Esophageal perforation</td> </tr> <tr> <td>Esophageal sclerotherapy</td> </tr> <tr> <td>Enteral feeding tube in pleural space</td> </tr> <tr> <td>Radiofrequency ablation of pulmonary neoplasms</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy-related</td> </tr> <tr> <td>Carcinoma</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Mesothelioma</td> </tr> <tr> <td>Leukemia</td> </tr> <tr> <td>Chylothorax</td> </tr> <tr> <td>Paraproteinemia (multiple myeloma, Waldenstrom's macroglobulinemia)</td> </tr> <tr> <td class=\"subtitle1_single\">Other inflammatory disorders</td> </tr> <tr> <td>Pancreatitis (acute, chronic)</td> </tr> <tr> <td>Benign asbestos pleural effusion</td> </tr> <tr> <td>Pulmonary embolism</td> </tr> <tr> <td>Radiation therapy</td> </tr> <tr> <td>Uremic pleurisy</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Postcardiac injury syndrome</td> </tr> <tr> <td>Hemothorax</td> </tr> <tr> <td>Acute respiratory distress syndrome (ARDS)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increased negative intrapleural pressure with accompanying pleural malignancy or inflammation</td> </tr> <tr> <td>Lung entrapment</td> </tr> <tr> <td>Cholesterol effusion</td> </tr> <tr> <td class=\"subtitle1_single\">Connective tissue disease</td> </tr> <tr> <td>Lupus pleuritis</td> </tr> <tr> <td>Rheumatoid pleurisy</td> </tr> <tr> <td>Mixed connective tissue disease</td> </tr> <tr> <td>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td>Familial mediterranean fever</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine dysfunction</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td>Ovarian hyperstimulation syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Lymphatic abnormalities</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td>Chylothorax</td> </tr> <tr> <td>Yellow nail syndrome</td> </tr> <tr> <td>Lymphangioleiomyomatosis</td> </tr> <tr> <td>Lymphangiectasia</td> </tr> <tr> <td class=\"subtitle1_single\">Movement of&nbsp;liquid from abdomen to pleural space</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Pancreatic pseudocyst</td> </tr> <tr> <td>Meigs' syndrome</td> </tr> <tr> <td>Chylous ascites</td> </tr> <tr> <td>Malignant ascites</td> </tr> <tr> <td>Subphrenic abscess</td> </tr> <tr> <td>Hepatic abscess (bacterial, amebic)</td> </tr> <tr> <td>Splenic abscess, infarction</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54055 Version 9.0</div></div></div>"},"54056":{"type":"graphic_figure","displayName":"Position of subcarinal nodes","title":"Schematic representation of the anatomic relationships of the subcarinal lymph nodes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic representation of the anatomic relationships of the subcarinal lymph nodes</div><div class=\"cntnt\"><img style=\"width:368px; height:245px;\" src=\"images/PULM/54056_Position_of_subcarinal_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Kavuru, MS, Mehta, AC. Applied anatomy of the airways. In: Wang, KP, Mehta, AC (Eds), Flexible Bronchoscopy, Blackwell Science Inc, Cambridge, MA 1995.</div><div id=\"graphicVersion\">Graphic 54056 Version 1.0</div></div></div>"},"54057":{"type":"graphic_diagnosticimage","displayName":"Retinal vasculitis fluoroscein","title":"Fluorescein angiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fluorescein angiogram</div><div class=\"cntnt\"><img style=\"width:380px; height:252px;\" src=\"images/RHEUM/54057_Retinal_vasculitis_fluorosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorescein angiography showing early vessel perfusion (left) and late perivascular staining (right).</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 54057 Version 3.0</div></div></div>"},"54058":{"type":"graphic_picture","displayName":"Child with fetal alcohol syndrome","title":"Child with fetal alcohol syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Child with fetal alcohol syndrome</div><div class=\"cntnt\"><img style=\"width:319px; height:432px;\" src=\"images/PEDS/54058_Child_fetal_alcohol_syndr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Child with the typical facial features of alcohol syndrome including short palpebral fissures, thin vermilion border of the upper lip, smooth philtrum, and flattened midface.</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler T. Langman's Medical Embryology, 9th ed, Lippincott Williams &amp; Wilkins, Baltimore, MD&nbsp;2003. Copyright &#169; Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54058 Version 2.0</div></div></div>"},"54059":{"type":"graphic_diagnosticimage","displayName":"PVNS knee MRI","title":"Tenosynovial giant cell tumor (formerly pigmented villonodular synovitis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tenosynovial giant cell tumor (formerly pigmented villonodular synovitis)</div><div class=\"cntnt\"><img style=\"width:396px; height:399px;\" src=\"images/RHEUM/54059_PVNS_knee_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T1-weighted MRI of the knee demonstrates suprapatellar (arrow) and intraarticular (arrowheads) nodular masses, which show low signal intensity (dark) from hemosiderin deposition.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 54059 Version 8.0</div></div></div>"},"54060":{"type":"graphic_table","displayName":"Chemotherapy drug eruptions","title":"Cytotoxic chemotherapy agents associated with fixed drug eruptions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytotoxic chemotherapy agents associated with fixed drug eruptions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Dacarbazine</td> </tr> <tr> <td>Hydroxyurea</td> </tr> <tr> <td>Paclitaxel </td> </tr> <tr> <td>Procarbazine</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54060 Version 5.0</div></div></div>"},"54061":{"type":"graphic_table","displayName":"Warfarin interactions PI","title":"Medications that interfere with the effect of warfarin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications that interfere with the effect of warfarin</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">May increase anti-clotting effect (and possibly increase risk of bleeding)</td> </tr> <tr> <td class=\"subtitle2_single\">Antibiotics</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Examples: Amoxicillin (brand name: Amoxil), amoxicillin-clavulanate (brand name: Augmentin), ciprofloxacin (brand name: Cipro), levofloxacin (brand name: Levaquin), metronidazole (brand name: Flagyl), trimethoprim-sulfamethoxazole (brand name: Bactrim); others</td> </tr> <tr> <td class=\"subtitle2_single\">Antifungals</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Example: Fluconazole (brand name: Diflucan); posaconazole (brand name: Noxafil), voriconazole (brand name: Vfend); others</td> </tr> <tr> <td class=\"subtitle2_single\">Hormones</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Examples: Methyltestosterone (brand name: Methitest), oxandrolone (brand name: Oxandrin), testosterone (brand names: Androderm, AndroGel, Axiron, Fortesta, Testim); others</td> </tr> <tr> <td class=\"subtitle2_single\">Antidepressants or nerve pain</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Examples: Amitriptyline (brand name: Elavil), duloxetine (brand name: Cymbalta), fluoxetine (brand names: Prozac, Sarafem), sertraline (brand name: Zoloft), venlafaxine (brand name: Effexor); others</td> </tr> <tr> <td class=\"subtitle2_single\">Cancer</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Examples: Capecitabine (brand name: Xeloda), fluorouracil, imatinib (brand name: Gleevec); tamoxifen (brand name: Nolvadex, Soltamox); others</td> </tr> <tr> <td class=\"subtitle2_single\">Cholesterol</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Examples: Fenofibrate (brand name: Lofibra, Tricor, Trilipix, others), gemfibrozil (brand name: Lopid), most statin drugs (brand names include: Crestor, Lescol, Mevacor, Zocor)</td> </tr> <tr> <td class=\"subtitle2_single\">Gout</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Allopurinol (brand names: Aloprim, Zyloprim)</td> </tr> <tr> <td class=\"subtitle2_single\">Heart</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Example: Amiodarone (brand names: Cordarone, Pacerone)</td> </tr> <tr> <td class=\"subtitle2_single\">Pain relievers and cough/cold medicines that contain aspirin or an NSAID</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Examples: Aspirin, celecoxib (brand name: Celebrex), ibuprofen (brand names: Advil, Motrin), naproxen (brand names: Aleve, Naprosyn), tramadol (brand names: Ultram, Ultracet); others <ul class=\"decimal_heading\"> <li>Many over-the-counter pain relievers and cough/cold medicines contain an NSAID </li> <li>Always discuss all new medicines, including over-the-counter pain relievers and cough/cold medicines with your doctor </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Stomach and heartburn relief</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cimetidine (brand name: Tagamet), omeprazole (brand name: Prilosec)</td> </tr> <tr> <td class=\"subtitle2_single\">Steroids (glucocorticoids)</td> </tr> <tr> <td class=\"indent1\">Examples: Methylprednisolone (brand name: Medrol, Medrol Dose Pack), prednisone, prednisolone (brand name: Orapred); others</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">May decrease anti-clotting effect (and possibly increase risk of blood clots)</td> </tr> <tr> <td class=\"subtitle2_single\">Antibiotics and anti-tuberculosis medications</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Examples: Dicloxacillin, nafcillin, rifampin (brand names: Rifadin, Rifamate, Rifater), rifapentine</td> </tr> <tr> <td class=\"subtitle2_single\">Cancer</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Example: Enzalutamide (anti-androgen, brand name: Xtandi)</td> </tr> <tr> <td class=\"subtitle2_single\">Cholesterol</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cholestyramine (brand names: Prevalite, Questran)</td> </tr> <tr> <td class=\"subtitle2_single\">Herbs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Example: St. Johns wort</td> </tr> <tr> <td class=\"subtitle2_single\">Rheumatoid arthritis, transplant anti-rejection, control of immune system</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Azathioprine (brand name: Imuran)</td> </tr> <tr> <td class=\"subtitle2_single\">Seizures or nerve pain</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Examples: Carbamazepine (brand name: Tegretol), fosphenytoin (brand name: Cerebyx), phenobarbital (brand name: Luminal), phenytoin (brand name: Dilantin); others</td> </tr> <tr> <td class=\"subtitle2_single\">Stomach and nausea</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Aprepitant (brand name: Emend), fosaprepitant (brand name: Emend IV), sucralfate (brand name: Carafate)</td> </tr> <tr> <td class=\"subtitle2_single\">Vitamin K</td> </tr> <tr> <td class=\"indent1\">Avoid vitamin K supplements except the small amount in a daily multiple vitamin (\"multivitamin\") pill. If you take a multivitamin be sure to take it every day. If you stop taking a multivitamin, let your doctor know.</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This is only a <strong>partial list</strong>. Many other drugs can interact with warfarin. Always tell your doctor before starting or stopping any drug when you are on warfarin, including over-the-counter and herbs/natural supplements. You may need a blood test and a change in your warfarin dose when you start or stop another medicine that can interact with warfarin.</div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug.</div><div id=\"graphicVersion\">Graphic 54061 Version 3.0</div></div></div>"},"54064":{"type":"graphic_picture","displayName":"Tonsillectomy post-op","title":"Posterior pharynx after tonsillectomy","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Posterior pharynx after tonsillectomy</div><div class=\"cntnt\"><img style=\"width:546px; height:447px;\" src=\"images/PEDS/54064_Tonsillectomypostop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Postoperative day 6.<br />(B) Postoperative day 14.<br />(C) Postoperative one year.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 54064 Version 3.0</div></div></div>"},"54065":{"type":"graphic_table","displayName":"Pulm mets surgery","title":"Surgical approaches for resection of pulmonary metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surgical approaches for resection of pulmonary metastases</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Procedure\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Pain\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Exposure\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Lung palpation\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Postoperative respiratory compromise\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Wound complication\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Adhesions\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>VATS</td>\r\n  \r\n   <td>(+)</td>\r\n  \r\n   <td>(++)</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>(+)</td>\r\n  \r\n   <td>(+)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Thoracotomy</td>\r\n  \r\n   <td>(+++)</td>\r\n  \r\n   <td>(+++)</td>\r\n  \r\n   <td>(+++)</td>\r\n  \r\n   <td>(+++)</td>\r\n  \r\n   <td>(+)</td>\r\n  \r\n   <td>(+++)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sternotomy</td>\r\n  \r\n   <td>(++)</td>\r\n  \r\n   <td>(+)</td>\r\n  \r\n   <td>(+++)</td>\r\n  \r\n   <td>(+)</td>\r\n  \r\n   <td>(++)*</td>\r\n  \r\n   <td>(+++)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Clamshell</td>\r\n  \r\n   <td>(++++)</td>\r\n  \r\n   <td>(++++)</td>\r\n  \r\n   <td>(++++)</td>\r\n  \r\n   <td>(++++)</td>\r\n  \r\n   <td>(++)*</td>\r\n  \r\n   <td>(+++)</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">VATS: video-assisted thoracoscopic surgery.<br>* Related to morbidity not incidence of sternal wound infection.</div><div id=\"graphicVersion\">Graphic 54065 Version 1.0</div></div></div>"},"54066":{"type":"graphic_picture","displayName":"Gram stain CSF 5C with answer","title":"Listeria monocytogenes motility","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Listeria monocytogenes motility</div><div class=\"cntnt\"><img style=\"width:206px; height:366px;\" src=\"images/ID/54066_Gram_stain_CSF_5C_with_answ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Test for motility of <EM>Listeria monocytogenes</EM> in semi-solid agar. <EM>L. monocytogenes</EM> is motile, as can be seen by the growth spreading outward from the central stab.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 54066 Version 3.0</div></div></div>"},"54067":{"type":"graphic_table","displayName":"Glomerular versus extraglomerular hematuria","title":"Distinguishing extraglomerular from glomerular hematuria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing extraglomerular from glomerular hematuria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Extraglomerular</td> <td class=\"subtitle1\">Glomerular</td> </tr> <tr> <td>Color (if macroscopic)</td> <td>Red or pink</td> <td>Red, smoky brown, or \"Coca-Cola\"</td> </tr> <tr> <td>Clots</td> <td>May be present</td> <td>Absent</td> </tr> <tr> <td>Proteinuria</td> <td>&#60;500 mg/day</td> <td>May be &#62;500 mg/day</td> </tr> <tr> <td>RBC morphology</td> <td>Normal</td> <td>Some RBCs are dysmorphic</td> </tr> <tr> <td>RBC casts</td> <td>Absent</td> <td>May be present</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">9</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=36516&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">RBC: red blood cell.</div><div id=\"graphicVersion\">Graphic 54067 Version 3.0</div></div></div>"},"54070":{"type":"graphic_table","displayName":"Interpretation neonatal hyperoxia test","title":"Hyperoxia test results in neonates with cyanosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hyperoxia test results in neonates with cyanosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">PaO<sub>2</sub> (percent saturation)<br /> when FiO<sub>2</sub> = 0.21</td> <td class=\"subtitle1\">PaO<sub>2</sub> (percent saturation)<br /> when Fi0<sub>2</sub> = 1</td> <td class=\"subtitle1\">PaCO<sub>2</sub></td> </tr> <tr> <td><strong>Normal</strong></td> <td colspan=\"2\">&#62;70 (&#62;95)</td> <td>&#62;300 (100)</td> <td>35</td> </tr> <tr> <td><strong>Pulmonary disease</strong></td> <td colspan=\"2\">50 (85)</td> <td>&#62;150 (100)</td> <td>50</td> </tr> <tr> <td><strong>Neurologic disease</strong></td> <td colspan=\"2\">50 (85)</td> <td>&#62;150 (100)</td> <td>50</td> </tr> <tr> <td><strong>Methemoglobinemia</strong></td> <td colspan=\"2\">&#62;70 (&#60;85)</td> <td>&#62;200 (&#60;85)</td> <td>35</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\"><strong>Cardiac disease</strong></td> </tr> <tr> <td class=\"sublist1\">Parallel circulation*</td> <td class=\"sublist_other\" colspan=\"2\">&#60;40 (&#60;75)</td> <td class=\"sublist_other\">&#60;50 (&#60;85)</td> <td class=\"sublist_other\">35</td> </tr> <tr> <td class=\"sublist1\">Mixing with reduced PBF<sup>&#182;</sup></td> <td class=\"sublist_other\" colspan=\"2\">&#60;40 (&#60;75)</td> <td class=\"sublist_other\">&#60;50 (&#60;85)</td> <td class=\"sublist_other\">35</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Mixing without restricted PBF<sup>&#916;</sup></td> <td class=\"sublist_other\" colspan=\"2\">40 to 60 (75 to 93)</td> <td class=\"sublist_other\">&#60;150 (&#60;100)</td> <td class=\"sublist_other\">35</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td class=\"centered\"><strong>Preductal</strong></td> <td class=\"centered\"><strong>Postductal</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Differential cyanosis<sup>&#9674;</sup></td> <td class=\"sublist_other\">70 (95)</td> <td class=\"sublist_other\">&#60;40 (&#60;75)</td> <td class=\"sublist_other\">Variable</td> <td class=\"sublist_other\">35 to 50</td> </tr> <tr> <td class=\"sublist1\">Reverse differential cyanosis<sup>&#167;</sup></td> <td class=\"sublist_other\">&#60;40 (&#60;75)</td> <td class=\"sublist_other\">&#62;50 (&#62;90)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hyperoxia test: The typical results of partial pressure of oxygen (PaO<sub>2</sub>) and percent of oxygen saturation following administration of room air (FiO<sub>2</sub> = 0.21) or 100 percent oxygen (FiO<sub>2</sub> = 1) to neonates with different causes of cyanosis.</div><div class=\"graphic_footnotes\">FiO<SUB>2</SUB>: fractional inspired oxygen concentration; PBF: pulmonary blood flow.<br />* D-transposition of the great arteries with or without ventricular septal defect.<br />¶ Tricuspid atresia with pulmonary stenosis or pulmonary atresia, pulmonary atresia or critical pulmonary stenosis with intact ventricular septum, tetralogy of Fallot.<br />Δ Truncus arteriosus, total anomalous pulmonary venous connection without obstruction, hypoplastic left heart syndrome, single ventricle without pulmonary stenosis or pulmonary atresia.<br /><FONT class=lozenge>◊</FONT> Persistent pulmonary hypertension of the newborn, interrupted aortic arch, severe coarctation.<br />§ D-transposition of the great arteries associated with either coarctation or suprasystemic pulmonary vascular resistance.</div><div class=\"graphic_reference\">Reproduced with permission from: Marino BS, Bird GL, Wernovsky G. Diagnosis and management of the newborn with suspected congenital heart disease. Clin Perinatol 2001; 28:91. Copyright &copy; 2001.</div><div id=\"graphicVersion\">Graphic 54070 Version 13.0</div></div></div>"},"54071":{"type":"graphic_figure","displayName":"Functional reach test","title":"Diagram of functional reach test to assess balance in elderly persons","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of functional reach test to assess balance in elderly persons</div><div class=\"cntnt\"><img style=\"width:413px; height:399px;\" src=\"images/PC/54071_Functional_reach_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subject stands with fist extended alongside a wall. Subject leans forward as far as possible, moving fist along wall without taking a step or losing stability. Length of fist movement is measured. Distances of less than 6 in (15 cm) indicate an increased risk of falling.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleming KC, Evand JM, Weber DC, Chutka DS. Practical Functional Assessment of Elderly Persons: A Primary-Care Approach [Symposium on Geriatrics-Part III]. Mayo Clinic Proceedings 1995; 70:890. Copyright &#169; 1995 Mayo Foundation.</div><div id=\"graphicVersion\">Graphic 54071 Version 5.0</div></div></div>"},"54072":{"type":"graphic_table","displayName":"Wheat alternatives","title":"Nutrients to be replaced on a wheat avoidance diet and alternative dietary sources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutrients to be replaced on a wheat avoidance diet and alternative dietary sources</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Nutrients in wheat </td> <td class=\"subtitle1\">Alternative dietary sources </td> </tr> <tr> <td>Carbohydrates</td> <td> <p>Products made with alternative grains or flours - Rice, oat, corn, buckwheat, potato, tapioca, chickpea, amaranth, millet, quinoa</p> <p>Fruits and vegetables</p> </td> </tr> <tr> <td>Fiber</td> <td>Fruits, vegetables, alternative whole grains</td> </tr> <tr> <td>Niacin (vitamin B3)</td> <td>Meat, fish, poultry, liver, peanuts, sunflower seeds, legumes, enriched and whole grain alternative grain products</td> </tr> <tr> <td>Thiamine (vitamin B1)</td> <td>Liver, pork, other meats, sunflower seeds, enriched and whole grain alternative grain products, nuts, and legumes</td> </tr> <tr> <td>Riboflavin</td> <td>Cow's milk, dark green leafy vegetables, enriched and whole grain alternative grain products</td> </tr> <tr> <td>Iron</td> <td> <p>Heme iron - Meat, fish, shellfish, poultry</p> <p>Non-heme irons - Enriched and whole grain alternative grain products, legumes, and dried fruits</p> </td> </tr> <tr> <td>Folic acid</td> <td>Enriched and whole grain alternative grain products, beef liver, green leafy vegetables, legumes, seeds, orange juice</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54072 Version 4.0</div></div></div>"},"54074":{"type":"graphic_table","displayName":"Complications of pulmonary AVMs","title":"Complications of pulmonary AVMs in all published series 1948-1999","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of pulmonary AVMs in all published series 1948-1999</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mean, percent</td> <td class=\"subtitle1\">Range, percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Respiratory</td> </tr> <tr> <td class=\"indent1\">Asymptomatic</td> <td>50</td> <td>25 to 58</td> </tr> <tr> <td class=\"indent1\">Dyspnea</td> <td>48</td> <td>27 to 71</td> </tr> <tr> <td class=\"indent1\">Chest pain</td> <td>14</td> <td>6 to 18</td> </tr> <tr> <td class=\"indent1\">Haemoptysis</td> <td>11</td> <td>4 to 18</td> </tr> <tr> <td class=\"indent1\">Haemothorax</td> <td>&#60;1</td> <td>0 to 2</td> </tr> <tr> <td class=\"indent1\">Cyanosis</td> <td>30</td> <td>9 to 73</td> </tr> <tr> <td class=\"indent1\">Clubbing</td> <td>32</td> <td>6 to 68</td> </tr> <tr> <td class=\"indent1\">Bruit</td> <td>49</td> <td>25 to 58</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Embolic phenomenon</td> </tr> <tr> <td class=\"indent1\">Cerebral abscess</td> <td>10</td> <td>0 to 25</td> </tr> <tr> <td class=\"indent1\">CVA or TIA</td> <td>27</td> <td>11 to 55</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54:714.</div><div id=\"graphicVersion\">Graphic 54074 Version 2.0</div></div></div>"},"54076":{"type":"graphic_picture","displayName":"Autonomic nerve scleroderma EM","title":"Autonomic nerve in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autonomic nerve in scleroderma</div><div class=\"cntnt\"><img style=\"width:328px; height:287px;\" src=\"images/RHEUM/54076_Autonomic_nerve_scleroderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of an autonomic nerve in the intestine from a patient with scleroderma. The two main changes are axonal degeneration (up arrow) and collagenous cuffing of the nerve (down arrow).</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 54076 Version 1.0</div></div></div>"},"54077":{"type":"graphic_table","displayName":"TEE approach to cardioversion of AF","title":"Advantages and disadvantages of the transesophageal echocardiography-guided approach to cardioversion of patients with atrial fibrillation undergoing cardioversion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of the transesophageal echocardiography-guided approach to cardioversion of patients with atrial fibrillation undergoing cardioversion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>Transesophageal echocardiography (TEE) should be able to detect left atrial appendage thrombi, which increase the risk of embolic stroke after electrical cardioversion, thus sparing patients with thrombi from undergoing cardioversion</td> <td>TEE is performed without any definitive guidelines about who should receive the procedure (high versus low risk)</td> </tr> <tr> <td>In the majority of patients without left atrial appendage thrombi, earlier cardioversion may shorten the period of anticoagulation and lower the corresponding risk of bleeding complications</td> <td>Residual thrombus on repeat TEE may diminish the cost-effectiveness of the TEE-guided approach</td> </tr> <tr> <td>A TEE-guided approach may prove more cost-effective owing to the reduction in laboratory monitoring costs and the reduction in bleeding complications</td> <td>Transesophageal echocardiography requires a level III-trained physician and availability of expensive echocardiographic machines</td> </tr> <tr> <td>Earlier cardioversion is believed to increase the likelihood of a successful return to and maintenance of sinus rhythm</td> <td>Transesophageal echocardiography may miss thrombi that may embolize after cardioversion. In contrast, TEE may render false positive results by erroneously identifying spontaneous echocardiographic contrast, sludge, multilobed appendages or pectinate muscles as thrombus.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from: The American College of Cardiology. J Am Coll of Cardiol 2001; 37:691-704. <A spellcheck=true href=\"https://www.journals.elsevier.com/jacc-journal-of-the-american-college-of-cardiology\" target=_blank>https://www.journals.elsevier.com/jacc-journal-of-the-american-college-of-cardiology</A>.</div><div id=\"graphicVersion\">Graphic 54077 Version 5.0</div></div></div>"},"54078":{"type":"graphic_picture","displayName":"Port wine stain - leg","title":"Port wine stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Port wine stain</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/54078_Port_wine_stain_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A port wine stain, manifesting as an erythematous patch with multiple small, vascular papules, is present on the leg of this adult.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54078 Version 3.0</div></div></div>"},"54079":{"type":"graphic_figure","displayName":"Bruise PI","title":"How bruises heal","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">How bruises heal</div><div class=\"cntnt\"><img style=\"width:509px; height:650px;\" src=\"images/PI/54079_Bruise-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows how a bruise changes color as it heals. A bruise starts off red in color (as shown in A) and then turns blue or purple (as shown in B). As a bruise heals, it can turn green and yellow (as shown in C).</div><div id=\"graphicVersion\">Graphic 54079 Version 4.0</div></div></div>"},"54080":{"type":"graphic_figure","displayName":"Type II AC joint injury","title":"Type II acromioclavicular joint injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Type II acromioclavicular joint injury</div><div class=\"cntnt\"><img style=\"width:430px; height:301px;\" src=\"images/EM/54080_Type_II_AC_joint_sprain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The drawing depicts a Type&nbsp;II acromioclavicular (AC) injury. The AC ligament is completely disrupted, but there is only a partial tear or stretching of the coracoclavicular ligament. Superior displacement of the clavicle, if present at all, is minimal.</div><div id=\"graphicVersion\">Graphic 54080 Version 4.0</div></div></div>"},"54083":{"type":"graphic_picture","displayName":"Measles pneumonia light microscopy","title":"Measles pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measles pneumonia</div><div class=\"cntnt\"><img style=\"width:368px; height:259px;\" src=\"images/ID/54083_Measles_pneumonia_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a lung biopsy from a patient with measles pneumonia shows a nodular pattern with acute and chronic inflammation and areas of necrosis and fibrosis. Multinucleated giant cells with inclusions (arrows) are also shown (hematoxylin-eosin, 500X).</div><div class=\"graphic_reference\">Reproduced with permission from Angel JB, Walpita P, Lerch RA, et al, Ann Intern Med 1998; 129:104.</div><div id=\"graphicVersion\">Graphic 54083 Version 3.0</div></div></div>"},"54086":{"type":"graphic_picture","displayName":"Atrophic vaginitis","title":"Atrophic vaginitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrophic vaginitis</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/OBGYN/54086_Atrophic_vaginitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">External genitalia show scarce pubic hair, diminished elasticity and turgor of the vulvar skin, decreased introital moisture, and fusion of the labia minora.</div><div class=\"graphic_reference\">Courtesy of Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 54086 Version 1.0</div></div></div>"},"54087":{"type":"graphic_figure","displayName":"Pelvic floor dyssynergia","title":"Dyssynergic defecation","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Dyssynergic defecation</div><div class=\"cntnt\"><img style=\"width:478px; height:307px;\" src=\"images/GAST/54087_Pelvic_floor_dyssynerg_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Defecation normally involves the coordinated relaxation of the puborectalis and external anal sphincter muscles as pressure is building in the rectum (control panel, left). However, in patients with dyssynergic defecation (patient panel, right), ineffective defecation is associated with a failure to relax, or inappropriate contraction of, the puborectalis and external anal sphincter muscles as pressure increases in the rectum.</div><div class=\"graphic_reference\">Adapted from: Preston DM, Lennard-Jones JE, Dig Dis Sci 1985; 30:413.</div><div id=\"graphicVersion\">Graphic 54087 Version 3.0</div></div></div>"},"54089":{"type":"graphic_picture","displayName":"Normal human myelocyte","title":"Normal human myelocyte","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal human myelocyte</div><div class=\"cntnt\"><img style=\"width:433px; height:288px;\" src=\"images/HEME/54089_Normal_human_myelocyte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear shows a normal human myelocyte. As the myelocyte divides and matures, the nucleus becomes smaller and irregularly round, nuclear chromatin becomes coarse and clumped, and nucleoli are sparse to absent. The nuclear to cytoplasmic ratio is reduced compared to promyelocytes. Specific granules are difficult to see on light microscopy.</div><div class=\"graphic_reference\">Courtesy of Robert L Baehner, MD.</div><div id=\"graphicVersion\">Graphic 54089 Version 1.0</div></div></div>"},"54090":{"type":"graphic_figure","displayName":"Pathophysiology MR in HCM","title":"Mechanism of mitral regurgitation in hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanism of mitral regurgitation in hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:418px; height:277px;\" src=\"images/CARD/54090_PathophysiologyMRinHCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Differences in leaflet length and mobility influence the extent of mitral regurgitation. Panel A: The anterior and posterior mitral valve leaflets visibly coapt over a longer distance (contact length, C), resulting in a small amount of mitral regurgitation. Panel B: The posterior leaflet is limited in its ability to move anteriorly and the mitral leaftlets fail to coapt, resulting in a visible gap (G) and a greater degree of mitral regurgitation. The ability to coapt is determined both by the length of the posterior leaflet and by the range of motion permitted by its chordal and papillary muscle connections.</div><div class=\"graphic_footnotes\">α: angle between posterior left ventricular wall and basal part of posterior mitral leaflet; β: angle between basal and apical (more distal) parts of posterior mitral leaflet.</div><div class=\"graphic_reference\">Reprinted with permission from Schwammenthal E, Nakatani S, He S, et al. Circulation 1998; 98:856.</div><div id=\"graphicVersion\">Graphic 54090 Version 2.0</div></div></div>"},"54091":{"type":"graphic_diagnosticimage","displayName":"TEE transverse aorta and aortic arch","title":"Transverse aorta (aortic arch) on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse aorta (aortic arch) on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:397px; height:317px;\" src=\"images/CARD/54091_TEE_transverse_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Horizontal (0&deg;) imaging plane demonstrates the transverse aorta (TrAo).<br />(Panel B) With gentle flexion and anterior rotation the ascending aorta (AAo) may be seen.<br />(Panel C) Color flow Doppler imaging demonstrates normal flow in the aorta (red-orange) with lower velocity superior vena caval (SVC) flow in the opposite direction (blue).</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 54091 Version 4.0</div></div></div>"},"54092":{"type":"graphic_figure","displayName":"Prevalence food allergy","title":"Percentage of children under age 18 years who had a reported food or digestive allergy in the past 12 months, by age group: United States, 1997-2007","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Percentage of children under age 18 years who had a reported food or digestive allergy in the past 12 months, by age group: United States, 1997-2007</div><div class=\"cntnt\"><img style=\"width:454px; height:258px;\" src=\"images/ALLRG/54092_Prevalence_food_allergy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Significant increasing linear trend for food and skin allergy from 1997-1999 to 2009-2011.</div><div class=\"graphic_reference\">Reproduced from: Jackson KD, Howie LD, Akinbami LJ. Trends in allergic conditions among children: United States, 1997-2011. NCHS Data Brief 2013; 121:1. Available at: <A href=\"http://www.cdc.gov/nchs/data/databriefs/db121.htm\" target=_blank>http://www.cdc.gov/nchs/data/databriefs/db121.htm</A>.</div><div id=\"graphicVersion\">Graphic 54092 Version 2.0</div></div></div>"},"54093":{"type":"graphic_diagnosticimage","displayName":"Posterior shoulder dislocation radiograph","title":"Posterior shoulder dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior shoulder dislocation</div><div class=\"cntnt\"><img style=\"width:432px; height:425px;\" src=\"images/EM/54093_Shoulder_post_DL_AP_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the &quot;light bulb&quot; appearance of the humeral head on the AP view and the greater than normal overlap between the anterior glenoid rim and medial aspect of the humeral head.</div><div id=\"graphicVersion\">Graphic 54093 Version 2.0</div></div></div>"},"54094":{"type":"graphic_table","displayName":"Drawing up insulin PI","title":"Technique for drawing up insulin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique for drawing up insulin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Gather injection supplies, including insulin bottle(s), syringe, alcohol swab, and diabetes log book. If you use a bottle and syringe, be sure you are using the correct syringe for your type of insulin (if you use U-500 insulin, use the specially marked syringe).&nbsp;Wash hands with soap and water or alcohol-based hand gel.</td> </tr> <tr> <td>Clean the rubber top of the insulin bottle(s) with alcohol swab. New bottles of insulin may have a hard plastic cap that must be snapped off to reveal the rubber top.</td> </tr> <tr> <td>Remove the syringe cap. Pull on the plunger to draw air into the syringe, equal to the amount of insulin to be given. For example, if 10 units of insulin will be given, draw back 10 units of air.</td> </tr> <tr> <td>Insert the needle into the insulin bottle and depress the plunger, injecting the air into the bottle. If clear and cloudy insulin are used, inject air into the cloudy insulin first, followed by the clear insulin. Leave the needle inside the clear insulin bottle.</td> </tr> <tr> <td>Hold the bottle with one hand and turn it upside down, keeping the needle inside the bottle. Slowly pull the plunger back to draw the correct insulin dose into the syringe.</td> </tr> <tr> <td class=\"sublist1_start\">Remove bubbles from the syringe, if needed. Bubbles are not harmful if injected subcutaneously, but they can decrease the amount of insulin in the syringe and potentially affect blood glucose levels.</td> </tr> <tr> <td class=\"sublist1\">Draw up insulin slowly and steadily. Bubbles form in the syringe if it is drawn up too quickly. If bubbles are seen, push the insulin back into the bottle and slowly re-draw. Do this as many times as needed until the bubbles are gone.</td> </tr> <tr> <td class=\"sublist1\">Draw two more units of insulin into the syringe than needed. If bubbles are seen, flick the syringe with the middle finger and thumb to make the bubbles rise. Once the bubbles are at the top, push the extra two units of insulin back into the bottle. Don't forget to push the extra insulin back into the vial - even if there are no air bubbles in the syringe.</td> </tr> <tr> <td class=\"sublist1\">If clear and cloudy insulin are used, it is only possible to remove bubbles from the clear insulin, which is drawn up first. Draw up cloudy insulin slowly and carefully to avoid forming bubbles.</td> </tr> <tr> <td>Remove the needle from the insulin bottle.</td> </tr> <tr> <td>If cloudy insulin is also needed, it must first be mixed. Gently turn the bottle up and down 20 times to mix it. Inject the needle into the cloudy insulin bottle. Carefully turn the bottle upside down (with the needle in place) and withdraw the dose needed.</td> </tr> <tr> <td>Withdraw the needle from the insulin bottle and replace the needle cap.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54094 Version 4.0</div></div></div>"},"54098":{"type":"graphic_algorithm","displayName":"Intracellular signaling in graft rejection","title":"Schematic representation of intracellular signaling in graft rejection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic representation of intracellular signaling in graft rejection</div><div class=\"cntnt\"><img style=\"width:425px; height:466px;\" src=\"images/NEPH/54098_Overview_alloimmune_respons.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once T cell activation occurs, a chain of intracellular events is triggered under the influence of a variety of growth and differentiation factors, of which the best characterized is IL-2. These events lead to clonal expansion of antigen-specific T cells. Such cells are differentiated into CD8+ cytotoxic T cells (which directly induce donor cell death), and CD4+ helper T cells (which help B cells produce alloantibodies and help macrophages induce delayed type hypersensitivity responses). All of these mechanisms are active in graft rejection.</div><div class=\"graphic_footnotes\">IL-2: interleukin-2; DTH: delayed-type hypersensitivity.</div><div id=\"graphicVersion\">Graphic 54098 Version 4.0</div></div></div>"},"54099":{"type":"graphic_figure","displayName":"Lymph node levels of the neck","title":"Lymph node levels of the neck","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Lymph node levels of the neck</div><div class=\"cntnt\"><img style=\"width:498px; height:499px;\" src=\"images/ONC/54099_Lymph_node_levels_of_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Level I, submental (IA) and submandibular (IB); level II, upper internal jugular nodes; level III, middle jugular nodes; level IV, low jugular nodes; level V, posterior triangle nodes; level VI, central compartment; level VII, superior mediastinal nodes.</div><div class=\"graphic_reference\">Adapted from: American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 54099 Version 15.0</div></div></div>"},"54101":{"type":"graphic_figure","displayName":"Button battery schematic","title":"Button battery schematic","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Button battery schematic</div><div class=\"cntnt\"><img style=\"width:504px; height:245px;\" src=\"images/PEDS/54101_Battery_schematic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic demonstrates the common design of a button battery including the seal/crimp area, anode, cathode, and electrolyte-soaked separator which usually consists of potassium or sodium hydroxide solution.</div><div class=\"graphic_reference\">Courtesy of Kelly Sinclair, MD.</div><div id=\"graphicVersion\">Graphic 54101 Version 2.0</div></div></div>"},"54102":{"type":"graphic_figure","displayName":"Basic shoulder anatomy lateral view","title":"Lateral view of shoulder anatomy","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Lateral view of shoulder anatomy</div><div class=\"cntnt\"><img style=\"width:510px; height:531px;\" src=\"images/EM/54102_Shoulder_anatomy_lateral.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54102 Version 4.0</div></div></div>"},"54103":{"type":"graphic_figure","displayName":"Structure of beta-2 integrins","title":"Structure of beta-2 integrins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of beta-2 integrins</div><div class=\"cntnt\"><img style=\"width:389px; height:371px;\" src=\"images/ALLRG/54103_Structureofbeta2integri.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The beta-2 integrins are composed of an alpha and a common beta-2 protein chain and function as adhesive molecules. The beta-2 integrins are LFA-1 or CD18/CD11a (beta-2, alpha-L), Mac-1 or CD18/CD11b (beta-2, alpha-M), and glycoprotein 150/95 (gp150/95) or CD18/CD11c (beta-2, alpha-X).</div><div class=\"graphic_footnotes\">LFA-1: lymphocyte function-associated antigen-1; Mac-1: macrophage antigen-1.</div><div id=\"graphicVersion\">Graphic 54103 Version 6.0</div></div></div>"},"54104":{"type":"graphic_figure","displayName":"Acid output and H pylori","title":"Gastric acid secretion and Helicobacter pylori infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric acid secretion and Helicobacter pylori infection</div><div class=\"cntnt\"><img style=\"width:351px; height:298px;\" src=\"images/GAST/54104_Acid_output_H_pylori_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastric acid secretion in response to stimulation with gastrin-releasing peptide in subjects of different <em>Helicobacter pylori</em> status. Stimulated acid output is increased in infected volunteers and, to a greater degree, in infected patients with duodenal ulcer (DU). This response returned to normal one year after eradication of <em>H. pylori</em>.</div><div class=\"graphic_reference\">Data from: McColl KEL. Helicobacter pylori: Clinical aspects. J Infect 1997; 34:7.</div><div id=\"graphicVersion\">Graphic 54104 Version 4.0</div></div></div>"},"54105":{"type":"graphic_picture","displayName":"Vaginal cuff brachythr apps","title":"Vaginal cuff brachytherapy applicators","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vaginal cuff brachytherapy applicators</div><div class=\"cntnt\"><img style=\"width:371px; height:376px;\" src=\"images/OBGYN/54105_Vaginal_cuff_brachythr_apps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vaginal ovoids (A) and vaginal cylinders (B) for vaginal cuff brachytherapy for endometrial cancer.</div><div class=\"graphic_reference\">Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.</div><div id=\"graphicVersion\">Graphic 54105 Version 2.0</div></div></div>"},"54106":{"type":"graphic_table","displayName":"CAGE questionnaire","title":"CAGE questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CAGE questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t<tr>\n\t\t\t<td>Have you ever felt you should <strong>C</strong>ut down on your drinking?</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Have people <strong>A</strong>nnoyed you by criticizing your drinking?</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Have you ever felt bad or <strong>G</strong>uilty about your drinking?</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Have you ever had a drink first thing in the morning to steady your nerves or to get rid of a hangover (<strong>E</strong>ye opener)?</td>\n\t\t</tr>\n\n\t\t</table>\n\t\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">7/27/2006 perm requested - faxed request to Bowles\r\n8/11/2006 perm not needed, not copyrighted.</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57723&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>CAGE_questionnaire.htm</title></head></div><div class=\"graphic_lgnd\">Scoring: Item responses on the CAGE are scored 0 or 1, with a higher score an indication of alcohol problems. A total score of 2 or greater is considered clinically significant.</div><div class=\"graphic_reference\">Ewing, JA. Detecting Alcoholism: The CAGE Questionnaire. JAMA 1984; 252:1905-1907.</div><div id=\"graphicVersion\">Graphic 54106 Version 1.0</div></div></div>"},"54107":{"type":"graphic_picture","displayName":"Severe cystic acne PI","title":"Severe cystic acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe cystic acne</div><div class=\"cntnt\"><img style=\"width:396px; height:316px;\" src=\"images/PI/54107_Severe_cystic_acne_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient was subsequently treated with isotretinoin (Accutane).</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54107 Version 3.0</div></div></div>"},"54109":{"type":"graphic_picture","displayName":"Sialogram submandibular gland","title":"Sialectasis of submandibular gland in Sjögren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sialectasis of submandibular gland in Sjögren's syndrome</div><div class=\"cntnt\"><img style=\"width:383px; height:265px;\" src=\"images/RHEUM/54109_Sialogram_submandibular_gla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sialogram of left submandibular gland showing sialectasis. The main duct is of normal caliber. There is dilation of the intraglandular duct portion with pruning of the peripheral branches.</div><div class=\"graphic_reference\">Courtesy of Paul Creamer, MD, MRCP.</div><div id=\"graphicVersion\">Graphic 54109 Version 3.0</div></div></div>"},"54110":{"type":"graphic_picture","displayName":"Lateral canthal rhytides botulinum toxin injection sites","title":"Botulinum toxin injection sites for lateral canthal rhytides","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Botulinum toxin injection sites for lateral canthal rhytides</div><div class=\"cntnt\"><img style=\"width:504px; height:512px;\" src=\"images/DERM/54110_Lat_canth_rhyt_inject_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of sites for botulinum toxin injection of the orbicularis oculi muscle for the treatment of lateral canthal rhytides.</div><div id=\"graphicVersion\">Graphic 54110 Version 3.0</div></div></div>"},"54111":{"type":"graphic_figure","displayName":"Anatomy of the kidney and ureter - male","title":"Anatomy of the kidney and ureter - male","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Anatomy of the kidney and ureter - male</div><div class=\"cntnt\"><img style=\"width:530px; height:575px;\" src=\"images/SURG/54111_Kidney-and-ureter-male.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure depicts the retroperitoneal relationship of the kidneys and ureters in the male. The anatomic location of the ureters make them particularly vulnerable to injury during pelvic operations.</div><div id=\"graphicVersion\">Graphic 54111 Version 2.0</div></div></div>"},"54112":{"type":"graphic_picture","displayName":"Percutaneous cholangioscope","title":"Percutaneous cholangioscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Percutaneous cholangioscope</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/GAST/54112_Percutaneous_cholangioscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The percutaneous cholangiscope must be used under sterile conditions.</div><div class=\"graphic_reference\">Courtesy of Jurgen F Riemann, MD, PhD.</div><div id=\"graphicVersion\">Graphic 54112 Version 1.0</div></div></div>"},"54113":{"type":"graphic_table","displayName":"JE vaccine recommendations","title":"Recommendations for use of Japanese encephalitis vaccine in travelers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for use of Japanese encephalitis&nbsp;vaccine in travelers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_single\">Recommendations:</td> </tr> <tr> <td class=\"indent1\">JE vaccine is recommended for travelers who plan to spend a month or longer in endemic areas during the JEV transmission season. This includes long-term travelers, recurrent travelers, or expatriates who will be based in urban areas but are likely to visit endemic rural or agricultural areas during a high-risk period of JEV transmission.</td> </tr> <tr> <td class=\"subtitle2_single\">JE vaccine should be considered for the following:</td> </tr> <tr> <td> <ul> <li>Short-term travelers (&#60;1 month) to endemic areas during the JEV transmission season if they plan to travel outside of an urban area and have an increased risk of JEV exposure. Examples of higher risk activities or itineraries include: (1) Spending substantial time outdoors in rural or agricultural areas, especially during the evening or night; (2) Participating in extensive outdoor activities (eg, camping, hiking, trekking, biking, fishing, hunting, or farming); and (3) Staying in accommodations without air conditioning, screens, or bed nets. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Travelers to an area with an ongoing JE outbreak </li> </ul> </td> </tr> <tr> <td> <ul> <li>Travelers to endemic areas who are uncertain of specific destinations, activities, or duration of travel </li> </ul> </td> </tr> <tr> <td>JE vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas or times outside of a well-defined JEV transmission season.</td> </tr> <tr> <td>Information on expected JEV transmission by country can be obtained from the CDC at <a href=\"http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/japanese-encephalitis\">http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/japanese-encephalitis</a>. These data should be interpreted cautiously since JEV transmission activity varies within countries and from year to year.</td> </tr> <tr> <td>JE vaccine is also recommended for laboratory personnel with potential for exposure to infectious JEV. Vaccinated, at-risk laboratory personnel should receive appropriate booster doses of JE vaccine or be evaluated regularly for JEV-specific neutralizing antibodies to assure adequate titers.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">JE: Japanese encephalitis; JEV: Japanese encephalitis virus; CDC: Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 54113 Version 6.0</div></div></div>"},"54114":{"type":"graphic_picture","displayName":"Nocardia mycetoma-like lesion","title":"Mycetoma-like lesion caused by <EM>Nocardia asteroides</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mycetoma-like lesion caused by <EM>Nocardia asteroides</EM></div><div class=\"cntnt\"><img style=\"width:396px; height:257px;\" src=\"images/ID/54114_Nocardia_mycetoma-like_lesi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lesion of the hand and arm was caused by <EM>Nocardia asteroides</EM>.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Lippincott Williams &amp; Wilkins, Baltimore 1995. p.60.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 54114 Version 10.0</div></div></div>"},"54116":{"type":"graphic_table","displayName":"Mech supple oxy may red dys","title":"Mechanisms by which supplemental oxygen may reduce dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanisms by which supplemental oxygen may reduce dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Reversal of hypoxemia</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Reduced serum lactic acid</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Reduced pulmonary artery pressure</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Reduced dynamic hyperinflation</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Reduced ventilatory muscle and diaphragm fatigue</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Relief of bronchoconstriction</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Stimulation of facial, nasal or pharyngeal receptors</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased capacity for exercise training</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Placebo effect</td>\n\n\t\t\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54116 Version 1.0</div></div></div>"},"54117":{"type":"graphic_diagnosticimage","displayName":"Biliary atresia type 3a","title":"Biliary atresia type 3a","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Biliary atresia type 3a</div><div class=\"cntnt\"><img style=\"width:503px; height:393px;\" src=\"images/PEDS/54117_Biliary_atresia_type_3a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biliary atresia type 3a. Visualization of narrow and irregular distal common bile duct and common hepatic duct with biliary lakes at the porta hepatis.</div><div class=\"graphic_reference\">Reproduced with permission from: Guelrud M, Carr-Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment. Isis Medical Media, London 1997. Copyright © 1997 Taylor and Francis.</div><div id=\"graphicVersion\">Graphic 54117 Version 11.0</div></div></div>"},"54120":{"type":"graphic_picture","displayName":"Scorpion fluorescence","title":"Scorpion exhibiting fluorescence under ultraviolet light","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scorpion exhibiting fluorescence under ultraviolet light</div><div class=\"cntnt\"><img style=\"width:396px; height:328px;\" src=\"images/EM/54120_Scorpion_fluorescence.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Banner Good Samaritan Medical Center, Department of Medical Toxicology.</div><div id=\"graphicVersion\">Graphic 54120 Version 1.0</div></div></div>"},"54121":{"type":"graphic_table","displayName":"Abx prophylaxis regimens","title":"Antibiotic regimens: Prophylaxis for endoscopic procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic regimens: Prophylaxis for endoscopic procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Condition(s)</td> <td class=\"subtitle1\">Antibiotic and dose*</td> <td class=\"subtitle1\">Interval for intraoperative re-dose for prolonged procedure<br /> (timed from initiation of preoperative dose)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">High-risk endoscopic procedures needing antibiotic prophylaxis<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">PEG/PEJ placement</td> <td>MRSA risk absent</td> <td>Cefazolin 2 g for patients weighing &#60;120 kg, 3 g for patients weighing &#8805;120 kg (pediatric dose 30 mg/kg) IV within 60 minutes before procedure. <strong>If penicillin or cephalosporin hypersensitivity:</strong> Clindamycin 900 mg (pediatric dose 10 mg/kg) IV within 60 minutes before procedure.</td> <td> <p>Cefazolin: four hours</p> Clindamycin: six hours</td> </tr> <tr> <td> <p>MRSA risk present</p> <p>Pre-procedural screening for MRSA and attempted decontamination before feeding tube placement is recommended if practical</p> </td> <td>Vancomycin 15 mg/kg (maximum 2 g) IV infused over 60 to 90 minutes and beginning within 120 minutes before surgical incision.</td> <td>Vancomycin: re-dosing is generally not required</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">ERCP<sup>&#9674;</sup></td> <td rowspan=\"4\"> <p>- Biliary obstruction AND cholangitis</p> <p>- Biliary obstruction unlikely to be successfully drained at ERCP (including malignant hilar obstruction and primary sclerosing cholangitis)</p> <p>- Inadequate biliary drainage following ERCP</p> - Biliary complications following liver transplantation if drainage is unlikely</td> <td> <p>Ciprofloxacin 500 mg (pediatric dose 15 mg/kg<sup>&#167;</sup>) orally given within 60 to 90 minutes prior to procedure or 400 mg (pediatric dose 10 mg/kg<sup>&#167;</sup>) IV over 60 minutes beginning within 120 minutes prior to procedure</p> <strong>AND/OR</strong></td> <td>Ciprofloxacin: re-dosing is generally not required</td> </tr> <tr> <td> <p>Amoxicillin-clavulanate 1750 mg (pediatric dose 45 mg/kg) orally within 60 minutes prior to procedure or ampicillin-sulbactam 3 grams (pediatric dose 50 mg/kg ampicillin component) IV within 60 minutes prior to procedure</p> <strong>OR</strong></td> <td>Amoxicillin-clavulanate: two hours</td> </tr> <tr> <td>Ampicillin 2 grams (pediatric dose 50 mg/kg) IV <strong>plus</strong> gentamicin<sup>&#165;</sup> 5 mg/kg (pediatric 2.5 mg/kg) IV within 60 minutes before procedure. <strong>If penicillin hypersensitivity:</strong> Substitute vancomycin 15 mg/kg (maximum 2 g) IV infused over 60 to 90 minutes beginning within 120 minutes before procedure plus gentamicin<sup>&#165;</sup> 5 mg/kg IV (pediatric 2.5 mg/kg) within 60 minutes before procedure.</td> <td> <p>Ampicillin: two hours</p> <p>Vancomycin: re-dosing is generally not required</p> Gentamicin: single dose only</td> </tr> <tr> <td><strong>ALL</strong> above regimens are discontinued post-procedure when drainage is established absent evidence of cholangitis. For antibiotic dosing post-procedure with incomplete drainage, refer to the individual Lexicomp drug information monograph.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">EUS-FNA of cystic lesion(s)<sup>&#135;</sup><br /> </td> <td> <p>- Mediastinal cysts</p> </td> <td>Ciprofloxacin 500 mg orally (pediatric dose 15 mg/kg<sup>&#167;</sup>) 60 to 90 minutes prior to procedure or 400 mg IV (pediatric dose 10 mg/kg<sup>&#167;</sup>) IV given over 60 minutes beginning within 120 minutes prior to procedure. Continue 3 days post-procedure.</td> <td>Ciprofloxacin: re-dosing is generally not required</td> </tr> <tr> <td class=\"indent1\">Interventional EUS procedures including transmural or transluminal drainage of pancreatic fluid collections</td> <td>- Mediastinal cysts <p>- Pancreatic cysts</p> <p>- Cysts outside pancreas (excluding solid lesions)</p> <p>- Walled-off pancreatic necrosis</p> </td> <td>&nbsp;Ciprofloxacin 500 mg orally (pediatric dose 15 mg/kg<sup><span style=\"font-size: 13px;\">&#167;</span></sup>) 60 to 90 minutes prior to procedure or 400 mg IV (pediatric dose 10 mg/kg<sup><span style=\"font-size: 13px;\">&#167;</span></sup>) IV given over 60 minutes beginning within 120 minutes prior to procedure. Continue 3 days post-procedure.</td> <td>&nbsp;Ciprofloxacin: re-dosing is generally not required</td> </tr> <tr> <td class=\"indent1\">Natural orifice transluminal endoscopic surgery (NOTES)</td> <td>Insufficient data to make recommendation. Antibiotic prophylaxis seems reasonable.</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">High-risk patients needing antibiotic prophylaxis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"> <p>All endoscopic procedures with high risk of bacteremia, including procedures&nbsp;not listed above (eg, routine endoscopy with esophageal stricture dilation or endoscopic sclerotherapy);</p> <p>For procedures in the biliary tree (eg, ERCP with drainage or EUS-FNA of any lesion type) in a patient who is at high risk for infection, refer to antibiotic recommendations listed above</p> </td> <td rowspan=\"2\"> <p>- Immunocompromised patients (eg, severe neutropenia [absolute neutrophil count &#60;500 cells/mm<sup>3</sup>], advanced hematologic malignancy)<sup>&#134;</sup></p> - Cirrhosis with ascites**</td> <td> <p>Amoxicillin 2 grams (pediatric dose 50 mg/kg) orally within 60 minutes before procedure</p> <strong>OR</strong></td> <td>Amoxicillin: two hours</td> </tr> <tr> <td>Ampicillin 2 grams (pediatric dose 50 mg/kg) IV or IM within 60 minutes prior to procedure. <strong>If penicillin hypersensitivity:</strong> Clindamycin 600 mg (pediatric dose 20 mg/kg) orally within 60 minutes before procedure or 900 mg IV (pediatric dose 10 mg/kg IV) within 60 minutes prior to procedure.</td> <td> <p>Ampicillin: two hours</p> Clindamycin: six hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The preprocedural antibiotic recommendations presented in this table are generally consistent with those of American Society for Gastrointestinal Endoscopy<SUP>[1]</SUP> and the 2013 guidelines developed jointly by the American Society of Health-System Pharmacists and collaborating organizations<SUP>[2]</SUP>. A 2009 guideline available from the British Society of Gastroenterology<SUP>[3]</SUP> also recommends antibiotic prophylaxis in these conditions, but includes, in some cases, different choices and dosing regimens depending upon specific clinical scenarios. When available, recent culture and sensitivity results should be considered in selecting antibiotic prophylaxis.</div><div class=\"graphic_footnotes\">PEG: percutaneous endoscopic gastrostomy; MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>; ERCP: endoscopic retrograde cholangiopancreatography; EUS-FNA: endoscopic ultrasound-guided fine-needle aspiration; GI: gastrointestinal.<br />* Pediatric dose should generally not exceed adult dose. Doses shown in table are for patients with normal renal function. Dose modification for renal impairment is needed for some agents. <br />¶ Antibiotic prophylaxis solely to prevent infective endocarditis is <STRONG>not </STRONG>recommended in patients undergoing endoscopic procedures. For patients with the highest-risk cardiac conditions (eg, prosthetic heart valve, prior endocarditis) who have ongoing GI or genitourinary tract infection or who are undergoing a procedure for which antibiotic therapy to prevent wound infection or sepsis is indicated, the American Society for Gastrointestinal Endoscopy (ASGE) and American Heart Association (AHA) suggest an antibiotic regimen that includes an agent active against enterococci (eg, ampicillin, piperacillin-tazobactam, or vancomycin). Refer to topic review of antimicrobial prophylaxis for bacterial endocarditis section on gastrointestinal tract.<br />Δ A separate table that summarizes the types of procedures and patients needing antibiotic prophylaxis is available in UpToDate. Low-risk endoscopic procedures that do not need routine antibiotic prophylaxis in most patients (eg, routine upper endoscopy, colonoscopy, flexible sigmoidoscopy, others) are listed in that table.<br /><FONT class=lozenge>◊</FONT> Patients with cholangitis require antibiotic therapy and additional prophylaxis is not required.<br />§ While fluoroquinolones have been associated with an increased risk of tendinitis/tendon rupture in all ages, use of these agents for single-dose prophylaxis is generally safe.<br />¥ Gentamicin use for surgical antibiotic prophylaxis should be limited to a single dose given preoperatively. Dosing is based on the patient's actual body weight. For overweight and obese patients (ie, actual weight is greater than 120% of ideal body weight), a dosing weight should be used. A calculator to determine ideal body weight and dosing weight is available in UpToDate.<br />‡ While antibiotic prophylaxis is recommended by the ASGE for all patients undergoing EUS-FNA of cystic lesions, we generally reserve antibiotic prophylaxis for patients undergoing EUS-FNA of mediastinal lesions and in those who are at high risk for infection. Antibiotic prophylaxis is not required for patients undergoing EUS-FNA of solid lesions.<br />† Patients at high risk for postprocedural infections may also include those with decreased gastric acidity and motility resulting from malignancy or acid suppression.<br />** In patients with cirrhosis and upper gastrointestinal bleeding, antibiotics are indicated even if endoscopy is not planned.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>ASGE Standards of Practice Committee, Khashab MA, Chithadi KV, et al. Anti­biotic prophylaxis for GI endoscopy. Gastrointest Endosc 2015; 81:81.</li>&#xD;&#xA;    <li>Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. Am J Health Syst Pharm 2013; 70:195.</li>&#xD;&#xA;    <li>Allison MC, Sandoe JA, Tighe R, et al. Antibiotic prophylaxis in gastrointestinal endoscopy. Gut 2009; 58:868.</li>&#xD;&#xA;</ol>&#xD;&#xA;Additional data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012, p.808.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 54121 Version 9.0</div></div></div>"},"54124":{"type":"graphic_table","displayName":"Typical radiographic presentation of select tumors in bone","title":"Typical radiographic presentation to select tumors in bone*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical radiographic presentation to select tumors in bone*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Predominantly osteoblastic</td> </tr> <tr> <td class=\"indent1\">Prostate</td> </tr> <tr> <td class=\"indent1\">Carcinoid</td> </tr> <tr> <td class=\"indent1\">Small cell lung cancer</td> </tr> <tr> <td class=\"indent1\">Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Medulloblastoma</td> </tr> <tr> <td class=\"indent1\">POEMS syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Predominantly osteolytic</td> </tr> <tr> <td class=\"indent1\">Renal cell cancer</td> </tr> <tr> <td class=\"indent1\">Melanoma</td> </tr> <tr> <td class=\"indent1\">Multiple myeloma</td> </tr> <tr> <td class=\"indent1\">Non-small cell lung cancer</td> </tr> <tr> <td class=\"indent1\">Thyroid cancer</td> </tr> <tr> <td class=\"indent1\">Non-Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"subtitle1_single\">Mixed osteoblastic and osteolytic</td> </tr> <tr> <td class=\"indent1\">Breast cancer</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal cancers</td> </tr> <tr> <td class=\"indent1\">Squamous cancers at most primary sites</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">POEMS: polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.<br />* These represent the most common patterns of metastatic involvement; individual variations may occur.</div><div id=\"graphicVersion\">Graphic 54124 Version 6.0</div></div></div>"},"54125":{"type":"graphic_table","displayName":"Severe asthma exacerbation in adults rapid overview","title":"Severe asthma exacerbation in adults: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severe asthma exacerbation in adults: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical danger signs</td> </tr> <tr> <td><span class=\"red\">Use of accessory muscles of respiration; brief, fragmented speech; inability to lie supine; profound diaphoresis; agitation; severe symptoms that fail to improve with initial emergency department treatment</span></td> </tr> <tr> <td><span class=\"red\">Life-threatening airway obstruction can still occur when these signs are <strong>NOT</strong> present</span></td> </tr> <tr> <td><span class=\"red\"><strong>Signs of imminent respiratory arrest: cyanosis, inability to maintain respiratory effort, and depressed mental status</strong></span></td> </tr> <tr> <td class=\"subtitle1_single\">Assessment</td> </tr> <tr> <td>Measurement of expiratory airflow (peak expiratory flow rate or PEFR) is the best measure of severity; PEFR &#60;40 percent predicted (or &#60;200 L/minute in most adults) indicates severe obstruction; patients in severe distress are often unable to perform peak flow tests</td> </tr> <tr> <td><strong>Severe hypoxemia</strong> (eg, SpO<sub>2</sub> &#8804;95 percent despite high flow O<sub>2</sub> treatment by nonrebreather mask) <strong>portends imminent respiratory arrest</strong> or possibly severe complication (eg, pneumothorax); continuous pulse oximetry monitoring should be performed</td> </tr> <tr> <td>Patients in extremis should be managed clinically without waiting for arterial blood gases (ABGs). ABGs can aid assessment&nbsp;of hypercapnia or&nbsp;impending respiratory failure: hypercapnia usually does not occur unless&nbsp;PEF is &#60;25 percent of normal (generally &#60;100 to 150 L/min).</td> </tr> <tr> <td>Chest radiograph is generally unhelpful; obtain if complications suspected (eg, pneumonia, pneumothorax), diagnosis is in doubt, or patient is high-risk (eg, IV drug abuser, immunosuppressed, chronic pulmonary disease, heart failure)</td> </tr> <tr> <td class=\"subtitle1_single\">Standard treatments</td> </tr> <tr> <td><strong>Inhaled beta agonist:</strong> give <strong>albuterol</strong> 2.5 to 5 mg&nbsp;by nebulization every 20 minutes for three doses, then 2.5 to&nbsp;5 mg every one to four hours as needed, or give 4 to 8 puffs by metered dose inhaler (MDI) with spacer every 20 minutes for three doses, then every one to four hours as needed.&nbsp;Alternatively, for severe exacerbations, 10 to 15 mg can be administered by continuous nebulization over one hour.</td> </tr> <tr> <td><strong>Oxygen:</strong> give sufficient oxygen to maintain SpO<sub>2</sub> &#8805;92 percent (&#62;95 percent in pregnancy)</td> </tr> <tr> <td><strong>IV:</strong> establish intravenous access; may give normal saline for repletion, if patient is dehydrated due to&nbsp;reduced intake and prolonged episode</td> </tr> <tr> <td><strong>Ipratropium bromide:</strong> give 500 mcg by nebulization every 20 minutes for 3 doses, or 4 to 8 puffs by MDI with spacer every 20 minutes as needed for up to 3 hours</td> </tr> <tr> <td><strong>Systemic glucocorticoids:</strong> for patients with impending respiratory failure, give methylprednisolone 60 to 125 mg IV. For the majority of less severe asthma exacerbations, give prednisone 40 to 60 mg orally; alternatives include: dexamethasone 6 to 10 mg IV or hydrocortisone 150 to 200 mg IV; glucocorticoids may be given IM or orally if IV access is unavailable.</td> </tr> <tr> <td><strong>Magnesium sulfate:</strong> give 2 g (8 mmol) IV over 20 minutes for life-threatening exacerbations and exacerbations that remain severe after one hour of intensive bronchodilator therapy</td> </tr> <tr> <td class=\"subtitle1_single\">Potential additional treatments*</td> </tr> <tr> <td>Epinephrine: for patients suspected of having an anaphylactic reaction or unable to use inhaled bronchodilators for severe asthma exacerbation, give epinephrine 0.3 to 0.5 mg IM (eg, 0.3 to 0.5 mL of 1 mg/mL [also labeled 1:1000] solution); if severe asthma but no evidence of anaphylaxis, can give epinephrine 0.3 to 0.5 mg SC (eg, 0.3 to 0.5 mL of 1 mg/mL [also labeled 1:1000] solution); give epinephrine OR terbutaline but not both</td> </tr> <tr> <td>Terbutaline: may give 0.25 mg by SC injection every 20 minutes times 3 doses for severe asthma unresponsive to standard therapies; give terbutaline OR epinephrine but not both</td> </tr> <tr> <td class=\"subtitle1_single\">Endotracheal intubation and ventilation</td> </tr> <tr> <td>The decision to intubate during the first few minutes of a severe asthma attack is clinical. Slowing of the respiratory rate, depressed mental status, inability to maintain respiratory effort, or severe hypoxemia suggests the patient requires intubation. In the absence of anticipated intubation difficulty, rapid sequence intubation is preferred. Nasal intubation is not recommended.</td> </tr> <tr> <td>The goal of mechanical ventilation is to maintain adequate oxygenation and ventilation while minimizing elevations in airway pressures. This is accomplished by using low tidal volumes (6 to 8 mL/kg), and low respiratory rates (10 to 12/minute). In some patients, elevations in PaCO<sub>2</sub> must be tolerated to avoid barotrauma (ie, permissive hypercapnia).<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscular; IV: intravenous; MDI: metered dose inhaler; PEFR: peak expiratory flow rate; SC: subcutaneous; SpO<SUB>2</SUB>: pulse oxygen saturation.<br />* For information on additional therapies for severe asthma exacerbations, please refer to the UpToDate topic on the management of asthma exacerbations.<br />¶&nbsp;Please refer to the UpToDate topics on mechanical ventilation in adults with acute severe asthma and permissive hypercapnia.</div><div id=\"graphicVersion\">Graphic 54125 Version 7.0</div></div></div>"},"54126":{"type":"graphic_picture","displayName":"Skin lesion in mixed cryo","title":"Skin lesion in mixed cryoglobulinemia","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Skin lesion in mixed cryoglobulinemia</div><div class=\"cntnt\"><img style=\"width:483px; height:360px;\" src=\"images/RHEUM/54126_Skinlesioninmixedcryo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy of a purpuric skin lesion in mixed cryoglobulinemia with PAS stain. Cryoprecipitates, which are intensely PAS-positive) can be seen occluding multiple vessels (left panel). High-power view (right panel) shows both cryoprecipitates and the deposition of fibrin in the vascular lumen and vessel wall.</div><div class=\"graphic_footnotes\">PAS: periodic acid-Schiff.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 54126 Version 3.0</div></div></div>"},"54128":{"type":"graphic_picture","displayName":"Primary biliary cholangitis I","title":"Primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/GAST/54128_Primary_biliary_cirrhosis_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of liver biopsy in primary biliary cholangitis. A damaged bile duct (BD)&nbsp;is visible in the center of an intense inflammatory cell reaction in an enlarged portal triad. The bile duct appears to be the target of this inflammatory reaction.</div><div class=\"graphic_reference\">Courtesy of Sanjiv Chopra, MD.</div><div id=\"graphicVersion\">Graphic 54128 Version 2.0</div></div></div>"},"54129":{"type":"graphic_picture","displayName":"Eumycetoma foot B","title":"Eumycetoma tumors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eumycetoma tumors</div><div class=\"cntnt\"><img style=\"width:432px; height:298px;\" src=\"images/ID/54129_Large_eumycetoma_tumors.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Beatriz Bustamante, MD.</div><div id=\"graphicVersion\">Graphic 54129 Version 1.0</div></div></div>"},"54131":{"type":"graphic_picture","displayName":"CyA induced tubular injury","title":"Light micrograph showing cyclosporine-induced renal tubular injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing cyclosporine-induced renal tubular injury</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/54131_CyA_induced_tubular_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph shows vacuolization of the proximal tubular cells (arrows) due to cyclosporine nephrotoxicity.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 54131 Version 3.0</div></div></div>"},"54132":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound left renal agenesis","title":"Prenatal ultrasound left renal agenesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound left renal agenesis</div><div class=\"cntnt\"><img style=\"width:366px; height:334px;\" src=\"images/OBGYN/54132_Left_renal_agenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 54132 Version 2.0</div></div></div>"},"54134":{"type":"graphic_figure","displayName":"Face Arm Speech Test","title":"Face Arm Speech Test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Face Arm Speech Test</div><div class=\"cntnt\"><img style=\"width:381px; height:527px;\" src=\"images/NEURO/54134_Face_arm_speech_test2.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Harbison J, Hossain O, Jenkinson D, et al. Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test. Stroke 2003; 34:71. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54134 Version 7.0</div></div></div>"},"54135":{"type":"graphic_figure","displayName":"TMD nerves","title":"Nerves of the temporomandibular region","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Nerves of the temporomandibular region</div><div class=\"cntnt\"><img style=\"width:605px; height:432px;\" src=\"images/PC/54135_TMD_nerves.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright © 2011 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 54135 Version 1.0</div></div></div>"},"54138":{"type":"graphic_figure","displayName":"Pathophysiology of achalasia","title":"Pathophysiology of achalasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of achalasia</div><div class=\"cntnt\"><img style=\"width:316px; height:213px;\" src=\"images/GAST/54138_Pathophysiology_of_achalasi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the pathophysiology of achalasia which results from the degeneration of neurons in the esophageal wall. Histologic examination reveals decreased numbers of neurons (ganglion cells) in the myenteric plexuses, and the ganglion cells that remain often are surrounded by lymphocytes and, less prominently, by eosinophils. This inflammatory degeneration preferentially involves the nitric oxide-producing, inhibitory neurons that effect the relaxation of esophageal smooth muscle, resulting in an elevation in basal lower esophageal sphincter&#160;(LES) pressure and an inability of the sphincter muscle to relax normally; the cholinergic neurons that contribute to LES tone by causing smooth muscle contraction are relatively spared<sup>[1]</sup>. In some patients, degenerative changes also are found in the ganglion cells of the dorsal motor nucleus of the vagus in the brainstem, and Wallerian degeneration has been observed in the vagal fibers that supply the esophagus.</div><div class=\"graphic_reference\">Reference:<br> &#160; 1. Holloway RH, Dodds WJ, Helm JF, et al. Integrity of cholinergic innervation to the lower esophageal sphincter in achalasia. Gastroenterology 1986; 90:924.<br> Reprinted, courtesy of the Clinical Teaching Project of the American Gastroenterological Association&#169;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner- Fenwick, Inc. at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 54138 Version 2.0</div></div></div>"},"54139":{"type":"graphic_table","displayName":"Sources contact stomatitis","title":"Sources of sensitization in contact and irritant stomatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sources of sensitization in contact and irritant stomatitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Flavoring agents in toothpaste/mouthwashes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Flavoring agents in candy, gums, fruits</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Dental restoration materials</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Eugenol </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Balsam of Peru</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Colophony</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Dental procedure exposures</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Latex, antibiotics, anesthetics</td>\n    </tr>\n    <tr>\n\n      <td>Acrylic resins</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54139 Version 1.0</div></div></div>"},"54142":{"type":"graphic_figure","displayName":"Cervical plexus","title":"Cervical plexus","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Cervical plexus</div><div class=\"cntnt\"><img style=\"width:518px; height:616px;\" src=\"images/SURG/54142_Cervical_plexus_edit2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cervical plexus is composed of the ventral rami of the first four cervical spinal nerves (ie, C1 through C4). The anterior rami of C2 through C4 emerge from the posterior border of the sternocleidomastoid muscle.</div><div id=\"graphicVersion\">Graphic 54142 Version 4.0</div></div></div>"},"54143":{"type":"graphic_picture","displayName":"Oral lichen planus - gingiva","title":"Oral lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral lichen planus</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/54143_Oral_lichen_planus_gingiva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and erosions on the gingiva in a patient with oral lichen planus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54143 Version 4.0</div></div></div>"},"54145":{"type":"graphic_table","displayName":"Hypertensive emergencies","title":"Hypertensive emergencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypertensive emergencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Grades III to IV hypertensive retinopathy with severely elevated blood pressures</td> </tr> <tr> <td class=\"sublist1_start\">Cerebrovascular</td> </tr> <tr> <td class=\"sublist1\">Hypertensive encephalopathy</td> </tr> <tr> <td class=\"sublist1\">Atherothrombotic brain infarction with severe hypertension</td> </tr> <tr> <td class=\"sublist1\">Intracerebral hemorrhage</td> </tr> <tr> <td class=\"sublist1\">Subarachnoid hemorrhage</td> </tr> <tr> <td class=\"sublist1_start\">Cardiac</td> </tr> <tr> <td class=\"sublist1\">Acute aortic dissection</td> </tr> <tr> <td class=\"sublist1\">Acute left ventricular failure</td> </tr> <tr> <td class=\"sublist1\">Acute or impending myocardial infarction</td> </tr> <tr> <td class=\"sublist1\">After coronary bypass surgery</td> </tr> <tr> <td class=\"sublist1_start\">Renal</td> </tr> <tr> <td class=\"sublist1\">Acute glomerulonephritis</td> </tr> <tr> <td class=\"sublist1\">Renal crises from collagen vascular diseases</td> </tr> <tr> <td class=\"sublist1\">Severe hypertension after kidney transplantation</td> </tr> <tr> <td class=\"sublist1\">Microangiopathic hemolytic anemia</td> </tr> <tr> <td class=\"sublist1_start\">Excessive circulating catecholamines</td> </tr> <tr> <td class=\"sublist1\">Pheochromocytoma crisis</td> </tr> <tr> <td class=\"sublist1\">Food or drug interactions with monoamine-oxidase inhibitors</td> </tr> <tr> <td class=\"sublist1\">Sympathomimetic drug use (cocaine)</td> </tr> <tr> <td class=\"sublist1\">Rebound hypertension after sudden cessation of antihypertensive drugs</td> </tr> <tr> <td>Eclampsia</td> </tr> <tr> <td class=\"sublist1_start\">Surgical</td> </tr> <tr> <td class=\"sublist1\">Severe hypertension in patients requiring immediate surgery</td> </tr> <tr> <td class=\"sublist1\">Postoperative hypertension</td> </tr> <tr> <td class=\"sublist1\">Postoperative bleeding from vascular suture lines</td> </tr> <tr> <td>Severe body burns</td> </tr> <tr> <td>Severe epistaxis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54145 Version 5.0</div></div></div>"},"54147":{"type":"graphic_table","displayName":"Mitochondrial dysfunction","title":"Symptoms of mitochondrial dysfunction associated with antiretroviral agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of mitochondrial dysfunction associated with antiretroviral agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical symptoms</td> <td class=\"subtitle1\">NRTI side effects</td> </tr> <tr> <td>Polyneuropathy</td> <td>d4T, ddI, ddC</td> </tr> <tr> <td>Myopathy</td> <td>AZT</td> </tr> <tr> <td>Cardiomyopathy</td> <td>AZT, d4T</td> </tr> <tr> <td>Hepatic steatosis, lactic acidosis</td> <td>AZT, ddI, d4T</td> </tr> <tr> <td>Pancreatitis</td> <td>ddI</td> </tr> <tr> <td>Pancytopenias</td> <td>AZT</td> </tr> <tr> <td>Lipodystrophy</td> <td>d4T, AZT</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NRTI: nucleoside reverse transcriptase inhibitor; d4T: stavudine; ddI: didanosine; ddC: zalcitabine (no longer available); AZT: zidovudine.</div><div id=\"graphicVersion\">Graphic 54147 Version 4.0</div></div></div>"},"54148":{"type":"graphic_picture","displayName":"Amyloid EM","title":"Electron micrograph showing renal amyloidosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph showing renal amyloidosis</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/54148_Amyloid_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph showing expansion of the mesangium by amyloid fibrils, which can measure 7 to 12 nanometers in diameter.&nbsp;The fibrillar appearance is best appreciated at the arrow.&nbsp;These fibrils are smaller than those seen in fibrillary and immunotactoid glomerulonephritis.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 54148 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"54149":{"type":"graphic_picture","displayName":"Long-standing lichen sclerosus","title":"Severe lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:263px; height:360px;\" src=\"images/OBGYN/54149_LS_55_yrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-standing vulvar&nbsp;lichen sclerosus&nbsp;in a 55-year-old&nbsp;woman with severe pruritus for eight years. She woke up most nights scratching. Clitoris is almost buried. The inner labia minora and vulvar trigone are thick, firm, and white with two biopsy sites visible on the left side.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD,&nbsp;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 54149 Version 6.0</div></div></div>"},"54150":{"type":"graphic_picture","displayName":"Infiltrating lobular carcinoma of the breast","title":"Infiltrating lobular carcinoma of the breast","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Infiltrating lobular carcinoma of the breast</div><div class=\"cntnt\"><img style=\"width:587px; height:227px;\" src=\"images/ONC/54150_Lobular_breast_ca_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Low power view of an infiltrating lobular breast carcinoma shows small tumor cells that infiltrate the stroma singly and in a single file pattern.<br />(Panel B) High power view demonstrates that the tumor cells are relatively small and uniform in appearance.</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 54150 Version 3.0</div></div></div>"},"54151":{"type":"graphic_diagnosticimage","displayName":"Compression fracture C6 and C7","title":"Compression fracture of C6 and C7 lateral and AP views","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Compression fracture of C6 and C7 lateral and AP views</div><div class=\"cntnt\"><img style=\"width:514px; height:299px;\" src=\"images/EM/54151_Compression_fx_C6_C7.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographs of an 11 year old male who dove into a shallow pool and struck the top of his head. He presented with neck pain and demonstrated slight compression of C6 and 50 percent compression of C7 from this axial load (arrows on lateral view (A), arrows on AP view (B)).</div><div class=\"graphic_reference\">Courtesy of Alison Chantal Caviness, MD.</div><div id=\"graphicVersion\">Graphic 54151 Version 2.0</div></div></div>"},"54156":{"type":"graphic_table","displayName":"Causes malnutrition older adults","title":"Mnemonic for common causes of malnutrition in older adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mnemonic for common causes of malnutrition in older adults</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\" colspan=\"2\">MEALS ON WHEELS</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>M</strong></td>\n\t\t\t\t\t<td>Medications</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>E</strong></td>\n\t\t\t\t\t<td>Emotional problems (depression)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>A</strong></td>\n\t\t\t\t\t<td>Anorexia (nervosa or tardive)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>L</strong></td>\n\t\t\t\t\t<td>Late-life paranoia or alcoholism</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>S</strong></td>\n\t\t\t\t\t<td>Swallowing disorders</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\" colspan=\"2\">&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>O</strong></td>\n\t\t\t\t\t<td>Oral factors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>N</strong></td>\n\t\t\t\t\t<td>No money</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\" colspan=\"2\">&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>W</strong></td>\n\t\t\t\t\t<td>Wandering (in patients with dementia)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>H</strong></td>\n\t\t\t\t\t<td>Hyperthyroidism, hyperparathyroidism</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>E</strong></td>\n\t\t\t\t\t<td>Entry problems/malabsorption</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>E</strong></td>\n\t\t\t\t\t<td>Eating problems (severe tremor, stroke, weakness)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>L</strong></td>\n\t\t\t\t\t<td>Low-salt or low-cholesterol diets</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td><strong>S</strong></td>\n\t\t\t\t\t<td>Shopping and food preparation problems</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">5/18/2007 - perm request using contact info from EA.mt\r\n5/24/2007 - publisher responded, but message was really confusing. Asking for clarification and suggesting an appropriate citation to include.mt\r\n5/25/2007 - granted. to TH to make.mt</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57777&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Causes_malnutrition_elders.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Saint Louis University Geriatric Evaluation Mnemonics Screening Tools. Compiled by faculty from Saint Louis University Geriatrics Division. Copyright ©2002 Saint Louis University.</div><div id=\"graphicVersion\">Graphic 54156 Version 2.0</div></div></div>"},"54157":{"type":"graphic_figure","displayName":"Skin anatomy","title":"Skin anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin anatomy</div><div class=\"cntnt\"><img style=\"width:426px; height:432px;\" src=\"images/PC/54157_Skin_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin and common disorders. The skin is the body's largest organ. It covers the entire body and weighs approximately six pounds. The skin includes two primary layers: the outer epidermis and the inner dermis. The epidermis has important protective functions. It protects against injury and excessive water loss. It also prevents disease-causing microorganisms from entering the body. The thick dermis contains blood vessels, nerve endings, and glands that respond to heat, pressure, and pain. Beneath the dermis, the subcutaneous layer is made up of loose connective tissue and fat (adipose) tissue. This layer acts as a cushion for the skin, helps maintain body heat, and is a store of energy.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright &#169; 2009.</div><div id=\"graphicVersion\">Graphic 54157 Version 3.0</div></div></div>"},"54159":{"type":"graphic_figure","displayName":"Duodenal switch","title":"Biliopancreatic diversion with duodenal switch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biliopancreatic diversion with duodenal switch</div><div class=\"cntnt\"><img style=\"width:443px; height:526px;\" src=\"images/SURG/54159_BPD_duodenal_switch_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biliopancreatic diversion with duodenal switch procedure involves a partial sleeve gastrectomy with preservation of the pylorus, and creation of a Roux limb with a short common channel. This procedure has significant risks of long-term malabsorption and is used only for patients with very severe obesity (BMI &gt;50 kg/m<sup>2</sup>).</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 54159 Version 4.0</div></div></div>"},"54160":{"type":"graphic_diagnosticimage","displayName":"CT scan showing infected pancreatic necrosis","title":"CT scan showing infected pancreatic necrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan showing infected pancreatic necrosis</div><div class=\"cntnt\"><img style=\"width:432px; height:277px;\" src=\"images/SURG/54160_Infected_pancr_necrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infected pancreatic necrosis can be diagnosed by the identification of air bubbles within an area of necrosis seen on contrast enhanced CT scan (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 54160 Version 5.0</div></div></div>"},"54161":{"type":"graphic_table","displayName":"Classification of FMD","title":"Classification of fibromuscular dysplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of fibromuscular dysplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Histologic classification</td> <td class=\"subtitle1\" colspan=\"3\">Angiographic classification</td> </tr> <tr> <td class=\"subtitle2\">Class</td> <td class=\"subtitle2\">Frequency</td> <td class=\"subtitle2\">Pathology</td> <td class=\"subtitle2\">French/Belgian consensus (2012)</td> <td class=\"subtitle2\">American Heart Association (2014)</td> <td class=\"subtitle2\">Angiographic appearance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Medial dysplasia</td> </tr> <tr> <td class=\"indent1\">Medial fibroplasia</td> <td>75-80 percent</td> <td> <p>Alternating areas of thinned media and thickened fibromuscular ridges containing collagen</p> Internal elastic membrane may be lost in some areas</td> <td class=\"divider_bottom\" rowspan=\"3\">Multifocal</td> <td class=\"divider_bottom\" rowspan=\"3\">Multifocal</td> <td>\"String of Beads\" appearance where the diameter of the \"beading\" is larger than the diameter of the artery</td> </tr> <tr> <td class=\"indent1\">Perimedial fibroplasia</td> <td>10-15 percent</td> <td>Extensive collagen deposition in the outer half of the media</td> <td>\"Beading\" in which the \"beads\" are smaller than the diameter of the artery</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Medial hyperplasia</td> <td>1-2 percent</td> <td>True smooth muscle cell hyperplasia without fibrosis</td> <td>Concentric smooth stenosis (similar to intimal disease)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Intimal fibroplasia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td>&#60;10 percent</td> <td> <p>Circumferential or eccentric deposition of collagen in the intima</p> <p>No lipid or inflammatory component</p> Internal elastic lamina fragmented or duplicated</td> <td> <p>Unifocal (&#60;1 cm)</p> Tubular (&#8805;1 cm)</td> <td>Focal*</td> <td> <p>Concentric focal band</p> Long smooth narrowing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Adventitial (periarterial) fibroplasia</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>&#60;1 percent</td> <td>Dense collagen replaces the fibrous tissue of the adventitia and may extend into surrounding tissue</td> <td> <p>Unifocal (&#60;1 cm)</p> Tubular (&#8805;1 cm)</td> <td>Focal*</td> <td>Sharply localized, tubular areas of stenosis (based on limited angiographic data)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* There may be multiple areas of focal disease (eg, renal artery and carotid artery in the same patient).</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Begelman SM, Olin JW. Fibromuscular dysplasia. Curr Opin Rheumatol 2000; 12:41.</LI>&#xD;&#xA;<LI>Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia:&nbsp;State of the science and critical unanswered questions.&nbsp;Circulation 2014; 129:1048.&nbsp;</LI></OL></div><div id=\"graphicVersion\">Graphic 54161 Version 9.0</div></div></div>"},"54163":{"type":"graphic_diagnosticimage","displayName":"Electroanatomic mapping ARVD","title":"Echocardiographic and electroanatomic mapping of the right ventricle in arrhythmogenic right ventricular dysplasia","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Echocardiographic and electroanatomic mapping of the right ventricle in arrhythmogenic right ventricular dysplasia</div><div class=\"cntnt\"><img style=\"width:453px; height:451px;\" src=\"images/CARD/54163_ElectroanatomicmappingARV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional echocardiographic apical view of a patient with arrhythmogenic right ventricular dysplasia shows severe enlargement of the right ventricle (RV) and right atrium (RA) (panel A).&nbsp;The RV unipolar voltage maps, generated by electroanatomic mapping, are seen in the anteroposterior (panel B) and left anterior oblique views (panel C). There is extensive area of low voltage (red indicates &lt;2 mV) in the apex and anterolateral free wall of the RV, with the septum being spared (purple indicates &gt;5 mV).</div><div class=\"graphic_footnotes\">LA: left atrium; RVOT: RV outflow tract.</div><div class=\"graphic_reference\">Reproduced with permission from: Boulos M, Lashevsky I, Reisner S, Gepstein L. J Am Coll Cardiol 2001; 38:2020. Copyright © 2001 American College of Cardiology.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 54163 Version 4.0</div></div></div>"},"54164":{"type":"graphic_table","displayName":"Causes of tertiary adrenal insufficiency","title":"Causes of tertiary adrenal insufficiency in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of tertiary adrenal insufficiency in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Isolated ACTH deficiency</td> </tr> <tr> <td>CRH gene defect</td> </tr> <tr> <td>CRH receptor defect</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital malformations of the brain</td> </tr> <tr> <td>Optic nerve hypoplasia / Septo-optic dysplasia</td> </tr> <tr> <td class=\"subtitle1_single\">Infiltrative diseases (also cause secondary adrenal insufficiency)</td> </tr> <tr> <td>Hemochromatosis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"subtitle1_single\">Brain injury</td> </tr> <tr> <td>Brain tumor</td> </tr> <tr> <td>Brain hemorrhage</td> </tr> <tr> <td>Brain surgery</td> </tr> <tr> <td>Cranial radiation</td> </tr> <tr> <td class=\"subtitle1_single\">Temporary isolated ACTH deficiency due to suppression of hypothalamic CRH secretion</td> </tr> <tr> <td>Cessation of pharmacologic glucocorticoid therapy</td> </tr> <tr> <td>Megestrol acetate (Megace) therapy</td> </tr> <tr> <td>Resection of a unilateral cortisol-secreting tumor</td> </tr> <tr> <td>Resection of an ACTH-secreting tumor</td> </tr> <tr> <td>Infants born to steroid treated mothers</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTH: adrenocorticotropic hormone; CRH: corticotropin releasing hormone.</div><div id=\"graphicVersion\">Graphic 54164 Version 7.0</div></div></div>"},"54165":{"type":"graphic_picture","displayName":"Marasmus wasting","title":"Muscle wasting in a child with marasmus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Muscle wasting in a child with marasmus</div><div class=\"cntnt\"><img style=\"width:307px; height:228px;\" src=\"images/PEDS/54165_Marasmus_wasting.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe degree of atrophy of muscle and subcutaneous fat in a malnourished infant with marasmus. Note absence of dermatosis and edema.</div><div class=\"graphic_reference\">Courtesy of Dr. Buford Nichols.</div><div id=\"graphicVersion\">Graphic 54165 Version 3.0</div></div></div>"},"54166":{"type":"graphic_table","displayName":"Modified Bell staging NEC","title":"Modified Bell staging criteria for necrotizing enterocolitis (NEC) in neonates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Bell staging criteria for necrotizing enterocolitis (NEC) in neonates</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup span=\"4\" width=\"23%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Classification of NEC</td> <td class=\"subtitle1\">Systemic signs</td> <td class=\"subtitle1\">Abdominal signs</td> <td class=\"subtitle1\">Radiographic signs</td> </tr> <tr class=\"divider_bottom\"> <td>IA</td> <td>Suspected</td> <td>Temperature instability, apnea, bradycardia, lethargy</td> <td>Gastric retention, abdominal distention, emesis, heme-positive stool</td> <td>Normal or mild intestinal dilation, mild ileus</td> </tr> <tr class=\"divider_bottom\"> <td>IB</td> <td>Suspected</td> <td>Same as above</td> <td>Grossly bloody stool</td> <td>Same as above</td> </tr> <tr class=\"divider_bottom\"> <td>IIA</td> <td>Definite, mildly ill</td> <td>Same as above</td> <td>Same as above, plus absent bowel sounds with or without abdominal tenderness</td> <td>Intestinal dilation, ileus, pneumatosis intestinalis</td> </tr> <tr class=\"divider_bottom\"> <td>IIB</td> <td>Definite, moderately ill</td> <td>Same as above, plus mild metabolic acidosis and thrombocytopenia</td> <td>Same as above, plus absent bowel sounds, definite tenderness, with or without abdominal cellulitis or right lower quadrant mass</td> <td>Same as IIA, plus ascites</td> </tr> <tr class=\"divider_bottom\"> <td>IIIA</td> <td>Advanced, severely ill, intact bowel</td> <td>Same as IIB, plus hypotension, bradycardia, severe apnea, combined respiratory and metabolic acidosis, DIC, and neutropenia</td> <td>Same as above, plus signs of peritonitis, marked tenderness, and abdominal distention</td> <td>Same as IIA, plus ascites</td> </tr> <tr> <td>IIIB</td> <td>Advanced, severely ill, perforated bowel</td> <td>Same as IIIA</td> <td>Same as IIIA</td> <td>Same as above, plus pneumoperitoneum</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DIC: disseminated intravascular coagulation.</div><div class=\"graphic_reference\">Adapted from: Neu J. Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Pediatr Clin North Am 1996; 43:409.</div><div id=\"graphicVersion\">Graphic 54166 Version 5.0</div></div></div>"},"54167":{"type":"graphic_picture","displayName":"Bacterial colonization of biliary stents","title":"Bacterial colonization of biliary stents","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacterial colonization of biliary stents</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/GAST/54167_Biliary_stents_bacteria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sections of whole biliary stents are hybridized with the universal Eub338 Cy3 probe. Bacteria in orange color (arrows) can be clearly identified by their form within the yellowish sludge that covers the inner surface (panels A and B) in partially occluded stents. Bacteria disappear from the stent lumen with increasing occlusion of the bile duct stent (panel C: stent center; panel D: stent wall), when only yellowish masses of cholesterol and other sludge can be seen. (Magnification x1000).</div><div id=\"graphicVersion\">Graphic 54167 Version 4.0</div></div></div>"},"54169":{"type":"graphic_figure","displayName":"Progression of hiatal hernia","title":"Progressive anatomic disruption of the gastroesophageal membrane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Progressive anatomic disruption of the gastroesophageal membrane</div><div class=\"cntnt\"><img style=\"width:374px; height:486px;\" src=\"images/GAST/54169_Progr_hiatal_herni_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance, looking upward from the gastric cardia toward the hiatus. The normal view is shown, followed by progressively increasing laxity of the phrenoesophageal membrane, leading to gross incompetence (grade IV) and a type I hiatal hernia.</div><div class=\"graphic_reference\">Reproduced with permission from: Hill LD, Kraemer SJ, Aye RW, et al. Laparoscopic Hill repair. Contemp Surg 1994; 44:13.</div><div id=\"graphicVersion\">Graphic 54169 Version 3.0</div></div></div>"},"54170":{"type":"graphic_diagnosticimage","displayName":"Sonogram endometrial polyp","title":"Single endometrial polyp in 44-year-old woman who presented with excessive bleeding","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Single endometrial polyp in 44-year-old woman who presented with excessive bleeding</div><div class=\"cntnt\"><img style=\"width:513px; height:223px;\" src=\"images/OBGYN/54170_Sonogram_endometrial_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal transvaginal sonogram shows endometrial polyp (arrows) in fundus. Endometrium appears thick and is difficult to measure. (B) Sagittal sonohysterogram shows single round 1.9-cm echogenic polyp (arrow). Note otherwise thin endometrium (2 mm).</div><div class=\"graphic_reference\">Reproduced with permission from Joizzo, JR, Chen, MY, Riccio, GJ, Endometrial Polyps: Sonohysterographic Evaluation. AJR Am J Roentgenol 2001; 176:617. Copyright © 2001 American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 54170 Version 4.0</div></div></div>"},"54171":{"type":"graphic_figure","displayName":"Alcohol impairment chart","title":"Alcohol impairment charts for men and women","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Alcohol impairment charts for men and women</div><div class=\"cntnt\"><img style=\"width:510px; height:656px;\" src=\"images/PC/54171_Alcohol_impairment_ch.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subtract 0.01 percent for every 40 minutes of drinking.</div><div class=\"graphic_footnotes\">* As approximated in the United States.</div><div id=\"graphicVersion\">Graphic 54171 Version 4.0</div></div></div>"},"54172":{"type":"graphic_picture","displayName":"Confluent and reticulated papillomatosis - close view","title":"Confluent and reticulated papillomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Confluent and reticulated papillomatosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54172_Confl_retic_papill_CV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Close view of hyperpigmented, reticulated thin plaques in confluent reticulated papillomatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54172 Version 3.0</div></div></div>"},"54173":{"type":"graphic_picture","displayName":"Seborrheic dermatitis scalp","title":"Seborrheic dermatitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis of the scalp</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54173_Seborrheic_derma_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse, fine scaliness of the scalp without underlying erythema.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54173 Version 4.0</div></div></div>"},"54174":{"type":"graphic_table","displayName":"Esophageal perforation prognostic variables","title":"Prognostic variables for mortality associated with esophageal perforation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic variables for mortality associated with esophageal perforation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mortality (percent)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Etiology (n = 431)</td> </tr> <tr> <td class=\"indent1\">Spontaneous</td> <td>36</td> </tr> <tr> <td class=\"indent1\">Iatrogenic</td> <td>19</td> </tr> <tr> <td class=\"indent1\">Traumatic</td> <td>7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Location (n = 397)</td> </tr> <tr> <td class=\"indent1\">Cervical</td> <td>6</td> </tr> <tr> <td class=\"indent1\">Thoracic</td> <td>27</td> </tr> <tr> <td class=\"indent1\">Abdominal</td> <td>21</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Time to diagnosis (n = 396)</td> </tr> <tr> <td class=\"indent1\">&#60;24 hrs</td> <td>14</td> </tr> <tr> <td class=\"indent1\">&#62;24 hrs</td> <td>27</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows the higher mortality rates associated with a sponteous perforation, a thoracic perforation, and a delay in diagnosis.</div><div class=\"graphic_reference\">Data from: Brinster CJ, Singhal S, Lee L, et al. Evolving options in the management of esophageal perforation. Ann Thorac Surg 2004; 77:1475.</div><div id=\"graphicVersion\">Graphic 54174 Version 2.0</div></div></div>"},"54175":{"type":"graphic_picture","displayName":"Trichuriasis eggs","title":"Trichuriasis eggs","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Trichuriasis eggs</div><div class=\"cntnt\"><img style=\"width:544px; height:545px;\" src=\"images/ID/54175_Trichuriasis_eggs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Egg of <em>T. trichiura</em> in an iodine-stained wet mount.<br />(B) Egg of <em>T. trichiura</em> in an unstained wet mount.<br />(C) Egg of <em>T. trichiura</em> in an unstained wet mount.<br />(D) Two eggs of <em>T. trichiura</em>, showing the variability in size of the species.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Trichuriasis. Available at: <A href=\"http://www.cdc.gov/dpdx/trichuriasis/index.html\">http://www.cdc.gov/dpdx/trichuriasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 54175 Version 5.0</div></div></div>"},"54176":{"type":"graphic_figure","displayName":"Lymphocyte subset analysis by flow cytometry I","title":"Lymphocyte subset analysis by flow cytometry","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Lymphocyte subset analysis by flow cytometry</div><div class=\"cntnt\"><img style=\"width:480px; height:380px;\" src=\"images/ALLRG/54176_Lymphocyte_subset_anal_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow cytometry profile of normal peripheral blood.</div><div id=\"graphicVersion\">Graphic 54176 Version 2.0</div></div></div>"},"54177":{"type":"graphic_diagnosticimage","displayName":"Xanthogranulomatous chol CT","title":"Xanthogranulomatous cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xanthogranulomatous cholecystitis</div><div class=\"cntnt\"><img style=\"width:360px; height:247px;\" src=\"images/GAST/54177_Xanthogranulomatous_chol_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of the abdomen in a patient with xanthogranulomatous cholecystitis showing a thickened gallbladder wall (arrow) with intramural hypodense nodules.</div><div class=\"graphic_reference\">Courtesy Faripour Forouhar, MD.</div><div id=\"graphicVersion\">Graphic 54177 Version 4.0</div></div></div>"},"54178":{"type":"graphic_picture","displayName":"Nipple areola reconstruction","title":"Reconstruction of the nipple-areolar complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reconstruction of the nipple-areolar complex</div><div class=\"cntnt\"><img style=\"width:380px; height:268px;\" src=\"images/ONC/54178_Nipple_areola_reconstructio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nipple-areolar complex reconstruction is carried out with a combination of local tissue rearrangement and tattooing.</div><div class=\"graphic_reference\">Courtesy of Jorge de la Pedraja, MD.</div><div id=\"graphicVersion\">Graphic 54178 Version 2.0</div></div></div>"},"54179":{"type":"graphic_table","displayName":"Causes of back pain in children","title":"Causes of back pain in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of back pain in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Musculoskeletal</td> </tr> <tr> <td class=\"indent1\">Nonspecific musculoskeletal back pain</td> </tr> <tr> <td class=\"indent1\">Spondylolysis/spondylolisthesis</td> </tr> <tr> <td class=\"indent1\">Scoliosis</td> </tr> <tr> <td class=\"indent1\">Scheuermann (juvenile) kyphosis</td> </tr> <tr> <td class=\"indent1\">Disc degeneration and/or prolapse</td> </tr> <tr> <td class=\"sublist2_start\">Other:</td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Intervertebral disc calcification</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Congenital absence of pedicle</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Vertebral apophyseal fracture</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Aneurysmal bone cyst</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Sacroiliac joint stress reaction</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\"> <ul> <li>Idiopathic juvenile osteoporosis</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td class=\"indent1\">Discitis</td> </tr> <tr> <td class=\"indent1\">Vertebral osteomyelitis, including tuberculosis (Pott disease)</td> </tr> <tr> <td class=\"indent1\">Epidural abscess</td> </tr> <tr> <td class=\"indent1\">Sacroiliac joint infection</td> </tr> <tr> <td class=\"sublist2_start\">Nonspinal infection:</td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Paraspinous muscle abscess</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Pyelonephritis</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Pneumonia</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Pelvic inflammatory disease</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Endocarditis</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Viral myalgias</li> </ul> </td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Ankylosing spondylitis</td> </tr> <tr> <td class=\"indent1\">Psoriatic arthritis</td> </tr> <tr> <td class=\"indent1\">IBD-associated arthritis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Reactive arthritis</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplastic</td> </tr> <tr> <td class=\"indent1\">Osteoid osteoma</td> </tr> <tr> <td class=\"indent1\">Leukemia or lymphoma</td> </tr> <tr> <td class=\"indent1\">Solid malignancy, primary or metastatic</td> </tr> <tr> <td class=\"sublist2_start\">Other benign tumor:</td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Neurofibroma</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\"> <ul> <li>Vascular malformation</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Appendicitis</td> </tr> <tr> <td class=\"indent1\">Sickle cell pain crisis</td> </tr> <tr> <td class=\"indent1\">Syringomyelia</td> </tr> <tr> <td class=\"indent1\">Cholecystitis</td> </tr> <tr> <td class=\"indent1\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\">Chronic recurrent multifocal osteomyelitis</td> </tr> <tr> <td class=\"indent1\">Psychosomatic illness</td> </tr> <tr> <td class=\"indent1\">Nephrolithiasis</td> </tr> <tr> <td class=\"indent1\">Ureteropelvic junction obstruction</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease.</div><div id=\"graphicVersion\">Graphic 54179 Version 4.0</div></div></div>"},"54180":{"type":"graphic_figure","displayName":"Anatomy of the medial nasal wall","title":"Anatomy of the medial nasal wall","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Anatomy of the medial nasal wall</div><div class=\"cntnt\"><img style=\"width:534px; height:414px;\" src=\"images/PC/54180_Anatomy_medial_nasal_wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood supply to the nasal septum, demonstrating Kiesselbach's plexus.</div><div id=\"graphicVersion\">Graphic 54180 Version 3.0</div></div></div>"},"54181":{"type":"graphic_picture","displayName":"Purulent drainage ABRS","title":"Endoscopic image of purulent drainage from the middle meatus in a patient with acute bacterial rhinosinusitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic image of purulent drainage from the middle meatus in a patient with acute bacterial rhinosinusitis</div><div class=\"cntnt\"><img style=\"width:324px; height:324px;\" src=\"images/PC/54181_Purulent_drainage_ABRS.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54181 Version 2.0</div></div></div>"},"54185":{"type":"graphic_figure","displayName":"Serosal repair after myomectomy","title":"Serosal repair after myomectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serosal repair after myomectomy</div><div class=\"cntnt\"><img style=\"width:450px; height:320px;\" src=\"images/OBGYN/54185_Serosal_repair_after_myomec.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 54185 Version 1.0</div></div></div>"},"54186":{"type":"graphic_figure","displayName":"Biclonal gammopathy on SPEP","title":"Biclonal gammopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biclonal gammopathy</div><div class=\"cntnt\"><img style=\"width:334px; height:404px;\" src=\"images/HEME/54186_Biclonal_gammopathy_on_SPEP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel B: A biclonal pattern, with two small, discrete gamma bands, is seen on serum protein electrophoresis on agarose gel (anode on left). Panel A: Densitometer tracing of these findings shows the two protein peaks with gamma mobility.</div><div id=\"graphicVersion\">Graphic 54186 Version 1.0</div></div></div>"},"54187":{"type":"graphic_diagnosticimage","displayName":"T-shaped acetabular fracture","title":"Radiographic appearance of T-shaped acetabular fracture","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Radiographic appearance of T-shaped acetabular fracture</div><div class=\"cntnt\"><img style=\"width:515px; height:469px;\" src=\"images/EM/54187_Acetab_fx_T_shape.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The appearance on the anteroposterior pelvis radiograph may be distinguished from the transverse fracture by the presence of the fracture of the ischial ramus (arrow). Displacement of the stem of the T may cause the ilioischial line to appear duplicated (small arrowheads). Likewise, the relationship between the ilioischial line, which remains with the posterior column, and the teardrop, which remains with the anterior column, may be disrupted (large arrowhead).<br />(B) The obturator oblique shows the break in the iliopectineal line (dashed arrow). It also allows better visualization of the stem of the T (short arrow) as it enters the roof of the obturator foramen and is associated with the ischial ramus fracture (thick arrow).<br />(C) The iliac oblique view demonstrates the disruption of the greater sciatic notch and subluxation of the femoral head.</div><div class=\"graphic_reference\">Originally published in: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Reproduced with permission. Copyright &copy; Berton R. Moed, MD.</div><div id=\"graphicVersion\">Graphic 54187 Version 3.0</div></div></div>"},"54188":{"type":"graphic_diagnosticimage","displayName":"Acute ischemic stroke on CTA-SI","title":"Acute ischemic stroke on CT angiography source image","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Acute ischemic stroke on CT angiography source image</div><div class=\"cntnt\"><img style=\"width:529px; height:582px;\" src=\"images/NEURO/54188_Acute_ischemic_stroke_CTASI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An 88-year-old woman admitted with acute left hemiparesis and dysarthria 90 minutes after the onset of symptoms. Baseline noncontrast head CT (A) shows early ischemic changes in the right MCA territory (arrows). CTA-SI image (B) reveals hypoattenuation in the right MCA territory (arrows), which corresponds to the final infarct (C) on follow-up CT scan (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography; MCA: middle cerebral artery; CTA-SI: CT angiography source image.</div><div class=\"graphic_reference\">Reproduced with permission from: Bhatia R, Bal SS, Shobha N, et al. CT angiographic source images predict outcome and final infarct volume better than noncontrast CT in proximal vascular occlusions. Stroke 2011; 42:1575. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54188 Version 5.0</div></div></div>"},"54189":{"type":"graphic_table","displayName":"Feminizing effects in male-to-female transgender persons","title":"Feminizing effects in male-to-female transgender persons","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Feminizing effects in male-to-female transgender persons</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Effect</td> <td class=\"subtitle1\">Onset*</td> <td class=\"subtitle1\">Maximum*</td> </tr> <tr> <td>Redistribution of body fat</td> <td>3 to 6 months</td> <td>2 to 3 years</td> </tr> <tr> <td>Decrease in muscle mass and strength</td> <td>3 to 6 months</td> <td>1 to 2 years</td> </tr> <tr> <td>Softening of skin/decreased oiliness</td> <td>3 to 6 months</td> <td>Unknown</td> </tr> <tr> <td>Decreased libido</td> <td>1 to 3 months</td> <td>3 to 6 months</td> </tr> <tr> <td>Decreased spontaneous erections</td> <td>1 to 3 months</td> <td>3 to 6 months</td> </tr> <tr> <td>Male sexual dysfunction</td> <td>Variable</td> <td>Variable</td> </tr> <tr> <td>Breast growth</td> <td>3 to 6 months</td> <td>2 to 3 years</td> </tr> <tr> <td>Decreased testicular volume</td> <td>3 to 6 months</td> <td>2 to 3 years</td> </tr> <tr> <td>Decreased sperm production</td> <td>Unknown</td> <td>&#62;3 years</td> </tr> <tr> <td>Decreased terminal hair growth</td> <td>6 to 12 months</td> <td>&#62;3 years<sup>&#182;</sup></td> </tr> <tr> <td>Scalp hair</td> <td>No regrowth</td> <td>&#916;</td> </tr> <tr> <td>Voice changes</td> <td>None</td> <td>&#9674;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Estimates represent clinical observations.<br />¶ Complete removal of male sexual hair requires electrolysis, or laser treatment, or both.<br />Δ Familial scalp hair loss may occur if estrogens are stopped.<br /><FONT class=lozenge>◊</FONT> Treatment by speech pathologists for voice training is most effective.</div><div class=\"graphic_reference\">Reproduced with permission from: Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132. Copyright &copy; 2009 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 54189 Version 7.0</div></div></div>"},"54190":{"type":"graphic_picture","displayName":"IPEX GI biopsy","title":"IPEX GI biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">IPEX GI biopsy</div><div class=\"cntnt\"><img style=\"width:432px; height:270px;\" src=\"images/ALLRG/54190_IPEX_GI_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastrointestinal biopsy from a patient with IPEX demonstrates villous atrophy and lymphocytic infiltrates of the bowel mucosa.</div><div class=\"graphic_footnotes\">IPEX: immune dysregulation, polyendocrinopathy, enteropathy, X-linked; GI: gastrointestinal.</div><div id=\"graphicVersion\">Graphic 54190 Version 2.0</div></div></div>"},"54191":{"type":"graphic_figure","displayName":"Protein structure of ghrelin","title":"Protein structure of ghrelin","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Protein structure of ghrelin</div><div class=\"cntnt\"><img style=\"width:469px; height:210px;\" src=\"images/ENDO/54191_Protein_structure_ghrelin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the octanoyl group on the serine residue at position three. This fatty acid modification is necessary for biological activity.</div><div id=\"graphicVersion\">Graphic 54191 Version 2.0</div></div></div>"},"54193":{"type":"graphic_figure","displayName":"HBIG post liver transplantation","title":"Effect of hepatitis B immunoglobulin after liver transplantation for hepatitis B virus-associated cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Effect of hepatitis B immunoglobulin after liver transplantation for hepatitis B virus-associated cirrhosis</div><div class=\"cntnt\"><img style=\"width:546px; height:276px;\" src=\"images/GAST/54193_HBIG_post_liver_transplanta.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with hepatitis B virus-associated cirrhosis were randomized to long-term or short-term hepatitis B immunoglobulin (HBIG) or no immunoprophylaxis after liver transplantation. Patients treated with long-term HBIG had both a lower incidence of HBsAg recurrence (left panel) and a higher rate of survival (right panel).</div><div class=\"graphic_reference\">Data from: Samuel D, Muller R, Alexander G, et al. N Engl J Med 1993; 329:1842.</div><div id=\"graphicVersion\">Graphic 54193 Version 3.0</div></div></div>"},"54194":{"type":"graphic_picture","displayName":"Two varices banded Endosc","title":"Esophageal varix band ligation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal varix band ligation</div><div class=\"cntnt\"><img style=\"width:360px; height:277px;\" src=\"images/GAST/54194_Two_varices_banded_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy shows two varices in the distal esophagus that have been banded. The black bands are indicated with the arrows. The two strings in the right of the field are connected to the trigger device used to deploy the bands.</div><div class=\"graphic_reference\">Courtesy of Laurence Bailen, MD.</div><div id=\"graphicVersion\">Graphic 54194 Version 2.0</div></div></div>"},"54195":{"type":"graphic_table","displayName":"Clinical history in returning travelers","title":"Key elements of the history in returning travelers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key elements of the history in returning travelers</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Geography</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Countries visited or passed through; urban or rural</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Dates of travel and duration of stay in each place</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Means of transportation</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Accommodations (eg, hotel, dormitory, local household, tent)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Activities and exposures during travel</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sex or other intimate contact (eg, type, number of partners, barrier protection)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Animals, including birds (eg, shared living quarters or physical proximity, seeing rodents, bites, licks) or animal products (eg, hunting, skinning, other)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Arthropod (eg, seeing or receiving bites from mosquitoes, flies, ticks, fleas, other)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Needle and blood exposure (eg, shared needles, injections, acupuncture, tattoos, ear or other body piercing, dental work, transfusions, surgery)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Food and beverages (eg, raw or undercooked flesh, unpasteurized milk, tap or surface water, local delicacies)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Soil and water contact (eg, recreational, such as hiking, boating, swimming, hunting, spelunking or professional activities, such as archeological digs)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Host factors</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Age and sex</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Medical problems and past surgery (eg, splenectomy, gastrectomy, HIV infection)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Past infections and vaccines</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Medications, including immunosuppressive and immunomodulating agents, over the counter drugs, antipyretics</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Past medical history, including immunosuppression</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Preparation for travel (eg, vaccines, chemoprophylaxis)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pregnancy</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 54195 Version 3.0</div></div></div>"},"54197":{"type":"graphic_picture","displayName":"Longitudinal melanonychia","title":"Longitudinal melanonychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal melanonychia</div><div class=\"cntnt\"><img style=\"width:360px; height:370px;\" src=\"images/PEDS/54197_Longitudinal_melanonychia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A biopsy of the nail matrix revealed a junctional melanocytic nevus.</div><div class=\"graphic_reference\">Reproduced with permission from: Schaffer JV, Bolognia JL. The clinical spectrum of pigmented lesions. Clin Plast Surg 2000; 27:391. Copyright &#169; 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 54197 Version 3.0</div></div></div>"},"54198":{"type":"graphic_table","displayName":"NAC established therapies","title":"National Autism Center's Standards Report summary of established* behavioral interventions used in education for children with autism spectrum disorders (ASD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">National Autism Center's Standards Report summary of established* behavioral interventions used in education for children with autism spectrum disorders (ASD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Intervention </td> <td class=\"subtitle1\">Description </td> </tr> <tr> <td>Antecedent package</td> <td>Interventions that involve changing triggers (antecedents) that usually come before an identified target behavior to increase positive behavior and decrease negative behavior. This includes treatments in the fields of applied behavior analysis (ABA), behavioral psychology, and positive behavior supports.</td> </tr> <tr> <td>Behavioral package</td> <td>Interventions that use the principles of behavior modification to encourage functional behaviors and skills as replacement for negative ones. These include treatments in the fields of ABA, behavioral psychology, and positive behavior support.</td> </tr> <tr> <td>Comprehensive behavioral treatment for young children</td> <td>Interventions involve a combination of ABA procedures delivered to young children with a low student-to-teacher ratio</td> </tr> <tr> <td>Joint attention intervention</td> <td>Interventions teach the child to respond to the nonverbal social bids of others or to initiate joint attention interactions (eg, pointing, showing, following eye gaze)</td> </tr> <tr> <td>Modeling</td> <td>Interventions involve imitation of target behaviors that are demonstrated by an adult or peer</td> </tr> <tr> <td>Naturalistic teaching strategies</td> <td>Interventions use child-directed interactions to teach functional skills in the natural environment; interventions provide a stimulating environment, model how to play, encourage conversation, provide choices, and directly or naturally reinforce and reward reasonable attempts</td> </tr> <tr> <td>Peer training package</td> <td>Siblings or classmates without disabilities are taught strategies for facilitating play and social interactions with children with autism spectrum disorders (ASD)</td> </tr> <tr> <td>Pivotal response treatment</td> <td>Targets pivotal behavior areas (eg, motivation to engage in social communication, self-initiation, self-management); parent involvement and intervention in the natural environment are key aspects</td> </tr> <tr> <td>Schedules</td> <td>Present a task list that communicates a series of activities or steps required to complete a specific activity</td> </tr> <tr> <td>Self-management</td> <td>Teaches individuals with ASD to regulate their behavior by recording the occurrence/nonoccurrence of the target behavior, and securing reinforcement for doing so</td> </tr> <tr> <td>Story-based intervention package</td> <td>Involves a written description of the situation under which specific behaviors are expected to occur; stories may be supplemented with additional components (eg, prompting, reinforcement, discussion, etc). This includes social stories.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Established treatments are those for which there is evidence of benefit from several well-controlled studies.</div><div class=\"graphic_reference\">Data from: The National Autism Center's National Standards Report. National Autism Center, Randolph, MA, 2009. Available at: www.nationalautismcenter.org/pdf/NAC%20Standards%20Report.pdf. Accessed on May 18, 2010.</div><div id=\"graphicVersion\">Graphic 54198 Version 2.0</div></div></div>"},"54199":{"type":"graphic_table","displayName":"Drugs as immunogens","title":"Drugs as immunogens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs as immunogens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mechanism </td> <td class=\"subtitle1\">Examples </td> <td class=\"subtitle1\">Type of reaction generated </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Complete allergens </td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Foreign macromolecules </td> <td>Recombinant proteins (eg, cetuximab, rituximab)</td> <td rowspan=\"7\">Type I </td> </tr> <tr> <td>Insulin and other hormones</td> </tr> <tr> <td>Enzymes and protamine</td> </tr> <tr> <td>Antisera</td> </tr> <tr> <td>Vaccines</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Functionally-multivalent chemicals </td> <td>Quaternary ammonium compounds (eg, neuromuscular-blocking agents, such as succinylcholine)</td> </tr> <tr> <td>Carboxymethyl cellulose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Direct haptenation </td> </tr> <tr> <td rowspan=\"3\">&nbsp; </td> <td>Beta-lactam antibiotics</td> <td rowspan=\"3\"> <p>Type I</p> <p>Type II</p> <p>Type III</p> <p>Type IV</p> </td> </tr> <tr> <td>Penicillamine</td> </tr> <tr> <td>Heavy metals (gold, cisplatinum)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Metabolism to haptenic form* </td> </tr> <tr> <td rowspan=\"5\">&nbsp; </td> <td>Sulfonamides<sup>&#182;</sup>&nbsp;</td> <td rowspan=\"5\"> <p>Type I</p> <p>Type II</p> <p>Type III</p> <p>Type IV</p> </td> </tr> <tr> <td>Acetaminophen<sup>&#916;</sup>&nbsp;</td> </tr> <tr> <td>Phenacetin<sup>&#182;</sup>&nbsp;</td> </tr> <tr> <td>Procainamide<sup>&#182;</sup></td> </tr> <tr> <td>Halothane<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Direct stimulation of immune receptors (the p-i concept) </td> </tr> <tr> <td class=\"indent1\" rowspan=\"6\">&nbsp; </td> <td>Sulfamethoxazole</td> <td rowspan=\"6\">Type IV </td> </tr> <tr> <td>Abacavir</td> </tr> <tr> <td>Lidocaine, mepivacaine</td> </tr> <tr> <td>Carbamazepine, lamotrigine</td> </tr> <tr> <td>Flucloxacillin<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td>Allopurinol/oxypurinol</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>* </FONT><FONT color=black><FONT color=red><FONT color=black>The generation of haptenic forms&nbsp;is not conclusively&nbsp;known to be involved in the pathogenesis of hypersensitivity reactions to these drugs.</FONT> <br />​</FONT>¶ <FONT color=black>Postulated intermediate: Hydroxylamine.<br />Δ Postulated intermediate: Quinone imine.<br />◊ Postulated intermediate: Radicals, acyl halides.<br />§ Can also act as hapten.</FONT></FONT></div><div class=\"graphic_reference\">Original figure modified for this publication. Celik G, Pichler WJ, Adkinson NF Jr. Drug Allergy. In: Middleton's Allergy Principles &amp; Practice, 8th ed, Adkinson NF, et al (Ed), Elsevier, Philadelphia 2014. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 54199 Version 6.0</div></div></div>"},"54201":{"type":"graphic_figure","displayName":"Types of surgical needles","title":"Types of surgical needles","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Types of surgical needles</div><div class=\"cntnt\"><img style=\"width:486px; height:379px;\" src=\"images/SURG/54201_Types_of_needles.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54201 Version 3.0</div></div></div>"},"54202":{"type":"graphic_table","displayName":"Disorders associated with aVWS","title":"Disorders associated with acquired von Willebrand syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders associated with acquired von Willebrand syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Malignant diseases</td> </tr> <tr> <td class=\"indent1\">Lymphoproliferative disorders</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Monoclonal gammopathy of undetermined significance (MGUS) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Multiple myeloma </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Non-Hodgkin lymphoma (NHL) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Chronic lymphocytic leukemia (CLL) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Waldenstr&#246;m macroglobulinemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Myeloproliferative neoplasms (MPNs)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Essential thrombocythemia (ET) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Polycythemia vera (PV) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Chronic myeloid leukemia (CML) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Primary myelofibrosis (PMF) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Wilms tumor</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other carcinomas</td> </tr> <tr> <td class=\"subtitle1_single\">Immune disorders</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus (SLE)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other autoimmune diseases</td> </tr> <tr> <td class=\"subtitle1_single\">States of high vascular flow</td> </tr> <tr> <td class=\"indent1\">Ventricular septal defect</td> </tr> <tr> <td class=\"indent1\">Congenital heart disease with high flow state</td> </tr> <tr> <td class=\"indent1\">Aortic stenosis</td> </tr> <tr> <td class=\"indent1\">Mitral valve prolapse</td> </tr> <tr> <td class=\"indent1\">Ventricular assist device (LVAD)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Extracorporeal membrane oxygenation (ECMO) device</td> </tr> <tr> <td class=\"subtitle1_single\">Other disorders</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal angiodysplasia</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs and other agents</td> </tr> <tr> <td class=\"indent1\">Valproic acid</td> </tr> <tr> <td class=\"indent1\">Hydroxyethyl starch</td> </tr> <tr> <td class=\"indent1\">Antibiotics: Griseofulvin, ciprofloxacin</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table includes a disorder only if there were three or more reports in the literature on its association with acquired von Willebrand disease.</div><div class=\"graphic_reference\">Adapted from: Veyradier A, Jenkins CS, Fressinaud E, et al. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost 2000; 84:175 and Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84:346.</div><div id=\"graphicVersion\">Graphic 54202 Version 6.0</div></div></div>"},"54203":{"type":"graphic_diagnosticimage","displayName":"Benign solid nodule","title":"Benign solid nodule on mammogram and ultrasound","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Benign solid nodule on mammogram and ultrasound</div><div class=\"cntnt\"><img style=\"width:515px; height:435px;\" src=\"images/PC/54203_Benign_solid_nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A well defined ovoid nodule (arrow) is seen in the lateral aspect of the breast on CC and spot CC views (Panels A and B). On ultrasound (Panel C) it has benign features and is consistent with a fibroadenoma.</div><div class=\"graphic_footnotes\">CC: craniocaudal.</div><div id=\"graphicVersion\">Graphic 54203 Version 2.0</div></div></div>"},"54204":{"type":"graphic_picture","displayName":"Cutaneous sarcoidosis - histopathology high power","title":"Cutaneous sarcoidosis - histopathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous sarcoidosis - histopathology</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54204_Cutaneous_sarcoid_histo_HP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large aggregates of histiocytes forming tight, well-demarcated granulomas are present in the dermis. The granulomas lack any signs of caseating necrosis and are surrounded by a small number of lymphocytes.</div><div class=\"graphic_reference\">Courtesy of Shane A Meehan, MD.</div><div id=\"graphicVersion\">Graphic 54204 Version 1.0</div></div></div>"},"54205":{"type":"graphic_picture","displayName":"Morbilliform drug eruption","title":"Exanthematous (morbilliform) drug eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exanthematous (morbilliform) drug eruption</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54205_Morbilliformdrugeruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous erythematous macules and papules are present in this child with a morbilliform drug eruption.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54205 Version 7.0</div></div></div>"},"54206":{"type":"graphic_figure","displayName":"Anatomy of the esophagus","title":"Anatomy of the esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the esophagus</div><div class=\"cntnt\"><img style=\"width:422px; height:701px;\" src=\"images/SURG/54206_Anatomy-of-the-esophagus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The esophagus has three anatomical points of narrowing that are prone to perforation. These sites include the cricopharyngeus muscle, the broncho-aortic constriction, and the esophagogastric junction. The esophagogastric junction is the most common site of perforation.</div><div id=\"graphicVersion\">Graphic 54206 Version 4.0</div></div></div>"},"54207":{"type":"graphic_picture","displayName":"Ocular cicatricial pemphigoid stage 3","title":"Stage 3 ocular cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Stage 3 ocular cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:540px; height:353px;\" src=\"images/DERM/54207_Ocular_cicatricial_stage_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the symblepharon bridging between the eyeball and the eyelid.</div><div id=\"graphicVersion\">Graphic 54207 Version 1.0</div></div></div>"},"54208":{"type":"graphic_picture","displayName":"Actinic keratosis histopathology 2","title":"Actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Actinic keratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:327px;\" src=\"images/DERM/54208_Actinic_keratosis_histo_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Partial thickness epidermal dysplasia is present.</div><div id=\"graphicVersion\">Graphic 54208 Version 1.0</div></div></div>"},"54209":{"type":"graphic_picture","displayName":"Focal nodular hyperplasia Gross","title":"Focal nodular hyperplasia of the liver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal nodular hyperplasia of the liver</div><div class=\"cntnt\"><img style=\"width:397px; height:257px;\" src=\"images/GAST/54209_Focal_nodular_hyperplasia_G.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen showing a mass lesion within a noncirrhotic liver. Note the central stellate scar.</div><div class=\"graphic_reference\">Courtesy of Frank A Mitros, MD.</div><div id=\"graphicVersion\">Graphic 54209 Version 2.0</div></div></div>"},"54210":{"type":"graphic_table","displayName":"Mayo model survival PSC","title":"Mayo model for predicted survival in primary sclerosing cholangitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mayo model for predicted survival in primary sclerosing cholangitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td>R = 0.03 (age [yrs]) + 0.54<sub>e</sub>(bilirubin [mg/dL]) + 0.54 log<sub>e</sub>(AST [IU/L]) + 1.24 (variceal bleeding [0=no/1=yes]) - 0.84 (albumin [g/dL]).]</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Survival function coefficient [S<sub>0</sub>(t)]</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>1 year = 0.963</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>2 years = 0.919</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>3 years = 0.873</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>4 years = 0.833</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Calculated patient survival</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Probability of survival at time t years is calculated as S(t)= S<sub>0</sub>(t)<sup>exp(R-1.00)</sup></td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75:688. Calculator for this model available at: http://www.mayoclinic.org/gi-rst/mayomodel3.html (Accessed on September 11, 2007).</div><div id=\"graphicVersion\">Graphic 54210 Version 2.0</div></div></div>"},"54211":{"type":"graphic_picture","displayName":"CPAM type 2 gross pathology","title":"Gross pathology of a type 2 congenital pulmonary airway malformation (CPAM)*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross pathology of a type 2 congenital pulmonary airway malformation (CPAM)*</div><div class=\"cntnt\"><img style=\"width:432px; height:281px;\" src=\"images/PEDS/54211_CCAM_type_2_gross_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross pathology specimen from the lung of an infant with a type 2 congenital pulmonary airway malformation (CPAM). The lesion is a mixture of relatively solid regions and small cysts.</div><div class=\"graphic_footnotes\">* CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).</div><div class=\"graphic_reference\">Courtesy of Christopher M Oermann, MD, and Claire Langston, MD</div><div id=\"graphicVersion\">Graphic 54211 Version 5.0</div></div></div>"},"54212":{"type":"graphic_picture","displayName":"Macrosomic IDM","title":"Macrosomic infant of diabetic mother","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Macrosomic infant of diabetic mother</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/PEDS/54212_Macrosomic_IDM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A newborn macrosomic infant of a diabetic mother. The main abnormalities are disproportionate growth with a plethoric appearance and excessive fat accumulation.</div><div class=\"graphic_reference\">Courtesy of G Cabrera- Mesa, MD.</div><div id=\"graphicVersion\">Graphic 54212 Version 2.0</div></div></div>"},"54214":{"type":"graphic_picture","displayName":"Acute tinea pedis","title":"Acute tinea pedis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute tinea pedis</div><div class=\"cntnt\"><img style=\"width:378px; height:268px;\" src=\"images/PC/54214_Acute_tinea_pedis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The medial aspect of the left great toe demonstrates erythematous, papulovesicular lesions caused by <EM>Trichophyton mentagrophytes</EM>.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 54214 Version 3.0</div></div></div>"},"54215":{"type":"graphic_table","displayName":"Sterilization failure rates vs LARC","title":"Sterilization failure rates compared with long-acting reversible contraceptives","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sterilization failure rates compared with long-acting reversible contraceptives</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Contraceptive method</td> <td class=\"subtitle1\" colspan=\"3\">Pregnancies per 1000 procedures (follow-up interval in years)</td> </tr> <tr> <td class=\"subtitle2\">1 to 2 years</td> <td class=\"subtitle2\">3 to 5 years</td> <td class=\"subtitle2\">7 to 12 years</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle3_left\" colspan=\"4\">Female sterilization</td> </tr> <tr> <td class=\"subtitle4_left\" colspan=\"4\">Postpartum sterilization</td> </tr> <tr> <td class=\"indent2\">Postpartum partial salpingectomy</td> <td class=\"centered\">1.2 (1)</td> <td class=\"centered\">6.3 (5)</td> <td class=\"centered\">7.5 (10)</td> </tr> <tr> <td class=\"indent2\">Postpartum titanium clips (Filshie clips)</td> <td class=\"centered\">17 (2)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"subtitle4_left\" colspan=\"4\">Interval sterilization</td> </tr> <tr> <td class=\"indent2\">Interval partial salpingectomy</td> <td class=\"centered\">7.3 (1)</td> <td class=\"centered\">15.1 (5)</td> <td class=\"centered\">20.1 (10)</td> </tr> <tr> <td class=\"indent2\">Interval titanium clips (Filshie clips)</td> <td class=\"centered\">4 (2)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent2\">Silicone rubber band (Falope ring)</td> <td class=\"centered\">3 (1 to 2)</td> <td class=\"centered\">10 (5)</td> <td class=\"centered\">17.7 (10)</td> </tr> <tr> <td class=\"indent2\">Electrosurgery*</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">3.2* (5)</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Hysteroscopic sterilization (Essure)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">2.5 (5)</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"subtitle3_left\"><strong>Vasectomy</strong></td> <td class=\"divider_bottom centered\">1.5 (1)</td> <td class=\"divider_bottom centered\">&ndash;</td> <td class=\"divider_bottom centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle3_left\" colspan=\"4\">Long-acting reversible contraception</td> </tr> <tr> <td class=\"subtitle4_left\" colspan=\"4\">Intrauterine devices</td> </tr> <tr> <td class=\"indent2\">LNg 52/5 (Mirena)<sup>&#182;</sup></td> <td class=\"centered\">2 (1)</td> <td class=\"centered\">7 (5)</td> <td class=\"centered\">11 (7)</td> </tr> <tr> <td class=\"indent2\">LNg 52/3 (Liletta)<sup>&#916;</sup></td> <td class=\"centered\">1.4 (1)</td> <td class=\"centered\">5.5 (3)</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent2\">LNg 13.5/3 (Skyla)<sup>&#9674;</sup></td> <td class=\"centered\">4.1 (1)</td> <td class=\"centered\">9 (3)</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent2\">TCu380A copper IUD (ParaGard)</td> <td class=\"centered\">8 (1)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">14 (7); 22 (12)</td> </tr> <tr> <td class=\"indent2\">Etonogestrel implant (Nexplanon)</td> <td class=\"centered\">0.5 (1)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* With three contiguous sites of fulguration along the fallopian tube (a total length of fulguration of approximately 3 cm).<br />&para; Levonorgestrel (LNg)-releasing intrauterine device containing 52 mg LNg at initial placement and with an initial LNg release rate of 20 mcg/day for five years (Mirena).<br />&Delta; LNg-releasing intrauterine device containing 52 mg LNg at initial placement and with an initial LNg release rate of 18.6 mcg/day for three years (Liletta).<br /><span class=\"lozenge\">&loz;</span> LNg-releasing intrauterine device containing 13.5 mg LNg at initial placement and with an initial LNg release rate of 14 mcg/day for three years (Skyla).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996; 174:1161.</LI>&#xD;&#xA;<LI>Peterson HB, Xia Z, Wilcox LS, et al. Pregnancy after tubal sterilization with bipolar electrocoagulation. U.S. Collaborative Review of Sterilization Working Group. Obstet Gynecol 1999; 94:163.</LI>&#xD;&#xA;<LI>Rodriguez MI, Edelman AB, Kapp N. Postpartum sterilization with the titanium clip: a systematic review. Obstet Gynecol 2011; 118:143.</LI>&#xD;&#xA;<LI>Lawrie TA, Kulier R, Nardin JM. Techniques for the interruption of tubal patency for female sterilization. Cochrane Database Syst Rev 2015; 9:CD003034.</LI>&#xD;&#xA;<LI>Rios-Castillo JE, Velasco E, Arjona-Berral JE, et al., Efficacy of Essure hysteroscopic sterilization--5 years follow up of 1200 women. Gynecol Endocrinol 2013; 29:580.</LI>&#xD;&#xA;<LI>Hatcher RA, Trussell J, Nelson AL, et al. Contraceptive Technology, 20th ed, Ardent Media, Inc, New York 2011.</LI>&#xD;&#xA;<LI>Eisenberg DL, Schreiber CA, Turok DK, et al. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception 2015; 92:10.</LI>&#xD;&#xA;<LI>Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol 2013; 122:1205.</LI>&#xD;&#xA;<LI>Sivin I, Stern J, Cutinho E, et. al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380Ag IUDs. Contraception 1991; 44:473.</LI>&#xD;&#xA;<LI>Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception 1997; 56:341.</LI></OL></div><div id=\"graphicVersion\">Graphic 54215 Version 4.0</div></div></div>"},"54216":{"type":"graphic_figure","displayName":"Uterine and vaginal development","title":"Schematic diagram of the formation of the uterus and vagina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic diagram of the formation of the uterus and vagina</div><div class=\"cntnt\"><img style=\"width:447px; height:241px;\" src=\"images/OBGYN/54216_Uterine_and_vaginal_develop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: At nine weeks, the uterine septum has disappeared. Middle panel: At 13 weeks, the sinovaginal bulbs have begun to grow out of the pelvic part of the urogenital sinus and form a solid plate. Right panel: In the newborn, the upper third of the vagina and the fornices are formed by vacuolization of the paramesonephric tissue and the lower-thirds of the vagina is formed by vacuolization of the sinovaginal bulbs.</div><div class=\"graphic_reference\">Adapted from Langman, J, Medical Embryology, 4th ed, Williams &amp; Wilkins, Baltimore, 1981. p. 253.</div><div id=\"graphicVersion\">Graphic 54216 Version 1.0</div></div></div>"},"54218":{"type":"graphic_picture","displayName":"Axonal swelling","title":"Axonal swelling on skin biopsy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Axonal swelling on skin biopsy</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/NEURO/54218_Axonal_swelling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large axonal swelling is observed in this skin biopsy.</div><div class=\"graphic_reference\">Courtesy of&nbsp;A. Gordon Smith, MD</div><div id=\"graphicVersion\">Graphic 54218 Version 3.0</div></div></div>"},"54219":{"type":"graphic_figure","displayName":"Intercostal muscle flap","title":"Harvesting an intercostal muscle flap","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Harvesting an intercostal muscle flap</div><div class=\"cntnt\"><img style=\"width:530px; height:461px;\" src=\"images/SURG/54219_Intercostal-muscle-flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts harvesting an intercostal muscle flap as a pedicle flap for repair of a thoracic esophageal perforation.</div><div id=\"graphicVersion\">Graphic 54219 Version 1.0</div></div></div>"},"54220":{"type":"graphic_figure","displayName":"GWAS Stages","title":"Stages of a genome-wide association study","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Stages of a genome-wide association study</div><div class=\"cntnt\"><img style=\"width:588px; height:793px;\" src=\"images/PC/54220_GWAS_stages_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>(1, 2)</strong> Well-characterized cases and controls of similar ancestry are genotyped using oligonucleotide microarrays, typically consisting of assays for 500,000 to 1,000,000 SNPs. A representative cartesian plot of results for one such assay is presented. Individuals homozygous for the major allele are plotted in blue, homozygotes for the minor allele in red, and heterozygotes in green.<br> <strong>(3)</strong> Next, extensive quality control analysis is conducted, including assessments at the level of the individual samples (microarray quality, subject genotype completion rates, gender inconsistencies) and individual assays (assay quality scores, genotype completion rates, Hardy Weinberg equilibrium, parent-child genotype inconstancies). Screens for cryptic sample relatedness are performed using Identity By State statistics. Data are then filtered, with removal of results for problematic subjects or assays.<br> <strong>(4)</strong> Principal components analysis (shown) enables screening for evidence of population stratification. If detected, outlier subjects can be removed from consideration, and the eigenvectors generated can be used as covariates in the subsequent association testing.<br> <strong>(5)</strong> Using reference genotype panels, additional SNP genotypes for untyped variants (grey SNPs) can be imputed from the typed variants (in black) and considered for association testing.<br> <strong>(6)</strong> Statistical inference is performed by testing individual variants for association by logistic regression for case-control studies or linear regression for quantitative traits, with adjustment for relevant covariates, including eigenvectors. To accommodate the large number of hypotheses tested, p-values must be adjusted, with more stringent cutoffs p-values designated in advance.<br> <strong>(7)</strong> Results can be visualized using so-called &quot;Manhattan Plots,&quot; where the individual -log10 p-values are plotted as a function of physical position.<br> <strong>(8)</strong> Significant associations can be passed for additional validation, including replication studies in independent cohorts, sequencing and fine-mapping studies to identify causal variants, and experimental validation to confirm biological relevance and function. Additional modeling, including gene-by-gene interaction and gene-by-environment modeling, can also be conducted.</div><div id=\"graphicVersion\">Graphic 54220 Version 2.0</div></div></div>"},"54221":{"type":"graphic_picture","displayName":"Gonorrhea penile edema","title":"Penile edema in gonorrhea","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Penile edema in gonorrhea</div><div class=\"cntnt\"><img style=\"width:504px; height:353px;\" src=\"images/DERM/54221_Gonorrhea_penile_edema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 2-year-old boy developed a urethral discharge (positive for Neisseria gonorrhoeae), followed by painless swelling of the distal penile shaft. This condition is more common in adolescent and young adult males.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54221 Version 1.0</div></div></div>"},"54222":{"type":"graphic_figure","displayName":"Metagonimiasis life cycle","title":"Metagonimiasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Metagonimiasis life cycle</div><div class=\"cntnt\"><img style=\"width:599px; height:475px;\" src=\"images/ID/54222_Metagonimiasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adults release fully embryonated eggs each with a fully developed miracidium, and eggs are passed in the host's feces <STRONG>(1)</STRONG>. After ingestion by a suitable snail (first intermediate host), the eggs hatch and release miracidia, which penetrate the snail's intestine <STRONG>(2)</STRONG>. Snails of the genus <EM>Semisulcospira</EM> are the most frequent intermediate host for <EM>Metagonimus yokogawai</EM>. The miracidia undergo several developmental stages in the snail [ie, sporocysts <STRONG>(2a)</STRONG>, rediae <STRONG>(2b)</STRONG>, and cercariae <STRONG innerHtml>(2c)</STRONG>]. Many cercariae are produced from each rediae. The cercariae are released from the snail <STRONG>(3)</STRONG> and encyst as metacercariae in the tissues of a suitable fresh- or brackish-water fish (second intermediate host) <STRONG>(4)</STRONG>. The definitive host becomes infected by ingesting undercooked or salted fish containing metacercariae <STRONG>(5)</STRONG>. After ingestion, the metacercariae excyst, attach to the mucosa of the small intestine <STRONG>(6)</STRONG>, and mature into adults (measuring 1.0 mm to 2.5 mm by 0.4 mm to 0.75 mm) <STRONG>(7)</STRONG>. In addition to humans, fish-eating mammals (eg, cats and dogs) and birds can also be infected by <EM>M. yokogawai</EM> <STRONG>(8)</STRONG>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Metagonimiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/metagonimiasis/index.html\">http://www.cdc.gov/dpdx/metagonimiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 54222 Version 5.0</div></div></div>"},"54223":{"type":"graphic_figure","displayName":"SO phasic waves manometry","title":"Sphincter of Oddi manometry","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Sphincter of Oddi manometry</div><div class=\"cntnt\"><img style=\"width:492px; height:251px;\" src=\"images/GAST/54223_SO_phasic_waves_manometry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sphincter of Oddi (SO) pressure profile obtained by catheter pull-through from the common bile duct (CBD) into the duodenum. The three recording tips (proximal to distal) encompass a 4 mm length. The basal SO pressure and superimposed SO phasic waves are demonstrated in all tips.</div><div class=\"graphic_reference\">Courtesy of Walter J Hogan, MD.</div><div id=\"graphicVersion\">Graphic 54223 Version 1.0</div></div></div>"},"54225":{"type":"graphic_movie","displayName":"VSD in Tetrology of Fallot parasternal long axis echo","title":"Ventricular septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventricular septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/54225_palaxvsdconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:258px; height:225px;\" src=\"images/CARD/54225_palaxvsd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long axis view from a 2-D echocardiogram with color flow Doppler shows a ventricular septal defect (VSD) of the membraneous septum with left to right shunting of blood.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 54225 Version 3.0</div></div></div>"},"54227":{"type":"graphic_figure","displayName":"Murless head elevator","title":"Murless head elevator","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Murless head elevator</div><div class=\"cntnt\"><img style=\"width:374px; height:426px;\" src=\"images/OBGYN/54227_Murless_head_elevator.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54227 Version 3.0</div></div></div>"},"54228":{"type":"graphic_table","displayName":"Common causes pneumonia child","title":"Common etiologic agents of pediatric pneumonia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common etiologic agents of pediatric pneumonia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Microbial agent</td> <td class=\"subtitle1\">Susceptible hosts</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Chlamydia trachomatis</em></td> <td>First 3 months of life</td> </tr> <tr> <td class=\"indent1\"><em>Mycoplasma hominis</em></td> <td>First 3 months of life</td> </tr> <tr> <td class=\"indent1\"><em>Treponema pallidum</em></td> <td>First 3 months of life</td> </tr> <tr> <td class=\"indent1\"><em>Ureaplasma urealyticum</em></td> <td>First 3 months of life</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> <td>Primarily children &#60;5 years</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus pyogenes</em></td> <td>Primarily children &#60;5 years</td> </tr> <tr> <td class=\"indent1\"><em>Chlamydia pneumoniae</em></td> <td>Primarily children &#8805;5 years</td> </tr> <tr> <td class=\"indent1\"><em>Mycoplasma pneumoniae</em></td> <td>Primarily children &#8805;5 years</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus pneumoniae</em></td> <td>All</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Viruses</td> </tr> <tr> <td class=\"indent1\">Respiratory syncytial virus</td> <td>Primarily children &#60;5 years</td> </tr> <tr> <td class=\"indent1\">Influenza A and B</td> <td>Primarily children &#60;5 years&nbsp;</td> </tr> <tr> <td class=\"indent1\">Human metapneumovirus</td> <td>Primarily children &#60;5 years</td> </tr> <tr> <td class=\"indent1\">Parainfluenza viruses&nbsp;1, 2, and 3</td> <td>Primarily children &#60;5 years</td> </tr> <tr> <td class=\"indent1\">Coronaviruses (including SARS and MERS)</td> <td>Primarily children &#60;5 years&nbsp;</td> </tr> <tr> <td class=\"indent1\">Adenoviruses</td> <td>Primarily children &#60;5 years</td> </tr> <tr> <td class=\"indent1\">Enterovirus D68&nbsp;</td> <td>Primarily children &#60;5 years</td> </tr> <tr> <td class=\"indent1\">Rhinovirus</td> <td>Primarily children &#60;5 years</td> </tr> <tr> <td class=\"indent1\">Human bocavirus</td> <td>Primarily children &#60;5 years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SARS: severe acute respiratory syndrome; MERS: Middle East respiratory syndrome.<br />* Excluding neonatal pneumonia (in infants &lt;28 days of age).</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Byington CL, Bradley JS. Pediatric community-acquired pneumonia. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7<SUP>th</SUP> ed, Cherry JD, Harrison GJ, Kaplan SL, et al. (Eds), Elsevier Saunders, Philadelphia 2014. p.283.</LI>&#xD;&#xA;<LI>Cherry JD, Nadipuram S. Adenoviruses. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7<SUP>th</SUP> ed,&nbsp;Cherry JD, Harrison GJ, Kaplan SL, et al. (Eds), Elsevier Saunders, Philadelphia 2014. p.1888.</LI>&#xD;&#xA;<LI>Gaston B. Pneumonia. Pediatr Rev 2002; 23:132.</LI>&#xD;&#xA;<LI>McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.</LI>&#xD;&#xA;<LI>Sandora T, Harper MB. Pneumonia in hospitalized children. Pediatr Clin North Am 2005; 52:1059.</LI></OL></div><div id=\"graphicVersion\">Graphic 54228 Version 11.0</div></div></div>"},"54229":{"type":"graphic_picture","displayName":"Intra TM squamous pearl","title":"Intratympanic inclusion cyst (squamous pearl) without middle ear extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intratympanic inclusion cyst (squamous pearl) without middle ear extension</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/PEDS/54229_Intra_TM_squamous_pearl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An intratympanic inclusion cyst (squamous pearl) without middle ear extension.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 54229 Version 1.0</div></div></div>"},"54230":{"type":"graphic_picture","displayName":"Dermatomyositis - neck and chest","title":"Dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatomyositis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54230_Dermatomyositis_neck_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent areas of violaceous erythema are present on the neck, chest, and upper arms of this patient with dermatomyositis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54230 Version 4.0</div></div></div>"},"54231":{"type":"graphic_picture","displayName":"Cholangioscopy following electrohydraulic lithotripsy","title":"Cholangioscopy following electrohydraulic lithotripsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholangioscopy following electrohydraulic lithotripsy</div><div class=\"cntnt\"><img style=\"width:357px; height:378px;\" src=\"images/GAST/54231_Cholangio_electrohydraulic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangioscopy of the bile duct following fragmentation of a bile duct stone using electrohydraulic lithotripsy.</div><div class=\"graphic_reference\">Courtesy of Yang K Chen, MD.</div><div id=\"graphicVersion\">Graphic 54231 Version 4.0</div></div></div>"},"54232":{"type":"graphic_picture","displayName":"Erythema multiforme leg","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54232_Erythema_multiforme_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child with widespread erythema multiforme had multiple lesions on the trunk and extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54232 Version 4.0</div></div></div>"},"54234":{"type":"graphic_picture","displayName":"Necrotic adenoca colon Endosc","title":"Necrotic adenocarcinoma of the colon","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Necrotic adenocarcinoma of the colon</div><div class=\"cntnt\"><img style=\"width:460px; height:225px;\" src=\"images/GAST/54234_Necrotic_adenoca_colon_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy showing necrotic colonic lesions that usually suggest an advanced stage of malignancy. Panel A: severe tissue destruction has led to necrosis and bleeding; Panel B: the longstanding tumor has extended deeply into the mucosa and become necrotic.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 54234 Version 1.0</div></div></div>"},"54236":{"type":"graphic_figure","displayName":"Normal versus refluxing ureterovesical junctions","title":"Normal versus refluxing ureterovesical junctions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal versus refluxing ureterovesical junctions</div><div class=\"cntnt\"><img style=\"width:378px; height:429px;\" src=\"images/PEDS/54236_Normal_vs_reflux.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Pediatric Nephrology, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott, Philadelphia, PA 2004. p.1028.</div><div id=\"graphicVersion\">Graphic 54236 Version 4.0</div></div></div>"},"54237":{"type":"graphic_table","displayName":"DiGeorge features","title":"Phenotypic findings in DiGeorge syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phenotypic findings in DiGeorge syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Ocular hypertelorism</td> </tr> <tr> <td>Upslanting palpebral fissures</td> </tr> <tr> <td>Hooded eyelids</td> </tr> <tr> <td>Low-set posteriorly rotated ears</td> </tr> <tr> <td>Widened area below nasal bridge</td> </tr> <tr> <td>Bulbous nose tip</td> </tr> <tr> <td>Micrognathia</td> </tr> <tr> <td>Short philtrum</td> </tr> <tr> <td>High-arched palate</td> </tr> <tr> <td>Submucosal cleft palate/bifid uvula</td> </tr> <tr> <td>Tapered fingers</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54237 Version 4.0</div></div></div>"},"54238":{"type":"graphic_figure","displayName":"Urinary flow patterns","title":"Normal and abnormal urinary flow patterns in the evaluation of bladder dysfunction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal and abnormal urinary flow patterns in the evaluation of bladder dysfunction</div><div class=\"cntnt\"><img style=\"width:368px; height:431px;\" src=\"images/PEDS/54238_Uroflow_patterns.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abnormal urine flow patterns can be helpful in identifying underlying causes of voiding dysfunction. A tower curve pattern may be seen in patients with an overactive bladder, a plateau curve in patients with bladder obstruction, a plateau or staccato curve in patients with dysfunctional voiding, and an interrupted curve in patients with an underactive bladder.</div><div id=\"graphicVersion\">Graphic 54238 Version 2.0</div></div></div>"},"54239":{"type":"graphic_figure","displayName":"ROC curve","title":"Receiver operating characteristic curve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Receiver operating characteristic curve</div><div class=\"cntnt\"><img style=\"width:381px; height:350px;\" src=\"images/PC/54239_ROC_curve.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The receiver operating characteristic curve (ROC) plots sensitivity against 1- specificity (ie, the false positive rate). Cutoff values for the diagnostic test (such as serum ALT concentrations) vary along the length of the black curve, reflecting the interchange between sensitivity and specificity. The area under the ROC curve represents the accuracy of the test. A test that performs no better than chance would be represented by a straight line (red line) with an area under the ROC of 0.5. A near perfect test would have a rectangular configuration (blue line) with an area under the ROC approaching 1.00.</div><div id=\"graphicVersion\">Graphic 54239 Version 1.0</div></div></div>"},"54240":{"type":"graphic_figure","displayName":"Anatomy of dorsalis pedis artery","title":"Anatomy of dorsalis pedis artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of dorsalis pedis artery</div><div class=\"cntnt\"><img style=\"width:450px; height:644px;\" src=\"images/SURG/54240_Anatomy_of_dorsalis_pedis_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dorsalis pedis artery is located lateral to the extensor hallucis longus tendon.</div><div class=\"graphic_reference\">Redrawn from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.</div><div id=\"graphicVersion\">Graphic 54240 Version 4.0</div></div></div>"},"54241":{"type":"graphic_figure","displayName":"Grafting technique for Peyronies disease","title":"Grafting technique for Peyronies disease","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Grafting technique for Peyronies disease</div><div class=\"cntnt\"><img style=\"width:518px; height:685px;\" src=\"images/SURG/54241_PD_graft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grafting procedures can be performed in men with Peyronie's disease who have a short penis, extensive plaque, or complex deformities. Grafting lengthens and straightens the concave side of the penis. Dissection of the neurovascular bundle and/or corpus spongiosum may be required depending upon the location of the plaque.</div><div id=\"graphicVersion\">Graphic 54241 Version 2.0</div></div></div>"},"54244":{"type":"graphic_table","displayName":"WHO MEC for potential drug interactions","title":"World Health Organization medical eligibility for contraceptive use: Drug interactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization medical eligibility for contraceptive use: Drug interactions</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Condition\n   </td>\n   <td  class=\"subtitle1\">\n   COC\n   </td>\n   <td  class=\"subtitle1\">\n   CIC\n   </td>\n   <td  class=\"subtitle1\">\n   P/R\n   </td>\n   <td  class=\"subtitle1\">\n   POP\n   </td>\n   <td  class=\"subtitle1\">\n   \t<p>DMPA</p>\n\t<p> \tNET-EN</p>\n   </td>\n   <td  class=\"subtitle1\">\n   \t<p>LNG/ETG</p>\n\t<p> \tImplants</p>\n   </td>\n   <td  class=\"subtitle1\">\n   Cu-IUD\n   </td>\n   <td  class=\"subtitle1\">\n   LNG-IUD\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"9\" rowspan=\"1\">\n   Drugs which affect liver enzymes\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Rifampicin or rifabutin\n   </td>\n   <td>3</td>\n   <td>2</td>\n   <td>3</td>\n   <td>3</td>\n   <td>\t<p>DMPA 1</p>\n\t<p> \tNET-EN 2</p>\n</td>\n   <td>2</td>\n   <td>1</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine)\n   </td>\n   <td>3</td>\n   <td>2</td>\n   <td>3</td>\n   <td>3</td>\n   <td>\t<p>DMPA 1</p>\n\t<p> \tNET-EN 2</p>\n</td>\n   <td>2</td>\n   <td>1</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Lamotrigine\n   </td>\n   <td>3</td>\n   <td>3</td>\n   <td>3</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"9\" rowspan=\"1\">\n   Antimicrobials (excluding rifampicin)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Broad spectrum antibiotics\n   </td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Antifungals and Antiparasites\n   </td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"9\">\n   Antiretroviral therapy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Nucleoside reverse transcriptase inhibitors\n   </td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>\t<p>DMPA 1</p>\n\t<p> \tNET-EN 1</p>\n</td>\n   <td>1</td>\n   <td>\t<p>Initiation: 2/3</p>\n\t<p> \tContinuation: 2</p>\n</td>\n   <td>\t<p>Initiation: 2/3</p>\n\t<p> \tContinuation: 2</p>\n</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Non-nucleoside reverse transcriptase inhibitors\n   </td>\n   <td>2</td>\n   <td>2</td>\n   <td>2</td>\n   <td>2</td>\n   <td>\t<p>DMPA 1</p>\n\t<p> \tNET-EN 2</p>\n</td>\n   <td>2</td>\n   <td>\t<p>Initiation: 2/3</p>\n\t<p> \tContinuation: 2</p>\n</td>\n   <td>\t<p>Initiation: 2/3</p>\n\t<p> \tContinuation: 2</p>\n</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Ritonavir-boosted protease inhibitors\n   </td>\n   <td>3</td>\n   <td>3</td>\n   <td>3</td>\n   <td>3</td>\n   <td>\t<p>DMPA 1</p>\n\t<p> \tNET-EN 2</p>\n</td>\n   <td>2</td>\n   <td>\t<p>Initiation: 2/3</p>\n\t<p> \tContinuation: 2</p>\n</td>\n   <td>\t<p>Initiation: 2/3</p>\n\t<p> \tContinuation: 2</p>\n</td>\n   </tr>\n </table></div><div class=\"graphic_lgnd\">WHO comments: Although the interaction of rifampicin or rifabutin with POPs, NET-EN and LNG/ETG implants is not harmful to women, it is likely to reduce the effectiveness of POPs, NET-EN and LNG/ETG implants. Use of other contraceptives should be encouraged for women who are long-term users of any of these drugs.Whether increasing the hormone dose of POPs alleviates this concern remains unclear.<br>Use of DMPA is a Category 1 because its effectiveness is not decreased by the use of rifampicin or rifabutin.</div><div class=\"graphic_footnotes\">1: A condition for which there is no restriction for the use of the contraceptive method.<br> 2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.<br> 3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.<br> 4: A condition which represents an unacceptable health risk if the contraceptive method is used.<br> COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.</div><div class=\"graphic_reference\">Reproduced with permission from: Medical Eligibility Criteria for Contraceptive Use - 3rd Ed. Available at: http://www.who.int/reproductive-health/publications/mec/summary.html. Copyright &#169;2006 World Health Organization. Revised from: Medical Eligibility Criteria for Contraceptive Use, 2008 update. Available at: http://www.who.int/reproductive-health/publications/mec/.</div><div id=\"graphicVersion\">Graphic 54244 Version 2.0</div></div></div>"},"54246":{"type":"graphic_table","displayName":"ESC driving after ICD","title":"European Society of Cardiology guidelines for driving restriction following implantation of an implantable cardioverter-defibrillator","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Society of Cardiology guidelines for driving restriction following implantation of an implantable cardioverter-defibrillator</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup width=\"35%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of arrhythmia</td> <td class=\"subtitle1\">Noncommercial driving</td> <td class=\"subtitle1\">Commercial driving</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Class I</td> </tr> <tr> <td class=\"sublist2_start\">Prophylactic ICD (primary prevention)</td> <td rowspan=\"4\">No restriction</td> <td rowspan=\"4\">Total restriction</td> </tr> <tr> <td class=\"sublist2\">Strong family history of SCD</td> </tr> <tr> <td class=\"sublist2\">Nonsustained VT with LV dysfunction</td> </tr> <tr> <td class=\"sublist2\">Patients enrolled in ICD research protocols</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">If appropriate shock during follow-up, particularly if with disabling symptoms</td> <td>Six months</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Class II</td> </tr> <tr> <td class=\"sublist2_start\">All patients with ICD except for prophylaxis</td> <td>Six months</td> <td class=\"divider_bottom\" rowspan=\"3\">Total restriction</td> </tr> <tr> <td class=\"sublist2\">If no ICD therapy for six months (class IIA)</td> <td class=\"sublist_other\">No restriction</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">If ICD therapy at any time, with or without syncope or presyncope (class IIB)</td> <td class=\"sublist_other\">Six months*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Class III</td> </tr> <tr> <td class=\"indent1\">High risk patients in class IIB with NYHA class III or IV, LVEF &#60;40 percent, VT rate &#8805;180 beats/min, and/or three or more arrhythmia episodes per six months</td> <td>Total restriction until satisfactory control of arrhythmia is achieved<sup>&#182;</sup></td> <td>Total restriction</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator; SCD: sudden cardiac death; VT: ventricular tachycardia; LV: left ventricular; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction.<br />* Subsequent decision based upon the nature, frequency, and severity of arrhythmia recurrences. The level of consciousness from arrhythmia onset until ICD termination should be considered when deciding the fitness to drive. The patient may be allowed to drive after six months if recurrences are well tolerated and do not alter the level of consciousness. The patient should be advised not to drive if there are any disabling symptoms during arrhythmia recurrence.<br />&para; In very selected patients, an exception can be made in patients who do not have impaired consciousness during arrhythmia episodes (eg, asymptomatic and well-tolerated VT that is reliably and reproducibly terminated by antitachycardia pacing without arrhythmia acceleration).</div><div class=\"graphic_reference\">Adapted from Jung W, Anderson M, Camm AJ, et al. Recommendations for driving of patients with implantable cardioverter defibrillators. Study Group on 'ICD and Driving' of the Working Groups on Cardiac Pacing and Arrhythmias of the European Society of Cardiology. Eur Heart J 1997; 18:1210.</div><div id=\"graphicVersion\">Graphic 54246 Version 3.0</div></div></div>"},"54248":{"type":"graphic_figure","displayName":"High frequency vent modes","title":"Modes of high frequency ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Modes of high frequency ventilation</div><div class=\"cntnt\"><img style=\"width:401px; height:312px;\" src=\"images/PULM/54248_High_frequency_vent_modes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Modes of high frequency ventilation. With high frequency positive pressure ventilation (top), high-pressure conditioned gas (a) is delivered during inhalation and flows predominantly through an endotracheal tube (b) to the patient with partial escape to the atmosphere. During exhalation, the gas exits through an optional one-way valve (c). With high frequency jet ventilation (middle), conditioned high-pressure gas enters from a cannula (a) at a selected level along the endotracheal tube or trachea (c). This gas entrains additional conditioned gas (b) by the Venturi effect. During exhalation the gas exits passively through an optional one-way valve (d). With high frequency oscillation (bottom), the piston or diaphragm (a) oscillates while fresh conditioned gas (bias flow) enters (b) and exhaust gas exits (c) at a balanced constant rate. The bias flow ports can be positioned anywhere along the path from the external tip of the endotracheal tube to within the trachea itself.</div><div id=\"graphicVersion\">Graphic 54248 Version 1.0</div></div></div>"},"54250":{"type":"graphic_picture","displayName":"Autopsy specimen atherosclerosis","title":"Autopsy specimen of atherosclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autopsy specimen of atherosclerosis</div><div class=\"cntnt\"><img style=\"width:202px; height:648px;\" src=\"images/SURG/54250_Autopsy_specimen_atheroscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Autopsy specimen from a patient with cholesterol crystal embolism demonstrates severe atherosclerosis of the aorta.</div><div class=\"graphic_reference\">Courtesy of Dr. Amy Rapkiewicz.</div><div id=\"graphicVersion\">Graphic 54250 Version 1.0</div></div></div>"},"54251":{"type":"graphic_algorithm","displayName":"Surgery for endocarditis","title":"Surgery for endocarditis","html":"<div class=\"graphic\"><div style=\"width: 829px\" class=\"figure\"><div class=\"ttl\">Surgery for endocarditis</div><div class=\"cntnt\"><img style=\"width:809px; height:510px;\" src=\"images/CARD/54251_Surgery_for_endocarditis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Class I - There is evidence and/or general agreement that TTE or TEE should be performed in patients with native or prosthetic valve IE.<br />Class IIa - The weight of evidence or opinion is in favor of the usefulness of TTE or TEE in patients with native or prosthetic valve IE.<br />Class IIb - The weight of evidence or opinion is less well-established for the usefulness of TTE or TEE in patients with native or prosthetic valve IE.</div><div class=\"graphic_footnotes\">HF: heart failure; ICD: implantable cardioverter-defibrillator; IE: infective endocarditis; NVE: native valve endocarditis; PVE: prosthetic valve endocarditis; Rx: therapy; <em>S. aureus</em>: <em>Staphylococcus aureus</em>; TEE: transesophageal echocardiography; TTE: transthoracic echocardiography; VKA: vitamin K antagonist.<br />* Early surgery defined as during initial hospitalization before completion of a full therapeutic course of antibiotics.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; e136. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 54251 Version 5.0</div></div></div>"},"54252":{"type":"graphic_diagnosticimage","displayName":"Dilation of the esophagus in a patient with achalasia","title":"Dilation of the esophagus in a patient with achalasia (barium esophagram)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dilation of the esophagus&nbsp;in a patient with achalasia&nbsp;(barium esophagram)</div><div class=\"cntnt\"><img style=\"width:360px; height:395px;\" src=\"images/GAST/54252_Classic_achalasia_Ba_swallo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium&nbsp;esophagram in a 62-year-old man demonstrates a dilated, barium-filled esophagus with a region of persistent narrowing (arrow) at the gastroesophageal junction, producing the so-called bird's beak appearance. Achalasia was confirmed with manometry and the patient underwent successful dilation of the esophagus.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 54252 Version 4.0</div></div></div>"},"54253":{"type":"graphic_table","displayName":"Selectivity of NSAIDs","title":"Selected nonsteroidal antiinflammatory drugs (NSAIDs) and other analgesics: Selectivity for cyclooxygenase-2 and potency in inhibiting gastric COX activity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected nonsteroidal antiinflammatory drugs (NSAIDs) and other analgesics: Selectivity for cyclooxygenase-2 and potency in inhibiting gastric COX activity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">COX-2 selectivity*</td> <td class=\"subtitle1\">Gastric IC50 (&#181;M)&#182;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">NSAIDs</td> </tr> <tr> <td class=\"indent1\">Ketoprofen</td> <td>0.1</td> <td>0.08</td> </tr> <tr> <td class=\"indent1\">Ibuprofen</td> <td>0.6</td> <td>0.70</td> </tr> <tr> <td class=\"indent1\">Indomethacin</td> <td>0.7</td> <td>0.85</td> </tr> <tr> <td class=\"indent1\">Naproxen</td> <td>1.0</td> <td>0.52</td> </tr> <tr> <td class=\"indent1\">Piroxicam</td> <td>1.3</td> <td>0.87</td> </tr> <tr> <td class=\"indent1\">Ketoralac</td> <td>1.5</td> <td>0.33</td> </tr> <tr> <td class=\"indent1\">Nabumetone</td> <td>1.6</td> <td>0.48</td> </tr> <tr> <td class=\"indent1\">Etodolac</td> <td>7.9</td> <td>3.20</td> </tr> <tr> <td class=\"indent1\">Celecoxib</td> <td>9.2</td> <td>11.14</td> </tr> <tr> <td class=\"indent1\">Mefenamic acid</td> <td>12.1</td> <td>0.70</td> </tr> <tr> <td class=\"indent1\">Nimesulide (not available in US)</td> <td>58.3</td> <td>1.49</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other analgesics</td> </tr> <tr> <td class=\"indent1\">Aspirin (acetylsalicylic acid)</td> <td>0.3</td> <td>0.03</td> </tr> <tr> <td class=\"indent1\">Salsalate (salicylsalicylic acid)</td> <td>&#8805;2.8</td> <td>&#62;100</td> </tr> <tr> <td class=\"indent1\">Acetaminophen</td> <td>4.0</td> <td>&#62;100</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In whole blood assays in man. A number ≅1 indicates COX non-selectivity while numbers much &gt;1 indicate COX-2 selectivity. Values for nabumetone are for its active metabolite, 6-MNA.<br />¶&nbsp;Concentration of drug that inhibits human gastric mucosal COX activity by 50 percent and thus gastric mucosal PG production by 50 percent. The lower the IC50, the more potent the inhibition of gastric COX activity for a given drug.</div><div class=\"graphic_reference\">Adapted from: Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104:413.</div><div id=\"graphicVersion\">Graphic 54253 Version 6.0</div></div></div>"},"54254":{"type":"graphic_movie","displayName":"TEE aortic regurgitation","title":"Transesophageal echocardiogram with color flow Doppler bicuspid aortic valve with aortic regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram with color flow Doppler bicuspid aortic valve with aortic regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/54254_teeaoregconv.mp4\" style=\"width:431px;height:322px\"></div><img style=\"width:450px; height:263px;\" src=\"images/CARD/54254_teeaoreg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram with color-flow Doppler shows mild or moderate aortic regurgitation in a patient with a bicuspid aortic valve.</div><div class=\"graphic_footnotes\">MV: mitral valve leaflet; Ao: aorta; LV: left ventricle; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 54254 Version 4.0</div></div></div>"},"54258":{"type":"graphic_figure","displayName":"Immunohistochem CUP","title":"Immunohistochemistry in undifferentiated neoplasms","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Immunohistochemistry in undifferentiated neoplasms</div><div class=\"cntnt\"><img style=\"width:571px; height:717px;\" src=\"images/ONC/54258_Immunohistochem_CUP.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Dabbs DJ. Immunohistology of metastatic carcinoma of unknown primary. In: Diagnostic Immunohistochemistry, 2nd edition, Dabbs DJ (Ed), Elsevier, Philadelphia 2006. p. 180. Copyright ©2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 54258 Version 2.0</div></div></div>"},"54259":{"type":"graphic_table","displayName":"NCCN followup guide HNC","title":"National Comprehensive Cancer Network (NCCN) recommended follow-up for head and neck cancers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">National Comprehensive Cancer Network (NCCN) recommended follow-up for head and neck cancers</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1\">\n   Posttreatment year\n   </td>\n   <td   class=\"subtitle1\">\n   Physical examination frequency\n   </td>\n   </tr>\n   <tr>\n   <td>1</td>\n   <td>Every one to three months</td>\n   </tr>\n   <tr>\n   <td>2</td>\n   <td>Every two to four months</td>\n   </tr>\n   <tr>\n   <td>3-5</td>\n   <td>Every four to six months</td>\n   </tr>\n   <tr>\n   <td>&#62;5</td>\n   <td>Every six to twelve months</td>\n   </tr>\n </table></div><div class=\"graphic_lgnd\">Frequency of physical examination is the same across head and neck cancer sites: paranasal sinus, salivary gland, lip, oral cavity, oropharynx, larynx, hypopharynx, and nasopharynx.<br>Additional screening examinations include: thyroid stimulating hormone (TSH) every 6-12 months, if the neck was irradiated; chest imaging as indicated; speech, hearing, and swallowing evaluation and rehabilitation as indicated; and dental evaluation as indicated.</div><div class=\"graphic_reference\">Data from: National Comprehensive Cancer Network guidelines. Available online at:http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed February 26, 2010)./u003c/div/u003e/u003cdiv id/u003d\"graphicVersion\">Graphic 54259 Version 1.0</div></div></div>"},"54260":{"type":"graphic_diagnosticimage","displayName":"Tracheal diverticulum CT","title":"Tracheal diverticulum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal diverticulum</div><div class=\"cntnt\"><img style=\"width:322px; height:280px;\" src=\"images/PULM/54260_Tracheal_diverticulum_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan demonstrates a tracheal diverticulum originating from the right posterolateral wall of the trachea at the thoracic inlet.</div><div id=\"graphicVersion\">Graphic 54260 Version 2.0</div></div></div>"},"54262":{"type":"graphic_figure","displayName":"Tongue sweep","title":"Tongue sweep during laryngoscopy","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Tongue sweep during laryngoscopy</div><div class=\"cntnt\"><img style=\"width:526px; height:278px;\" src=\"images/EM/54262_Tongue_sweep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tongue control during laryngoscopy. A and B) Poor visualization of the cords due to incorrect positioning of the blade. Note how the tongue folds over the blade and obscures the view. C) Correct positioning of the blade to control and move the tongue to the left, providing an optimal view for intubation.</div><div class=\"graphic_reference\">Reproduced with permission from: Brown CA, Carleton SC, Reardon RF. Supplemental Oxygen. In: Manual of Emergency Airway Management, 4th ed, Walls RM, Murphy MF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54262 Version 11.0</div></div></div>"},"54263":{"type":"graphic_diagnosticimage","displayName":"Thyroid nodule with halo echo","title":"Thyroid nodule with halo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thyroid nodule with halo</div><div class=\"cntnt\"><img style=\"width:276px; height:417px;\" src=\"images/ENDO/54263_Thyroid_nodule_with_halo_Ec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Top panel) A sonogram of the left lobe of the thyroid gland that shows a hypoechoic nodule that is surrounded by a \"halo.\"<br />(Lower panel) Doppler image shows that the \"halo\" is vascular.</div><div class=\"graphic_footnotes\">L: thyroid lobe; N: nodule.</div><div class=\"graphic_reference\">Courtesy of Manfred Blum, MD.</div><div id=\"graphicVersion\">Graphic 54263 Version 5.0</div></div></div>"},"54267":{"type":"graphic_picture","displayName":"Optic nerve coloboma","title":"Optic nerve coloboma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic nerve coloboma</div><div class=\"cntnt\"><img style=\"width:333px; height:305px;\" src=\"images/PEDS/54267_Optic_nerve_coloboma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left: Optic nerve coloboma. Note the well-demarcated inferior excavation with thinning of the inferior neuroretinal rim and preservation of the superior rim. Right: The normal fellow optic disc.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 54267 Version 1.0</div></div></div>"},"54268":{"type":"graphic_table","displayName":"Antimicrob activity abx A","title":"Antimicrobial activity of topical antibiotics used for external otitis: Part A","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial activity of topical antibiotics used for external otitis: Part A</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Organism</td> <td class=\"subtitle1\" colspan=\"2\">Quinolones</td> <td class=\"subtitle1\" colspan=\"2\">Tetracycline</td> <td class=\"subtitle1\" colspan=\"2\">Sulfonamides</td> </tr> <tr> <td class=\"subtitle2\">Ciprofloxacin</td> <td class=\"subtitle2\">Ofloxacin</td> <td class=\"subtitle2\">Tetracycline</td> <td class=\"subtitle2\">Oxytetracycline</td> <td class=\"subtitle2\">Sulfacetamide</td> <td class=\"subtitle2\">Sulfisoxazole</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Gram-positive</td> </tr> <tr> <td class=\"indent1\"><em>Corynebacterium diphtheriae</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus</em> spp</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em><em>Staphylococcus</em>&nbsp;aureus</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em><em>Staphylococcus</em>&nbsp;epidermidis</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus</em> spp</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em><em>Streptococcus</em>&nbsp;pneumoniae</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em><em>Streptococcus</em>&nbsp;pyogenes</em> (group A beta-hemolytic)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Gram-negative</td> </tr> <tr> <td class=\"indent1\"><em>Bacteroides fragilis</em></td> <td>&nbsp;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Citrobacter</em> spp</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Enterobacter aerogenes</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Enterobacter</em> spp</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Escherichia coli</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus influenzae</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Klebsiella pneumoniae</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Klebsiella</em> spp</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Proteus</em> spp</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Bojrab DI, Bruderly T, Abdulrazzak Y, Otolaryngol Clin North Am 1996; 29:761.</div><div id=\"graphicVersion\">Graphic 54268 Version 3.0</div></div></div>"},"54270":{"type":"graphic_table","displayName":"MRI screening recommendations, ACS","title":"ACS recommendations for breast MRI screening as an adjunct to mammography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACS recommendations for breast MRI screening as an adjunct to mammography</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Recommend annual MRI screening (based on high risk of breast cancer and high sensitivity of MRI*) </td> </tr> <tr> <td><em>BRCA</em> mutation</td> </tr> <tr> <td>First-degree relative of <em>BRCA</em> carrier, but untested</td> </tr> <tr> <td>Lifetime risk &#62;20 to 25% or greater, as defined by BRCAPRO or other models that are largely dependent on family history</td> </tr> <tr> <td class=\"subtitle1_single\">Recommend annual MRI screening (based on high risk of breast cancer) </td> </tr> <tr> <td>Radiation to chest between age 10 and 30 years</td> </tr> <tr> <td>Li-Fraumeni syndrome and first-degree relatives</td> </tr> <tr> <td>Cowden and Bannayan-Riley-Ruvalcaba syndromes and first-degree relatives</td> </tr> <tr> <td class=\"subtitle1_single\">Insufficient evidence to recommend for or against MRI screening<sup>&#916;</sup> </td> </tr> <tr> <td>Lifetime risk 15 to 20%, as defined by BRCAPRO or other models that are largely dependent on family history</td> </tr> <tr> <td>Lobular carcinoma in situ or atypical lobular hyperplasia</td> </tr> <tr> <td>Atypical ductal hyperplasia</td> </tr> <tr> <td>Heterogeneously or extremely dense breast on mammography</td> </tr> <tr> <td>Women with a personal history of breast cancer, including ductal carcinoma in situ</td> </tr> <tr> <td class=\"subtitle1_single\">Recommend against MRI screening (based on expert consensus opinion) </td> </tr> <tr> <td>Women at &#60;15% lifetime risk</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACS: American Cancer Society; MRI: magnetic resonance imaging.<br />* Evidence from nonrandomized screening trials and observational studies.<br />Δ Payment should not be a barrier. Screening decisions should be made on a case-by-case basis, as there may be particular factors to support MRI.</div><div class=\"graphic_reference\">Reproduced with permission from: Saslow D, Boetes C, Burke W, et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. CA Cancer J Clin 2007; 57:75. Copyright © 2007 John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 54270 Version 5.0</div></div></div>"},"54271":{"type":"graphic_picture","displayName":"Flea bites thigh","title":"Flea bites thigh","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Flea bites thigh</div><div class=\"cntnt\"><img style=\"width:451px; height:287px;\" src=\"images/ALLRG/54271_Flea_bites_thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insect bites. These flea bites are grouped in a characteristic nonfollicular pattern.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54271 Version 1.0</div></div></div>"},"54272":{"type":"graphic_figure","displayName":"Anatomy of the conjunctiva","title":"Anatomy of the conjunctiva","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Anatomy of the conjunctiva</div><div class=\"cntnt\"><img style=\"width:542px; height:238px;\" src=\"images/ID/54272_Anatomy_of_the_conjunctiva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The conjunctiva is a thin, transparent tissue that covers the outer surface of the eye. It consists of two continuous parts, one on the inner surface of the eyelid (the tarsal conjunctiva), and the other over the sclera (the bulbar conjunctiva). These are outlined in the drawing as a thin pink line.</div><div id=\"graphicVersion\">Graphic 54272 Version 4.0</div></div></div>"},"54273":{"type":"graphic_figure","displayName":"Paracoccidioidomycosis distribution map","title":"Distribution of paracoccidioidomycosis by incidence","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Distribution of paracoccidioidomycosis by incidence</div><div class=\"cntnt\"><img style=\"width:530px; height:532px;\" src=\"images/ID/54273_Paracocci_distribution_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Geographic distribution of paracoccidioidomycosis.</div><div class=\"graphic_reference\">Reproduced from: Colombo AL, Queiroz-Telles F. Paracoccidioidomycosis. In: Atlas of Fungal Infections, 2nd ed, Kauffman CA (Ed), Springer, Philadelphia 2007; with kind permission from Springer Science + Business Media B.V. Copyright © 2007.</div><div id=\"graphicVersion\">Graphic 54273 Version 6.0</div></div></div>"},"54274":{"type":"graphic_figure","displayName":"Female cystectomy PI","title":"Surgery to treat bladder cancer in women (cystectomy)","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Surgery to treat bladder cancer in women (cystectomy)</div><div class=\"cntnt\"><img style=\"width:464px; height:652px;\" src=\"images/PI/54274_Female_cystectomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some people with bladder cancer must have surgery to remove the bladder and nearby organs. In women, the surgeon removes the bladder, the uterus, the ovaries, and the tubes that connect the ovaries to the uterus (shown inside the dotted line).</div><div id=\"graphicVersion\">Graphic 54274 Version 3.0</div></div></div>"},"54275":{"type":"graphic_figure","displayName":"Endarterectomy stroke ACAS","title":"Carotid endarterectomy in asymptomatic men","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carotid endarterectomy in asymptomatic men</div><div class=\"cntnt\"><img style=\"width:299px; height:462px;\" src=\"images/CARD/54275_Endarterec_stroke_ACAS_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the ACAS trial, 1662 patients with an asymptomatic carotid stenosis ≥60 percent were randomized to medical therapy with aspirin or CEA and followed for a mean of 2.2 years.<br />(Top panel) There was no difference between the two groups in the incidence of major stroke or death.<br />(Bottom panel) The incidence of any ipsilateral TIA or stroke or death was lower in the surgical group (p = 0.004).</div><div class=\"graphic_footnotes\">CEA: carotid endarterectomy; TIA: transient ischemic attack.</div><div class=\"graphic_reference\">Data from: Executive Committee for the Asymptomatic Carotid Atherosclerosis Trial. JAMA 1995; 273:1421.</div><div id=\"graphicVersion\">Graphic 54275 Version 4.0</div></div></div>"},"54276":{"type":"graphic_picture","displayName":"Spider veins ankle PI","title":"Telangiectasias (spider veins) on the lower leg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Telangiectasias (spider veins) on the lower leg</div><div class=\"cntnt\"><img style=\"width:216px; height:274px;\" src=\"images/PI/54276_Spider_veins_ankle_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a picture of telangiectasias (spider veins), which are small veins that are swollen. These are also called &quot;hyphen webs&quot; or &quot;thread veins.&quot;</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 54276 Version 3.0</div></div></div>"},"54278":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber color Doppler diastole","title":"Apical four chamber view with color flow Doppler during diastole","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical four chamber view with color flow Doppler during diastole</div><div class=\"cntnt\"><img style=\"width:369px; height:288px;\" src=\"images/CARD/54278_4_chamber_color_Doppler_dia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown is the apical four chamber view with color flow Doppler during diastole. There is physiolgic flow (tagged red) into the left ventricle (LV) that extends from the right superior pulmonary veins (RSPV) to the apex of the LV. This color signal is used to position a pulsed wave Doppler sample volume so that quantitatable signals of flow can be obtained from the pulmonary veins and from the mitral leaflet tips.</div><div class=\"graphic_footnotes\">RA: right atrium; RV: right ventricle; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 54278 Version 6.0</div></div></div>"},"54279":{"type":"graphic_table","displayName":"Discharge checklist","title":"Ideal discharge of the elderly patient: A hospitalist checklist","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ideal discharge of the elderly patient: A hospitalist checklist</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Data elements</td> <td class=\"subtitle1\" colspan=\"3\">Processes</td> </tr> <tr> <td class=\"subtitle2\">Discharge summary</td> <td class=\"subtitle2\">Patient instructions</td> <td class=\"subtitle2\">Communication to follow-up clinician on day of discharge</td> </tr> <tr> <td>Presenting problem that precipitated hospitalization</td> <td>x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Key findings and test results</td> <td>x</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>Final primary and secondary diagnoses</td> <td>x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Brief hospital course</td> <td>x</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>Condition at discharge, including functional status and cognitive status if relevant</td> <td> <p>x - functional status</p> <p>o - cognitive status</p> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Discharge destination (and rationale if not obvious)</td> <td>x</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Discharge medications:</td> </tr> <tr> <td class=\"sublist1\">Written schedule</td> <td class=\"sublist_other\">x</td> <td class=\"sublist_other\">x</td> <td class=\"sublist_other\">x</td> </tr> <tr> <td class=\"sublist1\">Include purpose and cautions (if appropriate) for each</td> <td class=\"sublist_other\">o</td> <td class=\"sublist_other\">x</td> <td class=\"sublist_other\">o</td> </tr> <tr> <td class=\"sublist1\">Comparison with pre-admission medications (new, changes in dose/frequency, unchanged, meds should no longer take)</td> <td class=\"sublist_other\">x</td> <td class=\"sublist_other\">x</td> <td class=\"sublist_other\">x</td> </tr> <tr> <td>Follow-up appointments with name of provider, date, address, phone number, visit purpose, suggested management plan</td> <td>x</td> <td>x</td> <td>x</td> </tr> <tr> <td>All pending labs or tests, responsible person to whom results will be sent</td> <td>x</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>Recommendations of any sub-specialty consultants</td> <td>x</td> <td>&nbsp;</td> <td>o</td> </tr> <tr> <td>Documentation of patient education and understanding</td> <td>x</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Any anticipated problems and suggested interventions</td> <td>x</td> <td>x</td> <td>x</td> </tr> <tr> <td>24/7 call-back number</td> <td>x</td> <td>x</td> <td>&nbsp;</td> </tr> <tr> <td>Identify referring and receiving providers</td> <td>x</td> <td>x</td> <td>&nbsp;</td> </tr> <tr> <td>Resuscitation status and any other pertinent end-of-life issues</td> <td>o</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">x: required element; o: optional element.</div><div class=\"graphic_reference\">Derived and expanded from: Halasyamani L, Kripalani S, Coleman E, et al. Transition of care for hospitalized elderly patients: Development of a discharge checklist for hospitalists. J Hosp Med 2006; 1:354.</div><div id=\"graphicVersion\">Graphic 54279 Version 5.0</div></div></div>"},"54280":{"type":"graphic_figure","displayName":"Laparoscopic transcystic bile duct exploration","title":"Laparoscopic transcystic bile duct exploration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic transcystic bile duct exploration</div><div class=\"cntnt\"><img style=\"width:384px; height:342px;\" src=\"images/SURG/54280_Lap_trans_bileduct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laparoscopic transcystic bile duct exploration.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland, MW, Maier, RV, et al. Greenfield's Surgery: Scientific Principles and Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54280 Version 1.0</div></div></div>"},"54289":{"type":"graphic_table","displayName":"GA by crown chin length","title":"Gestational age by crown chin length","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gestational age by crown chin length</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n\t\t<tr>\r\n\t\t\t<td class=\"subtitle1\">Gestational age</td>\r\n\t\t\t<td class=\"subtitle1\">2.5th percentile</td>\r\n\t\t\t<td class=\"subtitle1\">50th percentile</td>\r\n\t\t\t<td class=\"subtitle1\">97.5th percentile</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>10 wk 0 days</td>\r\n\t\t\t<td>12.1</td>\r\n\t\t\t<td>17.2</td>\r\n\t\t\t<td>22.3</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>10 wk 1 days</td>\r\n\t\t\t<td>12.7</td>\r\n\t\t\t<td>17.8</td>\r\n\t\t\t<td>23.0</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>10 wk 2 days</td>\r\n\t\t\t<td>13.4</td>\r\n\t\t\t<td>18.5</td>\r\n\t\t\t<td>23.6</td>\r\n\t\t</tr>\r\n\t\t<tr>\t\t\t\r\n\t\t\t<td>10 wk 3 days</td>\r\n\t\t\t<td>14.1</td>\r\n\t\t\t<td>19.2</td>\r\n\t\t\t<td>24.2</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>10 wk 4 days</td>\r\n\t\t\t<td>14.7</td>\r\n\t\t\t<td>19.8</td>\r\n\t\t\t<td>24.9</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>10 wk 5 days</td>\r\n\t\t\t<td>15.4</td>\r\n\t\t\t<td>20.5</td>\r\n\t\t\t<td>25.5</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>10 wk 6 days</td>\r\n\t\t\t<td>16.0</td>\r\n\t\t\t<td>21.1</td>\r\n\t\t\t<td>26.2</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>11 wk 0 days</td>\r\n\t\t\t<td>16.7</td>\r\n\t\t\t<td>21.8</td>\r\n\t\t\t<td>26.8</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>11 wk 1 days</td>\r\n\t\t\t<td>7.3</td>\r\n\t\t\t<td>22.4</td>\r\n\t\t\t<td>27.5</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>11 wk 2 days</td>\r\n\t\t\t<td>18.0</td>\r\n\t\t\t<td>23.1</td>\r\n\t\t\t<td>28.1</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>11 wk 3 days</td>\r\n\t\t\t<td>18.7</td>\r\n\t\t\t<td>23.7</td>\r\n\t\t\t<td>28.8</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>11 wk 4 days</td>\r\n\t\t\t<td>19.3</td>\r\n\t\t\t<td>24.4</td>\r\n\t\t\t<td>29.4</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>11 wk 5 days</td>\r\n\t\t\t<td>20.0</td>\r\n\t\t\t<td>25.0</td>\r\n\t\t\t<td>30.1</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>11 wk 6 days</td>\r\n\t\t\t<td>20.6</td>\r\n\t\t\t<td>25.7</td>\r\n\t\t\t<td>30.7</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>12 wk 0 days</td>\r\n\t\t\t<td>21.3</td>\r\n\t\t\t<td>26.3</td>\r\n\t\t\t<td>31.4</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>12 wk 1 days</td>\r\n\t\t\t<td>21.9</td>\r\n\t\t\t<td>27.0</td>\r\n\t\t\t<td>32.0</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>12 wk 2 days</td>\r\n\t\t\t<td>22.6</td>\r\n\t\t\t<td>27.6</td>\r\n\t\t\t<td>32.7</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>12 wk 3 days</td>\r\n\t\t\t<td>23.2</td>\r\n\t\t\t<td>28.3</td>\r\n\t\t\t<td>33.3</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>12 wk 4 days</td>\r\n\t\t\t<td>23.9</td>\r\n\t\t\t<td>28.9</td>\r\n\t\t\t<td>34.0</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>12 wk 5 days</td>\r\n\t\t\t<td>24.9</td>\r\n\t\t\t<td>29.6</td>\r\n\t\t\t<td>34.6</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>12 wk 6 days</td>\r\n\t\t\t<td>25.2</td>\r\n\t\t\t<td>30.2</td>\r\n\t\t\t<td>35.3</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>13 wk 0 days</td>\r\n\t\t\t<td>25.8</td>\r\n\t\t\t<td>30.9</td>\r\n\t\t\t<td>35.9</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>13 wk 1 days</td>\r\n\t\t\t<td>26.5</td>\r\n\t\t\t<td>31.5</td>\r\n\t\t\t<td>36.6</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>13 wk 2 days</td>\r\n\t\t\t<td>27.1</td>\r\n\t\t\t<td>32.2</td>\r\n\t\t\t<td>37.2</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>13 wk 3 days</td>\r\n\t\t\t<td>27.8</td>\r\n\t\t\t<td>32.8</td>\r\n\t\t\t<td>37.9</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>13 wk 4 days</td>\r\n\t\t\t<td>28.4</td>\r\n\t\t\t<td>33.5</td>\r\n\t\t\t<td>38.6</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>13 wk 5 days</td>\r\n\t\t\t<td>29.4</td>\r\n\t\t\t<td>34.1</td>\r\n\t\t\t<td>39.2</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>13 wk 6 days</td>\r\n\t\t\t<td>29.7</td>\r\n\t\t\t<td>34.8</td>\r\n\t\t\t<td>39.9</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>14 wk 0 days</td>\r\n\t\t\t<td>30.3</td>\r\n\t\t\t<td>35.4</td>\r\n\t\t\t<td>40.5</td>\r\n\t\t</tr>\r\n\t</table></div><div class=\"graphic_lgnd\">Prediction of gestational age based on crown-chin length in normal fetuses. Crown-chin length is below the 2.5th percentile in anencephalic fetuses.</div><div class=\"graphic_reference\">Reprinted from Sepulveda, W, Sebire, NJ, Fung, TY, Pip, E, Nicolaides, KH. Crown-chin length in normal and anencephalic fetuses at 10 to 14 weeks' gestation. Am J Obstet Gynecol 1997; 176:852. Original Table #1. Copyright &#169;1997 with permission from Elsevier.</div><div id=\"graphicVersion\">Graphic 54289 Version 1.0</div></div></div>"},"54290":{"type":"graphic_figure","displayName":"Typical atrioventricular nodal reentrant tachycardia","title":"Typical atrioventricular nodal reentrant tachycardia","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Typical atrioventricular nodal reentrant tachycardia</div><div class=\"cntnt\"><img style=\"width:468px; height:146px;\" src=\"images/CARD/54290_ECG_common_AVNRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first two complexes are normal sinus beats with a normal P wave followed by a QRS complex. The third complex, an atrial premature beat (APB), has a prolonged PR interval; it initiates a common or typical atrioventricular nodal reentrant tachycardia (AVNRT) in which antegrade conduction to the ventricle is via the slow pathway and retrograde atrial activation is by the fast pathway. Although no distinct P wave is seen, the QRS complex has a small terminal deflection, known as a pseudo r', which is the P wave superimposed upon the terminal portion of the QRS complex.</div><div id=\"graphicVersion\">Graphic 54290 Version 3.0</div></div></div>"},"54291":{"type":"graphic_figure","displayName":"Pedicled TRAM flap reconstruction after mastectomy","title":"Pedicled TRAM flap reconstruction after mastectomy","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Pedicled TRAM flap reconstruction after mastectomy</div><div class=\"cntnt\"><img style=\"width:532px; height:699px;\" src=\"images/SURG/54291_PedicledTRAMflapbreastreconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One of the most commonly used autogenous tissue reconstructions is the TRAM (transverse rectus abdominus myocutaneous) flap.<br />The drawing depicts reconstruction performed in a delayed fashion, which is sometimes necessary to allow chest wall radiation. However, the procedure can also be performed at the time of mastectomy to provide immediate reconstruction. Either the contralateral or ipsilateral rectus abdominus muscle can be utililized. Incision placement and size will vary based on the patient's body habitus. There are many ways to perform nipple reconstruction; one method is pictured here. The nipple is reconstructed after the flap heals and is then tattooed to the appropriate color so that there is symmetry with the contralateral breast.</div><div id=\"graphicVersion\">Graphic 54291 Version 6.0</div></div></div>"},"54292":{"type":"graphic_figure","displayName":"Schematic continuous murmurs","title":"Schematic of continuous murmurs","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Schematic of continuous murmurs</div><div class=\"cntnt\"><img style=\"width:468px; height:274px;\" src=\"images/CARD/54292_Schematic_continuous_murmur.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous murmurs begin in systole and continue without interruption through the second heart sound (S2) into all or part of diastole. The continuous murmurs shown here are aortopulmonary, systemic arterial, and systemic venous. A holosystolic murmur (SM) followed by a holodiastolic murmur (DM) represents two separate murmurs, not one continuous murmur.</div><div class=\"graphic_reference\">With permission from Heart Disease: A Textbook of Cardiovascular Medicine, Braunwald E (Ed), WB Saunders, Philadelphia, 1997.</div><div id=\"graphicVersion\">Graphic 54292 Version 3.0</div></div></div>"},"54293":{"type":"graphic_diagnosticimage","displayName":"Pelvic lateral compression fracture type II","title":"Pelvic lateral compression fracture: Type II","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic lateral compression fracture: Type II</div><div class=\"cntnt\"><img style=\"width:371px; height:511px;\" src=\"images/EM/54293_Pelvic_lat_comp_fx2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Type II lateral compression fracture with left sided rami and sacral fractures.<br />(B) CT scan illustrating the classic crescent fracture pattern.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jim Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 54293 Version 4.0</div></div></div>"},"54294":{"type":"graphic_figure","displayName":"T4 suppression of goiter","title":"Thyroxine suppresses goiter growth","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thyroxine suppresses goiter growth</div><div class=\"cntnt\"><img style=\"width:369px; height:238px;\" src=\"images/ENDO/54294_T4_suppression_of_goiter.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relative changes in thyroid volume in patients with nontoxic goiter treated with placebo, T4 plus CBZ, or T4 alone for nine months and then followed for an additional nine months. T4 suppressed thyroid volume, an effect that persisted only during the phase of active treatment.&nbsp;CBZ was of no added benefit.</div><div class=\"graphic_footnotes\">CBZ: carbimazole; T4: thyroxine.</div><div class=\"graphic_reference\">Data from: Berghout A, Wiersinga WM, Drexhage HA, et al. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre.&nbsp;Lancet 1990; 336:193.</div><div id=\"graphicVersion\">Graphic 54294 Version 3.0</div></div></div>"},"54296":{"type":"graphic_picture","displayName":"Histology metastatic melanoma","title":"Cutaneous metastatic melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous metastatic melanoma</div><div class=\"cntnt\"><img style=\"width:412px; height:249px;\" src=\"images/ONC/54296_Histology_metastatic_melano.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power light photomicrograph of a cutaneous metastasis of malignant melanoma demonstrating the lack of epidermal involvement (black arrows). The large dermal nodule (outlined by black arrows) contains epithelioid, hyperchromatic cells.</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 54296 Version 1.0</div></div></div>"},"54300":{"type":"graphic_table","displayName":"Therapy by category of COPD","title":"Management of stable COPD: Therapy based on the GOLD ABCD assessment of symptoms and risk of exacerbation*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of stable COPD: Therapy based on the GOLD ABCD assessment of symptoms and risk of exacerbation*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Risk</td> <td class=\"subtitle1\">Suggested treatment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">All</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <ul> <li>Avoidance of risk factor(s), such as smoking </li> <li>Annual influenza vaccination </li> <li>Pneumococcal vaccination </li> <li>Regular physical activity </li> <li>Regular review/correction of inhaler technique </li> <li>Long-term oxygen therapy if chronic hypoxemia </li> <li>Pulmonary rehabilitation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">A</td> <td> <p><strong>Less symptomatic</strong></p> Mild or infrequent symptoms (ie, breathless with strenuous exercise or when hurrying on level ground or walking up a slight hill)<sup>&#182;</sup> or CAT &#60;10<sup>&#916;</sup></td> <td> <p><strong>Low risk</strong></p> 0 or 1 exacerbations in the past year without associated hospitalization</td> <td> <p><strong>Recommendation:</strong> Short-acting bronchodilator or combination of short-acting beta-agonist and anticholinergic, as needed.</p> <strong>Alternative:</strong> Long-acting bronchodilator if beneficial.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">B</td> <td> <p><strong>More symptomatic</strong></p> Moderate to severe symptoms (ie, patient has to walk more slowly than others of same age due to breathlessness, has to stop to catch breath when walking on level ground at own pace, or has more severe breathlessness)<sup>&#182;</sup> or CAT &#8805;10<sup>&#916;</sup></td> <td> <p><strong>Low risk</strong></p> 0 or 1 exacerbations in the past year without associated hospitalization</td> <td> <p><strong>First choice:</strong> Regular treatment with a long-acting bronchodilator, either LAMA or LABA, based on symptom relief. Short-acting bronchodilator available for symptom control as needed.</p> <strong>For persistent symptoms:</strong> Regular treatment with a combination of LAMA and LABA.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">C</td> <td> <p><strong>Less symptomatic</strong></p> Mild or infrequent symptoms (ie, breathless with strenuous exercise or when hurrying on level ground or walking up a slight hill)<sup>&#182;</sup> or CAT &#60;10<sup>&#916;</sup></td> <td> <p><strong>High risk</strong></p> &#8805;2 exacerbations per year with one or more leading to hospitalization</td> <td> <p><strong>First choice:</strong> Regular treatment with a LAMA; SABA available for symptom control as needed.</p> <strong>For further exacerbations:</strong> Regular treatment with a LAMA plus LABA OR (less preferred) LABA plus ICS.</td> </tr> <tr> <td class=\"centered\">D</td> <td> <p><strong>More symptomatic</strong></p> Moderate to severe symptoms (ie, patient has to walk slower than others of same age due to breathlessness, has to stop to catch breath when walking on level ground at own pace, or has more severe breathlessness)<sup>&#182;</sup> or CAT &#8805;10<sup>&#916;</sup></td> <td> <p><strong>High risk</strong></p> &#8805;2 exacerbations per year with one or more leading to hospitalization</td> <td> <p><strong>First choice:</strong> Regular treatment with combination LABA plus LAMA. LABA plus inhaled glucocorticoid may be preferred, if features of asthma/COPD overlap. SABA available for symptom control as needed. LAMA alone, if LABA contraindicated.</p> <p><strong>For further exacerbations:</strong> Regular treatment with combination of LAMA plus LABA plus ICS OR (less preferred in absence of asthma overlap) switch to LABA plus ICS.</p> If exacerbations continue despite triple therapy, additional options for selected patients include roflumilast (if chronic bronchitis and FEV<sub>1</sub> &#60;50% predicted), theophylline, chronic therapy with a macrolide, and stopping inhaled glucocorticoids. Refer to UpToDate topic on the management of stable COPD.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients must be taught how and when to use their treatments, and treatment choices are adjusted based on patient responses. Medications being prescribed for other conditions should be reviewed. Refer to UpToDate topic on the diagnosis of COPD for further information about mMRC and CAT.</div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LAMA: long-acting muscarinic (anticholinergic) agent; LABA: long-acting beta agonist; SABA: short-acting beta agonist; ICS: inhaled corticosteroid (glucocorticoid); FEV<SUB>1</SUB>: forced expiratory volume in one second; FVC: forced vital capacity.<br />* All patients with COPD have a reduced FEV<SUB>1</SUB>/FVC ratio that is &lt;0.70% predicted or &lt;5th percentile lower limit of normal. The severity of airflow limitation is determined by the FEV<SUB>1</SUB>.<br />¶ Symptom severity based on: Modified Medical Research Council (mMRC) Dyspnea scale.<br />Δ COPD Assessment Test (CAT): <A href=\"http://www.catestonline.org/\" target=_blank>http://www.catestonline.org</A> (Accessed on February 10, 2017).</div><div class=\"graphic_reference\">Adapted from: Global Initiative for Chronic Obstructive Pulmonary Disease: Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2017 (Accessed February 10, 2017).<br />Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Fletcher CM, Elmes PC, Fairbairn MB, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2:257.</LI>&#xD;&#xA;<LI>Dodd JW, Hogg L, Nolan J, et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 2011; 66:425.</LI>&#xD;&#xA;<LI>Dodd JW, Marns PL, Clark AL, Ingram KA, Fowler RP, Canavan JL, et al. The COPD Assessment Test (CAT): short- and medium-term response to pulmonary rehabilitation. Copd 2012; 9:390.</LI>&#xD;&#xA;<LI>Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34:648.</LI>&#xD;&#xA;<LI><A href=\"http://www.catestonline.org/\" target=_blank>http://www.catestonline.org</A></LI></OL></div><div id=\"graphicVersion\">Graphic 54300 Version 8.0</div></div></div>"},"54301":{"type":"graphic_diagnosticimage","displayName":"Metatarsal stress fracture","title":"Metatarsal stress fracture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Metatarsal stress fracture</div><div class=\"cntnt\"><img style=\"width:504px; height:211px;\" src=\"images/RHEUM/54301_Metatarsal_stress_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In panel A, there is mild narrowing of the medullary canal of the second metatarsal, one of the earlier signs of stress fracture. Callus formation can be seen as early as four to five weeks after symptom onset (panel B). After three months, there is well organized callus (panel C).</div><div class=\"graphic_reference\">Reproduced with permission from: Eiff, MP, Hatch, RL, Calmbach, W (Eds). Fracture Management for Primary Care, 2nd Edition, W.B. Saunders Company, Philadelphia 2002. Copyright © 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 54301 Version 2.0</div></div></div>"},"54302":{"type":"graphic_diagnosticimage","displayName":"Bone scan in calciphylaxis","title":"Three phase bone scan (Technetium 99m methylene diphosphate bone scintography)","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Three&nbsp;phase bone scan (Technetium 99m methylene diphosphate bone scintography)</div><div class=\"cntnt\"><img style=\"width:522px; height:368px;\" src=\"images/NEPH/54302_Bone_scan_in_calciphylaxis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Bone scan showing no activity in the lungs and musculature of lower extremities&nbsp;five months prior to diagnosis of calciphylaxis.<br />(B) Extensive increase activity throughout both lungs and lower extremities suggestive of metastatic calcification in a patient with a diagnosis of calciphylaxis.</div><div class=\"graphic_reference\">Courtesy of Peter W. Santos, DO and L. Darryl Quarles, MD.</div><div id=\"graphicVersion\">Graphic 54302 Version 4.0</div></div></div>"},"54304":{"type":"graphic_table","displayName":"Split urine collection protocol","title":"Patient instructions for performing a split urine collection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient instructions for performing a split urine collection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Introduction</td> </tr> <tr> <td>A \"split urine test\" is a method to determine whether the protein discovered in your urine is due to a condition called orthostatic proteinuria. This&nbsp;is a harmless condition that is not uncommon in young people. For reasons that are not well understood, some people leak protein into the urine when they are standing or sitting but not while they are lying down. The split urine test is a simple way to determine if this condition is present.</td> </tr> <tr> <td class=\"subtitle1_single\">Equipment</td> </tr> <tr> <td>The test requires that you collect all of your urine for 24 hours. Pick a day when this would be convenient for you. Males might want to buy an inexpensive urinal for easy collection; females should buy an inexpensive basin urinal.</td> </tr> <tr> <td>You also need two jugs and a funnel. One-half gallon plastic jugs, thoroughly rinsed, are adequate if jugs are not provided. Label the two jugs: (1) Daytime urine and (2) Nighttime urine, respectively.</td> </tr> <tr> <td class=\"subtitle1_single\">Procedure</td> </tr> <tr> <td class=\"subtitle2_left\">Perform the following steps on the day that you are going to make the split urine collections.</td> </tr> <tr> <td class=\"indent1\">When you first get up, <strong>discard</strong> the first morning urine.</td> </tr> <tr> <td class=\"indent1\">For the rest of the day, <strong>collect</strong> all of the urine each time you void. Put this urine into the Daytime urine jug. You should be as active as you normally are during the day.</td> </tr> <tr> <td class=\"indent1\">In the evening, lie down for&nbsp;<strong>two hours</strong> before you go to sleep. Just before sleeping, void for the last time during the day and add this urine to the Daytime jug. Lying down for two hours before the nighttime collection avoids contamination of the nighttime collection with urine formed during the day when you were upright.</td> </tr> <tr> <td class=\"indent1\">The following morning (approximately eight hours after you went to sleep), collect the first-morning urine and put in the <strong>Nighttime</strong> urine jug.</td> </tr> <tr> <td class=\"indent1\">Take the two jugs to the laboratory.</td> </tr> <tr> <td class=\"subtitle2_left\">We will notify you when we get the results.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54304 Version 2.0</div></div></div>"},"54305":{"type":"graphic_diagnosticimage","displayName":"In utero fetal CMV infection","title":"In-utero cytomegalovirus infection at 23 postmenstrual weeks","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">In-utero cytomegalovirus infection at 23 postmenstrual weeks</div><div class=\"cntnt\"><img style=\"width:416px; height:291px;\" src=\"images/OBGYN/54305_In_utero_fet_CMV_infect_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panels A through C are serial coronal sections from anterior to posterior showing dilation of the lateral ventricles and periventricular calcifications. Panel D is an oblique section showing the dilation of the lateral ventricles, the dysmorphic choroid plexus, and periventricular calcifications.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 54305 Version 6.0</div></div></div>"},"54308":{"type":"graphic_table","displayName":"Rotterdam consensus criteria","title":"The Rotterdam consensus meeting criteria for definition of PCOS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Rotterdam consensus meeting criteria for definition of PCOS</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">2 out of 3 of the following:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1. Oligo and/or anovulation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. Clinical and/or biochemical signs of hyperandrogenism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3. Polycystic ovaries</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=15959&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Rotterdam_consensus_criteri.htm</title></head></div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome.</div><div class=\"graphic_reference\">Data from: The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41.</div><div id=\"graphicVersion\">Graphic 54308 Version 2.0</div></div></div>"},"54310":{"type":"graphic_diagnosticimage","displayName":"Intussusception Barium enema","title":"Intussusception","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intussusception</div><div class=\"cntnt\"><img style=\"width:314px; height:432px;\" src=\"images/GAST/54310_Intussusception_Barium_enem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium contrast enema showing intussusception in mid-transverse colon (arrow); the patient is in a prone position. </div><div class=\"graphic_reference\">Courtesy of Nancy Fitzgerald, MD and Taylor Chung, MD.</div><div id=\"graphicVersion\">Graphic 54310 Version 4.0</div></div></div>"},"54311":{"type":"graphic_picture","displayName":"Endobronchial lung cancer","title":"Endobronchial squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:322px; height:315px;\" src=\"images/PULM/54311_Endobronchial_lung_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopic image of the left upper lobe orifice in an 85-year-old male with hemoptysis. The lesion proved to be squamous cell cancer without evidence of invasion or metastasis.</div><div class=\"graphic_reference\">Courtesy of Armin Ernst, MD.</div><div id=\"graphicVersion\">Graphic 54311 Version 4.0</div></div></div>"},"54315":{"type":"graphic_picture","displayName":"Scabies wrist infant","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54315_Scabies_wrist_infant_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules are present on the wrist of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54315 Version 7.0</div></div></div>"},"54316":{"type":"graphic_figure","displayName":"ACTH Cushings disease","title":"Pulse analysis of plasma ACTH in Cushing's disease","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Pulse analysis of plasma ACTH in Cushing's disease</div><div class=\"cntnt\"><img style=\"width:546px; height:268px;\" src=\"images/ENDO/54316_ACTH_Cushings_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Analysis of specimens sampled at 10-minute intervals for 24 hours in normal subjects (left four panels) and patients with Cushing's disease (right four panels) reveals that in Cushing's disease, the amplitude and duration, but not the frequency of ACTH secretory episodes are increased.</div><div class=\"graphic_footnotes\">ACTH: corticotropin.</div><div class=\"graphic_reference\">Data from: van den Berg G, Frölich M, Veldhuis JD, Roelfsema F. Combined amplification of the pulsatile and basal modes of adrenocorticotropin and cortisol secretion in patients with Cushing's disease: evidence for decreased responsiveness of the adrenal glands.&nbsp;J Clin Endocrinol Metab 1995; 80:3750.</div><div id=\"graphicVersion\">Graphic 54316 Version 3.0</div></div></div>"},"54319":{"type":"graphic_picture","displayName":"White blood cell cast I","title":"Photomicrograph of urine sediment with white blood cell cast (I)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photomicrograph of urine sediment with white blood cell cast (I)</div><div class=\"cntnt\"><img style=\"width:360px; height:247px;\" src=\"images/NEPH/54319_White_cell_cast_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White cell cast in which blue stained white cells (arrow) are contained within a granular cast.</div><div class=\"graphic_reference\">Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.</div><div id=\"graphicVersion\">Graphic 54319 Version 3.0</div></div></div>"},"54321":{"type":"graphic_diagnosticimage","displayName":"Fetal pleural effusion unilater","title":"Longitudinal view of a unilateral pleural effusion in a fetus with hydrops","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal view of a unilateral pleural effusion in a fetus with hydrops</div><div class=\"cntnt\"><img style=\"width:355px; height:243px;\" src=\"images/OBGYN/54321_Fetal_pleural_effusion_unil.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Svena Julien, MD and Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 54321 Version 4.0</div></div></div>"},"54322":{"type":"graphic_table","displayName":"Cognit behav intervent fatigue","title":"Example of cognitive-behavioral interventions to assist patients with fatigue during cancer therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of cognitive-behavioral interventions to assist patients with fatigue during cancer therapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Self-care management</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Listen to a guided imagery tape daily</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Eat calorie and protein-dense foods</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Engage in low-impact exercise daily</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Take brief naps early in the day</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Information, decision-making, and problem solving</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Assess family and social resources and ask for help with daily tasks if needed</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Teach side effects of chemotherapy and when to anticipate the nadir</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prioritize daily activities</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Communication with health care providers</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tell the doctor if you have no energy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tell the doctor if you feel so exhausted you cannot move</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tell the doctor if you are unable to perform usual daily activities</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Counseling and support</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Encourage verbalization of how fatigue has altered lifestyle and has affected emotional well-being</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Given C, et al. J Clin Oncol 2004; 22:507.</div><div id=\"graphicVersion\">Graphic 54322 Version 2.0</div></div></div>"},"54323":{"type":"graphic_diagnosticimage","displayName":"RUL RML atelectasis-II","title":"Frontal chest radiograph shows combined atelectasis of the right upper and middle lobes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frontal chest radiograph shows combined atelectasis of the right upper and middle lobes</div><div class=\"cntnt\"><img style=\"width:432px; height:363px;\" src=\"images/PULM/54323_RUL_RML_atelectasis-II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An oval shadow obscures the right mediastinal contour, and displays a so-called elephant ear configuration (asterisk). The hyperlucent right lung apex is formed by hyperexpansion of the superior segment of the right lower lobe. Bilateral pleural effusions are present.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 54323 Version 2.0</div></div></div>"},"54324":{"type":"graphic_table","displayName":"Lupus arthritis versus RA","title":"Comparison of features of musculoskeletal disease in systemic lupus erythematosus or rheumatoid arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of features of musculoskeletal disease in systemic lupus erythematosus or rheumatoid arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Feature</td>\n<td class=\"subtitle1\">Lupus</td>\n<td class=\"subtitle1\">Rheumatoid arthritis</td>\n</tr>\n<tr>\n<td>Arthralgia</td>\n<td>Common</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>Arthritis</td>\n<td>Common</td>\n<td>Deforming</td>\n</tr>\n<tr>\n<td>Symmetry</td>\n<td>Yes</td>\n<td>Yes</td>\n</tr>\n<tr>\n<td>Joints involved</td>\n<td>PIP&#62;MCP&#62;wrist&#62;knee</td>\n<td>MCP&#62;wrist&#62;knee</td>\n</tr>\n<tr>\n<td>Synovial hypertrophy</td>\n<td>Rare</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>Synovial membrane abnormality</td>\n<td>Minimal</td>\n<td>Proliferative</td>\n</tr>\n<tr>\n<td>Synovial fluid</td>\n<td>Transudate</td>\n<td>Exudate</td>\n</tr>\n<tr>\n<td>Subcutaneous nodules</td>\n<td>Rare</td>\n<td>35 percent</td>\n</tr>\n<tr>\n<td>Erosions</td>\n<td>Very rare</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>Morning stiffness</td>\n<td>Minutes</td>\n<td>Hours</td>\n</tr>\n<tr>\n<td>Myalgia</td>\n<td>Common</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>Myositis</td>\n<td>Rare</td>\n<td>Uncommon</td>\n</tr>\n<tr>\n<td>Osteoporosis</td>\n<td>Variable</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>Avascular necrosis</td>\n<td>5 to 50 percent</td>\n<td>Uncommon</td>\n</tr>\n<tr>\n<td>Deforming arthritis</td>\n<td>Uncommon</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>Swan neck</td>\n<td>10 percent, reducible</td>\n<td>Common, not reducible</td>\n</tr>\n<tr>\n<td>Ulnar deviation</td>\n<td>5 percent, reducible</td>\n<td>Common, not reducible</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54324 Version 1.0</div></div></div>"},"54325":{"type":"graphic_figure","displayName":"Silent ischemia unstable angina","title":"Silent ischemia is more common than symptomatic angina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Silent ischemia is more common than symptomatic angina</div><div class=\"cntnt\"><img style=\"width:443px; height:321px;\" src=\"images/CARD/54325_Silent_ischemia_unstable_an.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results from seven studies of patients with unstable angina showing that the majority of ischemic episodes are silent.</div><div id=\"graphicVersion\">Graphic 54325 Version 1.0</div></div></div>"},"54326":{"type":"graphic_figure","displayName":"Transducer position for parasternal short axis view base","title":"Transducer position for obtaining the parasternal short axis view through the base of the heart","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transducer position for obtaining the parasternal short axis view through the base of the heart</div><div class=\"cntnt\"><img style=\"width:331px; height:330px;\" src=\"images/CARD/54326_Transducer_short_axis_base.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the upper diagram, the transducer is place at the base of the heart; ie, 2nd intercostal space to the left of the sternum; the plane runs from the right hip to the left shoulder. The portion of the heart labeled RV is actually the right ventricular outflow tract (RVOT). The lower panels show the echocardiographic images which are centered on the pulmonary artery, one of the most important targets for examination. In panel A, the pulmonary artery (MPA) is of normal caliber and two of the three leaflets of the pulmonary valve are seen (PV). Note that the RVOT narrows when it reaches the PV ring, that the bifurcation (Bi) of the MPA can be seen and that in normal anatomy the aortic root (Ao) and MPA differ slightly in caliber (MPA&gt;AO). In panel B, the MPA is dilated due to chronic pulmonary hypertension; the relation of the MPA to the Ao differs sharply from the normal.</div><div id=\"graphicVersion\">Graphic 54326 Version 6.0</div></div></div>"},"54327":{"type":"graphic_diagnosticimage","displayName":"Iliac spine avulsion fracture","title":"Iliac spine avulsion fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iliac spine avulsion fracture</div><div class=\"cntnt\"><img style=\"width:396px; height:371px;\" src=\"images/EM/54327_Iliac_spine_avulsion_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This AP radiograph shows an avulsion fracture of the left anterior superior iliac spine.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Jim Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 54327 Version 4.0</div></div></div>"},"54328":{"type":"graphic_table","displayName":"ACC AHA therapy VT VF MI","title":"ACC/AHA guideline summary: Ventricular tachycardia (VT)/ventricular fibrillation (VF) in acute myocardial infarction (MI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Ventricular tachycardia (VT)/ventricular fibrillation (VF) in acute myocardial infarction (MI)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Class I - There is evidence and/or general agreement for the following approaches to VT/VF in patients with acute MI</td>\n</tr>\n\n<tr>\n<td>&#8226;&nbsp; VF or pulseless VT should be treated with an unsynchronized electric shock with an initial monophasic shock energy of 200 J*; if unsuccessful, a second shock of 200 to 300 J should be given, and, if necessary, a third shock of 360 J.</td>\n</tr>\n\n<tr>\n<td>&#8226;&nbsp; Sustained (&#62;30 seconds or causing hemodynamic collapse) polymorphic VT should be treated with an unsynchronized electric shock using an initial monophasic shock energy of 200 J*; if unsuccessful, a second shock of 200 to 300 J should be given, and, if necessary, a third shock of 360 J.</td>\n</tr>\n\n<tr>\n<td>&#8226;&nbsp; Episodes of sustained monomorphic VT associated with angina, pulmonary edema, or hypotension (blood pressure &#60;90 mmHg) should be treated with a synchronized electric shock of 100 J initial monophasic shock energy*. Increasing energies may be used if not initially successful. Brief anesthesia is preferred if hemodynamically tolerable.</td>\n</tr>\n\n<tr>\n<td class=\"sublist1_start\">&#8226;&nbsp; Sustained monomorphic VT not associated with angina, pulmonary edema, or hypotension (blood pressure &#60;90 mmHg) should be treated with one of the following regimens:</td>\n</tr>\n\n<tr>\n<td class=\"sublist1\">1. Amiodarone: 150 mg infused over 10 minutes. If further therapy is necessary, repeat 150 mg infusion every 10 to 15 minutes as needed or a constant infusion of 1.0 mg/min for six hours followed by a maintenance infusion of 0.5 mg/min for 18 hours. The total cumulative dose, including additional doses during cardiac arrest, must not exceed 2.2 g over 24 hours.</td>\n</tr>\n\n<tr>\n<td class=\"sublist1\">2. Synchronized electrical cardioversion starting at 50 J monophasic energy. Brief anesthesia is necessary.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle1_single\">Class IIa - The weight of evidence or opinion is in favor of benefit for the following modalities in the treatment of VT/VF in patients with acute MI</td>\n</tr>\n\n\n<tr>\n<td>&#8226;&nbsp; For VF or pulseless VT refractory to electric shock, amiodarone (300 mg or 5 mg/kg bolus) followed by a repeat unsynchronized electric shock.</td>\n</tr>\n\n<tr>\n<td>&#8226;&nbsp; Electrolyte and acid-base disturbances should be corrected to prevent recurrent episodes of VT/VF when an initial episode of VT/VF has been treated. The serum potassium should be greater than 4.0 meq/L (4.0 mmol/L) and the serum magnesium should be greater than 2.0 mg/dL (0.8 mmol/L).</td>\n</tr>\n\t\n<tr>\n<td class=\"sublist1_start\">&#8226;&nbsp; For refractory polymorphic VT, in addition to potassium and magnesium balance:</td>\n</tr>\n\n<tr>\n<td class=\"sublist1\">1. Aggressive attempts to reduce myocardial ischemia, including therapies such as beta blockers, intra-aortic balloon pump, and emergency percutaneous coronary intervention or bypass surgery.</td>\n</tr>\n\n<tr>\n<td class=\"sublist1\">2. Temporary pacing at a higher rate, if the heart rate is less than 60 beats/min or the corrected QT interval is prolonged.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle1_single\">Class IIb - The evidence or opinion is less well established for the following modality in the treatment of VT/VF in patients with acute MI</td>\n</tr>\n\n<tr>\n<td>&#8226;&nbsp; Intravenous procainamide for VT or shock-refractory VF. The usual regimen is 20 to 30 mg/min loading infusion, up to 12 to 17 mg/kg, which may be followed by an infusion of 1 to 4 mg/min. The length of time required for administration limits the value of this approach.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle1_single\">Class III - There is evidence and/or general agreement that the following modalities are not useful in the treatment of VT/VF in patients with acute MI</td>\n</tr>\n\n<tr>\n<td>&#8226;&nbsp; The routine use of prophylactic lidocaine for suppression of isolated ventricular premature beats, couplets, runs of accelerated idioventricular rhythm, or nonsustained VT.</td>\n</tr>\n\t\n<tr>\n<td>&#8226;&nbsp; Prophylactic antiarrhythmic therapy when using fibrinolytic agents.</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* The initial shock energy required with biphasic defibrillators is approximately one-half that with monophasic defibrillators.</div><div class=\"graphic_reference\">Data from from Antman, EM, Anbe, DT, Armstrong, PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed August 24, 2006).</div><div id=\"graphicVersion\">Graphic 54328 Version 1.0</div></div></div>"},"54329":{"type":"graphic_table","displayName":"Fredrickson classification of lipid disorders","title":"Fredrickson classification of lipid disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fredrickson classification of lipid disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Frederickson phenotype</td> <td class=\"subtitle1\">Lipoprotein abnormality</td> <td class=\"subtitle1\">Typical lipid levels</td> </tr> <tr> <td>I</td> <td>Chylomicrons</td> <td>TG &#62;99<sup>th</sup> percentile</td> </tr> <tr> <td>IIa</td> <td>LDL</td> <td>TC &#62;90<sup>th</sup> percentile; depending upon type, may also see apolipoprotein B &#8805;90<sup>th</sup> percentile</td> </tr> <tr> <td>IIb</td> <td>LDL and VLDL</td> <td>Depending upon type, TC and/or TG &#8805;90<sup>th</sup> percentile and apolipoprotein B &#8805;90<sup>th</sup> percentile</td> </tr> <tr> <td>III</td> <td>Remnants of VLDL and chylomicrons</td> <td>TC and TG &#62;90<sup>th</sup> percentile</td> </tr> <tr> <td>IV</td> <td>VLDL</td> <td>TC &#62;90<sup>th</sup> percentile; depending upon type, may also see TG &#62;90<sup>th</sup> percentile or low HDL</td> </tr> <tr> <td>V</td> <td>Chylomicrons and VLDL</td> <td>TG &#62;99<sup>th</sup> percentile</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TG: triglycerides; TC: total cholesterol; LDL: low-density lipoprotein; VLDL: very low-density lipoprotein; HDL: high-density lipoprotein.</div><div class=\"graphic_reference\">Adapted from: Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med 1971; 75:471.</div><div id=\"graphicVersion\">Graphic 54329 Version 6.0</div></div></div>"},"54332":{"type":"graphic_table","displayName":"Fluorescence bronchoscopes","title":"Fluorescence bronchoscopes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fluorescence bronchoscopes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Manufacturer/device name</td> <td class=\"subtitle1\">Excitation, nm</td> <td class=\"subtitle1\">Detection, nm</td> <td class=\"subtitle1\">Image</td> <td class=\"subtitle1\">Abnormality/background</td> </tr> <tr> <td><em>Pinpoint</em></td> <td><em>395 to 445</em></td> <td><em>470 to 710</em></td> <td><em>Green fluorescence: red reflectance</em></td> <td><em>Brown-red on green</em></td> </tr> <tr> <td>Storz D-light</td> <td>380 to 440</td> <td>475 to 800</td> <td>Dual fluorescence: blue reflectance</td> <td>Brown-purple on blue-grey</td> </tr> <tr> <td><em>SAFE-1000</em></td> <td><em>420 to 450</em></td> <td><em>490 to 590</em></td> <td><em>Green fluorescence</em></td> <td><em>Dark green on light green</em></td> </tr> <tr> <td>SAFE-3000</td> <td>408</td> <td>430 to 700</td> <td>Dual fluorescence</td> <td>Red-purple on blue-green</td> </tr> <tr> <td>DAFE</td> <td>390 to 460</td> <td>500 to 590 and 600 to 700</td> <td>Dual fluorescence</td> <td>Purple on blue-grey</td> </tr> <tr> <td>Olympus</td> <td>390 to 440</td> <td>470 to 690</td> <td>Dual fluorescence</td> <td>Magenta on green</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Italics denote older devices.</div><div id=\"graphicVersion\">Graphic 54332 Version 3.0</div></div></div>"},"54333":{"type":"graphic_figure","displayName":"Insertion of Swan Ganz catheter","title":"Pulmonary artery catheter insertion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary artery catheter insertion</div><div class=\"cntnt\"><img style=\"width:406px; height:285px;\" src=\"images/PULM/54333_Insertion_of_Swan_Ganz_cath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic diagram shows the proper orientation of the pulmonary artery catheter when inserted through the left subclavian vein. The curvature of the catheter is oriented so that it will facilitate passage of the catheter through the cardiac chambers and into the pulmonary artery.</div><div id=\"graphicVersion\">Graphic 54333 Version 1.0</div></div></div>"},"54334":{"type":"graphic_table","displayName":"Prone improvement mechanisms","title":"Proposed mechanisms for prone response","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed mechanisms for prone response</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Physiologic effect</td> <td class=\"subtitle1\">Clinical result</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Improved configuration between lung and thorax</td> </tr> <tr> <td class=\"indent1\">Heart is dependent</td> <td>More homogeneous Ppl gradient in ventrodorsal and cephalocaudal planes</td> <td>Improved ventilation distribution</td> </tr> <tr> <td class=\"indent1\">Smaller volume of dependent lung </td> <td>&nbsp;</td> <td>Increased FRC (&#8595; shunt)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Abdomen is unsupported*</td> </tr> <tr> <td class=\"indent1\">Secretion mobilization</td> <td>Improved bronchial drainage</td> <td>Improved ventilation</td> </tr> <tr> <td class=\"indent1\">Improved aerosol delivery</td> <td>Improved effect of aerosolized meds</td> <td>Improved ventilation</td> </tr> <tr> <td class=\"subtitle2_left\">More homogeneous perfusion</td> <td>Less dependent perfusion</td> <td>Improved V/Q matching (&#8595; shunt)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ppl: Pleural pressure; FRC: functional residual capacity; V/Q: ventilation-perfusion.<BR>* Assumes prone positioning with the upper chest and pelvis supported and the abdomen suspended.</div><div id=\"graphicVersion\">Graphic 54334 Version 2.0</div></div></div>"},"54337":{"type":"graphic_picture","displayName":"Scleral plaques in NSF","title":"Picture showing scleral plaques in eyes of patient with nephrogenic system fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Picture showing scleral plaques in eyes of patient with nephrogenic system fibrosis</div><div class=\"cntnt\"><img style=\"width:396px; height:262px;\" src=\"images/NEPH/54337_Scleral_plaques_in_NSF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with nephrogenic systemic fibrosis has yellowish scleral plaques (arrows). These plaques do not affect vision.</div><div class=\"graphic_reference\">With permission from: Shawn E Cowper, MD.</div><div id=\"graphicVersion\">Graphic 54337 Version 3.0</div></div></div>"},"54338":{"type":"graphic_algorithm","displayName":"Decidual hemorrhage and PTB","title":"Decidual hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Decidual hemorrhage</div><div class=\"cntnt\"><img style=\"width:447px; height:363px;\" src=\"images/OBGYN/54338_Decidual_hemorrhage_and_PTB.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">F: factor; TF: tissue factor; MMP: matrix metalloproteinases; ECM: extracellular matrix; uPA: urokinase-type plasminogen activator; tPA: tissue-type plasminogen activator.</div><div class=\"graphic_reference\">Courtesy of Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 54338 Version 2.0</div></div></div>"},"54339":{"type":"graphic_waveform","displayName":"ECG of inferior MI with anterior ischemia","title":"ECG of inferior MI with anterior ischemia","html":"<div class=\"graphic normal\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">ECG of inferior MI with anterior ischemia</div><div class=\"cntnt\"><img style=\"width:492px; height:239px;\" src=\"images/CARD/54339_Inferior_MI_anterior_ischem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing ischemic changes in two areas of the myocardium: inferior myocardial infarction (Q waves and ST elevations in leads II, III, and aVF); and anterior ischemia (ST depressions in leads V2 and V3).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 54339 Version 4.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"54341":{"type":"graphic_picture","displayName":"Pemphigus foliaceus face","title":"Pemphigus foliaceus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigus foliaceus</div><div class=\"cntnt\"><img style=\"width:350px; height:374px;\" src=\"images/DERM/54341_Pemphigusfoliaceusface.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pemphigus foliaceus lesions exhibit erythema, scaling, and crusting. The face and scalp are often the initial sites of involvement.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54341 Version 2.0</div></div></div>"},"54342":{"type":"graphic_diagnosticimage","displayName":"Oblique fracture of middle phalanx - Lateral view","title":"Oblique fracture of middle phalanx: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique fracture of middle phalanx: Lateral view</div><div class=\"cntnt\"><img style=\"width:172px; height:432px;\" src=\"images/EM/54342_Mid_phalanx_oblique_fx2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fracture line is seen running obliquely through the mid-portion of the middle phalanx in this lateral radiograph. There is no displacement on this view.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 54342 Version 4.0</div></div></div>"},"54343":{"type":"graphic_picture","displayName":"Widow spider A","title":"Redback spider 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Redback spider 1</div><div class=\"cntnt\"><img style=\"width:418px; height:426px;\" src=\"images/EM/54343_Redback_spider_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Julian White, MD.</div><div id=\"graphicVersion\">Graphic 54343 Version 2.0</div></div></div>"},"54344":{"type":"graphic_table","displayName":"Hypoxia altitude test","title":"Interpreting results of hypoxia altitude simulation testing*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpreting results of hypoxia altitude simulation testing*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td class=\"subtitle1\">PaO<sub>2</sub> (mmHg)</td>\n    <td class=\"subtitle1\">PaO<sub>2</sub> (kPa)</td>\n    <td class=\"subtitle1\">SpO<sub>2</sub></td>\n    <td class=\"subtitle1\">Recommendation</td>\n  </tr>\n  <tr>\n    <td>&#62;55 mmHg</td>\n    <td>&#62;7.4 kPa</td>\n    <td>&#62;88 percent</td>\n    <td>In-flight oxygen not advised</td>\n  </tr>\n  <tr>\n    <td>50-55 mmHg</td>\n    <td>6.6-7.4 kPa</td>\n    <td>84-88 percent</td>\n    <td>Borderline, a walk test may be helpful</td>\n  </tr>\n  <tr>\n    <td>&#60;50 mmHg</td>\n    <td>&#60;6.6 kPa</td>\n    <td>&#60;84 percent</td>\n    <td>In-flight oxygen advised</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">PaO<sub>2</sub>: arterial partial pressure of oxygen; SpO<sub>2</sub>: oxygen saturation by pulse oximetry.<br> * Hypoxia altitude simulation testing involves breathing a gas mixture of nitrogen with oxygen at 15.1 percent for 20 minutes, as tolerated.</div><div id=\"graphicVersion\">Graphic 54344 Version 1.0</div></div></div>"},"54346":{"type":"graphic_picture","displayName":"Spindle cell variant of thymic carcinoid","title":"Spindle cell variant of thymic carcinoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spindle cell&nbsp;variant of&nbsp;thymic carcinoid</div><div class=\"cntnt\"><img style=\"width:360px; height:231px;\" src=\"images/PULM/54346_Spindle_cell_thymic_carcino.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows a carcinoid tumor with a prominent spindle cell appearance, which should not be misdiagnosed as thymoma. (Hematoxylin and eosin, magnification 100x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 54346 Version 2.0</div></div></div>"},"54347":{"type":"graphic_picture","displayName":"Perivascular sheathing retina","title":"Perivascular sheathing of retinal vasculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perivascular sheathing of retinal vasculitis</div><div class=\"cntnt\"><img style=\"width:350px; height:252px;\" src=\"images/RHEUM/54347_Perivascular_sheathing_reti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Funduscopic examination shows perivascular sheathing.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 54347 Version 3.0</div></div></div>"},"54350":{"type":"graphic_movie","displayName":"TTE with color Doppler post-ASD repair","title":"Transthoracic echocardiogram with color Doppler post-repair of an atrial septal defect showing a small residual defect","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transthoracic echocardiogram with color Doppler post-repair of an atrial septal defect showing a small residual defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/54350_asdpopcdconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:284px; height:236px;\" src=\"images/CARD/54350_asdpopcd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color flow Doppler demonstates that post-operatively, there is a small, residual atrial septal defect seen as a minimal amount of left to right atrial blood flow.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 54350 Version 4.0</div></div></div>"},"54351":{"type":"graphic_table","displayName":"Chicago protocol for treatment of IVH","title":"University of Illinois at Chicago protocol for intraventricular thrombolysis for IVH","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">University of Illinois at Chicago protocol for intraventricular thrombolysis for IVH</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Exclusions: Unsecured aneurysm or vascular malformation, coagulopathy</td> </tr> <tr> <td class=\"indent1\">1. Monitor ICP continuously</td> </tr> <tr> <td class=\"indent1\">2. Withdraw CSF volume equivalent to drug volume to be administered</td> </tr> <tr> <td class=\"sublist2_start\">3. Inject t-PA through ventriculostomy:</td> </tr> <tr> <td class=\"sublist2\">&#8226; Dose: 3 to 8 mg t-PA</td> </tr> <tr> <td class=\"sublist2\">&#8226; Maximum concentration: 4 mg/mL</td> </tr> <tr> <td class=\"sublist2\">&#8226; Usual dose: 3 to 5 mg</td> </tr> <tr> <td class=\"sublist2\">&#8226; High dose: 8 mg given for severe IVH with all ventricles affected</td> </tr> <tr> <td class=\"indent1\">4. Flush catheter with 1 to 1.5 mL of preservative-free normal saline</td> </tr> <tr> <td class=\"indent1\">5. Clamp EVD for 2 hours; unclamp if ICP &#62;25 mmHg, allowing 1 to 2 mL CSF to drain</td> </tr> <tr> <td class=\"indent1\">6. After 2 hours alternate EVD open to zero gravity and EVD closed for one hour at a time for a total of 12 hours</td> </tr> <tr> <td class=\"indent1\">7. Follow CT scan at 12 to 24 hours</td> </tr> <tr> <td class=\"indent1\">8. Consider repeat t-PA administration at 12 to 24 hours depending on CT scan results</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IVH: intraventricular hemorrhage; ICP: intracranial pressure; CSF: cerebrospinal fluid pressure; EVD: endoventricular drain; CT: computed tomography.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>Andrews CO, Engelhard HH. Fibrinolytic therapy in intraventricular hemorrhage. Ann Pharmacother 2001; 35:1435.</li>&#xD;&#xA;    <li>Engelhard HH, Andrews CO, Slavin KV, Charbel FT. Current management of intraventricular hemorrhage. Surg Neurol 2003; 60:15.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 54351 Version 3.0</div></div></div>"},"54352":{"type":"graphic_table","displayName":"Risk cats patients with LM","title":"Risk categories in patients with leptomeningeal metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk categories in patients with leptomeningeal metastases</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Poor risk</td>\n<td class=\"subtitle1\">Good risk</td>\n</tr>\n<tr>\n<td>KPS &#60;60</td>\n<td>KPS &#8805;60</td>\n</tr>\n<tr>\n<td>Multiple, fixed neurologic deficits</td>\n<td>Minimal or no fixed neurologic deficits</td>\n</tr>\n<tr>\n<td>Extensive systemic cancer without good treatment options</td>\n<td>Effective systemic treatment of cancer possible</td>\n</tr>\n<tr>\n<td>Encephalopathy or bulky CNS disease</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">KPS: Karnofsky Performance Status score.</div><div class=\"graphic_reference\">Modified with data from: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers, Version 1. 2005.</div><div id=\"graphicVersion\">Graphic 54352 Version 1.0</div></div></div>"},"54353":{"type":"graphic_table","displayName":"Gluten free foods PI","title":"Gluten-free foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gluten-free foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td>Amaranth</td> <td>Legumes</td> <td>Sorghum (milo)</td> </tr> <tr> <td>Arrowroot</td> <td>Millet</td> <td>Soy</td> </tr> <tr> <td>Beans/bean flours (garfava, etc)</td> <td>Nuts/nut flours</td> <td>Tapioca, tapioca starch</td> </tr> <tr> <td>Buckwheat</td> <td>Potato, potato starch, potato flour</td> <td>Teff</td> </tr> <tr> <td>Cassava</td> <td>Quinoa</td> <td>Wild rice</td> </tr> <tr> <td>Corn</td> <td>Rice</td> <td>Yucca</td> </tr> <tr> <td>Flax</td> <td>Sago</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Job's tears</td> <td>Seeds</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The foods listed above are naturally gluten-free. However, naturally gluten-free grains, flours, nuts, seeds, and products made from them may be contaminated with wheat, barley, and/or rye. Whenever possible, choose labeled gluten-free versions of these products.</div><div class=\"graphic_reference\">Adapted from: Dennis M, Case S. Going gluten-free: a primer for clinicians. Pract Gastroenterol 2004; 28:86.</div><div id=\"graphicVersion\">Graphic 54353 Version 8.0</div></div></div>"},"54354":{"type":"graphic_table","displayName":"Etiology of priapism","title":"Etiology of priapism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of priapism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary (idiopathic) </td> </tr> <tr> <td class=\"subtitle1_single\">Secondary </td> </tr> <tr> <td class=\"indent1\">Hematologic (sickle cell disease, leukemia, thalassemia, multiple myeloma, thrombotic thrombocytopenic purpura) </td> </tr> <tr> <td class=\"indent1\">Neurologic (spinal shock) </td> </tr> <tr> <td class=\"indent1\">Malignancy (metastatic cancer) </td> </tr> <tr> <td class=\"indent1\">Perineal, pelvic, or penile trauma </td> </tr> <tr> <td class=\"indent1\">Iatrogenic (intracavernous injections) </td> </tr> <tr> <td class=\"indent1\">Drugs (anticoagulants, antihypertensives, antidepressants, PDE5 inhibitors, intracavernous injections, alpha-blockers, methylphenidate, atomoxetine,&nbsp;cocaine) </td> </tr> <tr> <td class=\"indent1\">Infection (malaria, spider toxins) </td> </tr> <tr> <td class=\"indent1\">Metabolic disorders (gout, hemodialysis, high lipid content, total parenteral nutrition, diabetes mellitus, amyloidosis) </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PDE5: phosphodiesterase type 5.</div><div id=\"graphicVersion\">Graphic 54354 Version 4.0</div></div></div>"},"54355":{"type":"graphic_diagnosticimage","displayName":"Normal male breast","title":"Normal male breast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal male breast</div><div class=\"cntnt\"><img style=\"width:250px; height:425px;\" src=\"images/PC/54355_Normal_male_breast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral MLO views of a normal male breast showing small amount of fatty breast tissue.</div><div class=\"graphic_footnotes\">MLO: mediolateral oblique.</div><div id=\"graphicVersion\">Graphic 54355 Version 2.0</div></div></div>"},"54356":{"type":"graphic_table","displayName":"Causes of male infertility","title":"Causes of male infertility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of male infertility</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Endocrine and systemic disorders (hypogonadotropic hypogonadism)</td> </tr> <tr> <td class=\"subtitle2_single\">Congenital disorders </td> </tr> <tr> <td class=\"indent1\">Congenital GnRH deficiency (Kallmann syndrome) </td> </tr> <tr> <td class=\"indent1\">Iron overload syndromes</td> </tr> <tr> <td class=\"indent1\">Multiorgan genetic disorders (Prader-Willi syndrome, Laurence-Moon-Beidl syndrome, familial cerebellar ataxia) </td> </tr> <tr> <td class=\"subtitle2_single\">Acquired disorders </td> </tr> <tr> <td class=\"indent1\">Pituitary and hypothalamic tumors (pituitary macroadenoma, craniopharyngioma) </td> </tr> <tr> <td class=\"indent1\">Pituitary and hypothalamic infiltrative disorders (sarcoidosis, histiocytosis, tuberculosis, fungal infections) </td> </tr> <tr> <td class=\"indent1\">Pituitary and hypothalamic lymphocytic infundibulitis or hypophysitis&nbsp;</td> </tr> <tr> <td class=\"indent1\">Head trauma, intracranial radiation, or surgery</td> </tr> <tr> <td class=\"indent1\">Vascular (pituitary infarction, aneurysm) </td> </tr> <tr> <td class=\"indent1\">Hormonal (hyperprolactinemia, androgen excess, estrogen excess, cortisol excess) </td> </tr> <tr> <td class=\"indent1\">Drugs (exogenous androgens, opioids and psychotropic drugs, GnRH agonists or antagonists) </td> </tr> <tr> <td class=\"subtitle2_single\">Systemic disorders </td> </tr> <tr> <td class=\"indent1\">Severe systemic illness</td> </tr> <tr> <td class=\"indent1\">Nutritional deficiencies </td> </tr> <tr> <td class=\"indent1\">Morbid obesity </td> </tr> <tr> <td class=\"subtitle1_single\">Primary testicular defects in spermatogenesis</td> </tr> <tr> <td class=\"subtitle2_single\">Congenital disorders </td> </tr> <tr> <td class=\"indent1\">Klinefelter syndrome (XXY) and its variants (XXY/XY; XXXY) </td> </tr> <tr> <td class=\"indent1\">Cryptorchidism </td> </tr> <tr> <td class=\"indent1\">Myotonic dystrophy </td> </tr> <tr> <td class=\"indent1\">Functional prepubertal castrate syndrome (congenital anorchia) </td> </tr> <tr> <td class=\"indent1\">Androgen insensitivity syndromes </td> </tr> <tr> <td class=\"indent1\">5-alpha-reductase deficiency </td> </tr> <tr> <td class=\"indent1\">Estrogen receptor or synthesis disorders</td> </tr> <tr> <td class=\"subtitle2_single\">Acquired disorders </td> </tr> <tr> <td class=\"indent1\">Varicocele</td> </tr> <tr> <td class=\"indent1\">Infections - Viral orchitis (mumps, echovirus, arbovirus); granulomatous orchitis (leprosy, tuberculosis); epididymo-orchitis (gonorrhea, chlamydia)</td> </tr> <tr> <td class=\"indent1\">Drugs - Alkylating agents, alcohol, marijuana, antiandrogens, ketoconazole, spironolactone, histamine 2 receptor antagonists, ionizing radiation</td> </tr> <tr> <td class=\"indent1\">Environmental toxins -&nbsp;Dibromochloropropane, carbon disulfide, cadmium, lead, mercury, environmental estrogens and phytoestrogens; smoking; hyperthermia</td> </tr> <tr> <td class=\"indent1\">Immunologic disorders, including polyglandular autoimmune disease and antisperm antibodies</td> </tr> <tr> <td class=\"indent1\">Trauma</td> </tr> <tr> <td class=\"indent1\">Testicular torsion</td> </tr> <tr> <td class=\"subtitle2_single\">Systemic illness</td> </tr> <tr> <td class=\"indent1\">Idiopathic dysspermatogenesis<span class=\"indent1\"></span></td> </tr> <tr> <td class=\"indent1\">Renal failure, hepatic cirrhosis, cancer, sickle cell disease, amyloidosis, vasculitis, celiac disease</td> </tr> <tr> <td class=\"subtitle2_single\">Genetic causes of dysspermatogenesis</td> </tr> <tr> <td class=\"indent1\">Y chromosome microdeletions and related disorders</td> </tr> <tr> <td class=\"indent1\">Autosomal and X chromosome defects</td> </tr> <tr> <td class=\"indent1\">Mutations causing severe defects in sperm morphology</td> </tr> <tr> <td class=\"subtitle1_single\">Sperm transport disorders</td> </tr> <tr> <td class=\"indent1\">Epididymal dysfunction (drugs, infection)</td> </tr> <tr> <td class=\"indent1\">Abnormalities of the vas deferens (congenital absence, Young syndrome, infection, vasectomy) </td> </tr> <tr> <td class=\"indent1\">Seminal vesicles and prostate</td> </tr> <tr> <td class=\"indent1\">Ejaculatory ducts disorders</td> </tr> <tr> <td class=\"subtitle2_single\">Sexual dysfunction</td> </tr> <tr> <td class=\"indent1\">Infrequent vaginal intercourse, erectile dysfunction, and premature ejaculation</td> </tr> <tr> <td class=\"subtitle1_single\">Idiopathic male infertility </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone; LH: luteinizing hormone; FSH: follicle-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 54356 Version 3.0</div></div></div>"},"54358":{"type":"graphic_table","displayName":"Heme pathway enzymes","title":"The sequence of enzymes in the heme biosynthetic pathway, their subcellular localizations, gene symbols, chromosomal locations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The sequence of enzymes in the heme biosynthetic pathway, their subcellular localizations, gene symbols, chromosomal locations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Enzyme*</td> <td class=\"subtitle1\">Subcellular localization</td> <td class=\"subtitle1\">Gene symbol<sup>&#182;</sup> and chromosome location</td> <td class=\"subtitle1\">Number of known disease-related mutations</td> </tr> <tr> <td>&#948;-Aminolevulate synthase - housekeeping form (ALAS1)</td> <td>Mitochondria</td> <td> <p><em>ALAS1</em></p> 3p31.2</td> <td>None</td> </tr> <tr> <td>&#948;-Aminolevulate synthase - erythroid specific form (ALAS2)</td> <td>Mitochondria</td> <td> <p><em>ALAS2</em></p> Xp11.2</td> <td>&#62;25 in sex-linked sideroblastic anemia; 2 gain of function mutations in variant form of erythropoietic protoporphyria</td> </tr> <tr> <td>ALA dehydratase (ALAD)</td> <td>Cytosol</td> <td> <p><em>ALAD</em></p> 9q32</td> <td>11 in ALAD porphyria (6 known cases)</td> </tr> <tr> <td>PBG deaminase (PBGD)<sup>&#916;</sup></td> <td>Cytosol</td> <td> <p><em>HMBS</em></p> 11q23.2</td> <td>&#62;300 in acute intermittent porphyria</td> </tr> <tr> <td>Uroporphyrinogen III synthase (UROS)</td> <td>Cytosol</td> <td> <p><em>UROS</em></p> 10q26.2</td> <td>&#62;35 in congenital erythropoietic porphyria</td> </tr> <tr> <td>Uroporphyrinogen decarboxylase (UROD)</td> <td>Cytosol</td> <td> <p><em>UROD</em></p> 1p34.1</td> <td>&#62;70 in porphyria cutanea tarda (type 2) and hepatoerythropoietic porphyria</td> </tr> <tr> <td>Coproporphyrinogen oxidase (CPO)</td> <td>Mitochondria</td> <td> <p><em>CPO</em></p> 3q12.1</td> <td>&#62;40 in hereditary coproporphyria</td> </tr> <tr> <td>Protoporphyrinogen oxidase (PPO)</td> <td>Mitochondria</td> <td> <p><em>PPOX</em></p> 1q23.3</td> <td>&#62;120 in variegate porphyria</td> </tr> <tr> <td>Ferrochelatase (FECH)</td> <td>Mitochondria</td> <td> <p><em>FECH</em></p> 18q21.31</td> <td>&#62;90 in erythropoietic protoporphyria</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Standard abbreviations in parentheses.<br />¶ Gene symbols in italics, by convention.<br />Δ Also known as hydroxymethylbilane synthase (HMBS), and formerly as uroporphyrinogen I synthase.</div><div class=\"graphic_reference\">Karl Anderson, MD, FACP.</div><div id=\"graphicVersion\">Graphic 54358 Version 3.0</div></div></div>"},"54359":{"type":"graphic_table","displayName":"Toxicity preparative regimens","title":"Treatment modalities commonly utilized in hematopoietic cell transplantation preparative regimens and their dose limiting organ effects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment modalities commonly utilized in hematopoietic cell transplantation preparative regimens and their dose limiting organ effects</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Modality</td>\n<td class=\"subtitle1\">Major organ affected</td>\n</tr>\n<tr>\n<td>Radiation</td>\n<td>Lungs, heart</td>\n</tr>\n<tr>\n<td>Cyclophosphamide</td>\n<td>Heart</td>\n</tr>\n<tr>\n<td>Busulfan</td>\n<td>Lungs</td>\n</tr>\n<tr>\n<td>Etoposide</td>\n<td>Liver</td>\n</tr>\n<tr>\n<td>Carmustine</td>\n<td>Lungs</td>\n</tr>\n<tr>\n<td>Cytarabine</td>\n<td>CNS, nervous tissue</td>\n</tr>\n<tr>\n<td>Melphalan</td>\n<td>Lungs, gastrointestinal</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54359 Version 2.0</div></div></div>"},"54361":{"type":"graphic_algorithm","displayName":"Management central obstruction","title":"Algorithm for the endoscopic management of central airway obstruction","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Algorithm for the endoscopic management of central airway obstruction</div><div class=\"cntnt\"><img style=\"width:624px; height:476px;\" src=\"images/PULM/54361_Management_central_obstruct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm applies mostly to patients with central airway obstruction due to lung cancer, usually non-small cell lung cancer.</div><div class=\"graphic_footnotes\">* Rigid bronchoscopy preferred.<br />¶ Careful airway evaluation and airway computed tomograpy scan, ± flexible bronchoscopy, ± endobronchial ultrasound, ± autofluorescence.<br />Δ Possibly with presurgical endoscopic intervention.<br /><FONT class=lozenge>◊</FONT> Silicone/new hybrid stents generally preferred. Treatment may be followed by radiation if appropriate.<br />§ Can be used singly or in combination, may need stenting.</div><div class=\"graphic_reference\">Reproduced with permission from: Ernst A, Feller-Kopman D, Becker HD, Mehta AC. Central Airway obstruction. Am J Respir Crit Care Med 2004; 169:1278. Copyright &copy; 2004 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 54361 Version 3.0</div></div></div>"},"54364":{"type":"graphic_picture","displayName":"Oophoropexy for ovarian torsion","title":"Laparoscopic right oophoropexy in patient with prior left salpingo-oophorectomy","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Laparoscopic right oophoropexy in patient with prior left salpingo-oophorectomy</div><div class=\"cntnt\"><img style=\"width:548px; height:410px;\" src=\"images/OBGYN/54364_Oophoropexyovariantorsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four-year-old patient with a previous left salpingo-oophorectomy for ovarian torsion, presents with an enlarged right ovary. Images from a right oophoropexy are shown, with the utero-ovarian ligament sewn to the uterosacral ligament.<br> (A) Initial anatomy.<br> (B) Suture is placed in the utero-ovarian ligament in order to shorten the length of the ligament.<br> (C) Suture in place.<br> (D) A second suture has been placed to further shorten the utero-ovarian ligament.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54364 Version 11.0</div></div></div>"},"54367":{"type":"graphic_table","displayName":"Contraindications to coronary angiography","title":"Relative contraindications to coronary angiography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative contraindications to coronary angiography</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>Acute renal failure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic renal failure secondary to diabetes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Active gastrointestinal bleeding</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unexplained fever, which may be due to infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Untreated active infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute stroke</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Severe anemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Severe uncontrolled hypertension</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Severe symptomatic electrolyte imbalance</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Severe lack of cooperation by patient due to\npsychological or severe systemic illness</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Severe concomitant illness that drastically shortens\nlife expectancy or increases risk of therapeutic interventions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Refusal of patient to consider definitive therapy such\nas PTCA, CABG, or valve replacement</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Digitalis intoxication</td></tr>\n\n<tr><td> Documented anaphylactoid\nreaction to angiographic contrast media</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Severe peripheral vascular disease limiting vascular\naccess</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Decompensated heart failure or acute pulmonary\nedema&nbsp;&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Severe coagulopathy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aortic valve endocarditis</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">PTCA: percutaneoas transluminal coronary angioplasty; CABG: coronaryartety bypass graft.</div><div class=\"graphic_reference\">Reproduced with permission by Scanlon, PJ, Faxon, DP, Audet, AM, et al, J Am Coll Cardiol 1999; 33:1756.</div><div id=\"graphicVersion\">Graphic 54367 Version 2.0</div></div></div>"},"54368":{"type":"graphic_diagnosticimage","displayName":"Fetal limb body wall defect in first trimester","title":"Fetal limb body wall defect in first trimester","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal limb body wall defect in first trimester</div><div class=\"cntnt\"><img style=\"width:406px; height:240px;\" src=\"images/OBGYN/54368_1st_Trim_Limb_body_wall_def.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow points to herniated abdominal contents.</div><div class=\"graphic_reference\">Courtesy of Wendy Shaffer, RDMS and Joshua A Copel, MD, Yale University School of Medicine.</div><div id=\"graphicVersion\">Graphic 54368 Version 5.0</div></div></div>"},"54369":{"type":"graphic_figure","displayName":"Shoulder dystocia documentation form A","title":"Documentation of delivery complicated by shoulder dystocia","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Documentation of delivery complicated by shoulder dystocia</div><div class=\"cntnt\"><img style=\"width:483px; height:636px;\" src=\"images/OBGYN/54369_Shoulder_dystocia_doc_A.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54369 Version 2.0</div></div></div>"},"54371":{"type":"graphic_diagnosticimage","displayName":"Acute silicosis CXR","title":"Acute silicosis (silicoproteinosis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute silicosis (silicoproteinosis)</div><div class=\"cntnt\"><img style=\"width:402px; height:235px;\" src=\"images/PULM/54371_Acute_silicosis_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a bilateral alveolar filling process present in both lower lung zones.</div><div class=\"graphic_reference\">Courtesy Dr. E. L. Petsonk.</div><div id=\"graphicVersion\">Graphic 54371 Version 4.0</div></div></div>"},"54372":{"type":"graphic_figure","displayName":"Change in blood glucose forearm and fingerstick","title":"Change in blood glucose using forearm and fingerstick testing after a 75 g oral glucose load at time 0 and intravenous insulin at time 115 minutes","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Change in blood glucose using forearm and fingerstick testing after a 75 g oral glucose load at time 0 and intravenous insulin at time 115 minutes</div><div class=\"cntnt\"><img style=\"width:550px; height:230px;\" src=\"images/ENDO/54372_Chg_blood_glucose_fingers.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Jungheim K, Koschinsky T. Glucose monitoring at the arm: risky delays of hypoglycemia and hyperglycemia detection. Diabetes Care 2002; 25:956.</div><div id=\"graphicVersion\">Graphic 54372 Version 4.0</div></div></div>"},"54375":{"type":"graphic_table","displayName":"GRAALL 2003 regimen","title":"GRAALL-2003 chemotherapy regimen for acute lymphoblastic leukemia (ALL) in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">GRAALL-2003 chemotherapy regimen for acute lymphoblastic leukemia (ALL) in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Remission induction</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">Remission induction begins with a seven-day corticosteroid prephase followed by induction chemotherapy. The intensity of induction is modified based upon response. \"Poor early responders\" include those with a peripheral-blood blast cell count &#8805;1 x 10<sup>9</sup>/L after the corticosteroid prephase (corticoid-resistant) and/or bone marrow blast cells &#8805;5 percent after the first week of chemotherapy (chemotherapy-resistant). Patients who fail to obtain a complete remission (CR) with induction proceed to salvage therapy.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Corticosteroid prephase</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">The \"corticosteroid prephase\" consists of daily prednisone and a single administration of intrathecal methotrexate.</td> </tr> <tr> <td class=\"indent2\">Prednisone</td> <td>oral</td> <td>60 mg/m<sup>2</sup> per day on days minus 7 to minus 1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Methotrexate</td> <td>IT</td> <td>15 mg administered once between days minus 7 and minus 4</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Induction course</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Induction therapy is administered over 28 days. The intensity of cyclophosphamide is increased for \"poor early responders.\"</td> </tr> <tr> <td class=\"indent2\">Prednisone</td> <td>oral</td> <td>60 mg/m<sup>2</sup> per day on days 1 to 14</td> </tr> <tr> <td class=\"indent2\">Daunorubicin</td> <td>IV</td> <td> <p>50 mg/m<sup>2</sup> per day on days 1, 2, and 3</p> <p>30 mg/m<sup>2</sup> per day on days 15 and 16</p> </td> </tr> <tr> <td class=\"indent2\">Vincristine</td> <td>IV</td> <td>2 mg on days 1, 8, 15, and 22</td> </tr> <tr> <td class=\"indent2\">Asparaginase*</td> <td>IM<sup>&#182;</sup></td> <td>6000 units/m<sup>2</sup> per day on days 8, 10, 12, 20, 22, 24, 26, and 28</td> </tr> <tr> <td class=\"indent2\">Cyclophosphamide</td> <td>IV</td> <td> <p>750 mg/m<sup>2</sup> per day on day 1</p> <p><strong>then</strong></p> <p>Good early responders: 750 mg/m<sup>2</sup> on day 15</p> <p>Poor early responders: 500 mg/m<sup>2</sup> every 12 hours on days 15 and 16</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Lenograstim</td> <td>SC</td> <td>150 mcg/m<sup>2</sup> per day from day 17 to myeloid recovery</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Salvage course</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">For patients who fail to obtain a complete remission with induction.</td> </tr> <tr> <td class=\"indent2\">Idarubicin</td> <td>IV</td> <td>12 mg/m<sup>2</sup> per day on days 1 to 3</td> </tr> <tr> <td class=\"indent2\">Cytarabine</td> <td>IV</td> <td>2 grams/m<sup>2</sup> every 12 hours on days 1 to 4</td> </tr> <tr> <td class=\"indent2\">Lenograstim</td> <td>SC</td> <td>150 mcg/m<sup>2</sup> per day from day 9 until myeloid recovery</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Consolidation blocks</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">Consolidation consists of nine \"blocks\" of therapy scheduled to be administered every two weeks, with some modifications of schedule based upon hematologic recovery. Late intensification is administered between consolidation blocks 6 and 7. Allogeneic HCT is offered to patients with high risk disease after consolidation blocks 3 or 6, depending upon donor availability.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Blocks 1, 4, and 7</td> </tr> <tr> <td class=\"indent2\">Cytarabine</td> <td>IV</td> <td>2 grams/m<sup>2</sup> every 12 hours on days 1 and 2</td> </tr> <tr> <td class=\"indent2\">Dexamethasone</td> <td>oral</td> <td>10 mg every 12 hours on days 1 and 2</td> </tr> <tr> <td class=\"indent2\">Asparaginase*</td> <td>IM<sup>&#182;</sup></td> <td>10,000 units/m<sup>2</sup> on day 3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Lenograstim</td> <td>SC</td> <td>150 mcg/m<sup>2</sup> per day on days 7 to 13</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Blocks 2, 5, and 8</td> </tr> <tr> <td class=\"indent2\">Methotrexate</td> <td>IV</td> <td>3 grams/m<sup>2</sup> continuous infusion over 24 hours on day 15</td> </tr> <tr> <td class=\"indent2\">Leucovorin</td> <td>IV/oral</td> <td>15 mg every 6 hours for 8 doses starting 12 hours after the completion of methotrexate infusion; dose modifications made based upon methotrexate levels</td> </tr> <tr> <td class=\"indent2\">Vincristine</td> <td>IV</td> <td>2 mg on day 15</td> </tr> <tr> <td class=\"indent2\">Asparaginase*</td> <td>IM<sup>&#182;</sup></td> <td>10,000 units/m<sup>2</sup> on day 16</td> </tr> <tr> <td class=\"indent2\">Mercaptopurine</td> <td>IV</td> <td>60 mg/m<sup>2</sup> per day on days 15 to 21</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Lenograstim</td> <td>SC</td> <td>150 mcg/m<sup>2</sup> per day on days 22 to 27</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Blocks 3, 6, and 9</td> </tr> <tr> <td class=\"indent2\">Cyclophosphamide</td> <td>IV</td> <td>500 mg/m<sup>2</sup> per day on days 29 and 30</td> </tr> <tr> <td class=\"indent2\">Etoposide</td> <td>IV</td> <td>75 mg/m<sup>2</sup> per day on days 29 and 30</td> </tr> <tr> <td class=\"indent2\">Methotrexate</td> <td>IV</td> <td>25 mg/m<sup>2</sup> on day 29</td> </tr> <tr> <td class=\"indent2\">Lenograstim</td> <td>SC</td> <td>150 mcg/m<sup>2</sup> per day from day 31 until myeloid recovery</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Late intensification</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">Administered between consolidation blocks 6 and 7.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">For patients in CR after the first induction course</td> </tr> <tr> <td class=\"indent2\">Prednisone</td> <td>oral</td> <td>60 mg/m<sup>2</sup> per day on days 1 to 14</td> </tr> <tr> <td class=\"indent2\">Vincristine</td> <td>IV</td> <td>2 mg on days 1, 8, and 15</td> </tr> <tr> <td class=\"indent2\">Daunorubicin</td> <td>IV</td> <td>30 mg/m<sup>2</sup> per day on days 1 to 3</td> </tr> <tr> <td class=\"indent2\">Asparaginase*</td> <td>IM<sup>&#182;</sup></td> <td>6000 units/m<sup>2</sup> per day on days 8, 10, 12, 18, 20, and 22</td> </tr> <tr> <td class=\"indent2\">Cyclophosphamide</td> <td>IV</td> <td>500 mg/m<sup>2</sup> every 12 hours on day 15</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Lenograstim</td> <td>SC</td> <td>150 mcg/m<sup>2</sup> per day if neutrophil count &#60;500/microL, continued until myeloid recovery</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">For patients in CR after the salvage course</td> </tr> <tr> <td class=\"indent2\">Idarubicin</td> <td>IV</td> <td>9 mg/m<sup>2</sup> per day on days 1 to 3</td> </tr> <tr> <td class=\"indent2\">Cytarabine</td> <td>IV</td> <td>2 grams/m<sup>2</sup> every 12 hours on days 1 to 4</td> </tr> <tr> <td class=\"indent2\">Lenograstim</td> <td>SC</td> <td>150 mcg/m<sup>2</sup> per day from day 9 until myeloid recovery</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Maintenance therapy</td> </tr> <tr> <td colspan=\"3\">Maintenance therapy is administered for two years after the completion of consolidation therapy.</td> </tr> <tr> <td class=\"indent2\">Prednisone</td> <td>oral</td> <td>40 mg/m<sup>2</sup> per day on days 1 to 7 of a 28 day cycle, for 12 cycles</td> </tr> <tr> <td class=\"indent2\">Vincristine</td> <td>IV</td> <td>2 mg on day 1 of a 28 day cycle, for 12 cycles</td> </tr> <tr> <td class=\"indent2\">Methotrexate</td> <td>oral</td> <td>25 mg/m<sup>2</sup> weekly for 24 months</td> </tr> <tr> <td class=\"indent2\">Mercaptopurine</td> <td>oral</td> <td>60 mg/m<sup>2</sup> daily for 24 months</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">CNS-directed therapy</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Prophylaxis</td> </tr> <tr> <td class=\"indent2\">Triple intrathecal injections<sup>&#916;</sup></td> <td colspan=\"2\">Days 1 and 8 of induction; day 29 of each series of consolidation blocks; day 1 of late intensification.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Cranial irradiation</td> <td colspan=\"2\">18 Gy administered before start of maintenance therapy. Oral daily mercaptopurine 60 mg/m<sup>2</sup> per day is administered concurrent with radiation.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Treatment of patients with initial CNS involvement</td> </tr> <tr> <td class=\"indent2\">Triple intrathecal injections<sup>&#916;</sup></td> <td colspan=\"2\"> <p>Induction: Eight IT injections administered between days minus 7 and 21.</p> <p>Consolidation: Four IT injections administered during the first two blocks <strong>AND</strong> an IT injection administered on day 29 each of blocks 3 and 6.</p> </td> </tr> <tr> <td class=\"indent2\">Cranial irradiation</td> <td colspan=\"2\"> <p>15 Gy administered before HCT. Oral daily mercaptopurine 60 mg/m<sup>2</sup> per day is administered concurrent with radiation.</p> <p><strong>OR</strong></p> <p>24 Gy administered before start of maintenance therapy. Oral daily mercaptopurine 60 mg/m<sup>2</sup> per day is administered concurrent with radiation.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GRAALL: Group for Research on Adult Acute Lymphoblastic Leukemia; CR: complete remission; HCT: hematopoietic cell transplantation; IT: intrathecal; IM: intramuscular; IV: intravenous; SC: subcutaneous; CNS: central nervous system.<br />* Escherichia coli L-asparaginase.<br />&para; A preferred route of administration was not included in the original publication. Intravenous (IV) and, in some cases subcutaneous, administration of asparaginase are alternates. Intramuscular administration is not recommended in patients with severe thrombocytopenia. IV administration is associated with more frequent and severe immediate hypersensitivity reactions. For additional information see \"Infusion reactions to systemic chemotherapy\", section \"L-asparaginase.\"<br />&Delta; In the original publication, triple IT injections consisted of methotrexate 15 mg, cytarabine 40 mg, and methylprednisolone 40 mg. Some clinicians prefer to use a combination of methotrexate, cytarabine, and preservative-free hydrocortisone (50 mg) due to concerns regarding neurotoxicity with the intrathecal administration of methylprednisolone.</div><div class=\"graphic_reference\">Data from: Huguet F, Leguqy T, Raffoux E, et al. Pediatric-inspiried therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27:911.</div><div id=\"graphicVersion\">Graphic 54375 Version 6.0</div></div></div>"},"54376":{"type":"graphic_figure","displayName":"MF prognosis","title":"Mycosis fungoides: Impact of skin involvement (T stage) on survival","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides: Impact of skin involvement (T stage) on survival</div><div class=\"cntnt\"><img style=\"width:508px; height:290px;\" src=\"images/HEME/54376_SurvivalinMF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actuarial survival of 543 patients with&nbsp;mycosis fungoides&nbsp;managed at Stanford University. All patients had disease apparently limited to the skin. Survival is calculated from the date of referral to Stanford. 1:140 patients with limited patch/plaque disease (T1, clinical stage IA); 2:219 patients with generalized patch/plaque disease (T2, clinical stage IB/IIA); 3:108 patients with tumorous disease (T3, clinical stage IIB0; and 4:76 patients with erythroderma (T4, clinical stage III).</div><div class=\"graphic_reference\">Reproduced with permission from:&nbsp;Kim YH, Hoppe RT. Mycosis fungoides and Sézary Syndrome. Semin Oncol 1999; 26:276.</div><div id=\"graphicVersion\">Graphic 54376 Version 3.0</div></div></div>"},"54377":{"type":"graphic_table","displayName":"Cellular patterns in BAL","title":"Bronchoalveolar lavage: common cellular patterns in selected diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bronchoalveolar lavage: common cellular patterns in selected diseases</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   &nbsp;\n   </td>\n   <td  class=\"subtitle1\">\n   Lymph\n   </td>\n   <td  class=\"subtitle1\">\n   Neutro\n   </td>\n   <td  class=\"subtitle1\">\n   Eosino\n   </td>\n   <td  class=\"subtitle1\">\n   Mast cells\n   </td>\n   <td  class=\"subtitle1\">\n   Other features\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"6\" rowspan=\"1\" class=\"subtitle2_left\">\n   Inflammatory diseases\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   IPF\n   </td>\n   <td>+</td>\n   <td>+++</td>\n   <td>+</td>\n   <td>N</td>\n   <td>&nbsp;</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   PF-CTD\n   </td>\n   <td>+</td>\n   <td>+</td>\n   <td>+</td>\n   <td>N</td>\n   <td>Increased lymphocytes in early disease</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Cryptogenic organizing pneumonia\n   </td>\n   <td>+</td>\n   <td>+</td>\n   <td>+</td>\n   <td>+/-</td>\n   <td>Foamy macrophages; mixed pattern of increased cells characteristic; decreased CD4:CD8 ratio</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Eosinophilic pneumonia\n   </td>\n   <td>+</td>\n   <td>N</td>\n   <td>++++</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Asbestosis\n   </td>\n   <td>N</td>\n   <td>++</td>\n   <td>+</td>\n   <td>N</td>\n   <td>Ferruginous bodies</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Silica-exposed\n   </td>\n   <td>+/-</td>\n   <td>N</td>\n   <td>N</td>\n   <td>N</td>\n   <td>Dust particles by polarized light microscopy</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Coal workers' pneumoconiosis\n   </td>\n   <td>+</td>\n   <td>+</td>\n   <td>N</td>\n   <td>N</td>\n   <td>&nbsp;</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Aluminum potroom workers\n   </td>\n   <td>N</td>\n   <td>N</td>\n   <td>N</td>\n   <td>?</td>\n   <td>+ LTT</td>\n   </tr>\n   <tr>\n   <td  colspan=\"6\" rowspan=\"1\" class=\"subtitle2_left\">\n   Granulomatous diseases\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Sarcoidosis\n   </td>\n   <td>++</td>\n   <td>N or +</td>\n   <td>N</td>\n   <td>N</td>\n   <td>CD4/CD8 &#8805;2</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Hypersensitivity pneumonitis\n   </td>\n   <td>+++</td>\n   <td>N or +</td>\n   <td>N</td>\n   <td>+</td>\n   <td>CD4/CD8 &#60;1</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Chronic beryllium disease\n   </td>\n   <td>+++</td>\n   <td>N or +</td>\n   <td>N</td>\n   <td>N</td>\n   <td>+ LTT to beryllium salts</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">+: increase; N: normal values; lymph: lymphocytes; neutro: neutrophils; eosino: eosinophils; IPF: idiopathic pulmonary fibrosis; PF-CTD: pulmonary fibrosis associated with connective tissue disease; LTT: lymphocyte transformation test.</div><div id=\"graphicVersion\">Graphic 54377 Version 1.0</div></div></div>"},"54378":{"type":"graphic_diagnosticimage","displayName":"Cylindrical bronchiectasis","title":"Cylindrical bronchiectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cylindrical bronchiectasis</div><div class=\"cntnt\"><img style=\"width:354px; height:306px;\" src=\"images/PULM/54378_Cylndrcl_brnchcts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HRCT shows scarring with bibasal loss of volume in the posterobasal and laterobasal segments of both lower lobes. The segmental bronchi are mildly distended and distorted (arrows). They are wider in diameter than their accompanying segmental pulmonary artery branches and are close together. These changes are probably due to a previous, incompletely resolved pneumonia.</div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 54378 Version 4.0</div></div></div>"},"54379":{"type":"graphic_table","displayName":"Malignancy pulmonary nodule","title":"Likelihood ratios for malignancy in solitary pulmonary nodules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Likelihood ratios for malignancy in solitary pulmonary nodules</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Characteristic</td> <td class=\"subtitle1\" colspan=\"2\">Characteristic probability</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" rowspan=\"2\">Likelihood ratio for malignancy*</td> </tr> <tr> <td class=\"subtitle2\">Malignant nodules</td> <td class=\"subtitle2\">Benign nodules</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Size</td> </tr> <tr> <td class=\"indent1\">0-1 cm</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"4\">1063</td> <td>0.52</td> </tr> <tr> <td class=\"indent1\">1.1-2 cm</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>0.74</td> </tr> <tr> <td class=\"indent1\">2.1-3 cm</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>3.67</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;3 cm</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>5.23</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Edge (chest radiography)</td> </tr> <tr> <td class=\"indent1\">Ill defined</td> <td>0.71</td> <td>0.28</td> <td class=\"divider_bottom\" rowspan=\"3\">152</td> <td>2.51</td> </tr> <tr> <td class=\"indent1\">Well defined, lobular</td> <td>0.89</td> <td>0.7</td> <td>1.27</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Well defined, smooth</td> <td>0.11</td> <td>0.3</td> <td>0.36</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tomographic appearance</td> </tr> <tr> <td class=\"indent1\">Malignant</td> <td>0.44</td> <td>0.01</td> <td class=\"divider_bottom\" rowspan=\"3\">238</td> <td>37.2</td> </tr> <tr> <td class=\"indent1\">Indeterminate</td> <td>0.56</td> <td>0.76</td> <td>0.73</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Benign</td> <td>0</td> <td>0.23</td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Edge (CT)</td> </tr> <tr> <td class=\"indent1\">Smooth</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"3\">903</td> <td>0.3</td> </tr> <tr> <td class=\"indent1\">Lobulated</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>0.74</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Irregular/spicular</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>5.54</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Calcification at tomography</td> </tr> <tr> <td class=\"indent1\">Calcified</td> <td>0</td> <td>0.34</td> <td class=\"divider_bottom\" rowspan=\"2\">323</td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Noncalcified</td> <td>1</td> <td>0.66</td> <td>1.5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Calcification at CT</td> </tr> <tr> <td class=\"indent1\">in phantom (benign)</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">1041</td> <td>0.01<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">in phantom</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>2.2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Growth rate</td> </tr> <tr> <td class=\"indent1\">&#60;7 d</td> <td>0</td> <td>0.24</td> <td class=\"divider_bottom\" rowspan=\"3\">217</td> <td>0</td> </tr> <tr> <td class=\"indent1\">7-465 d</td> <td>0.99</td> <td>0.29</td> <td>3.4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;465 d</td> <td>0.01</td> <td>0.46</td> <td>0.01</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Location</td> </tr> <tr> <td class=\"indent1\">Upper/middle lobe</td> <td>0.74</td> <td>0.61</td> <td class=\"divider_bottom\" rowspan=\"2\">179</td> <td>1.22</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lower lobe</td> <td>0.26</td> <td>0.39</td> <td>0.66</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Maximal cavity wall thickness</td> </tr> <tr> <td class=\"indent1\">&#8804;4 mm</td> <td>0.03</td> <td>0.47</td> <td class=\"divider_bottom\" rowspan=\"3\">123</td> <td>0.07</td> </tr> <tr> <td class=\"indent1\">5-15 mm</td> <td>0.37</td> <td>0.52</td> <td>0.72</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;16 mm</td> <td>0.59</td> <td>0.02</td> <td>37.97</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Age</td> </tr> <tr> <td class=\"indent1\">20-29 y</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"6\">529</td> <td>0.05</td> </tr> <tr> <td class=\"indent1\">30-39 y</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>0.24</td> </tr> <tr> <td class=\"indent1\">40-49 y </td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>0.94</td> </tr> <tr> <td class=\"indent1\">50-59 y </td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>1.9</td> </tr> <tr> <td class=\"indent1\">60-69 y </td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>2.64</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;70 y</td> <td>&ndash;<sup>&#182;</sup></td> <td>&ndash;<sup>&#182;</sup></td> <td>4.16</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Smoking history</td> </tr> <tr> <td class=\"indent1\">Never smoked</td> <td>0.06</td> <td>0.33</td> <td class=\"divider_bottom\" rowspan=\"5\">9036</td> <td>0.19</td> </tr> <tr> <td class=\"indent1\">Current cigarette smoker</td> <td>0.58</td> <td>0.26</td> <td>2.27</td> </tr> <tr> <td class=\"indent1\">Pipe/cigar smoker</td> <td>0.08</td> <td>0.08</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Ex-cigarette smoker</td> <td>0.24</td> <td>0.26</td> <td>0.92</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ex-pipe/cigar smoker</td> <td>0.04</td> <td>0.08</td> <td>0.55</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Hemoptysis</td> <td>0.09</td> <td>0.02</td> <td>215</td> <td>5.08</td> </tr> <tr> <td class=\"subtitle2_left\">Previous malignancy</td> <td>0.15</td> <td>0.03</td> <td>845</td> <td>4.95</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The denominator of the likelihood ratio is omitted from the table for simplicity (eg, 0.52:1).<br />¶ A weighted likelihood ratio was estimated by combining results of studies.<br />Δ The standardization of the reference nodule has changed; 0.07 may be a better estimate for the likelihood ratio.</div><div class=\"graphic_reference\">Redrawn from Gurney, JW, Radiology 1993; 186:405.</div><div id=\"graphicVersion\">Graphic 54379 Version 2.0</div></div></div>"},"54380":{"type":"graphic_figure","displayName":"Expected lifetime based on renal replacement therapy","title":"Expected lifetime based on renal replacement therapy","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Expected lifetime based on renal replacement therapy</div><div class=\"cntnt\"><img style=\"width:502px; height:304px;\" src=\"images/PEDS/54380_Expected_lifetime_RRT.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: 2005 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD. Available at: <A href=\"http://optn.transplant.hrsa.gov/data/annualreport.asp\"target=_blank>http://optn.transplant.hrsa.gov/data/annualreport.asp</A> (Accessed June 23, 2011).</div><div id=\"graphicVersion\">Graphic 54380 Version 4.0</div></div></div>"},"54381":{"type":"graphic_picture","displayName":"Dermoscopy of scabies mite in burrow","title":"Scabies mite appearance on dermoscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scabies mite appearance on dermoscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/54381_Dermosc_scabies_mite_burrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dark triangular shape in this image represents the head of the scabies mite. This mite is located at the end of a burrow.</div><div class=\"graphic_reference\">Reproduced with permission from: DermNet NZ. For more information, visit <A spellcheck=true href=\"http://dermnetnz.org/\" target=_blank>http://dermnetnz.org/</A>. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 54381 Version 3.0</div></div></div>"},"54382":{"type":"graphic_picture","displayName":"Paraneoplastic pemphigus gingiva","title":"Paraneoplastic pemphigus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic pemphigus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/54382_Paraneo_pemphi_gingiva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gingival erosions are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54382 Version 3.0</div></div></div>"},"54383":{"type":"graphic_picture","displayName":"Light microscopy of Bartonella ","title":"Light microscopy of bacillary angiomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopy of bacillary angiomatosis</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/ID/54383_Bacillary_angiomatosis_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin stain of skin biopsy sample in a patient with bacillary angiomatosis. The histology shows uniformly appearing plump cells; many of these cells line the lumina of vascular channels.</div><div class=\"graphic_reference\">Courtesy of David H Spach, MD.</div><div id=\"graphicVersion\">Graphic 54383 Version 2.0</div></div></div>"},"54386":{"type":"graphic_picture","displayName":"Seborrheic keratosis hyperpigmented","title":"Hyperpigmented seborrheic keratosis ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperpigmented seborrheic keratosis </div><div class=\"cntnt\"><img style=\"width:360px; height:344px;\" src=\"images/OBGYN/54386_Seborrheic_keratosis_mons.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A seborrheic keratosis presenting as a dark brown/black,&nbsp;elevated, \"stuck on\" waxy lesion.</div><div class=\"graphic_reference\">Courtesy of Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 54386 Version 4.0</div></div></div>"},"54388":{"type":"graphic_table","displayName":"Preventing dietary lead exposure","title":"Nutritional interventions to prevent lead exposure and absorption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutritional interventions to prevent lead exposure and absorption</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Provide a balanced diet that provides a combination of fruits, vegetables, grains, protein, and dairy products</td> </tr> <tr> <td>Ensure children receive sufficient amounts of calcium, iron, zinc, and vitamin C</td> </tr> <tr> <td>Reduce consumption of foods high in fat</td> </tr> <tr> <td>Do not store food or liquids in lead crystal glassware or imported or old pottery</td> </tr> <tr> <td>If you reuse plastic bags to store or carry food, keep the printing on the outside of the bag</td> </tr> <tr> <td>Avoid eating produce that is grown in soil with a high lead content or sprayed with insecticides that contain lead</td> </tr> <tr> <td class=\"sublist1_start\">If lead-contaminated water is a concern:</td> </tr> <tr> <td class=\"sublist1\">Flush pipes for&nbsp;several minutes before drinking water or using it for cooking</td> </tr> <tr> <td class=\"sublist1\">Use only cold water for cooking, drinking, or preparing infant formula</td> </tr> <tr> <td class=\"sublist1\">Consider buying a HEPA* filter certified for lead removal. Call the Environmental Protection Agency's Safe Drinking Water Hotline: 800-426-4791.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* High-efficiency particulate air.</div><div class=\"graphic_reference\">Adapted from: www.epa.gov/lead/educationexesum.htm and www.psr.org/childled.htm.</div><div id=\"graphicVersion\">Graphic 54388 Version 7.0</div></div></div>"},"54389":{"type":"graphic_figure","displayName":"Supracondylar extension fracture","title":"Extension supracondylar fractures","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Extension supracondylar fractures</div><div class=\"cntnt\"><img style=\"width:516px; height:354px;\" src=\"images/EM/54389_ExtensionSCfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperextension forces. A) Most young children attempt to break their falls with the upper extremity extended. Because of the laxity of the ligaments, the elbow becomes locked into hyperextension. B) This converts the linear applied force (large arrow) to an anterior tension force. Posteriorly, the olecranon is forced into the depths of the olecranon fossa (small arrow). C) As the bending force continues, the distal humerus fails anteriorly in the supracondylar area. D) When the fracture is complete, the distal fragment becomes posteriorly displaced. The strong action of the triceps (large arrow) produces proximal displacement of the distal fragment.</div><div class=\"graphic_reference\">Reproduced with permission from: Skaggs DL, Flynn JM. Supracondylar Fractures of the Distal Humerus. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54389 Version 13.0</div></div></div>"},"54391":{"type":"graphic_figure","displayName":"Mesosalpingeal vessel ligation","title":"Mesosalpingeal vessels","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Mesosalpingeal vessels</div><div class=\"cntnt\"><img style=\"width:493px; height:306px;\" src=\"images/OBGYN/54391_Mesosalpingeal_vessel_ligat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomy of vasculature for mesosalpingeal vessel ligation.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 54391 Version 1.0</div></div></div>"},"54392":{"type":"graphic_waveform","displayName":"Advanced case 8","title":"Advanced case 8","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Advanced case 8</div><div class=\"cntnt\"><img style=\"width:540px; height:332px;\" src=\"images/CARD/54392_Advanced_case_8.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54392 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"54393":{"type":"graphic_table","displayName":"Clinical features of PVS coma and others","title":"Characteristics of the persistent vegetative state and related conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of the persistent vegetative state and related conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Self-awareness</td> <td class=\"subtitle1\">Sleep-wake cycles</td> <td class=\"subtitle1\">Experience of suffering</td> <td class=\"subtitle1\">Prognosis</td> </tr> <tr> <td>Persistent vegetative state</td> <td>Absent</td> <td>Intact</td> <td>No</td> <td>Depends upon cause</td> </tr> <tr> <td>Coma</td> <td>Absent</td> <td>Absent</td> <td>No</td> <td>Usually recovery, persistent vegetative state or death in 2 to 4 weeks</td> </tr> <tr> <td>Brain death</td> <td>Absent</td> <td>Absent</td> <td>No</td> <td>No recovery</td> </tr> <tr> <td>Locked-in syndrome</td> <td>Present</td> <td>Intact</td> <td>Yes</td> <td>Recovery unlikely, persistent quadriplegia with prolonged survival possible</td> </tr> <tr> <td>Akinetic mutism</td> <td>Present</td> <td>Intact</td> <td>Yes</td> <td>Recovery very unlikely (depends on cause)</td> </tr> <tr> <td>Dementia</td> <td>Present, but lost in late stages</td> <td>Intact</td> <td>Yes, but lost in late stages</td> <td>Irreversible (ultimate outcome depends on cause)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: N Engl J Med 1994; 330:1499.</div><div id=\"graphicVersion\">Graphic 54393 Version 4.0</div></div></div>"},"54395":{"type":"graphic_picture","displayName":"Ureteral endometriosis","title":"Ureteral endometriosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ureteral endometriosis</div><div class=\"cntnt\"><img style=\"width:432px; height:310px;\" src=\"images/OBGYN/54395_Ureteral_endometriosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">View of hydroureter prior to resection and ureteroneocystotomy.</div><div id=\"graphicVersion\">Graphic 54395 Version 1.0</div></div></div>"},"54396":{"type":"graphic_picture","displayName":"Hypertrophic lichen planus lesion","title":"Hypertrophic lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophic lichen planus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54396_Hypertroplichplanlesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This violaceous and hyperpigmented plaque is a lesion of hypertrophic lichen planus. Fine white lines (Wickham's striae)&nbsp;are visible on the plaque's surface.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54396 Version 5.0</div></div></div>"},"54397":{"type":"graphic_picture","displayName":"Ocular rosacea telangiectasias","title":"Ocular rosacea","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ocular rosacea</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/54397_Ocularrosacea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the lid margin telangiectasia and irregularity and the conjunctival hyperemia.</div><div class=\"graphic_reference\">Image created by Christopher J. Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54397 Version 7.0</div></div></div>"},"54398":{"type":"graphic_diagnosticimage","displayName":"Bankart lesion AP radiograph","title":"Bankart lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bankart lesion</div><div class=\"cntnt\"><img style=\"width:396px; height:336px;\" src=\"images/EM/54398_Bankart_lesion_AP_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bankart lesions occur when the glenoid labrum is disrupted with dislocation. Most involve soft tissue but a small percentage involve the avulsion of bone fragments, as seen in this AP (anterior-posterior)&nbsp;radiograph (arrow).</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD.</div><div id=\"graphicVersion\">Graphic 54398 Version 4.0</div></div></div>"},"54401":{"type":"graphic_table","displayName":"Differential diagnosis of papilledema","title":"Differential diagnosis of papilledema","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of papilledema</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bilateral disc abnormalities*</td> </tr> <tr> <td class=\"indent1\">Increased intracranial pressure</td> </tr> <tr> <td class=\"indent1\">Pseudopapilledema</td> </tr> <tr> <td class=\"indent1\">Malignant hypertension</td> </tr> <tr> <td class=\"indent1\">Diabetic papillopathy</td> </tr> <tr> <td class=\"indent1\">Others (hyperviscosity, toxins)</td> </tr> <tr> <td class=\"subtitle1_single\">Unilateral disc abnormalities*</td> </tr> <tr> <td class=\"indent1\">Anterior ischemic optic neuropathy</td> </tr> <tr> <td class=\"indent1\">Papillitis, neuroretinitis</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Central retinal vein occlusion</td> </tr> <tr> <td class=\"indent1\">Papillophlebitis</td> </tr> <tr> <td class=\"indent1\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Leber hereditary optic neuropathy</td> </tr> <tr> <td class=\"indent1\">Other causes (low intraocular pressure, ocular injury, radiation)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* There is some overlap between the two categories. Entities are classified here as to whether they are more usually bilateral versus unilateral.</div><div id=\"graphicVersion\">Graphic 54401 Version 4.0</div></div></div>"},"54402":{"type":"graphic_diagnosticimage","displayName":"Lacunar infarcts on brain MRI","title":"Acute lacunar infarction on brain MRI","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Acute lacunar infarction on brain MRI</div><div class=\"cntnt\"><img style=\"width:540px; height:358px;\" src=\"images/NEURO/54402_Lacunar_infarcts_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI of a 71-year-old woman with a two-day history of left-sided ataxic hemiparesis. Left panels: Diffusion-weighted MRI sequences show two acute lesions, one in the cerebellum (top panel) and one in the thalamocapsular region (bottom panel). T2-weighted (middle panels) and FLAIR (right panels) MRI sequences correctly identify the lesions (arrows), but neither could be called \"acute\" without diffusion imaging. A high-risk cardiac source (an akinetic left ventricular segment) was found on echocardiogram.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">Courtesy of Jamary Oliveira-Filho, MD.</div><div id=\"graphicVersion\">Graphic 54402 Version 4.0</div></div></div>"},"54403":{"type":"graphic_table","displayName":"High fiber foods PI","title":"High-fiber foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High-fiber foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Fiber (grams)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cereal (&#189; cup serving)</td> </tr> <tr> <td class=\"indent1\">Fiber One</td> <td class=\"centered\">13</td> </tr> <tr> <td class=\"indent1\">100% Bran</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\">All Bran</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\">Bran Buds</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\">Kashi Go Lean</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Kellogg's Complete Bran Flakes</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Grape Nuts</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Raisin Bran*</td> <td class=\"centered\">3 to 5</td> </tr> <tr> <td class=\"indent1\">Cracklin' Oat Bran*</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">100% Whole Grain Wheat Chex</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Fruit and Fiber</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Great Grains</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Frosted Mini Wheats</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Kellogg's Low-Fat Granola</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Cheerios</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Wheaties</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Instant oatmeal</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fruit</td> </tr> <tr> <td class=\"indent1\">Pear (one)</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Strawberries (1 cup)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Apple (one, with skin)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Dried fruits (eg, raisins) (3 tablespoons)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Papaya (one)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Peach (fresh)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Plums (two)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Mango</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Nectarine</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Avocado (&#189; medium)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tomato (one medium)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vegetables (cooked unless indicated)</td> </tr> <tr> <td class=\"indent1\">Pinto, kidney, black, lima beans (&#189; cup)</td> <td class=\"centered\">4 to 7</td> </tr> <tr> <td class=\"indent1\">Sweet potato (1 medium)</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Lentils (&#189; cup)</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Jicama (&#189; raw)</td> <td class=\"centered\">3 to 4</td> </tr> <tr> <td class=\"indent1\">Baked potato with skin (medium)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Corn (&#189; cup)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Peas (&#189; cup)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Broccoli (&#189; cup)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Cabbage (&#189; cup)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Spinach (&#189; cup)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Cauliflower (&#190; cup)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Carrots (1 medium raw, or &#189; cup cooked)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These cereals are also high in sugar (15 to 20 grams per serving).<br />&para; These foods contain relatively small amounts of fiber, but may still be helpful to provide a portion of the child's fiber intake.<br />&Delta; Reflects <strong>insoluble</strong> fiber, which is the most relevant type of fiber for prevention and treatment of constipation. <strong>Soluble</strong> fiber has different health benefits. Some \"high fiber\" forms of instant oatmeal contain up to 10 grams of fiber. However, most of this additional fiber is soluble, which may not be as valuable as insoluble fiber for prevention and treatment of constipation.</div><div id=\"graphicVersion\">Graphic 54403 Version 6.0</div></div></div>"},"54404":{"type":"graphic_picture","displayName":"Eosinophilic folliculitis B","title":"Eosinophilic folliculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic folliculitis</div><div class=\"cntnt\"><img style=\"width:360px; height:249px;\" src=\"images/DERM/54404_Eosinophilic_folliculitis_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HIV-associated eosinophilic folliculitis is characterized by recurrent, pruritic crops of discrete, erythematous, urticarial follicular papules and rare pustules, with a diameter of 3 to 5 mm.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Courtesy of Toby Maurer, MD.</div><div id=\"graphicVersion\">Graphic 54404 Version 4.0</div></div></div>"},"54405":{"type":"graphic_figure","displayName":"Blood supply hip","title":"Arterial blood supply of the proximal femur","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arterial blood supply of the proximal femur</div><div class=\"cntnt\"><img style=\"width:408px; height:360px;\" src=\"images/EM/54405_Bloodsupplyhip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arterial supply of the proximal femur. The capital femoral epiphysis and physis are supplied by the medial circumflex artery through two retinacular systems: the posterosuperior and posteroinferior. The lateral circumflex artery supplies the greater trochanter and the lateral portion of the proximal femoral physis and a small area of the anteromedial metaphysis.</div><div class=\"graphic_reference\">Reproduced with permission from: McCarthy J, Noonan K. Fractures and traumatic dislocations of the hip in children. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54405 Version 10.0</div></div></div>"},"54407":{"type":"graphic_figure","displayName":"Lower vaginal atresia","title":"Agenesis (atresia) of the lower vagina, or thick transverse vaginal septum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Agenesis (atresia) of the lower vagina, or thick transverse vaginal septum</div><div class=\"cntnt\"><img style=\"width:301px; height:246px;\" src=\"images/OBGYN/54407_Lowervaginalatresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54407 Version 13.0</div></div></div>"},"54410":{"type":"graphic_figure","displayName":"VO2 DO2 relationships","title":"Oxygen delivery (DO2) and consumption (VO2)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oxygen delivery (DO2) and consumption (VO2)</div><div class=\"cntnt\"><img style=\"width:336px; height:239px;\" src=\"images/PULM/54410_VO2_DO2_relationships.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the normal state (blue line), oxygen consumption is constant over a range of DO2, and decreases only when DO2 falls below a critical level (critical DO2). Pathologic changes caused by sepsis or systemic inflammatory responses (red line) cause increased VO2 and impaired peripheral oxygen utilization, resulting in an elevation in critical DO2.</div><div id=\"graphicVersion\">Graphic 54410 Version 1.0</div></div></div>"},"54412":{"type":"graphic_table","displayName":"Mortality of gastrointestinal-cutaneous fistulae","title":"Mortality of gastrointestinal-cutaneous fistulae","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mortality of gastrointestinal-cutaneous fistulae</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1946-1959</td> <td>45 percent (138 patients - MGH)</td> </tr> <tr> <td>1960-1970</td> <td>15 percent (119 patients - MGH)</td> </tr> <tr> <td>1970-1975</td> <td>19 percent (145 patients - MGH)</td> </tr> <tr> <td>1982-1991</td> <td>20 percent (79 patients - UH)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">20</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=91438&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced with permission from: Fischer JE, Evenson AR. Gastrointestinal-cutaneous fistulae. In: Mastery of Surgery, Fischer JE (Ed), Lippincott Williams &amp; Wilkins 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54412 Version 8.0</div></div></div>"},"54417":{"type":"graphic_table","displayName":"Disorders of glycogen - glucose metabolism","title":"Disorders of glycogen/glucose metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders of glycogen/glucose metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification</td> <td class=\"subtitle1\">Key clinical findings</td> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Therapy</td> </tr> <tr> <td>GSD 0a (MIM #240600, glycogen synthase 2 deficiency in liver)</td> <td>Ketotic hypoglycemia, no hepatomegaly</td> <td>Liver biopsy and enzyme testing; DNA testing</td> <td>Uncooked cornstarch, <span style=\"font-size: 10px;\"></span> <p>commercial glucose polymers (eg, Glycosade), liver transplantation</p> </td> </tr> <tr> <td>GSD 0b (MIM #611556, muscle glycogen synthase deficiency)</td> <td>Cardiomyopathy, exercise intolerance, weakness</td> <td>Muscle biopsy (glycogen depletion), enzyme assay, DNA testing</td> <td>No specific treatment</td> </tr> <tr> <td>GSD I (MIM #232200; GSD Ia, von Gierke disease, glucose-6-phosphatase deficiency; GSD Ib due to q transport defect)</td> <td>Ketotic hypoglycemia, hepatomegaly</td> <td>DNA testing, liver biopsy, and enzyme assay</td> <td>Cornstarch, allopurinol, granulocyte colony-stimulating factor (G-CSF), commercial glucose polymers (eg, Glycosade), liver transplantation</td> </tr> <tr> <td>Lysosomal acid maltase deficiency (MIM #232300, Pompe disease, GSD II*)</td> <td>Hypotonia, muscle weakness, hypertrophic cardiomyopathy, rhabdomyolysis</td> <td>Fibroblast, leukocyte, muscle, or liver enzyme assay; DNA testing</td> <td>Enzyme replacement therapy, commercial glucose polymers (eg, Glycosade), liver transplantation</td> </tr> <tr> <td>Lysosome-associated membrane protein 2 (LAMP2) deficiency (MIM #300257,&nbsp;Danon disease, GSD IIb<sup>*</sup>) </td> <td>Hypotonia, hypertrophic cardiomyopathy, rhabdomyolysis</td> <td>Muscle biopsy, DNA testing</td> <td>No specific treatment</td> </tr> <tr> <td>GSD III (MIM #232400, glycogen debrancher deficiency)</td> <td>Ketotic hypoglycemia, hepatomegaly</td> <td>Fibroblast or liver enzyme assay; DNA testing</td> <td>Uncooked cornstarch, <p>commercial glucose polymers (eg, Glycosade), liver transplantation</p> </td> </tr> <tr> <td>GSD IV (MIM #232500, glycogen branching enzyme deficiency)</td> <td>Hepatomegaly, cirrhosis, rare neuromuscular presentations, such as&nbsp;fetal akinesia sequence, myopathy, axonal neuropathy, adult polyglucosan body disease</td> <td>Fibroblast, muscle, or liver biopsy; DNA testing</td> <td> <p>Commercial glucose polymers (eg, Glycosade), liver transplantation</p> </td> </tr> <tr> <td>GSD V (MIM #232600, McArdle disease, muscle phosphorylase deficiency)</td> <td>Fatigability, myoglobinuria, rhabdomyolysis</td> <td>Muscle biopsy, muscle enzyme assay, DNA testing</td> <td>Sucrose prior to exercise</td> </tr> <tr> <td>GSD VI (MIM #232700, Hers disease, liver phosphorylase deficiency)</td> <td>Hepatomegaly, mild hypoglycemia</td> <td>Liver biopsy and enzyme assay; DNA testing</td> <td> <p>Commercial glucose polymers (eg, Glycosade), liver transplantation</p> </td> </tr> <tr> <td>GSD VII (MIM #232800, Tarui disease, phosphofructokinase deficiency in muscle)</td> <td>Fatigability, myoglobinuria, rhabdomyolysis</td> <td>Muscle enzyme assay, DNA testing</td> <td>No specific treatment</td> </tr> <tr> <td>Phosphoglycerate kinase deficiency (MIM #311800)</td> <td>Hemolysis, fatigability, myoglobinuria, CNS dysfunction, rhabdomyolysis</td> <td>Muscle/RBC enzyme assay; DNA testing</td> <td>Bone marrow transplantation</td> </tr> <tr> <td>GSD IX (phosphorylase kinase deficiency; IX a1, MIM #306000, formerly GSD VIII, alpha-2 subunit defect in liver; IXb, MIM #261750, beta subunit defect in liver; IXc, MIM #613027, gamma subunit defect in liver and muscle; IXd, MIM #300559, alpha subunit defect in muscle)</td> <td>Hepatomegaly, mild hypoglycemia, fatigability, exercise intolerance</td> <td>Liver/muscle biopsy; enzyme assay; DNA testing</td> <td> <p>Commercial glucose polymers (eg, Glycosade), liver transplantation</p> </td> </tr> <tr> <td>GSD X (MIM #261670, phosphoglycerate mutase deficiency)</td> <td>Fatigability, myoglobinuria, exercise intolerance, rhabdomyolysis</td> <td>Muscle biopsy and enzyme assay; DNA testing</td> <td>No specific treatment</td> </tr> <tr> <td>GSD XI (MIM #612933; lactate dehydrogenase&nbsp;A [LDHA, MIM #150000] deficiency and lactate dehydrogenase&nbsp;B deficiency [LDHB, MIM #150100])</td> <td>Fatigability, myoglobinuria, rhabdomyolysis</td> <td>Muscle or RBC enzyme assay; DNA testing</td> <td>No specific treatment</td> </tr> <tr> <td>GLUT2 deficiency (MIM #138160; Fanconi-Bickel syndrome)</td> <td>Growth retardation, renal Fanconi syndrome, galactosemia</td> <td>Clinical features, DNA testing</td> <td>Small meals, cornstarch, electrolytes as needed</td> </tr> <tr> <td>GSD XII (MIM #611881, aldolase A deficiency)</td> <td>Hemolysis, jaundice, myoglobinuria, muscle weakness, fatigability, rhabdomyolysis</td> <td>Muscle or RBC enzyme assay; DNA testing</td> <td>No specific treatment</td> </tr> <tr> <td>GSD XIII (MIM #612932, beta-enolase deficiency in muscle)</td> <td>Exercise intolerance, increased CPK, rhabdomyolysis</td> <td>Muscle biopsy, enzyme assay, DNA testing</td> <td>No specific treatment</td> </tr> <tr> <td>GSD XIV (MIM #612934, phosphoglucomutase 1 deficiency in muscle)</td> <td>Exercise intolerance, myoglobinuria, increased CPK, rhabdomyolysis, myoglobinuria</td> <td>Muscle biopsy, enzyme assay, DNA testing</td> <td>No specific treatment</td> </tr> <tr> <td>GSD XV (MIM #613507, glycogenin 1 deficiency in muscle)</td> <td>Muscle weakness, arrhythmias</td> <td>Muscle biopsy (glycogen depletion), DNA testing</td> <td>No specific treatment</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GSD: glycogen storage disease; MIM: Mendelian inheritance in man; DNA: deoxyribonucleic acid; CNS: central nervous system; RBC: red blood cell; GLUT2: glucose transporter 2; CPK: creatine phosphokinase.<br />* <FONT color=black><FONT color=black>These diseases were originally classified as glycogen storages diseases. It was subsequently recognized&nbsp;that the accumulation of glycogen in lysosomes&nbsp;seen in these diseases is&nbsp;due to defective lysosomal metabolism&nbsp;rather than&nbsp;energy deficiency from glycogen/glucose metabolism</FONT>. Thus, they are considered both glycogen storage diseases and lysosomal storage diseases.</FONT><br /></div><div id=\"graphicVersion\">Graphic 54417 Version 13.0</div></div></div>"},"54418":{"type":"graphic_table","displayName":"History in BRUE","title":"Clinical history for evaluating an infant after a brief resolved unexplained event (BRUE)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical history for evaluating an infant after a brief resolved unexplained event (BRUE)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Event</td> </tr> <tr> <td class=\"indent1\">State: Was the infant asleep, awake, or crying? What was the timing of the&nbsp;BRUE in relationship to feeding or vomiting? If the infant was sleeping, what was the sleep position and location (eg, alone in the crib versus in a bed with the parent).</td> </tr> <tr> <td class=\"indent1\">Respiratory effort: Were respiratory efforts none, shallow, or increased? Was the infant struggling or choking during the event?</td> </tr> <tr> <td class=\"indent1\">Color: Was the infant cyanotic, pallid, gray, red, purple?</td> </tr> <tr> <td class=\"indent1\">Color change: Did the color change affect the entire body, extremities, face, perioral area, or lips?</td> </tr> <tr> <td class=\"indent1\">Tone: Was the infant limp, rigid, or tonic/clonic?</td> </tr> <tr> <td class=\"indent1\">Eyes: Were the infant's eyes open, closed, dazed, staring, rolled, or bulging?</td> </tr> <tr> <td class=\"indent1\">Noise: Did the infant make any sound, such as a cough, choking, stridor, cry, or gasp?</td> </tr> <tr> <td class=\"indent1\">Fluid: Did the infant spit up or vomit anything? If so, was it mucus, milk, vomitus, or blood? Did this occur at the beginning of the BRUE, or later?</td> </tr> <tr> <td class=\"indent1\">Duration: How many seconds or minutes did the event last?</td> </tr> <tr> <td class=\"indent1\">Witnesses: Who was present before and during the event? Document the caretaker(s) present, and obtain a description of the event from each.</td> </tr> <tr> <td class=\"subtitle1_single\">Intervention</td> </tr> <tr> <td class=\"indent1\">None</td> </tr> <tr> <td class=\"indent1\">Gentle stimulation or \"puff of air in the face\"?</td> </tr> <tr> <td class=\"indent1\">Vigorous stimulation? If so, did this include vigorous shaking? </td> </tr> <tr> <td class=\"indent1\">Mouth to mouth resuscitation?</td> </tr> <tr> <td class=\"indent1\">CPR by&nbsp;trained personnel?</td> </tr> <tr> <td class=\"indent1\">Duration of the intervention?</td> </tr> <tr> <td class=\"subtitle1_single\">Past history</td> </tr> <tr> <td class=\"indent1\">Prior events: Have any similar events occurred in the past? If so, describe the event in detail, when and where it occurred, and which caretaker(s) was present.</td> </tr> <tr> <td class=\"indent1\">Medical history: Does the infant have any known medical problems, or other symptoms causing concern?</td> </tr> <tr> <td class=\"indent1\">Medications: Was the infant given any medication (prescription, over-the-counter, or herbal) in the day prior to the event? What medications are in the home?&nbsp;Is there any chance that the baby swallowed a medication or poison by accident?</td> </tr> <tr> <td class=\"indent1\">Birth history: Was the baby born \"on time\", and were there any problems with the delivery or in the nursery?</td> </tr> <tr> <td class=\"indent1\">Family history: Are there any siblings or other children in the household who have had similar events or early deaths, or who have other medical problems?</td> </tr> <tr> <td class=\"indent1\">Social history: Do the parents or other household members smoke, or use drugs or alcohol?&nbsp;Has the family been reported for possible child maltreatment in the past?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CPR: cardiopulmonary resuscitation.<br />*Brief resolved unexplained event (BRUE) was previously known as an apparent life-threatening event (ALTE).</div><div id=\"graphicVersion\">Graphic 54418 Version 8.0</div></div></div>"},"54419":{"type":"graphic_picture","displayName":"Scrotal hypospadias","title":"Scrotal hypospadias","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scrotal&nbsp;hypospadias</div><div class=\"cntnt\"><img style=\"width:392px; height:261px;\" src=\"images/PEDS/54419_Perineal_hypospadias.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scrotal&nbsp;hypospadias and bifid scrotum in 46,XY infant with Drash syndrome.</div><div class=\"graphic_reference\">Courtesy of Christopher P Houk, MD and Lynne L Levitsky, MD.</div><div id=\"graphicVersion\">Graphic 54419 Version 3.0</div></div></div>"},"54423":{"type":"graphic_table","displayName":"Strength examination of the elbow","title":"Strength examination of the elbow","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strength examination of the elbow</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Joint action</td> <td class=\"subtitle1\">Position and action for examination</td> <td class=\"subtitle1\">Muscles tested</td> </tr> <tr> <td>Extension</td> <td>Resisted extension</td> <td>Triceps</td> </tr> <tr> <td rowspan=\"3\">Flexion</td> <td>Forearm supinated - resisted flexion</td> <td>Biceps brachii</td> </tr> <tr> <td>Forearm&nbsp;neutral- resisted flexion</td> <td>Brachioradialis</td> </tr> <tr> <td>Forearm &nbsp;pronated- resisted flexion</td> <td>Brachialis</td> </tr> <tr> <td rowspan=\"2\">Supination</td> <td>Hand in neutral, perpendicular to ground</td> <td rowspan=\"2\">Biceps, supinator</td> </tr> <tr> <td>Resisted rotation of \"palm up\"</td> </tr> <tr> <td rowspan=\"2\">Pronation</td> <td>Hand in neutral, perpendicular to ground</td> <td rowspan=\"2\">Pronator teres, quadratus</td> </tr> <tr> <td>Resisted rotation of \"palm down\"</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=56181&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">The shoulder is in the neutral position with the elbow flexed at 90 degrees&nbsp;and touching the iliac crest.</div><div id=\"graphicVersion\">Graphic 54423 Version 3.0</div></div></div>"},"54426":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for schizophrenia","title":"DSM-5 diagnostic criteria for schizophrenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for schizophrenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\"><strong>A.</strong> Two (or more) of the following, each present for a significant portion of time during a one-month period (or less if successfully treated). At least one of these must be (1), (2), or (3):</td> </tr> <tr> <td class=\"indent1\">1) Delusions.</td> </tr> <tr> <td class=\"indent1\">2) Hallucinations.</td> </tr> <tr> <td class=\"indent1\">3) Disorganized speech (eg, frequent derailment or incoherence).</td> </tr> <tr> <td class=\"indent1\">4) Grossly disorganized or catatonic behavior.</td> </tr> <tr> <td class=\"indent1\">5) Negative symptoms (ie, diminished emotional expression or avolition).</td> </tr> <tr> <td><strong>B.</strong> For a significant portion of the time since the onset of the disturbance, level of functioning in one or more major areas, such as work, interpersonal relations, or self-care, is markedly below the level achieved prior to the onset (or when the onset is in childhood or adolescence, there is failure to achieve expected level of interpersonal, academic, or occupational functioning).</td> </tr> <tr> <td><strong>C.</strong> Continuous signs of the disturbance persist for at least 6 months. This six-month period must include at least 1 month of symptoms (or less if successfully treated) that meet Criterion A (ie, active-phase symptoms) and may include periods of prodromal or residual symptoms. During these prodromal or residual periods, the signs of the disturbance may be manifested by only negative symptoms or by two or more symptoms listed in Criterion A present in an attenuated form (eg, odd beliefs, unusual perceptual experiences).</td> </tr> <tr> <td><strong>D.</strong> Schizoaffective disorder and depressive or bipolar disorder with psychotic features have been ruled out because either 1) no major depressive or manic episodes have occurred concurrently with the active-phase symptoms, or 2) if mood episodes have occurred during active-phase symptoms, they have been present for a minority of the total duration of the active and residual periods of the illness.</td> </tr> <tr> <td><strong>E.</strong> The disturbance is not attributable to the direct physiological effects of a substance (eg, a drug of abuse, a medication) or another medical condition.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>F.</strong> If there is a history of autism spectrum disorder or a communication disorder of childhood onset, the additional diagnosis of schizophrenia is made only if prominent delusions or hallucinations, in addition to the other required symptoms of schizophrenia, are also present for at least one month (or less if successfully treated).</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> if:</td> </tr> <tr> <td class=\"sublist2_start\">The following course specifiers are only to be used after a 1-year duration of the disorder and if they are not in contradiction to the diagnostic course criteria.</td> </tr> <tr> <td class=\"indent2\"><strong>First episode, currently in acute episode:</strong> First manifestation of the disorder meeting the defining diagnostic symptom and time criteria. An acute episode is a time period in which the symptom criteria are fulfilled.</td> </tr> <tr> <td class=\"indent2\"><strong>First episode, currently in partial remission:</strong> Partial remission is a period of time during which an improvement after a previous episode is maintained and in which the defining criteria of the disorder are only partially fulfilled.</td> </tr> <tr> <td class=\"indent2\"><strong>First episode, currently in full remission:</strong> Full remission is a period of time after a previous episode during which no disorder-specific symptoms are present.</td> </tr> <tr> <td class=\"indent2\"><strong>Multiple episodes, currently in acute episode:</strong> Multiple episodes may be determined after a minimum of two episodes (ie, after a first episode, a remission and a minimum of one relapse).</td> </tr> <tr> <td class=\"indent2\"><strong>Multiple episodes, currently in partial remission.</strong></td> </tr> <tr> <td class=\"indent2\"><strong>Multiple episodes, currently in full remission.</strong></td> </tr> <tr> <td class=\"indent2\"><strong>Continuous:</strong> Symptoms fulfilling the diagnostic symptom criteria of the disorder are remaining for the majority of the illness course, with subthreshold symptom periods being very brief relative to the overall course.</td> </tr> <tr> <td class=\"indent2\"><strong>Unspecified.</strong></td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> if:</td> </tr> <tr> <td class=\"indent1\">With catatonia</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> current severity:</td> </tr> <tr> <td class=\"indent1\">Severity is rated by a quantitative assessment of the primary symptoms of psychosis, including delusions, hallucinations, disorganized speech, abnormal psychomotor behavior, and negative symptoms. Each of these symptoms may be rated for its current severity (most severe in the last seven days) on a 5-point scale ranging from 0 (not present) to 4 (present and severe).</td> </tr> <tr> <td class=\"indent1\"><strong>NOTE:</strong> Diagnosis of schizophrenia can be made without using this severity specifier.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright &copy; 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 54426 Version 12.0</div></div></div>"},"54427":{"type":"graphic_figure","displayName":"Segmental resection of a benign left colon lesion","title":"Segmental resection of a benign left colon lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Segmental resection of a benign left colon lesion</div><div class=\"cntnt\"><img style=\"width:434px; height:544px;\" src=\"images/SURG/54427_Segmental-benign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a limited or segmental resection of a benign lesion in the left colon. Note the smaller extent of colon and mesentery excised.</div><div id=\"graphicVersion\">Graphic 54427 Version 1.0</div></div></div>"},"54428":{"type":"graphic_figure","displayName":"Brain aneurysm PI","title":"Brain aneurysm","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Brain aneurysm</div><div class=\"cntnt\"><img style=\"width:504px; height:590px;\" src=\"images/PI/54428_Brain-aneurysm-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A brain aneurysm is a swollen bulge or “ballooning” in the wall of a blood vessel in the brain.</div><div id=\"graphicVersion\">Graphic 54428 Version 1.0</div></div></div>"},"54429":{"type":"graphic_picture","displayName":"Acute subacute paracocci","title":"Clinical presentations of acute/subacute paracoccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical presentations of acute/subacute paracoccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:380px; height:374px;\" src=\"images/ID/54429_Acute_subacute_paracocci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Young adults with acute/subacute paracoccidioidomycosis. (A) Lymphadenopathy in the supraclavicular, cervical, and submandibular regions. (B) The lymphadenopathy of paracoccidioidomycosis must be differentiated from hematologic diseases, such as lymphoma. (C) Ulcerating lesions on the cheek and near the ear with a verrucous appearance resulting from hematologic dissemination. (D) Papulonodular and ulcerating lesions resulting from hematologic dissemination.</div><div class=\"graphic_reference\">Reproduced with permission from: Shikanai-Yasuda MA, Queiroz Telles Filho F, Mendes RP, et al. Consenso em paracoccidioidomicose [Guidelines in paracoccidioidomycosis]. Revista da Sociedade Brasileira de Medicina Tropical 2006; 39:297-310. Copyright ©2006 Sociedade Brasileira de Medicina Tropical.</div><div id=\"graphicVersion\">Graphic 54429 Version 3.0</div></div></div>"},"54431":{"type":"graphic_movie","displayName":"Echo MR post MI four chamber color Doppler echo","title":"Echocardiogram four-chamber post MI mitral regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram four-chamber post MI mitral regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/54431_4chcmrpmconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:257px; height:436px;\" src=\"images/CARD/54431_4chcmrpm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram with color flow Doppler shows mitral regurgitation with a jet directed toward the posterior left atrial wall as a result of a previous anterior septal myocardial infarction and papillary muscle dysfunction involving primarily the anterior mitral valve leaflet.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 54431 Version 3.0</div></div></div>"},"54433":{"type":"graphic_figure","displayName":"4th nerve anatomy","title":"Origin and distribution of the trochlear nerve","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Origin and distribution of the trochlear nerve</div><div class=\"cntnt\"><img style=\"width:456px; height:244px;\" src=\"images/PEDS/54433_4th_nerve_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomic schematic showing the course of the fourth cranial nerve.</div><div class=\"graphic_reference\">Reproduced with permission from: Snell RS. Clinical Anatomy, 7th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54433 Version 2.0</div></div></div>"},"54434":{"type":"graphic_picture","displayName":"Circular retinal fold","title":"Circular retinal fold in abusive head injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circular retinal fold in abusive head injury</div><div class=\"cntnt\"><img style=\"width:360px; height:251px;\" src=\"images/PEDS/54434_Circular_retinal_fold.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fold extends inferiorly and superotemporally from the optic disk.</div><div class=\"graphic_reference\">Reproduced with permission from: Kivlin, JD. Ophthalmic manifestations of shaken baby syndrome. Journal of Aggression, Maltreatment and Trauma 2001; 5:137. Copyright &#169;2001 The Haworth Press, Inc.</div><div id=\"graphicVersion\">Graphic 54434 Version 1.0</div></div></div>"},"54435":{"type":"graphic_diagnosticimage","displayName":"Ultraound image of Doppler flow in abnormal axillary lymph node","title":"Ultrasound image of Doppler flow in abnormal axillary lymph node","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of Doppler flow in abnormal axillary lymph node</div><div class=\"cntnt\"><img style=\"width:393px; height:354px;\" src=\"images/SURG/54435_USDoppabnormaxln.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound image of abnormal lymph node. This shows Doppler blood flow within the node.</div><div id=\"graphicVersion\">Graphic 54435 Version 3.0</div></div></div>"},"54436":{"type":"graphic_diagnosticimage","displayName":"Mammogram of nipple inversion associated with malignancy","title":"Mammogram of nipple inversion associated with malignancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mammogram of nipple inversion associated with malignancy</div><div class=\"cntnt\"><img style=\"width:442px; height:334px;\" src=\"images/SURG/54436_Mamm_nipple_invers_malig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retroareolar breast cancers, within 2 cm of the nipple areolar complex, are likely to be associated with nipple inversion as shown here.</div><div id=\"graphicVersion\">Graphic 54436 Version 2.0</div></div></div>"},"54439":{"type":"graphic_table","displayName":"Differential diagnosis of pediatric scrotal pain","title":"Distinguishing features of conditions associated with scrotal pain in children and adolescents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing features of conditions associated with scrotal pain in children and adolescents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Testicular torsion</td> <td class=\"subtitle1\">Torsion of appendage</td> <td class=\"subtitle1\">Acute epididymitis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Historical features</td> </tr> <tr> <td class=\"indent1\">Peak incidence</td> <td>Perinatal and puberty</td> <td>Prepubertal</td> <td>&#60;2 years and postpubertal</td> </tr> <tr> <td class=\"indent1\">Onset of pain</td> <td>Usually sudden</td> <td>Usually sudden</td> <td>Usually gradual</td> </tr> <tr> <td class=\"indent1\">Duration of pain</td> <td>Usually &#60;12 hours</td> <td>Usually &#62;12 hours</td> <td>Usually &#62;24 hours</td> </tr> <tr> <td class=\"indent1\">Previous episodes</td> <td>Typical</td> <td>Unusual</td> <td>If previous episode</td> </tr> <tr> <td class=\"indent1\">Nausea and vomiting</td> <td>Common</td> <td>Uncommon</td> <td>Uncommon</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td>Unusual</td> <td>Unusual</td> <td>Common</td> </tr> <tr> <td class=\"indent1\">History of trauma</td> <td>Occasional</td> <td>Unusual</td> <td>Unusual</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dysuria or discharge</td> <td>Rare</td> <td>Rare</td> <td>Common</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Physical findings</td> </tr> <tr> <td class=\"indent1\">Suggestive findings</td> <td>Horizontal lie, high-riding testicle</td> <td>Palpable nodule \"blue dot\"</td> <td>None</td> </tr> <tr> <td class=\"indent1\">Cremasteric reflex</td> <td>Usually absent</td> <td>Usually present</td> <td>Usually present</td> </tr> <tr> <td class=\"indent1\">Tenderness</td> <td>Testicular initially, then diffuse</td> <td>Appendage initially, then testis</td> <td>Epididymis initially, then diffuse</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Scrotal erythema or edema</td> <td>Common &#62;12 hours</td> <td>Common &#62;12 hours</td> <td>Common &#62;12 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Laboratory tests</td> </tr> <tr> <td class=\"indent1\">Pyuria</td> <td>Unusual</td> <td>Unusual</td> <td>Common</td> </tr> <tr> <td class=\"indent1\">Positive smear, culture, rapid molecular testing,&nbsp;or NAAT for STD</td> <td>No</td> <td>No</td> <td>Often</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Leukocytosis</td> <td>Common</td> <td>Uncommon</td> <td>Common</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Perfuson studies</td> </tr> <tr> <td class=\"indent1\">Color Doppler ultrasound<sup>&#182;</sup></td> <td>Decreased blood flow, spermatic cord knot</td> <td>Normal or increased</td> <td>Normal or increased</td> </tr> <tr> <td class=\"indent1\">Radionuclide</td> <td>Decreased blood flow</td> <td>Normal or increased</td> <td>Normal or increased</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NAAT: nucleic acid amplification testing; STD: sexually transmitted diseases.</div><div class=\"graphic_footnotes\">*In some boys with scrotal pain, significant overlap in history, physical examination, and diagnostic studies exist. When testicular torsion cannot be excluded, surgical consultation is advised.<br />¶Color Doppler ultrasound is the preferred perfusion study.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Burgher SW. Acute scrotal pain. Emerg Med Clin North Am 1998; 16:781.</LI>&#xD;&#xA;<LI>Haynes BE, Bessen HA, Haynes VE. The diagnosis of testicular torsion. JAMA 1983; 249:2522.</LI></OL></div><div id=\"graphicVersion\">Graphic 54439 Version 9.0</div></div></div>"},"54440":{"type":"graphic_picture","displayName":"Gingival overgrowth","title":"Gingival overgrowth","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gingival overgrowth</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/PEDS/54440_Gingival_overgrowth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gingival overgrowth in a 14-year-old who is taking cyclosporin A following a liver transplant.</div><div class=\"graphic_reference\">Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright &#169; 2000, W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 54440 Version 2.0</div></div></div>"},"54441":{"type":"graphic_picture","displayName":"Preauricular pit excision","title":"Preauricular pit excision","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Preauricular pit excision</div><div class=\"cntnt\"><img style=\"width:756px; height:617px;\" src=\"images/PEDS/54441_Preauricular_pit_excision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Removal of the preauricular pit should include excision of the pit, the squamous-lined cyst, and the cartilage at the root of the helix en bloc to avoid recurrence.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 54441 Version 3.0</div></div></div>"},"54443":{"type":"graphic_table","displayName":"Antitrypanosomal drugs dosing","title":"Antitrypanosomal drugs for treatment of Chagas disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antitrypanosomal drugs for treatment of Chagas disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td rowspan=\"2\">Benznidazole*</td> <td>&#60;12 years</td> <td>5 to 7.5 mg/kg per day orally in two divided doses for 60 days</td> </tr> <tr> <td>12 years or older</td> <td>5 to 7 mg/kg per day orally in two divided doses for 60 days</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Nifurtimox<sup>&#182;</sup></td> <td>&#8804;10 years</td> <td>15 to 20 mg/kg per day orally in three or four divided doses for 90 days</td> </tr> <tr> <td>11 to 16 years</td> <td>12.5 to 15 mg/kg per day orally in three or four divided doses for 90 days</td> </tr> <tr> <td>17 years or older</td> <td>8 to 10 mg/kg per day orally in three or four divided doses for 90 to 120 days</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For additional notes regarding use, adverse effects, and availability, refer to the&nbsp;UpToDate topic on antitrypanosomal drug therapy.<br />Similar recommendations are included in the 2005 Brazilian Consensus on Chagas Disease, which recommend for adults 5 mg/kg of benznidazole per day in two or three divided doses for 60 days or 8 to 10 mg/kg of nifurtimox per day in three divided doses for 60 to 90 days; for children, these guidelines recommend 5 to 10 mg/kg of benznidazole for 60 days or 15 mg/kg of nifurtimox for 60 to 90 days.<SUP>[1]</SUP></div><div class=\"graphic_footnotes\">*&nbsp;Some investigators treat adults with 300 mg per day for 60 days, regardless of body weight,<SUP>[2]</SUP> whereas others use an upper limit of 300 mg per day but prolong treatment to complete the total dose corresponding to 5 mg per kilogram per day for 60 days.<SUP>[3]</SUP>&nbsp;<br />¶ There are no published recommendations regarding an upper dose limit. The standard nifurtimox dosing schedule for human African trypanosomiasis is 15 mg per kilogram per day for 10 days (in combination with efluornithine).<SUP>[4]</SUP> Dosing regimens of up to 30 mg per kilogram per day in multiple 21-day cycles have been used in trials for neuroblastoma involving children.<SUP>[5]</SUP> Some adverse effects appear to be related to length of treatment rather than daily dose; regimens from 60 days to 120 days have been used.<SUP>[6,7]</SUP> Because of the side effects, only 50 to 60 percent&nbsp;of adult patients complete the entire treatment course.<SUP innerHtml>[6]</SUP></div><div class=\"graphic_reference\">References:<br /><br /><OL>&#xD;&#xA;<LI>Ministério da Saúde. Secretaria de Vigilância em Saúde. [Brazilian Consensus on Chagas disease]. Rev Soc Bras Med Trop 2005; 38 Suppl 3:7.</LI>&#xD;&#xA;<LI>Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med 2014; 370:1899.&nbsp;</LI>&#xD;&#xA;<LI>Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas’ disease. Heart 2009; 95:524.</LI>&#xD;&#xA;<LI>Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial Lancet 2009; 374:56.</LI>&#xD;&#xA;<LI>Saulnier Sholler GL, Bergendahl GM, Brard L, et al. A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma J Pediatr Hematol Oncol 2011; 33:25.&nbsp;</LI>&#xD;&#xA;<LI>Jackson Y, Alirol E, Getaz L, et al. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis 2010; 51:e69.</LI>&#xD;&#xA;<LI>Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas’ infection: preliminary report. Arzneimittelforschung 1972; 22:1635. &nbsp;</LI></OL></div><div id=\"graphicVersion\">Graphic 54443 Version 6.0</div></div></div>"},"54444":{"type":"graphic_figure","displayName":"Radial head and olecranon ossification","title":"Radial head and olecranon ossification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radial head and olecranon ossification</div><div class=\"cntnt\"><img style=\"width:378px; height:586px;\" src=\"images/EM/54444_Radialheadolecranossific.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Limits of the border of olecranon ossification at birth, 8 years, and 12 years.<br> (B) Lateral view of elbow at age 6 months. The radial head is not visible and the proximal margin of the olecranon is perpindicular to the long axis of the ulna.<br> (C) Lateral view of the elbow at age 6 years. A small oval nucleus marks the initial ossification of the radial head. The proximal margin of the olecranon is now oblique to the long axis of the ulna.<br> (D) At 10 years of age, the radial head is now widened and flat and a secondary ossification center for the olecranon is forming along with a sclerotic border at the proximal olecranon metaphysis.<br> (E) Bipartite secondary ossification center of the olecranon. The larger center is the traction center (black arrow). The smaller, more proximal center is the articular center (white arrow).<br> (F) Before complete fusion of the radial head and olecranon, a partial line remains (arrows), bordered by a sclerotic margin.</div><div class=\"graphic_reference\">Reproduced with permission from:&nbsp;Erickson M,&nbsp;Garg S. Radial Neck and Olecranon Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins.&nbsp;<A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54444 Version 8.0</div></div></div>"},"54445":{"type":"graphic_table","displayName":"Fever and rash ddx by sign 2","title":"Differential diagnosis of fever and rash based upon accompanying signs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of fever and rash based upon accompanying signs</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Mucosal membrane lesions (enanthems)</td> </tr> <tr> <td>Herpes simplex</td> </tr> <tr> <td>Infectious mononucleosis (palatal petechiae)</td> </tr> <tr> <td>Measles (Koplick's spots)</td> </tr> <tr> <td class=\"sublist1\">Strawberry tongue</td> </tr> <tr> <td class=\"sublist1\">Atypical measles</td> </tr> <tr> <td class=\"sublist1\">Kawasaki disease</td> </tr> <tr> <td class=\"sublist1\">Scarlet fever</td> </tr> <tr> <td class=\"sublist1\">Toxic shock syndrome</td> </tr> <tr> <td>Varicella zoster</td> </tr> <tr> <td class=\"subtitle1_single\">Ulcerative or vesicular stomatitis</td> </tr> <tr> <td>Hand-foot-mouth disease</td> </tr> <tr> <td>Herpes simplex</td> </tr> <tr> <td>Histoplasmosis</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Secondary syphilis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Palm-sole involvement</td> </tr> <tr> <td>Acute meningococcemia</td> </tr> <tr> <td>Atypical measles</td> </tr> <tr> <td>Dengue</td> </tr> <tr> <td>Drug rash</td> </tr> <tr> <td>Erythema multiforme</td> </tr> <tr> <td>Hand-foot-mouth disease</td> </tr> <tr> <td>Kawasaki syndrome</td> </tr> <tr> <td>Measles</td> </tr> <tr> <td>Rocky Mountain spotted fever</td> </tr> <tr> <td>Secondary syphilis</td> </tr> <tr> <td><em>Staphylococcus aureus</em> endocarditis</td> </tr> <tr> <td class=\"subtitle1_single\">Rash predominantly on extremities</td> </tr> <tr> <td>Allergic purpura</td> </tr> <tr> <td>Brucellosis</td> </tr> <tr> <td>Disseminated gonococcal infection</td> </tr> <tr> <td>Ecthyma gangrenosum</td> </tr> <tr> <td>Erythema nodosum</td> </tr> <tr> <td>Sporotrichosis (fever rare)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Pulmonary infiltrate</td> </tr> <tr> <td>Atypical measles</td> </tr> <tr> <td>Coccidioidomycosis</td> </tr> <tr> <td>Cryptococcosis</td> </tr> <tr> <td>Fat embolism</td> </tr> <tr> <td>Histoplasmosis</td> </tr> <tr> <td><em>Mycoplasma pneumoniae</em></td> </tr> <tr> <td>North American blastomycosis</td> </tr> <tr> <td>Psittacosis</td> </tr> <tr> <td>Rocky Mountain spotted fever</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Varicella zoster</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. With permission from Hurst JW (Ed). Medicine for the Practicing Physician, 3rd ed, Butterworth-Heinemann, Boston, 1992, p. 273.</div><div id=\"graphicVersion\">Graphic 54445 Version 2.0</div></div></div>"},"54447":{"type":"graphic_diagnosticimage","displayName":"Congenital lobar emphysema chest radiograph","title":"Chest radiograph of a two-year-old girl with congenital lobar emphysema and minimal clinical symptoms","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a two-year-old girl with congenital lobar emphysema and minimal clinical symptoms</div><div class=\"cntnt\"><img style=\"width:477px; height:213px;\" src=\"images/PEDS/54447_CLE_chest_radiograph_2_yr_o.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph was obtained due to a mild acute upper respiratory tract infection. The marked hyperinflation of the left upper lobe was an incidental finding. Early signs of deformity of the left chest wall due to the hyperinflation can be seen. In retrospect, her family recalled that she had always been somewhat tachypneic, even at rest, and had some exercise intolerance.</div><div class=\"graphic_reference\">Courtesy of Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 54447 Version 3.0</div></div></div>"},"54448":{"type":"graphic_table","displayName":"DDx congenital torticollis","title":"Differential diagnosis of nonparoxysmal congenital torticollis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of nonparoxysmal congenital torticollis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other causes of head tilt or postural preference</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Musculoskeletal anomalies</td> </tr> <tr> <td class=\"indent2\">Klippel-Feil syndrome</td> <td> <p>Congenital fusion of variable numbers of cervical vertebrae resulting in short neck, low posterior hairline, and variably limited neck motion</p> Associated defects include elevation of the scapula, scoliosis, renal anomalies, congenital heart disease, and deafness</td> </tr> <tr> <td class=\"indent2\">Congenital scoliosis</td> <td> <p>Lateral deviation of the spine associated with congenital vertebral malformation (eg, hemivertebra, wedge vertebra, etc)</p> Often associated with intraspinal abnormalities (eg, myelomeningocele) and abnormalities of other organ systems</td> </tr> <tr> <td class=\"indent2\">Hemivertebra</td> <td> <p>Congenital vertebral malformation</p> May be associated with congenital scoliosis and abnormalities of other organ systems</td> </tr> <tr> <td class=\"indent2\">C1-C2 rotary displacement</td> <td>Tightness of SCM muscle on the side to which the chin is rotated (rather than the opposite side as in congenital muscular torticollis)</td> </tr> <tr> <td class=\"indent2\">Clavicle fracture</td> <td>Asymmetry of clavicles, crepitus, decreased/absent movement of the arm, crying with movement of the arm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Unilateral absence of SCM</td> <td>Asymmetric contours of the neck, prominent ipsilateral clavicle, normal range of motion of the neck</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Ocular torticollis</td> </tr> <tr> <td class=\"indent2\">4<sup>th</sup> cranial nerve palsy</td> <td>Vertical strabismus, limited EOM (impaired ability to look down and medially with the affected eye)</td> </tr> <tr> <td class=\"indent2\">Brown syndrome</td> <td>Vertical strabismus, limited EOM (impaired ability to look up with the affected eye)</td> </tr> <tr> <td class=\"indent2\">Congenital fibrosis of the extraocular muscles</td> <td>Vertical strabismus, limited EOM (impaired ability to look up with the affected eye), ptosis; family members may be similarly affected</td> </tr> <tr> <td class=\"indent2\">Duane syndrome</td> <td>Horizontal strabismus, limited EOM (impaired ability to look laterally with the affected dye)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Spasmus nutans</td> <td>Triad of nystagmus, head nodding/shaking, and torticollis</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">CNS abnormalities</td> </tr> <tr> <td class=\"indent2\">Chiari type II malformation (Arnold-Chiari malformation)</td> <td> <p>Downward displacement of the inferior cerebellar vermis, cerebellar tonsils, and medulla through the foramen magnum in association with myelomeningocele</p> <p>May be associated with dysphagia, arm weakness, stridor, apnea, or aspiration</p> May be associated with syringomyelia and scoliosis</td> </tr> <tr> <td class=\"indent2\">Neonatal encephalopathy</td> <td>Associated abnormalities may include abnormal state of consciousness, diminished spontaneous movements, respiratory or feeding difficulties, poor tone, absent primitive reflexes, seizures</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Posterior fossa tumor</td> <td>Abnormal neurologic findings (eg, cranial nerve palsy, recurrent vomiting)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other causes of limited cervical range of motion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pterygium colli</td> <td> <p>Web of skin that extends from the acromial process to the mastoid</p> May occur in trisomy 18, Turner syndrome, Noonan syndrome</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other neck masses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cystic hygroma</td> <td>Mass is cystic and transilluminates</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other causes of plagiocephaly</td> </tr> <tr> <td class=\"indent1\">Unilateral lambdoid craniosynostosis</td> <td>Palpable ridge along affected suture, head is shaped like a trapezoid when viewed from above</td> </tr> <tr> <td class=\"indent1\">Unilateral coronal craniosynostosis</td> <td>Palpable ridge along affected suture, anterior flattening of the skull, posterior skull is normal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">C1: first cervical vertebra; C2: second cervical vertebra; SCM: sternocleidomastoid; EOM: extraocular movements; CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 54448 Version 4.0</div></div></div>"},"54449":{"type":"graphic_figure","displayName":"Timeline injury","title":"Timeline of neonatal hypoxic-ischemic injury","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Timeline of neonatal hypoxic-ischemic injury</div><div class=\"cntnt\"><img style=\"width:523px; height:188px;\" src=\"images/PEDS/54449_Timeline_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypoxia-ischemia may have deleterious effects on vulnerable cell populations peculiar to the developmental stage.</div><div class=\"graphic_footnotes\">WM: white matter.</div><div class=\"graphic_reference\">Sidhartha Tan, MD.</div><div id=\"graphicVersion\">Graphic 54449 Version 2.0</div></div></div>"},"54450":{"type":"graphic_table","displayName":"Vomiting dx studies children","title":"Clinical utility of various diagnostic studies in the diagnosis of vomiting in a child","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical utility of various diagnostic studies in the diagnosis of vomiting in a child</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Name of study </td> <td class=\"subtitle1\">Utility </td> </tr> <tr> <td rowspan=\"2\">Complete blood count </td> <td>Anemia and iron deficiency may be associated with obstruction, IBD, gastritis, and ulcer disease.</td> </tr> <tr> <td>Elevated white blood cell count&nbsp;is associated with bacterial infections and sepsis.</td> </tr> <tr> <td rowspan=\"2\">Electrolytes, BUN/Creatinine </td> <td>Electrolyte abnormalities are associated with pyloric stenosis, adrenal insufficiency, and metabolic diseases. </td> </tr> <tr> <td>Elevated BUN/Creatinine are seen in renal disease.</td> </tr> <tr> <td>Liver function tests</td> <td>Elevated AST, ALT, total bilirubin, and GGT are seen in liver and gallbladder disease.</td> </tr> <tr> <td>Amylase, lipase</td> <td>Elevated in&nbsp;pancreatitis.</td> </tr> <tr> <td>Plasma ammonia, urine reducing substances&nbsp;</td> <td>If an inborn error of metabolism is suspected. Ammonia is elevated in urea cycle disorders and organic acidemias. Non-glucose reducing substances are usually present in&nbsp;the urine&nbsp;in galactosemia&nbsp;or hereditary fructose intolerance.&nbsp;&nbsp;</td> </tr> <tr> <td>Plain radiograph of the abdomen</td> <td>If intestinal obstruction is suspected.</td> </tr> <tr> <td>Upper gastrointestinal series</td> <td>If an anatomic abnormality of upper GI tract is suspected (eg, neonate with bilious vomiting).</td> </tr> <tr> <td>CT of the head</td> <td>If increased intracranial pressure is suspected (rule out mass).</td> </tr> <tr> <td>Abdominal ultrasound</td> <td>If pyloric stenosis or intussusception are suspected; also useful for&nbsp;evaluation of liver, gallbladder, kidneys, and pancreas.</td> </tr> <tr> <td>Radionucleotide gastric emptying study</td> <td>If gastroparesis is suspected.</td> </tr> <tr> <td>Endoscopy</td> <td>If peptic disease, eosinophilic esophagitis, IBD, or other causes of intestinal inflammation&nbsp;are suspected.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase; GI: gastrointestinal; CT: computerized tomography.</div><div id=\"graphicVersion\">Graphic 54450 Version 5.0</div></div></div>"},"54453":{"type":"graphic_table","displayName":"Related features of polycythemia vera","title":"Polycythemia vera: related clinical and laboratory features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Polycythemia vera: related clinical and laboratory features</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Persistent leukocytosis</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Persistent thrombocytosis</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Microcytosis due to iron deficiency</td>\n\n      \n    </tr>\n\n    <tr>\n      <td>Splenomegaly</td>\n    </tr>\n\n    <tr>\n      <td>Generalized pruritus (post-bath)</td>\n    </tr>\n\t<tr>\n      <td>Unusual thrombosis</td>\n    </tr>\n\t<tr>\n      <td>Erythromelalgia (acral dysesthesia and erythema)</td>\n    </tr>\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54453 Version 2.0</div></div></div>"},"54454":{"type":"graphic_diagnosticimage","displayName":"Mammographic occult breast cancer","title":"Mammographic occult breast cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mammographic occult breast cancer</div><div class=\"cntnt\"><img style=\"width:350px; height:582px;\" src=\"images/PC/54454_Mammo_occult_brst_ca_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A dense breast can obscure a cancer. CC and MLO views (panels A and B) in a woman with a palpable breast lump show dense breast parenchyma. No discrete mass or calcifications are seen. An MRI with contrast (panel C) in the same breast shows multiple enhancing masses (arrows) involving the upper half of the breast worrisome for malignancy. If there is a clinical suspicion for cancer, a negative mammogram should not stop further intervention.</div><div class=\"graphic_footnotes\">CC: craniocaudal; MLO: mediolateral oblique; MRI: magnetic resonance image.</div><div id=\"graphicVersion\">Graphic 54454 Version 6.0</div></div></div>"},"54456":{"type":"graphic_figure","displayName":"Transmetatarsal Lisfranc and Chopart amputations","title":"Transmetatarsal, Lisfranc and Chopart amputations","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Transmetatarsal, Lisfranc and Chopart amputations</div><div class=\"cntnt\"><img style=\"width:509px; height:483px;\" src=\"images/SURG/54456_Transmetatarsal-Lisfranc-Chopart-amputations.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54456 Version 3.0</div></div></div>"},"54457":{"type":"graphic_figure","displayName":"Relationship between ascending colon and posterior structures","title":"Relationship between ascending colon and posterior structures","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Relationship between ascending colon and posterior structures</div><div class=\"cntnt\"><img style=\"width:509px; height:559px;\" src=\"images/SURG/54457_Asc-colon-post.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the relationship of the right, ascending colon and the posterior structures, including the second portion of&#160;the duodenum, kidney, ureter, and gonadal vessels.</div><div id=\"graphicVersion\">Graphic 54457 Version 1.0</div></div></div>"},"54458":{"type":"graphic_picture","displayName":"Sappinia trophozoites","title":"<EM>Sappinia </EM>trophozoites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Sappinia </EM>trophozoites</div><div class=\"cntnt\"><img style=\"width:300px; height:299px;\" src=\"images/ID/54458_Sappinia_trophozoites_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four trophozoites (yellow arrows) of <EM>Sappinia diploidea</EM> in brain tissue, stained with hematoxylin-eosin. In three of the amebae, the two nuclei can easily be seen.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Free living amebic infections. Available at: <A href=\"http://www.cdc.gov/dpdx/freeLivingAmebic/index.html\">http://www.cdc.gov/dpdx/freeLivingAmebic/index.html</A>.</div><div id=\"graphicVersion\">Graphic 54458 Version 4.0</div></div></div>"},"54460":{"type":"graphic_picture","displayName":"Eye manifestations HSV 1","title":"Eye manifestations of HSV-1 infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eye manifestations of HSV-1 infection</div><div class=\"cntnt\"><img style=\"width:403px; height:266px;\" src=\"images/ID/54460_Eye_manifestations_HSV_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Different eye manifestations of herpes simplex virus-1 infection. Panel A: Corneal epithelial disease with damaged epithelial cells observed as &quot;dendrites&quot; after staining with dyes. Panel B: Corneal stromal disease or &quot;disciform keratitis;&quot; this reflects severe damage to infected epithelial cells, producing stromal edema with corneal clouding. Panel C: Necrotizing stromal disease in which infiltration of inflammatory cells and neovascularization results in destruction of the cornea, glaucoma, and dense scarring. Panel D: Keratouveitis in which mononuclear cell clusters, termed &quot;keratic precipitates,&quot; can be seen in the corneal epithelium.</div><div class=\"graphic_reference\">Reprinted from Immunology Today, 18(9), Streilein, JW, Dana, MR, Ksander, BR, HSV-1 Infections: Clinical presentation and diagnosis, 443-9, 1997, with permission from Elsevier Science.</div><div id=\"graphicVersion\">Graphic 54460 Version 2.0</div></div></div>"},"54461":{"type":"graphic_algorithm","displayName":"Rx algorithm SVC synd","title":"Treatment algorithm for superior vena cava syndrome","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for superior vena cava syndrome</div><div class=\"cntnt\"><img style=\"width:603px; height:559px;\" src=\"images/ONC/54461_Rx_algorithm_SVC_synd.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CXR: chest X-ray; CT: computed tomography; SVC: superior vena cava; NSCLC: non-small-cell lung cancer; SCLC: small-cell lung cancer; RT: radiation therapy.</div><div class=\"graphic_reference\">Reproduced with permission from: Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome-a proposed classification system and algorithm for management. J Thorac Oncol 2008; 3:811. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54461 Version 10.0</div></div></div>"},"54463":{"type":"graphic_picture","displayName":"Keloid morphea","title":"Keloid morphea","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Keloid morphea</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/PEDS/54463_Keloid_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keloid morphea can be single or multiple and are generally several centimeters in diameter. The plaque is indurated and resembles a posttraumatic scar.</div><div class=\"graphic_reference\">Courtesy of Francesco Zulian, MD.</div><div id=\"graphicVersion\">Graphic 54463 Version 2.0</div></div></div>"},"54464":{"type":"graphic_table","displayName":"Normal cerebrospinal fluid indices neonate","title":"Characteristics of cerebrospinal fluid in term and preterm neonates without bacterial meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of cerebrospinal fluid in term and preterm neonates without bacterial meningitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Mean WBC/mm<sup>3</sup><br /> (range or 90th percentile)</td> <td class=\"subtitle1\">ANC/mm<sup>3</sup> or percent PMNs<br /> (range)</td> <td class=\"subtitle1\">Mean protein (mg/dL)<br /> (range or &#177;SD)</td> <td class=\"subtitle1\">Mean glucose (mg/dL)<br /> (range or &#177;SD)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Term neonates evaluated in the nursery setting</td> </tr> <tr> <td class=\"indent1\">0 to 24 hours<br /> (n = 135)*<sup>[1]</sup></td> <td>5 (0 to 90)</td> <td>3/mm<sup>3</sup> (0 to 70)</td> <td>63 (32 to 240)</td> <td>51 (32 to 78)</td> </tr> <tr> <td class=\"indent1\">0 to 10 days<br /> (n = 87)<sup>&#182;[2]</sup></td> <td>8.2 (0 to 32)</td> <td>61.3 percent</td> <td>90 (20 to 170)</td> <td>52 (34 to 119)</td> </tr> <tr> <td class=\"indent1\">0 to 32 days<br /> (n = 24)<sup>&#182;[3]</sup></td> <td>11 (1 to 38)</td> <td>21 percent (0 to 100)</td> <td>NR</td> <td>NR</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Term neonates evaluated in the emergency department setting<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">0 to 7 days<br /> (n = 17)<sup>[4]</sup></td> <td>15.3 (1 to 130)</td> <td>4.4/mm<sup>3</sup> (0 to 65)</td> <td>80.8 (&#177;30.8)</td> <td>45.9 (&#177;7.5)</td> </tr> <tr> <td class=\"indent1\">0 to 7 days<br /> (n = 118)<sup>[5]</sup></td> <td>8.6 (90<sup>th</sup> percentile: 26)</td> <td>NR</td> <td>106.4 (90<sup>th</sup> percentile: 153)</td> <td>NR</td> </tr> <tr> <td class=\"indent1\">1 to 28 days<br /> (n = 297)<sup>[6]</sup></td> <td>6.1 (0 to 18)</td> <td>NR</td> <td>75.4 (15.8 to 131)</td> <td>45.3 (30 to 61)</td> </tr> <tr> <td class=\"indent1\">0 to 30 days<br /> (n = 108)<sup>[4]</sup></td> <td>7.3 (0 to 130)<sup>&#9674;</sup></td> <td>0.8/mm<sup>3</sup> (0 to 65)</td> <td>64.2 (&#177;24.2)</td> <td>51.2 (&#177;12.9)</td> </tr> <tr> <td class=\"indent1\">8 to 14 days<br /> (n = 101)<sup>[5]</sup></td> <td>3.9 (90<sup>th</sup> percentile: 9)</td> <td>NR</td> <td>77.6 (90<sup>th</sup> percentile: 103)</td> <td>NR</td> </tr> <tr> <td class=\"indent1\">8 to 14 days<br /> (n = 33)<sup>[4]</sup></td> <td>5.4 (0 to 18)</td> <td>0.1/mm<sup>3</sup> (0 to 1)</td> <td>69 (&#177;22.6)</td> <td>54.3 (&#177;17)</td> </tr> <tr> <td class=\"indent1\">15 to 22 days<br /> (n = 107)<sup>[5]</sup></td> <td>4.9 (90<sup>th</sup> percentile: 9)</td> <td>NR</td> <td>71 (90<sup>th</sup> percentile: 106)</td> <td>NR</td> </tr> <tr> <td class=\"indent1\">15 to 21 days<br /> (n = 25)<sup>[4]</sup></td> <td>7.7 (0 to 62)</td> <td>0.2/mm<sup>3</sup> (0 to 2)</td> <td>59.8 (&#177;23.4)</td> <td>46.8 (&#177;8.8)</td> </tr> <tr> <td class=\"indent1\">22 to 28 days<br /> (n = 141)<sup>[5]</sup></td> <td>4.5 (90<sup>th</sup> percentile: 9)</td> <td>NR</td> <td>68.7 (90<sup>th</sup> percentile: 85)</td> <td>NR</td> </tr> <tr> <td class=\"indent1\">22 to 30 days<br /> (n = 33)<sup>[4]</sup></td> <td>4.8 (0 to 18)</td> <td>0.1/mm<sup>3</sup> (0 to 1)</td> <td>54.1 (&#177;16.2)</td> <td>54.1 (&#177;16.2)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Preterm or low birth weight neonates</td> </tr> <tr> <td class=\"indent1\">0 to 28 days<br /> (n = 30<sup>&#167;</sup>)<sup>&#182;[2]</sup></td> <td>9 (0 to 29)</td> <td>57.2 percent</td> <td>115 (65 to 150)</td> <td>50 (24 to 63)</td> </tr> <tr> <td class=\"indent1\">0 to 32 days<br /> (n = 22<sup>&#165;</sup>)<sup>&#182;[3]</sup></td> <td>7 (0 to 28)</td> <td>16 percent (0 to 100)</td> <td>NR</td> <td>NR</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Very low birth weight neonates<sup>[7]</sup></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">&#60;1000 g</td> </tr> <tr> <td class=\"indent2\">0 to 7 days<br /> (n = 6)</td> <td>3 (1 to 8)</td> <td>11 percent (0 to 50)</td> <td>162 (115 to 222)</td> <td>70 (41 to 89)</td> </tr> <tr> <td class=\"indent2\">8 to 28 days<br /> (n = 17)</td> <td>4 (0 to 14)</td> <td>8 percent (0 to 66)</td> <td>159 (95 to 370)</td> <td>68 (33 to 217)</td> </tr> <tr> <td class=\"indent2\">29 to 84 days<br /> (n = 15)</td> <td>4 (0 to 11)</td> <td>2 percent (0 to 36)</td> <td>137 (76 to 269)</td> <td>49 (29 to 90)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">1000 to 1500 g</td> </tr> <tr> <td class=\"indent2\">0 to 7 days<br /> (n = 8)</td> <td>4 (1 to 10)</td> <td>4 percent (0 to 28)</td> <td>136 (85 to 176)</td> <td>74 (50 to 96)</td> </tr> <tr> <td class=\"indent2\">8 to 28 days<br /> (n = 14)</td> <td>7 (0 to 44)</td> <td>10 percent (0 to 60)</td> <td>137 (54 to 227)</td> <td>59 (39 to 109)</td> </tr> <tr> <td class=\"indent2\">29 to 84 days<br /> (n = 11)</td> <td>8 (0 to 23)</td> <td>11 percent (0 to 48)</td> <td>122 (45 to 187)</td> <td>47 (31 to 76)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WBC: white blood cell count; ANC: absolute neutrophil count; PMNs: polymorphonuclear leukocytes; SD: standard deviation; NR: not reported; CSF: cerebrospinal fluid.<br />* CSF obtained from term neonates without any obvious pathology.<br />¶&nbsp;CSF obtained from hospitalized neonates at high risk for infection (eg, unexplained jaundice, prolonged rupture of membranes, maternal fever, etc); infection excluded by sterile cultures (CSF, blood, urine) and lack of clinical evidence of bacterial or viral infection.<br />Δ CSF obtained in the emergency department during evaluation for possible infection; infection was excluded by sterile cultures (CSF, blood, urine, and negative polymerase chain reaction for enterovirus).<br /><FONT class=lozenge>◊</FONT> Only two infants had CSF WBC &gt;30/mm<SUP>3</SUP>: one &lt;7 days of age with 130 WBC/mm<SUP>3</SUP> and one 15 to 21 days of age with 62 WBC/mm<SUP>3</SUP>.<br />§ Includes 29 preterm infants and 1 infant who was 2190 g at 40 weeks' gestation.<br />¥ Includes all infants with birth weight &lt;2500 g.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Naidoo BT. The cerebrospinal fluid in the healthy newborn infant. S Afr Med J 1968; 42:933. </LI>&#xD;&#xA;<LI>Sarff LD, Lynn H, Platt MD, et al. Cerebrospinal fluid evaluation in neonates: Comparison of high risk infants with and without meningitis. J Pediatr 1976; 88:473. </LI>&#xD;&#xA;<LI>Pappu L. CSF cytology in the neonate. Am J Dis Child 1982; 136:297. </LI>&#xD;&#xA;<LI>Ahmed A. Cerebrospinal fluid values in the term neonate. Pediatr Infect Dis J 1996; 15:298. </LI>&#xD;&#xA;<LI>Chadwick SL, Wilson JW, Levin JE, Martin JM. Cerebrospinal fluid characteristics of infants who present to the emergency department with fever: Establishing normal values by week of age. Pediatr Infect Dis J 2011; 30:e63. </LI>&#xD;&#xA;<LI>Byington CL, Kendrick J, Sheng X. Normative cerebrospinal fluid profiles in febrile infants. J Pediatr 2011; 158:130. </LI>&#xD;&#xA;<LI>Rodriguez AF, Kaplan SL, Mason EO. Cerebrospinal fluid values in the very low birth weight infant. J Pediatr 1990; 116:971. </LI></OL></div><div id=\"graphicVersion\">Graphic 54464 Version 15.0</div></div></div>"},"54465":{"type":"graphic_table","displayName":"Suicide risk assessment1","title":"Suicide risk assessment for children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suicide risk assessment for children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Content and nature of suicidal ideation</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>What are the thoughts?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Are they active (volitional and with intent) or passive/non-volitional?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>How often do they occur?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Have they increased in intensity or frequency?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>How long do they last (duration)? Are they obsessive?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Can the thoughts be controlled?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>How powerful, intense is the urge?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>How do the thoughts make you feel?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Anticipated method/Planning</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Does the child or adolescent have a method in mind? If so, have the adolescent describe it <strong>explicitly</strong> (since this provides information about the adolescent's level of intent and planning) </td>\n\n\n\n\n    </tr>\n\n\n    \n\n    \n\n    <tr>\n\n\n      <td class=\"sublist1_start\">Sample questions include:</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n      <td class=\"sublist1\"> Do you have a plan?</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> What time would you do it?</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Where would you do it?</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Do you think it would work?</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Do you think this would kill you?</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Is there anyone who could find you and save you?</td>\n    </tr>\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Access to means</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Does the adolescent have <strong>access</strong> to the method they have in mind?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> What is the level of dangerousness or lethality of the means they are considering?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Does the child or adolescent have access to firearms and medications?</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"sublist1_start\">Sample questions include:</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"sublist1\"> Do you have any of these things (pills, gun, razor, etc) in your possession?</td>\n\n\n\n\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> How easy would it be for you to get them?</td>\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Jacobs, DG, Brewer, M, Klein-Benheim, M. Suicide assessment: An overview and recommended protocol. In: Harvard Medical School Guide to Assessment and Intervention in Suicide, Jacob, D (Ed). Jossey-Bass, San Francisco 1998. p.3.</div><div id=\"graphicVersion\">Graphic 54465 Version 1.0</div></div></div>"},"54469":{"type":"graphic_picture","displayName":"CLL smear","title":"Peripheral blood smear in a patient with chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smear in a patient with chronic lymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:405px; height:282px;\" src=\"images/HEME/54469_CLL_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood smear from a patient with B cell chronic lymphocytic leukemia. The predominant lymphocytes have a very sparse cytoplasm, round to slightly oval nuclei, and no evident nucleoli. Damaged lymphocytes (\"smudge cells\") are present (arrows).</div><div class=\"graphic_reference\">From: Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 54469 Version 3.0</div></div></div>"},"54470":{"type":"graphic_table","displayName":"Risk neuraxis involvement NHL","title":"Risk factors for neuraxis involvement by non-Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for neuraxis involvement by non-Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td>Stage III/IV disease*</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Presence of B symptoms</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Retroperitoneal lymph node involvement</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Bone marrow involvement</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Involvement of &#62;1 extranodal site*</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Elevated serum lactate dehydrogenase level*</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Low serum albumin concentration</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Age &#62;60 years*</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Aggressive or highly aggressive disease</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>High- or high-intermediate risk disease by the IPI#</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Testicular involvement (see text for other primary sites)</td>\n\n\n    </tr>\n\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_footnotes\">IPI: International Prognostic Index. <br> * Components of the IPI.</div><div id=\"graphicVersion\">Graphic 54470 Version 2.0</div></div></div>"},"54472":{"type":"graphic_picture","displayName":"Atrophic glossitis","title":"Atrophic glossitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrophic glossitis</div><div class=\"cntnt\"><img style=\"width:400px; height:463px;\" src=\"images/PEDS/54472_Atrophic_glossitis_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A smooth tongue that has lost its papillae and is often sore suggest a deficiency in riboflavin, niacin, folic acid, vitamin B12, or iron. This patient had vitamin B12 deficiency.</div><div class=\"graphic_reference\">Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54472 Version 5.0</div></div></div>"},"54473":{"type":"graphic_figure","displayName":"Thoracic vertebrae","title":"Thoracic vertebrae","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Thoracic vertebrae</div><div class=\"cntnt\"><img style=\"width:603px; height:342px;\" src=\"images/EM/54473_ThoracicvertebraePR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) T1 has a vertebral foramen and body similar to a cervical vertebra.<br> (B) T5-T9 vertebrae have typical characteristics of thoracic vertebrae.<br> (C) T12 has bony processes and a body size similar to a lumbar vertebra. The planes of the articular facets of thoracic vertebrae define an arc (red arrows) that centers on an axis traversing the vertebral bodies vertically.<br> (D) Superior and inferior costal facets (demifacets) on the vertebral body, costal facets on the transverse processes, and long sloping spinous processes are characteristic of thoracic vertebrae.</div><div class=\"graphic_reference\">Reproduced with permission from: Thorax. In: Moore KL, Agur AMR, Dalley AF. Clinically Oriented Anatomy, 7th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54473 Version 10.0</div></div></div>"},"54474":{"type":"graphic_figure","displayName":"Signature characteristics of stem cells","title":"Signature characteristics of stem cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Signature characteristics of stem cells</div><div class=\"cntnt\"><img style=\"width:379px; height:340px;\" src=\"images/PC/54474_Sig_char_stem_cells.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stem cells have two properties that distinguish them from other cell types. Stem cells can divide and result in daughter cells that either are replicates (self-renewal) or acquire features of more mature cell types (differentiation). The balance between these two outcomes may vary depending on the stem cell type and the context, but a stem cell must be capable of either outcome.</div><div id=\"graphicVersion\">Graphic 54474 Version 1.0</div></div></div>"},"54475":{"type":"graphic_picture","displayName":"Actinic lichen planus face","title":"Actinic lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Actinic lichen planus</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/54475_Actinic_lichen_planus_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple violaceous and hyperpigmented plaques are present on the lateral face. Note the annular configuration of several lesions.</div><div class=\"graphic_reference\">Copyright © Shahbaz A Janjua, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 54475 Version 4.0</div></div></div>"},"54477":{"type":"graphic_figure","displayName":"Antibody development syphilis","title":"Time course of antibody development during syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Time course of antibody development during syphilis</div><div class=\"cntnt\"><img style=\"width:371px; height:208px;\" src=\"images/ID/54477_Antibody_development_syphil.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A comparison of the reactivity of the Venereal Disease Research Laboratory (VDRL) and fluorescent treponemal antibody absorption (FTA-ABS) during the course of untreated syphilis. A substantial proportion of persons with primary syphilis may not have developed a diagnostic antibody response at the time the chancre of primary syphilis appears.</div><div class=\"graphic_reference\">Courtesy of Charles B Hicks, MD; modified from the VD Program, Centers for Disease Control, US Public Health Service.</div><div id=\"graphicVersion\">Graphic 54477 Version 2.0</div></div></div>"},"54479":{"type":"graphic_diagnosticimage","displayName":"TTTS6","title":"TTTS6","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TTTS6</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/OBGYN/54479_TTTS6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross section of the fetal chest and heart of the recipient fetus at&nbsp;approximately 25&nbsp;weeks of gestation. Arrows point to the thickened myocardial walls of the fetal heart. The interventricular septum is also thickened.</div><div class=\"graphic_reference\">Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.</div><div id=\"graphicVersion\">Graphic 54479 Version 3.0</div></div></div>"},"54481":{"type":"graphic_table","displayName":"Infectious causes of epiglottitis (supraglottitis)","title":"Infectious causes of epiglottitis (supraglottitis)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious causes of epiglottitis (supraglottitis)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bacterial causes</td> </tr> <tr> <td class=\"indent1\">Haemophilus influenzae type b (Hib)</td> </tr> <tr> <td class=\"indent1\">H. influenzae types A and F, and nontypeable strains</td> </tr> <tr> <td class=\"indent1\">Haemophilus parinfluenzae</td> </tr> <tr> <td class=\"indent1\">Streptococcus pneumoniae</td> </tr> <tr> <td class=\"indent1\">Staphylococcus aureus (methicillin susceptible and methicillin resistant)</td> </tr> <tr> <td class=\"indent1\">Beta-hemolytic streptococci: Groups A, B, C, F, G</td> </tr> <tr> <td class=\"indent1\">Pasteurella multocida</td> </tr> <tr> <td class=\"indent1\">Moraxella catarrhalis</td> </tr> <tr> <td class=\"indent1\">Klebsiella pneumoniae</td> </tr> <tr> <td class=\"indent1\">Neisseria spp</td> </tr> <tr> <td class=\"indent1\">Escherichia coli</td> </tr> <tr> <td class=\"indent1\">Enterobacter cloacae</td> </tr> <tr> <td class=\"indent1\">Pseudomonas aeruginosa*</td> </tr> <tr> <td class=\"subtitle1_single\">Viral causes<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus type 1</td> </tr> <tr> <td class=\"indent1\">Varicella zoster virus</td> </tr> <tr> <td class=\"indent1\">Parainfluenza virus type 3</td> </tr> <tr> <td class=\"indent1\">Influenza B viruses</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> </tr> <tr> <td class=\"subtitle1_single\">Fungal causes</td> </tr> <tr> <td class=\"indent1\">Candida*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Candidal and pseudomonal epiglottitis usually occur in immunocompromised patients.<br />¶ Epiglottitis may result from bacterial superinfection. </div><div id=\"graphicVersion\">Graphic 54481 Version 6.0</div></div></div>"},"54482":{"type":"graphic_picture","displayName":"Scaphocephaly","title":"Scaphocephaly (dolichocephaly)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scaphocephaly (dolichocephaly)</div><div class=\"cntnt\"><img style=\"width:294px; height:586px;\" src=\"images/PEDS/54482_Scaphocephaly_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scaphocephaly, side view (A) and top view (B). Marked increase in head length with narrowed width resulting from premature fusion of sagittal suture.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher MA. Physical diagnosis in neonatology. Philadelphia: Lippincott-Raven; 1998. Copyright &#169; 1998 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54482 Version 3.0</div></div></div>"},"54483":{"type":"graphic_picture","displayName":"Mesoscissioning procedure 1","title":"Mesoscissioning procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mesoscissioning procedure</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/EM/54483_Mesoscissioning_procedure_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mesoscissioning produces multiple small holes in the nail that allows subungual hematoma drainage.</div><div class=\"graphic_reference\">Reproduced with permission from: Path Scientific. Available at: www.pathscientific.com (Accessed on May 6, 2009).</div><div id=\"graphicVersion\">Graphic 54483 Version 1.0</div></div></div>"},"54484":{"type":"graphic_waveform","displayName":"12-lead ECG antidromic AVRT","title":"12-lead electrocardiogram (ECG) showing antidromic atrioventricular reentrant tachycardia (AVRT) in a patient with an accessory AV pathway","html":"<div class=\"graphic normal\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing antidromic atrioventricular reentrant tachycardia (AVRT) in a patient with an accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:530px; height:350px;\" src=\"images/CARD/54484_12leadECGantidrWPWedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12-lead ECG of a patient with Wolff-Parkinson-White shows a regular tachycardia. The QRS complexes are widened and are identical to the QRS complexes seen in sinus rhythm; the antegrade conduction to the ventricle is via the accessory pathway and retrograde conduction is via the normal His-atrioventricular node pathway. This is therefore an antidromic atrioventricular reentrant tachycardia (AVRT).</div><div class=\"graphic_reference\">Courtesy of Martin Burke, DO.</div><div id=\"graphicVersion\">Graphic 54484 Version 19.0</div></div><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">ECG in Wolff-Parkinson-White</div><div class=\"cntnt\"><img style=\"width:538px; height:365px;\" src=\"images/CARD/67181_12leadWPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12-lead ECG shows the typical features of Wolff-Parkinson-White; the PR interval is short (*) and the QRS duration prolonged as a result of a delta wave (arrow), indicating ventricular preexcitation.</div><div class=\"graphic_reference\">Courtesy of Martin Burke, DO.</div><div id=\"graphicVersion\">Graphic 67181 Version 3.0</div></div></div>"},"54485":{"type":"graphic_algorithm","displayName":"Eval Rx oropharyngeal dysphagia","title":"Evaluation and management of oropharyngeal dysphagia","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Evaluation and management of oropharyngeal dysphagia</div><div class=\"cntnt\"><img style=\"width:511px; height:420px;\" src=\"images/GAST/54485_Eval_Rx_oropharyngeal_dysph.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Summary of the clinical approach and key objectives in the management of oropharyngeal dysphagia.</strong> The objective is to reach a box targeted by a red arrow, which equates to a specific management strategy. Blue-headed arrows indicate a suggested pathway to proceed with the evaluation.</div><div class=\"graphic_footnotes\">CNS: central nervous system; Rx: therapy; CVA: cerebrovascular accident.</div><div class=\"graphic_reference\">Adapted from: Cook IJ, Kahrilas PJ. AGA: Technical review: Management of oropharyngeal dysphagia. Gastroenterology 1999; 116:455.</div><div id=\"graphicVersion\">Graphic 54485 Version 2.0</div></div></div>"},"54486":{"type":"graphic_figure","displayName":"Signals T cell activation","title":"The three signals of T cell activation","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">The three signals of T cell activation</div><div class=\"cntnt\"><img style=\"width:556px; height:369px;\" src=\"images/GAST/54486_Signals_T_cell_activation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>Signal I:</STRONG> Antigen presentation by APC to the T cell receptor.<br /><STRONG>Signal II:</STRONG> Costimulation - binding of additional APC ligands to specific T cell receptors.<br /><STRONG>Signal III:</STRONG> Newly synthesized IL-2 and growth factors feed back on T cell membrane receptors, causing clonal expansion of newly activated T cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Vierling, JM. Clinical Use of Immunosuppressive Drugs to Control the Immune Response. In: Liver Immunology: Principles and Practice, Gershwin, ME, Vierling, JM, Manns, MP (Eds), Humana Press, Totowa 2007. Copyright ©2007 Springer-Verlag.</div><div id=\"graphicVersion\">Graphic 54486 Version 2.0</div></div></div>"},"54487":{"type":"graphic_figure","displayName":"Endometrium layers","title":"Layers of the endometrium: Late proliferative phase of menstrual cycle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Layers of the endometrium: Late proliferative phase of menstrual cycle</div><div class=\"cntnt\"><img style=\"width:350px; height:435px;\" src=\"images/OBGYN/54487_Endometrium_layers.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright &#169; 2010 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 54487 Version 1.0</div></div></div>"},"54488":{"type":"graphic_picture","displayName":"Superotemporal BRVO with wedge-shaped pattern of hemorrhages","title":"Larger superotemporal branch retinal vein occlusion with wedge-shaped pattern of intraretinal hemorrhages","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Larger superotemporal branch retinal vein occlusion with wedge-shaped pattern of intraretinal hemorrhages</div><div class=\"cntnt\"><img style=\"width:432px; height:369px;\" src=\"images/PC/54488_Wedge_two.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54488 Version 4.0</div></div></div>"},"54489":{"type":"graphic_picture","displayName":"Bronchiolitis obliterans Light","title":"Bronchiolitis obliterans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiolitis obliterans</div><div class=\"cntnt\"><img style=\"width:374px; height:333px;\" src=\"images/PULM/54489_Bronchiolitis_obliterans_Li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing a polypoid mass of granulation tissue protruding into the bronchiolar lumen and attached to an area where the mucosa is ulcerated. There is fibrotic thickening of the bronchiolar wall.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 54489 Version 1.0</div></div></div>"},"54492":{"type":"graphic_table","displayName":"Cold water immersion tx of exertional heat illness","title":"Guidelines for cold water immersion treatment of exertional heat illness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for cold water immersion treatment of exertional heat illness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Contact emergency medical services (EMS) immediately.</td> </tr> <tr> <td>Assess airway, breathing, circulation, and mental status; measure vital signs before immersing the patient.</td> </tr> <tr> <td>If appropriate medical staff is present on-site (eg, team physician), equipment for aggressive cooling is readily available (eg, cold water immersion, ice/wet towel rotation, high-flow cold water dousing), and <strong>no other emergency medical treatment is needed</strong> other than rapid lowering of the body temperature, follow the \"cool-first, transport second\" guideline.</td> </tr> <tr> <td class=\"sublist1_start\">For patients to be treated with ice water immersion, prepare as follows:</td> </tr> <tr> <td class=\"indent1\">Get help.</td> </tr> <tr> <td class=\"indent1\">Move patient to a shaded area.</td> </tr> <tr> <td class=\"indent1\">Half fill a tub or wading pool with water and ice. Ice should cover the surface of the water at all times.</td> </tr> <tr> <td class=\"indent1\">A whirlpool tub filled with ice water may be used if the athlete collapses near an athletic training room.</td> </tr> <tr> <td>During ice water immersion treatment, assess the patient's core body temperature with a rectal thermistor continuously (a thermistor is a flexible thermometer that remains in place throughout the cooling and treatment process).</td> </tr> <tr> <td class=\"sublist1_start\">Obtain necessary assistance and cool the patient as follows:</td> </tr> <tr> <td class=\"indent1\">Place the athlete in the ice water immersion tub.</td> </tr> <tr> <td class=\"indent1\">Cover as much of the body as possible with ice water. If complete coverage is not possible, cover the torso as much as possible.</td> </tr> <tr> <td class=\"indent1\">Keep the athlete's head and neck above water. An assistant or two can do so by holding the victim under the axillae with a towel or sheet wrapped across the chest and under the arms.</td> </tr> <tr> <td class=\"indent1\">Place a towel soaked in ice water over the head and neck while the body is being cooled.</td> </tr> <tr> <td class=\"indent1\">Keep water temperature under 15&#176;C (60&#176;F).</td> </tr> <tr> <td class=\"indent1\">Vigorously circulate water throughout the cooling process.</td> </tr> <tr> <td>Monitor vital signs approximately every 10 minutes and mental status continually during cooling.</td> </tr> <tr> <td>Have several additional assistants immediately nearby in case the athlete becomes combative or must be lifted or rolled because of vomiting.</td> </tr> <tr> <td>Continue cooling until the patient's rectal temperature reaches 39&#176;C (102&#176;F). If the rectal temperature cannot be measured and on-site ice water immersion is indicated, cool for 10 to 15 minutes and then transport to the emergency department. Cooling via ice water immersion occurs at a rate of approximately 1&#176;C for every five minutes (or 1&#176;F every three minutes), if the water is aggressively stirred.</td> </tr> <tr> <td>Remove the patient from the immersion tub and transfer to the nearest emergency department or hospital after the rectal temperature reaches 39&#176;C (102&#176;F).</td> </tr> <tr> <td>If ice water immersion is not feasible given the constraints of the environment, and on-site cooling is appropriate, then cool the patient using the best available means. These may include any of the following three methods:</td> </tr> <tr> <td class=\"indent1\">Fill a cooler with ice, water, and 12 towels. Place six icy wet towels all over the patient's body. Leave them in place for two to three minutes, then place those back in cooler and replace them with the six others. Continue this rotation every two to three minutes.</td> </tr> <tr> <td class=\"indent1\">Douse the patient continuously with cold water using a shower or hose.</td> </tr> <tr> <td class=\"indent1\">If ice is available but no tub, place the patient in a tarp or sheet, cover the patient with a large amount of ice, and then wrap the tarp or sheet around them. Replenish the ice as soon as a moderate degree of melting occurs.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: The Korey Stringer Institute (ksi.uconn.edu) and Casa DJ, McDermott BM, Lee EC, et al. Cold-water immersion: The gold standard for exertional heat stroke treatment. Exercise and Sports Science Reviews. 2007; 35:141.</div><div id=\"graphicVersion\">Graphic 54492 Version 4.0</div></div></div>"},"54493":{"type":"graphic_diagnosticimage","displayName":"Comminuted clavicle fracture","title":"Comminuted clavicle fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comminuted clavicle fracture</div><div class=\"cntnt\"><img style=\"width:396px; height:269px;\" src=\"images/EM/54493_Clav_fx_comminution1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph shows a&nbsp;middle third clavicle fracture with comminution (3rd bone fragment clearly seen between proximal and distal fragments). Nonoperative management was chosen in part because displacement was&nbsp;less than the full width of the clavicle.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 54493 Version 3.0</div></div></div>"},"54494":{"type":"graphic_picture","displayName":"C perfringens Gram stain","title":"<em>Clostridium perfringens</em> Gram stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Clostridium perfringens</em> Gram stain</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/ID/54494_Cperfringens.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of exudate from a bulla at the site of injection of intravenous drugs (x1000) shows large gram-positive bacilli and the absence of leukocytes. <EM>Clostridium perfringens </EM>grew anaerobically from this specimen on blood agar. Clostridial infection may produce cellulitis or involve deeper tissues, as in gas gangrene.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 54494 Version 4.0</div></div></div>"},"54496":{"type":"graphic_figure","displayName":"Rates of acute symptomatic seizures by age","title":"Acute symptomatic seizures; rates by age, Rochester, Minnesota, 1975-1984","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Acute symptomatic seizures; rates by age, Rochester, Minnesota, 1975-1984</div><div class=\"cntnt\"><img style=\"width:520px; height:248px;\" src=\"images/NEURO/54496_Acute_symptomatic_seizures.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Annegers, JF, Hauser, WA, Lee, RJ, Rocca, WA. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984. Epilepsia 1995; 36:327.</div><div id=\"graphicVersion\">Graphic 54496 Version 2.0</div></div></div>"},"54497":{"type":"graphic_table","displayName":"Root versus nerve pain","title":"Clinical distinction between root and nerve pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical distinction between root and nerve pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Characteristic</td>\n\n      <td class=\"subtitle1\">Root pain</td>\n\n      <td class=\"subtitle1\">Nerve pain</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Duration</td>\n\n      <td>Brief</td>\n\n      <td>Persistent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Quality</td>\n\n      <td><p>Sharp</p>\n<p>Shooting</p></td>\n\n      <td><p>Burning</p>\n<p>\"Asleep\" or \"numb\"</p></td>\n\n    </tr>\n\n    <tr>\n\n      <td>Worse with</td>\n\n      <td><p>Coughing</p>\n<p>Straining</p>\n<p>Standing</p>\n<p>Sitting</p></td>\n\n      <td>Lying in bed at night</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Relieved by lying down</td>\n\n      <td>Yes</td>\n\n      <td>No</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54497 Version 1.0</div></div></div>"},"54498":{"type":"graphic_table","displayName":"Antidepressant warning","title":"Class suicidality labeling language for antidepressants - 2007 revisions indicating increased suicidality in young adults and emphasizing that depression itself is the largest risk factor for suicide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Class suicidality labeling language for antidepressants - 2007 revisions indicating increased suicidality in young adults and emphasizing that depression itself is the largest risk factor for suicide</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle1_single\">Black box warning</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_single\">Suicidality and antidepressant drugs</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of <strong>[Insert established name]</strong> or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\"><strong>[Insert Drug Name]</strong> is not approved for use in pediatric patients. [The previous sentence would be replaced with the sentence, below, for the following drugs:</td>\n  </tr>\n<tr>\n\t<td class=\"indent2\">Prozac: Prozac is approved for use in pediatric patients with MDD and obsessive compulsive disorder (OCD).</td>\n\t</tr>\n  <tr>\n\t<td class=\"indent2\">Zoloft: Zoloft is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD).</td>\n\t</tr>\n  <tr>\n\t<td class=\"indent2\">Fluvoxamine: Fluvoxamine is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD).]</td>\n\t</tr>\n  <tr>\n\t<td class=\"indent2\">(See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use.)</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_single\">Warnings: Clinical worsening and suicide risk</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">...The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs placebo), however, were relatively stable within age strata and across indications...</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">www.fda.gov/cder/drug/antidepressants/SSRIlabelChange.htm. (January 2, 2009)</div><div id=\"graphicVersion\">Graphic 54498 Version 1.0</div></div></div>"},"54500":{"type":"graphic_picture","displayName":"Hydroa vacciniforme 1","title":"Hydroa vacciniforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydroa vacciniforme</div><div class=\"cntnt\"><img style=\"width:432px; height:331px;\" src=\"images/DERM/54500_Hydroa_vacciniforme_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scars and crusted papules are present on the face. This 10-year-old boy had a history of recurrent blisters in sun-exposed areas that healed with depressed vaccination-like scars.</div><div class=\"graphic_reference\">Copyright © Shahbaz A Janjua, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 54500 Version 6.0</div></div></div>"},"54501":{"type":"graphic_picture","displayName":"Direct US IV placement","title":"Femoral vein catheter placement under direct ultrasound guidance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Femoral vein catheter placement under direct ultrasound guidance</div><div class=\"cntnt\"><img style=\"width:432px; height:284px;\" src=\"images/EM/54501_Direct_US_IV_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Operator inserting a needle into the common femoral vein under direct ultrasound guidance. A transverse position of the transducer in relation to the vein is recommended so that the operator can see the needle tip enter the center of the vein lumen. With a longitudinal approach, the entire needle course is seen in one image, but it is possible to be at or near the side wall of the vessel without realizing it.</div><div class=\"graphic_reference\">Courtesy of Lauren W Averill, MD.</div><div id=\"graphicVersion\">Graphic 54501 Version 1.0</div></div></div>"},"54502":{"type":"graphic_diagnosticimage","displayName":"Normal anal ultrasound","title":"Normal anal ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal anal ultrasound</div><div class=\"cntnt\"><img style=\"width:358px; height:342px;\" src=\"images/GAST/54502_Normal_anal_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anal ultrasound showing the anal sphincter muscles in cross section through the mid anal canal. The darker homogenous ring is the internal anal sphincter smooth muscle (i). The white heterogeneous ring surrounding this is the external anal sphincter (arrows; E). The top of the figure is anterior.</div><div id=\"graphicVersion\">Graphic 54502 Version 2.0</div></div></div>"},"54505":{"type":"graphic_diagnosticimage","displayName":"Primary ciliary dyskinesia CT","title":"Primary ciliary dyskinesia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary ciliary dyskinesia</div><div class=\"cntnt\"><img style=\"width:331px; height:243px;\" src=\"images/PULM/54505_Primary_ciliary_dyskinesi1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-resolution computed tomography of a 26-year-old man with primary ciliary dyskinesia demonstrating extensive bilateral bronchiectasis.</div><div class=\"graphic_reference\">Courtesy of Sten-Erik Bergström, MD.</div><div id=\"graphicVersion\">Graphic 54505 Version 3.0</div></div></div>"},"54507":{"type":"graphic_picture","displayName":"Resisted thumb extension","title":"Resisted thumb extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resisted thumb extension</div><div class=\"cntnt\"><img style=\"width:432px; height:334px;\" src=\"images/EM/54507_Resisted_thumb_ext_final.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54507 Version 1.0</div></div></div>"},"54508":{"type":"graphic_figure","displayName":"Mirizzi syndrome with erosion into the common hepatic duct","title":"Mirizzi syndrome with erosion of the stone into the common hepatic duct","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Mirizzi syndrome with erosion of the stone into the common hepatic duct</div><div class=\"cntnt\"><img style=\"width:527px; height:317px;\" src=\"images/SURG/54508_Mirizzi-IV-syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgery is the mainstay of therapy for Mirizzi syndrome, permitting removal of the causal factors: the inflamed gallbladder and the impacted stone. When the stone has eroded into the common bile duct or common hepatic duct, a bilioenteric anastomosis is typically required.</div><div id=\"graphicVersion\">Graphic 54508 Version 3.0</div></div></div>"},"54510":{"type":"graphic_picture","displayName":"NAION fundus","title":"Non-arteritic ischemic optic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non-arteritic ischemic optic neuropathy</div><div class=\"cntnt\"><img style=\"width:360px; height:344px;\" src=\"images/NEURO/54510_NAION_fundus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the elevated, swollen disc appearance with multiple splinter hemorrhages.</div><div id=\"graphicVersion\">Graphic 54510 Version 1.0</div></div></div>"},"54513":{"type":"graphic_waveform","displayName":"Holter of monomorphic VT","title":"Sustained ventricular tachycardia on ambulatory monitoring","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Sustained ventricular tachycardia on ambulatory monitoring</div><div class=\"cntnt\"><img style=\"width:542px; height:388px;\" src=\"images/CARD/54513_Holter_of_monomorphic_VT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ambulatory monitor in a patient being evaluated for syncope, which persisted after pacemaker insertion, shows sustained monomorphic ventricular tachycardia (SMVT) which terminates spontaneously. A brief period of ventricular pacing follows ventricular tachycardia termination.</div><div class=\"graphic_reference\">Reproduced with permission by Samuel Levy, MD.</div><div id=\"graphicVersion\">Graphic 54513 Version 2.0</div></div></div>"},"54514":{"type":"graphic_picture","displayName":"Rtxn pocket cholesteatoma","title":"Treatment of early retraction pocket cholesteatoma with middle ear ventilation","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Treatment of early retraction pocket cholesteatoma with middle ear ventilation</div><div class=\"cntnt\"><img style=\"width:503px; height:504px;\" src=\"images/PEDS/54514_Rtxn_pocket_cholesteatoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) Collapse of the drum with posterosuperior deep retraction pocket. Panel B) Retraction pocket after tube placement. Panel C) Reduction of the retraction.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 54514 Version 1.0</div></div></div>"},"54517":{"type":"graphic_picture","displayName":"Celiac ganglion aspirate","title":"Celiac ganglion aspirate showing nerve cell bodies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Celiac ganglion aspirate showing nerve cell bodies</div><div class=\"cntnt\"><img style=\"width:319px; height:442px;\" src=\"images/GAST/54517_Celiac_ganglion_aspirate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Diff Quick. B) Papanicolaou stains.</div><div class=\"graphic_reference\">Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.</div><div id=\"graphicVersion\">Graphic 54517 Version 9.0</div></div></div>"},"54520":{"type":"graphic_picture","displayName":"Nodular sclerosis HL","title":"Nodular sclerosis Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular sclerosis Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:250px; height:286px;\" src=\"images/HEME/54520_Nodular_sclerosis_HL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prominent fibrous bands divide this lymph node into nodules.</div><div class=\"graphic_reference\">From Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 54520 Version 3.0</div></div></div>"},"54521":{"type":"graphic_table","displayName":"Drugs causing anxiety symptoms","title":"Drugs that cause anxiety-like symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that cause anxiety-like symptoms</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Stimulants</td></tr>\n\t\t\t\t\t\t<tr><td>Amphetamine</td></tr>\n\t\t\t\t\t\t<tr><td>Aminophylline</td></tr>\n\t\t\t\t\t\t<tr><td>Caffeine</td></tr>\n\t\t\t\t\t\t<tr><td>Cocaine</td></tr>\n\t\t\t\t\t\t<tr><td>Methylphenidate</td></tr>\n\t\t\t\t\t\t<tr><td>Theophylline</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Sympathomimetics</td></tr>\n\t\t\t\t\t\t<tr><td>Ephedrine</td></tr>\n\t\t\t\t\t\t<tr><td>Epinephrine</td></tr>\n\t\t\t\t\t\t<tr><td>Phenylpropanolamine</td></tr>\n\t\t\t\t\t\t<tr><td>Pseudoephedrine</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Drug withdrawal</td></tr>\n\t\t\t\t\t\t<tr><td>Barbiturates</td></tr>\n\t\t\t\t\t\t<tr><td>Benzodiazepines</td></tr>\n\t\t\t\t\t\t<tr><td>Narcotics</td></tr>\n\t\t\t\t\t\t<tr><td>Alcohol</td></tr>\n\t\t\t\t\t\t<tr><td>Sedatives</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Anticholinergics</td></tr>\n\t\t\t\t\t\t<tr><td>Benztropine mesylate (Cogentin)</td></tr>\n\t\t\t\t\t\t<tr><td>Diphenhydramine (Benadryl)</td></tr>\n\t\t\t\t\t\t<tr><td>Meperidine (Demerol)</td></tr>\n\t\t\t\t\t\t<tr><td>Oxybutynin (Ditropan)</td></tr>\n\t\t\t\t\t\t<tr><td>Propantheline (Pro-Banthine)</td></tr>\n\t\t\t\t\t\t<tr><td>Tricyclics</td></tr>\n\t\t\t\t\t\t<tr><td>Trihexyphenidyl (Artane)</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Dopaminergics</td></tr>\n\t\t\t\t\t\t<tr><td>Amantadine</td></tr>\n\t\t\t\t\t\t<tr><td>Bromocriptine</td></tr>\n\t\t\t\t\t\t<tr><td>Levodopa (L-dopa)</td></tr>\n\t\t\t\t\t\t<tr><td>Levodopa-carbidopa (Sinemet)</td></tr>\n\t\t\t\t\t\t<tr><td>Metoclopramide</td></tr>\n\t\t\t\t\t\t<tr><td>Neuroleptics</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Miscellaneous</td></tr>\n\t\t\t\t\t\t<tr><td>Baclofen</td></tr>\n\t\t\t\t\t\t<tr><td>Cycloserine</td></tr>\n\t\t\t\t\t\t<tr><td>Hallucinogens</td></tr>\n\t\t\t\t\t\t<tr><td>Indomethacin</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58430&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Drugs_causing_anxiety_Sxs.htm</title></head></div><div class=\"graphic_reference\">Adapted from Goldberg RJ. Practical Guide to the Care of the Psychiatric Patient. Mosby Year Book, St. Louis 1995.</div><div id=\"graphicVersion\">Graphic 54521 Version 2.0</div></div></div>"},"54523":{"type":"graphic_figure","displayName":"Anorectal anatomy lateral view","title":"Anorectal anatomy, lateral view","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Anorectal anatomy, lateral view</div><div class=\"cntnt\"><img style=\"width:506px; height:476px;\" src=\"images/SURG/54523_ARFanalanatlateraledt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration depicts the lateral view of the antomy of the anus and rectum. Note the superficial and deep external sphincter muscles.</div><div id=\"graphicVersion\">Graphic 54523 Version 5.0</div></div></div>"},"54524":{"type":"graphic_picture","displayName":"Deep partial-thickness burn PI","title":"Deep partial-thickness burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep partial-thickness burn</div><div class=\"cntnt\"><img style=\"width:382px; height:271px;\" src=\"images/PI/54524_Deep_partial_thickness_burn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep partial-thickness burns form blisters and do not turn white when you press them.</div><div class=\"graphic_reference\">Courtesy of Eric D Morgan and William F Miser, MD.</div><div id=\"graphicVersion\">Graphic 54524 Version 1.0</div></div></div>"},"54525":{"type":"graphic_diagnosticimage","displayName":"Lung abscess","title":"Lung abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung abscess</div><div class=\"cntnt\"><img style=\"width:387px; height:586px;\" src=\"images/ID/54525_Lungabscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postanterior (A) and lateral (B) chest radiographs show dense right upper airspace consolidation. Contrast-enhanced computed tomography (CT) scan (C) demonstrates large focal area of decreased attentuation with rim enhancement (arrow) characteristic of lung abscess. Postanterior (D) and lateral (E) chest radiographs three weeks later show decreased size of lung abscess and development of cavitation with fluid level (arrows). The patient was a 43-year-old woman with lung abscess secondary to <EM>Haemophilus aphrophilus</EM>.</div><div class=\"graphic_reference\">Reproduced with permission from: Müller NL, Franquet T, Lee KS, Silva CIS. Bacterial pneumonia. In: Imaging of pulmonary infections, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54525 Version 11.0</div></div></div>"},"54527":{"type":"graphic_movie","displayName":"Short axis echo 2 HCM","title":"Parasternal short axis echocardiogram in a patient with hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal short axis echocardiogram in a patient with hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/54527_shax2hcm2conv.mp4\" style=\"width:314px;height:226px\"></div><img style=\"width:313px; height:209px;\" src=\"images/CARD/54527_shax2hcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis view from a two-dimensional echocardiogram shows asymmetric hypertrophy of the interventricular septum. During systole, there is near obliteration of the left ventricular cavity.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 54527 Version 3.0</div></div></div>"},"54531":{"type":"graphic_figure","displayName":"Home arm volumeter","title":"How to construct and use a home arm volumeter","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">How to construct and use a home arm volumeter</div><div class=\"cntnt\"><img style=\"width:592px; height:435px;\" src=\"images/ONC/54531_Home_arm_volumeter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Preparation of parts, (C) assembly, and (D) arm volume measurement procedure, including a longitudinal cross-section view.</div><div class=\"graphic_reference\">Reproduced with permission from: Lette, J. A simple and innovative device to measure arm volume at home for patients with lymphedema after breast cancer. J Clin Oncol 2006; 24:5434. Copyright &#169;2006 The American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 54531 Version 1.0</div></div></div>"},"54533":{"type":"graphic_diagnosticimage","displayName":"Trimalleolar fracture","title":"Trimalleolar fracture","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Trimalleolar fracture</div><div class=\"cntnt\"><img style=\"width:537px; height:330px;\" src=\"images/EM/54533_Trimalleolar_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An oblique fracture of the lateral malleolus (arrow on AP and lateral x-rays) proximal to the joint, in addition to fractures of the medial malleolus (arrowhead on AP view) and posterior malleolus (dashed arrow on lateral view), are seen here. Note how the posterior malleolar fracture and the displacement of the fibular fracture can only be seen on the lateral view. The diastasis between the tibia and fibula reflects a syndesmotic injury. The highly unstable nature of trimalleolar fractures is reflected in the loss of joint congruence and the abnormal increased width between the medial malleolus and the talus.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 54533 Version 3.0</div></div></div>"},"54536":{"type":"graphic_table","displayName":"Diffuse lung disease diagnosis","title":"Radiographic approach to the diagnosis of diffuse lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiographic approach to the diagnosis of diffuse lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Analysis of predominant opacities</td> </tr> <tr> <td>Shape</td> </tr> <tr> <td>Profusion (number of opacities per unit area)</td> </tr> <tr> <td>Zonal predilection</td> </tr> <tr> <td class=\"subtitle1_single\">Analysis of lung volumes</td> </tr> <tr> <td>Small</td> </tr> <tr> <td>Normal</td> </tr> <tr> <td>Large</td> </tr> <tr> <td class=\"subtitle1_single\">Distribution of disease</td> </tr> <tr> <td>Upper zone disease</td> </tr> <tr> <td>Basal disease</td> </tr> <tr> <td>Peripheral disease</td> </tr> <tr> <td>Central disease</td> </tr> <tr> <td class=\"subtitle1_single\">Associated findings</td> </tr> <tr> <td>Pleura</td> </tr> <tr> <td>Hilar regions</td> </tr> <tr> <td>Mediastinum</td> </tr> <tr> <td>Heart</td> </tr> <tr> <td>Pulmonary vasculature</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54536 Version 3.0</div></div></div>"},"54538":{"type":"graphic_waveform","displayName":"ECG_1 Polymorphic VT in ischemia","title":"ECG_1 showing polymorphic ventricular tachycardia in ischemia","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">ECG_1 showing polymorphic ventricular tachycardia in ischemia</div><div class=\"cntnt\"><img style=\"width:537px; height:272px;\" src=\"images/CARD/54538_Polymorphic_VT_in_ischemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous rhythm strip revealing several episodes of nonsustained ventricular tachycardia (VT) occurring during an acute ischemic event. The QRS complexes are variable in morphology and RR intervals; thus, the VT is polymorphic. The QT interval is normal. This form of VT should be distinguished from torsade de pointes in which polymorphic VT is associated with QT interval prolongation.</div><div id=\"graphicVersion\">Graphic 54538 Version 3.0</div></div></div>"},"54539":{"type":"graphic_table","displayName":"Clinical indicators of acute malignant hyperthermia","title":"Clinical indicators of acute malignant hyperthermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical indicators of acute malignant hyperthermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td rowspan=\"2\"><strong>Rigidity</strong></td> <td>Generalized muscular rigidity (sustained contracture) during anesthesia with triggering agents</td> </tr> <tr> <td>Severe masseter muscle spasm shortly following succinylcholine administration</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>Rhabdomyolysis</strong></td> <td>CK &#62;20,000 international units after anesthesia with succinylcholine</td> </tr> <tr> <td>CK &#62;10,000 international units after anesthesia without succinylcholine</td> </tr> <tr> <td>Cola-colored urine in perioperative period</td> </tr> <tr> <td>Urine myoglobin &#62;60 mcg/L</td> </tr> <tr> <td>Serum myoglobin &#62;170 mcg/L</td> </tr> <tr> <td>Serum K &#62;6 meq/L (without renal failure)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"8\"><strong>Acidosis</strong></td> <td class=\"sublist1_start\">Controlled ventilation:</td> </tr> <tr> <td class=\"sublist1\">P<sub>ET</sub>CO<sub>2</sub> &#62;55</td> </tr> <tr> <td class=\"sublist1\">P<sub>a</sub>CO<sub>2</sub> &#62;60</td> </tr> <tr> <td class=\"sublist1_start\">Spontaneous ventilation:</td> </tr> <tr> <td class=\"sublist1\">P<sub>ET</sub>CO<sub>2</sub> &#62;60</td> </tr> <tr> <td class=\"sublist1\">P<sub>a</sub>CO<sub>2</sub> &#62;65</td> </tr> <tr> <td>Inappropriate hypercarbia (judgement)</td> </tr> <tr> <td>Inappropriate tachypnea (judgement)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Fever</strong></td> <td>Inappropriate rapid increase in temperature (judgement)</td> </tr> <tr> <td>Inappropriate perioperative temperature &#62;38.8&#176;C (judgement)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Tachycardia</strong></td> <td>Inappropriate sinus tachycardia</td> </tr> <tr> <td>Ventricular tachycardia or ventricular fibrillation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Other</strong></td> <td>Base excess below &ndash;8 mEq/L</td> </tr> <tr> <td>Arterial pH &#60;7.25</td> </tr> <tr> <td>Rapid reversal of MH signs with dantrolene</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54539 Version 6.0</div></div></div>"},"54540":{"type":"graphic_figure","displayName":"Survival of dialysis patients who received ICD devices","title":"Survival of dialysis patients who received ICD devices","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Survival of dialysis patients who received ICD devices</div><div class=\"cntnt\"><img style=\"width:470px; height:322px;\" src=\"images/NEPH/54540_Survival_dialysis_pts_ICD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival of patients who received an implantable cardioverter-defibrillator (ICD) for secondary prevention compared with matched controls.</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator.</div><div class=\"graphic_reference\">Reproduced from: Charytan DM, Patrick AR, Liu J, et al. Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States. Am J Kidney Dis 2011; 58:409. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 54540 Version 2.0</div></div></div>"},"54541":{"type":"graphic_picture","displayName":"Bullous pemphigoid tense bullae","title":"Tense blisters in bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tense blisters in bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/54541_Bullous_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense bullae on inflamed skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54541 Version 5.0</div></div></div>"},"54546":{"type":"graphic_figure","displayName":"2nd trimester inhibin A levels","title":"Second trimester inhibin A levels","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Second trimester inhibin A levels</div><div class=\"cntnt\"><img style=\"width:488px; height:469px;\" src=\"images/OBGYN/54546_2ndtriinhibinAlvls.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Median maternal serum levels in unaffected pregnancies calculated from in-house data at Women and Infants Hospital, Providence, Rhode Island. These data are representative and not intended or appropriate for use in other laboratories.</div><div class=\"graphic_reference\">Courtesy of Glenn E Palomaki, PhD.</div><div id=\"graphicVersion\">Graphic 54546 Version 2.0</div></div></div>"},"54550":{"type":"graphic_figure","displayName":"Inflatable penile implant","title":"Inflatable penile implant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflatable penile implant</div><div class=\"cntnt\"><img style=\"width:231px; height:275px;\" src=\"images/ENDO/54550_Inflatable_implant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With an inflatable implant, erection is produced by squeezing a small pump (a) implanted in the scrotum. The pump causes fluid to flow from a reservoir (b) residing in the lower pelvis to two cylinders (c) residing in the penis. The cylinders expand to create the erection.</div><div id=\"graphicVersion\">Graphic 54550 Version 2.0</div></div></div>"},"54553":{"type":"graphic_table","displayName":"LRs for MI based on components of the chest pain history","title":"Likelihood ratios for myocardial infarction (MI) based on components of the chest pain history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Likelihood ratios for myocardial infarction (MI) based on components of the chest pain history</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Description of pain</td>\n\n      <td class=\"subtitle1\">Positive likelihood ratio (95%\nCI)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Descriptions\nincreasing the likelihood of MI</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Radiation to right arm or shoulder</td>\n\n      <td>4.7 (1.9-12)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Radiation to both arms or shoulders</td>\n\n      <td>4.1 (2.5-6.5)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Exertional</td>\n\n      <td>2.4 (1.5-3.8)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Radiation to left arm</td>\n\n      <td>2.3 (1.7-3.1)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Associated with diaphoresis</td>\n\n      <td>2.0 (1.9-2.2)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Associated with nausea or vomiting</td>\n\n      <td>1.9 (1.7-2.3)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Worse than previous angina or similar to previous MI</td>\n\n      <td>1.8 (1.6-2.0)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Described as pressure</td>\n\n      <td>1.3 (1.2-1.5)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Descriptions\ndecreasing the likelihood of MI</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Pleuritic</td>\n\n      <td>0.2 (0.1-0.3)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Positional</td>\n\n      <td>0.3 (0.2-0.5) </td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Sharp</td>\n\n      <td>0.3 (0.2-0.5)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Reproducible with palpation</td>\n\n      <td>0.3 (0.2-0.4)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Inframammary location</td>\n\n      <td>0.8 (0.7-0.9)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Nonexertional</td>\n\n      <td> 0.8 (0.6-0.9)</td>\n\n    </tr>\n\n\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=59173&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>History_and_LRs_for_MI.htm</title></head></div><div class=\"graphic_footnotes\">CI: confidence interval.</div><div class=\"graphic_reference\">Data from: Swap C, Nagurney J. Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. JAMA 2005; 294:2623.</div><div id=\"graphicVersion\">Graphic 54553 Version 2.0</div></div></div>"},"54558":{"type":"graphic_algorithm","displayName":"Proposed DM model","title":"Proposed model of dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Proposed model of dermatomyositis</div><div class=\"cntnt\"><img style=\"width:574px; height:691px;\" src=\"images/RHEUM/54558_Dermatomyositis_algo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69:2008. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54558 Version 11.0</div></div></div>"},"54562":{"type":"graphic_figure","displayName":"Flt 1 and sFlt 1","title":"Flt-1 and sFlt-1","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Flt-1 and sFlt-1</div><div class=\"cntnt\"><img style=\"width:462px; height:317px;\" src=\"images/OBGYN/54562_Flt_1_and_sFlt_1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Protein structure of vascular endothelial growth factor receptor (VEGF) and placental growth factor receptor (PIGF) Flt-1 and sFlt-1 are illustrated. Flt-1 has 7 immunoglobulin domains (lgG) which are thought to mediate ligand binding to VEGF and PIGF. sFlt-1 protein has a unique 31 AA C-terminus region derived from alternative splicing and lacks the transmembrane and cytoplasmic domains.</div><div class=\"graphic_reference\">Courtesy of S Ananth Karumanchi MD.</div><div id=\"graphicVersion\">Graphic 54562 Version 1.0</div></div></div>"},"54564":{"type":"graphic_figure","displayName":"Jellyfish species","title":"Jellyfish species","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jellyfish species</div><div class=\"cntnt\"><img style=\"width:429px; height:576px;\" src=\"images/EM/54564_Jellyfish_species.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ecological, morphological, and clinical features of dangerous jellyfish:<br />(A) Chironex fleckeri may reach a bell diameter of 20 cm, and prefers shallow coastal waters. Tentacle prints show the typical ladder pattern for this animal.<br />(B) Physalia species-in fact, not a single individual, but a colony of symbiotic polyps-floats on the water surface with the help of a gasfilled bladder and produces whip-like tentacle prints.<br />(C) Carukia barnesi (Irukandji), a pelagic box jellyfish, is the size of a human thumb. After heavy storms it may be found in the inward zone of a reef. The nematocysts of the bell produce a faint print on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from Junghanss, T, Bodio, M. Medically important venomous animals: Biology, prevention, first aid, and clinical management. CID 2006; 32:1309. Copyright © 2006 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 54564 Version 2.0</div></div></div>"},"54565":{"type":"graphic_figure","displayName":"Key structures involved in patellar function","title":"Key structures involved in patellar function","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Key structures involved in patellar function</div><div class=\"cntnt\"><img style=\"width:542px; height:560px;\" src=\"images/EM/54565_PFPS_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54565 Version 3.0</div></div></div>"},"54566":{"type":"graphic_picture","displayName":"Esoph cancer autofluorescence","title":"Autofluorescence image of esophageal cancer","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Autofluorescence image of esophageal cancer</div><div class=\"cntnt\"><img style=\"width:513px; height:228px;\" src=\"images/GAST/54566_Esoph_cancer_autofluorescen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White light endoscopic view of the distal esophagus in a patient with Barrett's esophagus (left panel). Corresponding autofluorescence image (right panel) showing a blue/purple color (right side) suggestive of early neoplasia, which was confirmed by biopsy. This lesion was first detected with autofluorescence and only retrospectively by white light imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Kara MA, Peters FP, Ten Kate FJ, et al. Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus. Gastrointest Endosc 2005; 61:679. Copyright © 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 54566 Version 2.0</div></div></div>"},"54567":{"type":"graphic_table","displayName":"ACC AHA Rx cardiogenic shock","title":"ACC/AHA/ESC guideline summary: Treatment of cardiogenic shock in patients with acute myocarial infarction (MI)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/ESC guideline summary: Treatment of cardiogenic shock in patients with acute myocarial infarction (MI)*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Class I - There is evidence and/or general agreement that the following approaches are indicated in the treatment of cardiogenic shock in patients with an acute MI:</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Intraaortic balloon counterpulsation when cardiogenic shock is not quickly reversed with pharmacologic therapy. The IABP is a stabilizing measure for angiography and prompt revascularization.</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Intraarterial monitoring.</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Early revascularization with either PCI or CABG for patients less than 75 years of age who develop shock within 36 hours of MI and who are suitable for revascularization that can be performed within 18 hours of shock. This recommendation does not apply when further support is futile because of the patient's wishes or contraindications to or unsuitability for further invasive care.</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Among patients with ST elevation MI, fibrinolytic therapy in those who are not suitable for revascularization and have no contraindications to fibrinolysis.</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Unless assessed by invasive testing, echocardiography to evaluate for possible mechanical complications.</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approaches in the treatment of cardiogenic shock in patients with an acute MI:</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Pulmonary artery catheterization</td>\n</tr>\n<tr>\n<td> &#8226;&nbsp; Early revascularization with either PCI or CABG for selected patients 75 years of age or older (eg, patients with good functional status who agree to invasive care) who develop shock within 36 hours of MI and who are suitable for revascularization that can be performed within 18 hours of shock.</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* These guidelines were for patients with ST elevation MI or MI associated with left bundle branch block. Similar principles apply to cardiogenic shock developing in patients with a non-ST elevation MI.</div><div class=\"graphic_reference\">Data from Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.</div><div id=\"graphicVersion\">Graphic 54567 Version 2.0</div></div></div>"},"54568":{"type":"graphic_diagnosticimage","displayName":"Fibrous pleural tumor Lateral","title":"Fibrous tumor of the pleura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrous tumor of the pleura</div><div class=\"cntnt\"><img style=\"width:292px; height:324px;\" src=\"images/PULM/54568_FibrouspleuraltumorLater.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest lateral view shows the mass projecting into the retrosternal region and mimicking an anterior mediastinal mass.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 54568 Version 3.0</div></div></div>"},"54569":{"type":"graphic_table","displayName":"Natural history of chronic AR","title":"Natural history of chronic aortic regurgitation mostly based upon data from nine series with a total of 593 patients followed for a mean of 6.6 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Natural history of chronic aortic regurgitation mostly based upon data from nine series with a total of 593 patients followed for a mean of 6.6 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Asymptomatic patients with normal left ventricular (LV) systolic function</td> </tr> <tr> <td>Progression to symptoms and/or LV dysfunction</td> <td>Less than 6 percent/year</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Progression to symptoms, LV dysfunction, or death</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">According to LV end-systolic dimension</td> </tr> <tr> <td class=\"sublist2\">&#62;50 mm</td> <td class=\"sublist_other\">19 percent/year</td> </tr> <tr> <td class=\"sublist2\">40 to 50 mm</td> <td class=\"sublist_other\">6 percent/year</td> </tr> <tr> <td class=\"sublist2\">&#60;40 mm</td> <td class=\"sublist_other\">0 percent/year</td> </tr> <tr> <td>Progression to asymptomatic LV dysfunction</td> <td>Less than 3.5 percent/year</td> </tr> <tr> <td>Sudden death</td> <td>Less than 0.2 percent/year</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Asymptomatic patients with LV systolic dysfunction</td> </tr> <tr> <td>Progression to cardiac symptoms</td> <td>More than 25 percent/year</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Symptomatic patients</td> </tr> <tr> <td>Mortality rate</td> <td>More than 10 percent/year</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Bonow RO, Lakatos E, Maron BJ, et al. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation 1991; 84:1625.</div><div id=\"graphicVersion\">Graphic 54569 Version 3.0</div></div></div>"},"54570":{"type":"graphic_figure","displayName":"Tiotropium bromide","title":"Tiotropium bromide","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tiotropium bromide</div><div class=\"cntnt\"><img style=\"width:382px; height:354px;\" src=\"images/PULM/54570_Tiotropium_bromide.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Data from: Kaiser HB, Findlay SR, Georgitis JW, et al. J Allergy Clin Immunol 1995; 95(5 Pt 2):1117.</div><div id=\"graphicVersion\">Graphic 54570 Version 2.0</div></div></div>"},"54571":{"type":"graphic_diagnosticimage","displayName":"DISH radiograph ankle","title":"Affected ankle in diffuse idiopathic skeletal hyperostosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Affected ankle in diffuse idiopathic skeletal hyperostosis</div><div class=\"cntnt\"><img style=\"width:322px; height:316px;\" src=\"images/RHEUM/54571_DISHradiographankle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of ankle and hindfoot in a patient with DISH reveals a small plantar osteophyte (large arrow) as well as a larger dorsal calcaneal spur (small arrow).</div><div class=\"graphic_footnotes\">DISH: diffuse idiopathic skeletal hyperostosis.</div><div class=\"graphic_reference\">Courtesy of John Esdaile, MD.</div><div id=\"graphicVersion\">Graphic 54571 Version 3.0</div></div></div>"},"54572":{"type":"graphic_figure","displayName":"Balloon brachytherapy","title":"Balloon brachytherapy","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Balloon brachytherapy</div><div class=\"cntnt\"><img style=\"width:542px; height:334px;\" src=\"images/SURG/54572_Balloon-brachytherapy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For intracavitary brachytherapy a radiation delivery device is placed into the partial mastectomy site either at the time of lumpectomy or several days later. High dose radioactive seeds are inserted into the device for a short period of time twice a day for five days. When treatment is completed, the device is removed. Single lumen and multi-lumen balloon catheter and non-balloon devices have all been used successfully.</div><div id=\"graphicVersion\">Graphic 54572 Version 2.0</div></div></div>"},"54573":{"type":"graphic_diagnosticimage","displayName":"2D TTE Parasternal short axis coronary arteries","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view at the level of the coronary arteries","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view at the level of the coronary arteries</div><div class=\"cntnt\"><img style=\"width:260px; height:261px;\" src=\"images/CARD/54573_Short_axis_coronary_arterie.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The origins of the right (RCA) and left (LCA) coronary arteries can be seen on the short axis precordial view, obtained through the aortic root (Ao) just above the valves; there is a vague &quot;pinwheel&quot; relationship of the sweep of the arteries. Additionally, the left atrial appendage (LAA) is seen just inferior to the LCA and the pulmonary valve (PV) just superior.</div><div class=\"graphic_footnotes\">LA: left atrium.</div><div id=\"graphicVersion\">Graphic 54573 Version 3.0</div></div></div>"},"54575":{"type":"graphic_table","displayName":"Canada guide timing age kidney transplantation","title":"Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General considerations</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendations</td> </tr> <tr> <td class=\"indent1\">1. All patients with end-stage renal disease should be considered for kidney transplantation provided no absolute contraindications exist (Grade A).</td> </tr> <tr> <td class=\"indent1\">2. Eligibility for kidney transplantation should be determined on medical and surgical grounds. Criteria for eligibility should be transparent and made available to patients and the public. Eligibility should not be based on social status, gender, race, or personal or public appeal (Grade C).</td> </tr> <tr> <td class=\"indent1\">3. A patient declined for transplantation should routinely be offered a second opinion from an alternative&nbsp;clinician or surgeon or a committee able to assess the relative risks and benefits of kidney transplantation (Grade C).</td> </tr> <tr> <td class=\"subtitle1_single\">Timing of referral</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendations</td> </tr> <tr> <td class=\"indent1\">1. Potential transplant recipients should be referred for evaluation by a transplant program once renal replacement therapy is expected to be required within the next 12 months (Grade C).</td> </tr> <tr> <td class=\"indent1\">2. Patients already requiring dialysis support should be referred for transplant evaluation as soon as their medical condition stabilizes (Grade C).</td> </tr> <tr> <td class=\"subtitle1_single\">Renal function</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendations</td> </tr> <tr> <td class=\"indent1\">1. Preemptive kidney transplantation is the preferred form of renal replacement therapy and should be encouraged where feasible (Grade A).</td> </tr> <tr> <td class=\"indent1\">2. Preemptive kidney transplantation should not proceed unless the measured or calculated glomerular filtration rate is &#60;20 mL/minute and there is evidence of progressive and irreversible deterioration in renal function over the previous 6 to 12 months. Exceptions may be made for patients receiving combined organ transplants where a kidney transplant is combined with a nonrenal organ. However, the appropriate policy on this issue is not clear at this time (Grade C).</td> </tr> <tr> <td class=\"subtitle1_single\">Age and functional capacity</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendations</td> </tr> <tr> <td class=\"indent1\">1. Advanced age per se is not a contraindication to kidney transplantation (Grade B).</td> </tr> <tr> <td class=\"indent1\">2. Transplant candidates should have a reasonable probability of surviving beyond current waiting times for transplantation, given the resources required to assess and maintain patients on the renal transplant waiting list (Grade C).</td> </tr> <tr> <td class=\"indent1\">3. Very young age and small size should not prevent early referral for transplant evaluation (Grade B).</td> </tr> <tr> <td class=\"indent1\">4. Cognitive or neurodevelopmental delay is not an absolute contraindication to renal transplantation in children (Grade B).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The strength of evidence supporting each recommendation was graded using the system developed by the Canadian Task Force on Preventive Health Care as follows:<br />Grade A - There is good evidence to support<br />Grade B - There is fair evidence to support<br />Grade C - The existing evidence is conflicting, but other factors may influence decision-making<br />Grade D - There is fair evidence to recommend against<br />Grade E - There is good evidence to recommend against</div><div class=\"graphic_reference\">Reproduced with permission from: Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation: Consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:S1. Copyright © 2005 CMA Media Inc.</div><div id=\"graphicVersion\">Graphic 54575 Version 4.0</div></div></div>"},"54580":{"type":"graphic_picture","displayName":"AU fibrin glue","title":"Injection of fibrin glue into the anal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Injection of fibrin glue into the anal fistula</div><div class=\"cntnt\"><img style=\"width:288px; height:166px;\" src=\"images/SURG/54580_AU_fibrin_glue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A catheter is inserted through the external opening and is gently advanced into the internal opening. A seal of fibrin is injected as the catheter is withdrawn.</div><div class=\"graphic_reference\">Courtesy of Bradley J Champagne, MD.</div><div id=\"graphicVersion\">Graphic 54580 Version 2.0</div></div></div>"},"54581":{"type":"graphic_picture","displayName":"Psoriasis plaque","title":"Plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54581_Psoriasis_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous plaque with coarse scale is present on the knee of this patient with psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54581 Version 5.0</div></div></div>"},"54582":{"type":"graphic_figure","displayName":"Salter-Harris classification of physeal fractures","title":"Salter-Harris classification of physeal fractures","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Salter-Harris classification of physeal fractures</div><div class=\"cntnt\"><img style=\"width:540px; height:277px;\" src=\"images/EM/54582_Salter_Harris_class.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The growth plate is shown in green. The mnemonic refers to the fracture line and its relationship to the growth plate. The metaphysis is the bone above the growth plate, and the epiphysis is the bone below. Type I fractures disrupt the physis. Type II fractures involve a break from the growth plate up into the metaphysis, with the periosteum usually remaining intact. Type III fractures are intraarticular fractures through the epiphysis that extend across the physis. Type IV fractures cross the epiphysis, physis, and metaphysis. Type V fractures are compression injuries to the physis.</div><div id=\"graphicVersion\">Graphic 54582 Version 4.0</div></div></div>"},"54583":{"type":"graphic_figure","displayName":"Spermatogenic response to gonadotropins","title":"Spermatogenic responses to gonadotropins depending on time of onset of secondary hypogonadism","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Spermatogenic responses to gonadotropins depending on time of onset of secondary hypogonadism</div><div class=\"cntnt\"><img style=\"width:532px; height:252px;\" src=\"images/ENDO/54583_Response_to_gonadotropins_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sperm counts in men with secondary hypogonadism (idiopathic hypogonadotropic hypogonadism) after treatment with hCG for six months alone and then, in those in whom the sperm count did not reach the normal range (more than 40 million/ejaculate), for eight months with hMG. Patients with postpubertal onset responded to hCG, those with prepubertal onset generally required the addition of hMG, and those with prepubertal onset and cryptorchidism were primarily resistant to therapy (right panel).</div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; hMG: human menopausal gonadotropin.</div><div class=\"graphic_reference\">Data from: Finkel DM, Phillips JL, Snyder PJ. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism.&nbsp;N Engl J Med 1985; 313:651.</div><div id=\"graphicVersion\">Graphic 54583 Version 3.0</div></div></div>"},"54584":{"type":"graphic_picture","displayName":"Flat adenoma indigo carmine","title":"Chromoendoscopy with indigo carmine of a colon adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chromoendoscopy with indigo carmine of a colon adenoma</div><div class=\"cntnt\"><img style=\"width:360px; height:269px;\" src=\"images/GAST/54584_Flat_adenoma_indigo_carmine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution endoscopic image of a small flat colon adenoma in a patient with familial adenomatous polyposis after spraying with indigo carmine. The indigo carmine is not absorbed and collects in the crevices between epithelial cells thereby enhancing the mucosal details.</div><div class=\"graphic_reference\">Courtesy of Francis Giardiello, MD.</div><div id=\"graphicVersion\">Graphic 54584 Version 2.0</div></div></div>"},"54585":{"type":"graphic_table","displayName":"NCEP very high risk","title":"Definition of \"very high risk\" in NCEP guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of &quot;very high risk&quot; in NCEP guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle2\">Established coronary heart disease</td>\n</tr>\n<tr>\n<td class=\"indent2\">PLUS</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">Multiple major risk factors (especially diabetes)</td>\n</tr>\n<tr>\n<td class=\"indent2\">&nbsp;OR</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">Severe and poorly controlled risk factors (especially continued smoking)</td>\n</tr>\n<tr>\n<td class=\"indent2\">&nbsp;OR</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">Multple risk factors of the metabolic syndrome (especially triglycerides &#8805;200 plus non-HDL-C &#8805;130 plus HDL-C &#60;40)</td>\n</tr>\n<tr>\n<td class=\"indent2\">&nbsp;OR</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">Acute coronary syndrome</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Grundy SM, Cleeman JI, Merz NB, et al. Circulation 2004; 110:227.</div><div id=\"graphicVersion\">Graphic 54585 Version 2.0</div></div></div>"},"54587":{"type":"graphic_picture","displayName":"Immature teratoma High","title":"Mediastinal immature teratoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal immature teratoma</div><div class=\"cntnt\"><img style=\"width:360px; height:228px;\" src=\"images/PULM/54587_Immature_teratoma_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph of a mediastinal immature teratoma shows immature neuroectodermal elements with rosette formation, lined by crowded basophilic cells with hyperchromatic nuclei (hematoxylin and eosin, magnification 100x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 54587 Version 2.0</div></div></div>"},"54589":{"type":"graphic_table","displayName":"Results bilateral LVRS in NETT","title":"Results of bilateral LVRS compared to medical therapy in patients with severe emphysema.","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of bilateral LVRS compared to medical therapy in patients with severe emphysema.</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Patients</td> <td class=\"subtitle1\" colspan=\"2\">90-day mortality</td> <td class=\"subtitle1\" rowspan=\"2\">P-value</td> <td class=\"subtitle1\" colspan=\"2\">Total mortality</td> <td class=\"subtitle1\" rowspan=\"2\">Risk ratio*</td> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">P-value</td> </tr> <tr> <td class=\"subtitle2\">LVRS</td> <td class=\"subtitle2\">Medical therapy</td> <td class=\"subtitle2\">LVRS</td> <td class=\"subtitle2\">Medical therapy</td> </tr> <tr> <td>Group A</td> <td>20/70 (28.6)</td> <td>0/70 (0)</td> <td>&#60;0.001</td> <td>42/70</td> <td>30/70</td> <td>1.82</td> <td colspan=\"2\">0.06</td> </tr> <tr> <td>Group B</td> <td>4/139 (2.9)</td> <td>5/151 (3.3)</td> <td>1.00</td> <td>26/139</td> <td>51/151</td> <td>0.47</td> <td colspan=\"2\">0.005</td> </tr> <tr> <td>Group C</td> <td>6/206 (2.9)</td> <td>2/213 (0.9)</td> <td>0.17</td> <td>34/206</td> <td>39/213</td> <td>0.98</td> <td colspan=\"2\">0.7</td> </tr> <tr> <td>Group D</td> <td>7/84 (8.3)</td> <td>0/65 (0)</td> <td>0.02</td> <td>28/84</td> <td>26/65</td> <td>0.81</td> <td colspan=\"2\">0.49</td> </tr> <tr> <td>Group E</td> <td>11/109 (10.1)</td> <td>1/111 (0.9)</td> <td>0.003</td> <td>27/109</td> <td>14/111</td> <td>2.06</td> <td colspan=\"2\">0.02</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">Patients</td> <td class=\"subtitle1\" colspan=\"4\">Improvement in exercise capacity<sup>&#182;</sup></td> <td class=\"subtitle1\" colspan=\"4\">Improvement in health-related quality of life<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2\">LVRS</td> <td class=\"subtitle2\">Medical therapy</td> <td class=\"subtitle2\">Odds ratio</td> <td class=\"subtitle2\">P-value</td> <td class=\"subtitle2\">LVRS</td> <td class=\"subtitle2\">Medical therapy</td> <td class=\"subtitle2\">Odds ratio</td> <td class=\"subtitle2\">P-value</td> </tr> <tr> <td>Group A</td> <td>4/58 (7)</td> <td>1/48 (2)</td> <td>3.48</td> <td>0.37</td> <td>6/58 (10)</td> <td>0/48 (0)</td> <td>---</td> <td>0.03</td> </tr> <tr> <td>Group B</td> <td>25/84 (30)</td> <td>0/92 (0)</td> <td>---</td> <td>&#60;0.001</td> <td>40/84 (48)</td> <td>9/92 (10)</td> <td>8.38</td> <td>&#60;0.001</td> </tr> <tr> <td>Group C</td> <td>17/115 (15)</td> <td>4/138 (3)</td> <td>5.81</td> <td>0.001</td> <td>47/115 (41)</td> <td>15/138 (11)</td> <td>5.67</td> <td>&#60;0.001</td> </tr> <tr> <td>Group D</td> <td>6/49 (12)</td> <td>3/41 (7)</td> <td>1.77</td> <td>0.5</td> <td>18/49 (37)</td> <td>3/41 (7)</td> <td>7.35</td> <td>0.001</td> </tr> <tr> <td>Group E</td> <td>2/65 (3)</td> <td>2/59 (3)</td> <td>0.9</td> <td>1</td> <td>10/65 (15)</td> <td>7/59 (12)</td> <td>1.35</td> <td>0.61</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Groups A-E are defined in the text.<br />Values in parentheses indicate percentage.</div><div class=\"graphic_footnotes\">LVRS: lung volume reduction surgery.<br />* Risk ratio for total mortality in surgically versus medically treated patients during a mean follow-up of 29.2 months.<br />¶ Increase in the maximal workload of more than 10W from the patient's postrehabilitation base-line value (24 months after randomization).<br />Δ Improvement in the health-related quality of life was defined as a decrease in the score on the St. George's Respiratory Questionnaire of more than 8 points (on a 100-point scale) from the patient's postrehabilitation baseline score (24 months after randomization).</div><div class=\"graphic_reference\">Adapted with permission from: Martinez FJ, Chang A. Surgical therapy for chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26:167. Copyright &copy; 2005 Thieme Medical Publishers, Inc.</div><div id=\"graphicVersion\">Graphic 54589 Version 9.0</div></div></div>"},"54590":{"type":"graphic_table","displayName":"Immunoglobulin genes in B cells","title":"Immunoglobulin (Ig) genes and protein expression during B cell development","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunoglobulin (Ig) genes and protein expression during B cell development</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"5\">Antigen-independent phase</td> <td class=\"subtitle1\" colspan=\"4\">Antigen-dependent phase</td> </tr> <tr> <td class=\"subtitle2\">Pre-pro B cell</td> <td class=\"subtitle2\">Pro-B cell</td> <td class=\"subtitle2\">Pre B cell</td> <td class=\"subtitle2\">Immature B cell</td> <td class=\"subtitle2\">Mature B cell</td> <td class=\"subtitle2\">Activated B cell</td> <td class=\"subtitle2\">Blast B cell</td> <td class=\"subtitle2\">Memory B cell</td> <td class=\"subtitle2\">Plasma B cell</td> </tr> <tr> <td>Surrogate light chain</td> <td>&nbsp;</td> <td>S</td> <td> <p>S + IgM</p> <p>H chain</p> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Ig genes</td> <td>GL</td> <td>DJH</td> <td>VDJH</td> <td> <p>VJL</p> <p>RE</p> </td> <td>&nbsp;</td> <td> <p>CS</p> <p>SM</p> <p>RE</p> </td> <td> <p>CS</p> <p>SM</p> <p>RE</p> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>IgM</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>C, H chain only</td> <td>S</td> <td>S</td> <td>S if no CS</td> <td>S if no CS</td> <td>S if no CS</td> <td>S if no CS</td> </tr> <tr> <td>IgD</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>S</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Note that the nomenclature of development stages varies among authors. A mature B cell may give rise to both memory cells and to plasma cells, but a single cell cannot be both. Memory cells may be activated, and subsequently divide and give rise either to new memory cells or plasma cells.<br />S: surface expression; GL: germline; D: diversity; J: joining; H: lg heavy chain; V: variable; RE: receptor editing; CS: class-switching; SM: somatic mutation; C: cytoplasmic expression.</div><div class=\"graphic_reference\">Data from: Bona, CA, Bonilla, FA, Textbook of Immunology, 2nd edition, Harwood Academic Publishers, Amsterdam, 1996. page 102 (no table number).</div><div id=\"graphicVersion\">Graphic 54590 Version 4.0</div></div></div>"},"54591":{"type":"graphic_waveform","displayName":"Atrial flutter RA recording","title":"Atrial flutter RA recording","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial flutter RA recording</div><div class=\"cntnt\"><img style=\"width:177px; height:254px;\" src=\"images/CARD/54591_Atrial_flutter_RA_recording.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial flutter which is inapparent in lead I (upper panel); suggested by prominent negativity in lead II (arrows, middle panel), which could also represent biphasic T waves; and documented by right atrial recording, which shows prominent negative deflections (arrows, lower panel).</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 54591 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"54592":{"type":"graphic_table","displayName":"Specimen collection methods II","title":"Microbiology specimen handling and collection - II","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microbiology specimen handling and collection - II</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Specimen</td> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\">Volume</td> <td class=\"subtitle1\">Storage temperature*</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Genital</td> </tr> <tr> <td class=\"indent1\">Fluids -&nbsp;endometrial, amniotic, pelvic (culdocentesis)</td> <td>Sterile anaerobic container</td> <td>1 to 10 mL</td> <td>4&ordm;C</td> <td>Anaerobic culture is appropriate only for specimens obtained without traversing colonized areas (eg, vagina).</td> </tr> <tr> <td class=\"indent1\"><em>Chlamydia trachomatis/Neisseria gonorrhoeae</em> (usually done together)</td> <td>Swab or chlamydia transport medium</td> <td>&nbsp;</td> <td>4&ordm;C</td> <td>Choice of swab depends upon test method (culture, EIA, DFA, molecular amplification). For culture specimens, avoid cotton swab on wooden stick.</td> </tr> <tr> <td class=\"indent1\"><em>Neisseria gonorrhoeae</em> culture</td> <td>Inoculate selective medium or transport kit immediately</td> <td>&nbsp;</td> <td>25&ordm;C</td> <td>For culture specimens, use CO<sub>2</sub> transport kits or devices and do not refrigerate. For molecular detection, use rayon or Dacron-tipped swab. </td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> <td>Swab in viral transport media</td> <td>&nbsp;</td> <td>4&ordm;C</td> <td>Choice of swab depends upon test method (culture, DFA, molecular amplification). For culture specimens, avoid cotton swab on wooden stick and calcium alginate swab.</td> </tr> <tr> <td class=\"indent1\">Vaginal</td> <td>Swab</td> <td>&nbsp;</td> <td>4&ordm;C</td> <td>For <em>Trichomonas</em>, <em>Candida</em>, etc.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Genitourinary</td> </tr> <tr> <td class=\"indent1\">Prostate</td> <td>Prostatic massage specimens in sterile container </td> <td>1 to 5 mL</td> <td>4&ordm;C</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">EIA: enzyme immunoassay; DFA: direct fluorescent antibody.</div><div class=\"graphic_footnotes\">* If immediate processing is not possible.</div><div id=\"graphicVersion\">Graphic 54592 Version 5.0</div></div></div>"},"54594":{"type":"graphic_picture","displayName":"Struvite crystals","title":"Urine sediment showing struvite (magnesium ammonium phosphate) crystals","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urine sediment showing struvite (magnesium ammonium phosphate) crystals</div><div class=\"cntnt\"><img style=\"width:378px; height:253px;\" src=\"images/NEPH/54594_Phosphate_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing multiple \"coffin lid\" magnesium ammonium phosphate crystals (struvite)&nbsp;that form only in an alkaline urine (pH usually above 7.0) caused by an upper urinary tract infection with a urease-producing bacteria.</div><div class=\"graphic_reference\">Courtesy of Harvard Medical School.</div><div id=\"graphicVersion\">Graphic 54594 Version 6.0</div></div></div>"},"54595":{"type":"graphic_figure","displayName":"Relationship between cerebral palsy and last BPP","title":"Inverse relationship between the last fetal biophysical profile (BPP) score and cerebral palsy (CP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inverse relationship between the last fetal biophysical profile (BPP) score and cerebral palsy (CP)</div><div class=\"cntnt\"><img style=\"width:448px; height:346px;\" src=\"images/OBGYN/54595_Cerebral_palsy_by_last_BPP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relationship between the fetal BPP score and CP is inverse, exponential, and highly significant (R<SUP>2 </SUP>= –0.096; p&lt;0.001). Infants were followed for five years after birth.</div><div class=\"graphic_reference\">Reproduced with permission from: Manning FA, Harman CR, Meticoglou S, et al. Fetal assessment by fetal biophysical profile score. IV: The incidence of cerebral palsy among tested and non-tested perinates. Am J Obstet Gynecol 1998; 178:696. Copyright &copy; 1998 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 54595 Version 4.0</div></div></div>"},"54596":{"type":"graphic_picture","displayName":"Lichen sclerosus and vulvar intraepithelial neoplasia","title":"Lichen sclerosus and vulvar intraepithelial neoplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus and vulvar intraepithelial neoplasia</div><div class=\"cntnt\"><img style=\"width:314px; height:383px;\" src=\"images/OBGYN/54596_VIN_3_LS.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 54596 Version 3.0</div></div></div>"},"54598":{"type":"graphic_figure","displayName":"Intertrochanteric hip fracture","title":"Intertrochanteric hip fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intertrochanteric hip fracture</div><div class=\"cntnt\"><img style=\"width:300px; height:498px;\" src=\"images/EM/54598_Intertroch_hip_fx_pict.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The intertrochanteric region contains a large amount of cancellous bone with a good blood supply. Therefore, intertrochanteric fractures typically heal well when properly repaired.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright © 2008 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 54598 Version 3.0</div></div></div>"},"54599":{"type":"graphic_figure","displayName":"Fracture probability age","title":"Ten-year fracture probabilities according to BMD T-score and age","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Ten-year fracture probabilities according to BMD T-score and age</div><div class=\"cntnt\"><img style=\"width:505px; height:354px;\" src=\"images/ENDO/54599_Fracture_probability_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relationship between BMD femoral neck T-score, age and hip fracture probability in women. The probability of hip fracture for any given T-score is higher with increasing age.</div><div class=\"graphic_footnotes\">BMD: bone mineral density; SD: standard deviation.</div><div class=\"graphic_reference\">Data from: Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12:989.</div><div id=\"graphicVersion\">Graphic 54599 Version 2.0</div></div></div>"},"54600":{"type":"graphic_waveform","displayName":"Doppler LA appendage flow during normal sinus rhythm","title":"Doppler interrogation of LA appendage flow during normal sinus rhythm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler interrogation of LA appendage flow during normal sinus rhythm</div><div class=\"cntnt\"><img style=\"width:288px; height:528px;\" src=\"images/CARD/54600_Leftatrialappendageflow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A diagram of left atrial appendage (LAA) flow in sinus rhythm is shown on panel A; panel B shows the pulsed-Doppler tracing of LAA flow. Phases of LAA flow include LAA contraction (1); LAA filing (2); systolic reflection waves (positive and negative) (3); early diastolic LAA outflow (4).</div><div class=\"graphic_reference\">Reprinted with permission from the American College of Cardiology (Journal of the American College of Cardiology, 1999, 34:1867-77.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 54600 Version 4.0</div></div></div>"},"54602":{"type":"graphic_figure","displayName":"Intracranial pressure volume and ICP","title":"The relationship between intracranial volume and pressure is nonlinear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The relationship between intracranial volume and pressure is nonlinear</div><div class=\"cntnt\"><img style=\"width:445px; height:282px;\" src=\"images/PULM/54602_Intracranial_pressure_volum.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An initial increase in volume results in a small increase in pressure because of intracranial compensation (blue line). Once intracranial compensation is exhausted, additional increases in intracranial volume result in a dramatic rise in intracranial pressure (red line).</div><div id=\"graphicVersion\">Graphic 54602 Version 2.0</div></div></div>"},"54604":{"type":"graphic_figure","displayName":"Muscular dystrophy inheritance pattern PI","title":"Muscular dystrophy inheritance pattern","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Muscular dystrophy inheritance pattern</div><div class=\"cntnt\"><img style=\"width:536px; height:506px;\" src=\"images/PI/54604_MD_inheritance_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Duchenne, Becker, and some forms of Emery-Dreifuss muscular dystrophy are carried by the female parent. These muscular dystrophies affect 50 percent of male infants of mothers who carry the genetic defect; this is called X-linked recessive&nbsp;inheritance. Females who inherit their mother's defective X chromosome generally have less severe disease than males.</div><div id=\"graphicVersion\">Graphic 54604 Version 5.0</div></div></div>"},"54605":{"type":"graphic_picture","displayName":"Cherry angiomas","title":"Cherry angiomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cherry angiomas</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/54605_Cherry_angiomas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple red and violaceous papules are present on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54605 Version 4.0</div></div></div>"},"54606":{"type":"graphic_picture","displayName":"Botfly extraction","title":"Botfly extraction from nodules","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Botfly extraction from nodules</div><div class=\"cntnt\"><img style=\"width:519px; height:262px;\" src=\"images/ID/54606_Botfly_extraction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;Extraction of <EM>Dermatobia hominis</EM> larva from a nodule on the scalp. The lesion was anesthetized with lidocaine intralesionally and then gently extracted in toto. <br />(B) An additional lesion from the same patient contained another larva.</div><div class=\"graphic_reference\">Courtesy of Peter Lio, MD.</div><div id=\"graphicVersion\">Graphic 54606 Version 4.0</div></div></div>"},"54607":{"type":"graphic_table","displayName":"Zoonoses from dogs B","title":"Zoonoses dogs, continued","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Zoonoses dogs, continued</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Transmission</td>\n<td class=\"subtitle1\">Organism</td>\n<td class=\"subtitle1\">Human symptoms</td>\n<td class=\"subtitle1\">Canine symptoms</td>\n<td class=\"subtitle1\">Geographic distribution</td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"8\">Insect bites</td>\n<td>B. burgdorferi</td>\n<td>Erythema migrans, Lyme disease (multisystem inflammatory disease)</td>\n<td>Sudden onset lameness, swollen joints</td>\n<td>Worldwide</td>\n</tr>\n<tr>\n\n<td>Rickettsia rickettsii</td>\n<td>Rocky Mountain spotted fever, Fever, headache, followed by rash</td>\n<td>Similar to human disease</td>\n<td>North America</td>\n</tr>\n<tr>\n\n<td>Ehrlichia chaffeensis and Anaplasma phagocytophilum</td>\n<td>Ehrlichiosis, Fever with variable symptoms (malaise, myalgias, headache)</td>\n<td>Similar to human disease</td>\n<td>Focal areas of United States</td>\n</tr>\n<tr>\n\n<td>Babesia microti or B. divergens</td>\n<td>Babesiosis, Asymptomatic to severe hemolytic anemia</td>\n<td>Similar to human disease</td>\n<td>Babesia microti (United States, primarily Northeast); Babesia divergens (Europe)</td>\n</tr>\n<tr>\n\n<td>Francisella tularensis</td>\n<td>Tularemia, Abrupt onset fever, chills, HA, single erythematous papuloulcerative lesion with eschar</td>\n<td>Fever, loss of appetite</td>\n<td>Majority in south central United States</td>\n</tr>\n<tr>\n\n<td>Yersinia pestis</td>\n<td>Plague, Abrupt onset fever, chills, HA Acute bubo</td>\n<td>Self-limited illness</td>\n<td>Worldwide except Australia; in United States, mostly Southwestern states</td>\n</tr>\n<tr>\n\n<td>Dirofilaria immitis</td>\n<td>Urticarial skin eruption; \"coin lesion\" in lung</td>\n<td>Heartworm Most asymptomatic Exercise intolerance Hemoptysis</td>\n<td>Worldwide; particularly common in the Mediterranean</td>\n</tr>\n<tr>\n\n<td>Leishmania</td>\n<td>Asymptomatic to cutaneous, mucocutaneous, or visceral disease</td>\n<td>Similar to human disease</td>\n<td>Focal areas of world</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54607 Version 1.0</div></div></div>"},"54610":{"type":"graphic_table","displayName":"Drugs reported to cause seizures or lower seizure threshold","title":"Drugs reported to cause seizures or lower seizure threshold","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs reported to&nbsp;cause seizures or lower seizure threshold</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"sublist1_start\">Psychotropic drugs</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Tricyclic, tetracyclic antidepressants</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Serotonin reuptake inhibitors</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Neuroleptic agents (phenothiazines, haloperiodol, clozapine)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Lithium</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Bupropion</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Methylxanthines (theophylline)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Narcotic analgesics (meperidine, propoxyphene)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1_start\">Antimicrobials</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Penicillins, cephalosporins in high dose</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Imipenem</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Isoniazid</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Antimalarials</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Cyclosporine</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"sublist1\">Nalidixic acid</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Chemotherapeutic agents (methotrexate, chlorambucil)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>General anesthetics (ketamine, enflurane)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Local anesthetics (lidocaine - in toxic doses, disopyramide, bupivicaine)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Stimulants (amphetamines, cocaine)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Antiarrhythmics (verapamil intoxication, mexiletine, procainamide, propranolol overdose)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Antihistamines (diphenydramine)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Baclofen</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Antiemetics (chlorpromazine)</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">10.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=40592&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Drugs_that_cause_seizures.htm</title></head></div><div class=\"graphic_reference\">1. Olson KR, Kearney TE, Dyer JE, et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1994; 12:392.<br />2. Shorvon SD, Tallis RC, Wallace HK. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry 2002; 72:114.<br />3. Messing RO, Closson, RG, Simon, RP. Drug-induced seizures: a 10-year experience. Neurology 1984; 34:1582.<br />4. Bey TA, Walter FJ. Seizures, in Ford: Clinical Toxicology, 1st ed., Copyright © 2001 W. B. Saunders Company.<br />5. Gilmore RL. Seizures associated with noneurologic medical conditions. In: The treatment of epilepsy: principles and practice, 3rd ed, Elaine Wyllie (Ed), Williams &amp; Wilkins, Baltimore 2001.</div><div id=\"graphicVersion\">Graphic 54610 Version 3.0</div></div></div>"},"54612":{"type":"graphic_figure","displayName":"Sleeve gastrectomy","title":"Sleeve gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Sleeve gastrectomy</div><div class=\"cntnt\"><img style=\"width:476px; height:430px;\" src=\"images/SURG/54612_Sleeve-gastrectomy-NEW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a sleeve gastrectomy, the majority of the greater curvature of the stomach is removed and a tubular stomach is created. The tubular stomach has a small capacity, is resistant to stretching due to the absence of the fundus, and has few ghrelin (a gut hormone involved in regulating food intake)-producing cells.</div><div id=\"graphicVersion\">Graphic 54612 Version 4.0</div></div></div>"},"54613":{"type":"graphic_table","displayName":"Mechs thyroid autoimm","title":"Mechanisms of thyroid autoimmunity with an emphasis on Hashimoto's thyroiditis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanisms of thyroid autoimmunity with an emphasis on Hashimoto's thyroiditis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Mediating mechanisms</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Molecular mimicry</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bystander activation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thyroid cell HLA antigen expression</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Precipitating causes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Genetic susceptibility</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Thyroid injury</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Infection</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Radiation</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Drugs</td>\n    </tr>\n    <tr>\n\n      <td>Stress</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sex steroids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pregnancy and fetal microchimerism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Iodine</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=15340&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Mechs_thyroid_autoimm.htm</title></head></div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div id=\"graphicVersion\">Graphic 54613 Version 2.0</div></div></div>"},"54615":{"type":"graphic_table","displayName":"Treatment internal radioactivity","title":"Treatment of selected internal radioactive contaminants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of selected internal radioactive contaminants</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Contaminant</td> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Principal action(s)</td> </tr> <tr> <td>Americium</td> <td rowspan=\"5\">Wound excision,&nbsp;Ca-DTPA or Zn-DTPA</td> <td rowspan=\"5\">Chelation</td> </tr> <tr> <td>Californium</td> </tr> <tr> <td>Plutonium</td> </tr> <tr> <td>Curium</td> </tr> <tr> <td>Cerium</td> </tr> <tr> <td>Cesium</td> <td rowspan=\"3\">Prussian Blue</td> <td rowspan=\"3\">Accelerates removal</td> </tr> <tr> <td>Rubidium</td> </tr> <tr> <td>Thallium</td> </tr> <tr> <td>Iodine</td> <td>Potassium iodide</td> <td>Blocks thyroid uptake</td> </tr> <tr> <td>Strontium</td> <td>Aluminum antacids, ammonium chloride, calcium, barium sulfate, phosphate</td> <td>Blocks GI absorption, promotes urinary excretion and mobilization from bone&nbsp;</td> </tr> <tr> <td>Tritium</td> <td>Fluids, diuretics</td> <td>Dilutes the isotope and promotes diuresis</td> </tr> <tr> <td>Uranium</td> <td>Sodium bicarbonate</td> <td>Decreases uranyl nephrotoxicity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DTPA: diethylenetriamine pentaacetate. </div><div class=\"graphic_reference\">Revised from: Gusev I, Guskova AK, Mettler FA (Eds). Medical Management of Radiation Accidents, 2nd ed, CRC Press, Boca Raton, FL 2001.</div><div id=\"graphicVersion\">Graphic 54615 Version 2.0</div></div></div>"},"54616":{"type":"graphic_figure","displayName":"SMLC plan prostate IMRT","title":"Intensity modulated radiation therapy of prostate cancer","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Intensity modulated radiation therapy of prostate cancer</div><div class=\"cntnt\"><img style=\"width:521px; height:144px;\" src=\"images/ONC/54616_SMLC_plan_prostate_IMRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental multileaf collimator (SMLC) shapes of three segments (A, B, C) of the right anterior oblique field from a beam's-eye-view, generated for the forward SMLC plan. The forward SMLC plan was generated using the UM-Plan software developed at the University of Michigan. The two dominant intraprostatic lesions (DILs) are depicted in lilac (white arrows), and the prostate depicted in magenta.</div><div class=\"graphic_reference\">Reproduced with permission from: Xia P, Pickett B, Vigneault E, et al. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001; 51:244. Copyright © 2001 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 54616 Version 6.0</div></div></div>"},"54617":{"type":"graphic_picture","displayName":"Rickets bow-legs","title":"Bowing of the legs in a child with rickets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bowing of the legs in a child with rickets</div><div class=\"cntnt\"><img style=\"width:290px; height:544px;\" src=\"images/PEDS/54617_Rickets_bow-legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nutritional rickets (vitamin D deficiency) in a three-year-old boy. Note the severe bowing of the lower extremities and the wider wrists and ankles.</div><div class=\"graphic_reference\">Reproduced with permission from: Becker KL, Bilezikian JP, Brenner WJ, et al. Principles and Practice of Endocrinology and Metabolism, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54617 Version 2.0</div></div></div>"},"54619":{"type":"graphic_figure","displayName":"Gail model accuracy","title":"Gail model accuracy","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Gail model accuracy</div><div class=\"cntnt\"><img style=\"width:516px; height:279px;\" src=\"images/PC/54619_Gail_model_accuracy_Edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ability of the Gail breast cancer risk prediction model to discriminate among women who did and did not develop breast cancer in the Nurses' Health Study. Concordance statistics = 0.58 (95% CI 0.56-0.60).</div><div class=\"graphic_reference\">Reproduced with permission from: Elmore JG, Fletcher SW. The risk of cancer risk prediction: \"What is my risk of getting breast cancer?\" J Nat Cancer Inst 2006; 98:1673. Copyright © 2006 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 54619 Version 8.0</div></div></div>"},"54622":{"type":"graphic_table","displayName":"Early symptomatic HIV","title":"Examples of non-AIDS-defining conditions in early symptomatic HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of non-AIDS-defining conditions in early symptomatic HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Thrush</td> </tr> <tr> <td>Vaginal candidiasis that is persistent, frequent, or difficult to manage</td> </tr> <tr> <td>Oral hairy leukoplakia</td> </tr> <tr> <td>Herpes zoster involving two episodes or more than one dermatome</td> </tr> <tr> <td>Peripheral neuropathy</td> </tr> <tr> <td>Bacillary angiomatosis</td> </tr> <tr> <td>Cervical dysplasia</td> </tr> <tr> <td>Cervical carcinoma in situ</td> </tr> <tr> <td>Constitutional symptoms such as fever (38.5&#176;C) or diarrhea for more than one month</td> </tr> <tr> <td>Idiopathic thrombocytopenic purpura</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These conditions can be seen with greater frequency and severity in the setting of HIV infection, even in the absence of severe immunosuppression (ie, CD4 cell count &lt;200 cells/microL).</div><div class=\"graphic_footnotes\">AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 54622 Version 5.0</div></div></div>"},"54623":{"type":"graphic_picture","displayName":"WNV fever and rash","title":"West Nile virus fever and rash","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">West Nile virus fever and rash</div><div class=\"cntnt\"><img style=\"width:504px; height:407px;\" src=\"images/ID/54623_WNV_fever_and_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four patients with West Nile virus fever and erythematous, maculopapular rashes on the back (top left), flank (top right), posterior thigh (bottom left), and back (bottom right).</div><div class=\"graphic_reference\">Reproduced with permission from: Ferguson DD, Gershman K, LeBailly A, Petersen LR. Characteristics of the rash associated with West Nile Virus fever. Clin Infect Dis 2005; 41:1204. Copyright &#169; 2005 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 54623 Version 2.0</div></div></div>"},"54626":{"type":"graphic_table","displayName":"Staging classification AIDS KS","title":"Staging classification for AIDS-related KS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Staging classification for AIDS-related KS</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Good risk (all of the following)</td> <td class=\"subtitle1\">Poor risk (any of the following)</td> </tr> <tr> <td><strong>Tumor, T</strong></td> <td>T0: Confined to skin and/or lymph nodes and/or minimal oral disease (non-nodular KS confined to palate)</td> <td> <p>T1:Tumor-associated edema or ulceration</p> <p>Extensive oral KS</p> <p>Gastrointestinal KS</p> KS in other non-nodal viscera</td> </tr> <tr> <td><strong>Immune system, I</strong></td> <td>I0: CD4 cell count &#62;200/&#181;L*</td> <td>I1: CD4 cell count &#60;200/&#181;L</td> </tr> <tr> <td><strong>Systemic illness, S</strong></td> <td> <p>S0: No history of OI or thrush<sup>&#182;</sup></p> <p>No \"B\" symptoms<sup>&#916;</sup></p> Karnofsky performance status &#62;70</td> <td> <p>S1: History of OI and/or thrush</p> <p>\"B\" symptoms present</p> <p>Karnofsky performance status &#60;70</p> Other HIV-related illness (eg, neurologic disease, lymphoma)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A CD4 lymphocyte cut-off of 150 &micro;L may be more discriminatory. (Krown, SE, Testa, MA, Huang, J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15:3085.).<br />&para; OI is opportunistic infection.<br />&Delta; \"B\" symptoms are unexplained fever, night sweats, &lt;10 percent involuntary weight loss, or diarrhea persisting more than two weeks.</div><div class=\"graphic_reference\">Adapted from: Krown, SE, Metroka, C, Wernz, JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989; 7:1201.</div><div id=\"graphicVersion\">Graphic 54626 Version 2.0</div></div></div>"},"54627":{"type":"graphic_picture","displayName":"Retained tube","title":"Retained tympanostomy tube with squamous debris creeping into the middle ear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retained tympanostomy tube with squamous debris creeping into the middle ear</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/54627_Retained_tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A retained tympanostomy tube with squamous debris creeping into the middle ear.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 54627 Version 1.0</div></div></div>"},"54628":{"type":"graphic_figure","displayName":"TUG flap breast reconstruction","title":"TUG flap breast reconstruction","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">TUG flap breast reconstruction</div><div class=\"cntnt\"><img style=\"width:478px; height:600px;\" src=\"images/SURG/54628_TUGflapbreastreconst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transverse upper gracilis (TUG) flap is based on the proximal gracilis muscle and its vascular pedicle, the ascending branch of the medial circumflex femoral artery. This flap utilizes tissue from the posterior upper thigh/lower buttock and provides another choice for women with insufficient lower abdominal fat for breast reconstruction.</div><div id=\"graphicVersion\">Graphic 54628 Version 2.0</div></div></div>"},"54629":{"type":"graphic_table","displayName":"Chest pain differentiation","title":"Differentiation of life-threatening causes of chest pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiation of life-threatening causes of chest pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Historical features</td> <td class=\"subtitle1\">Examination findings</td> <td class=\"subtitle1\">Electrocardiogram</td> <td class=\"subtitle1\">Chest radiograph</td> <td class=\"subtitle1\">Additional tests</td> <td class=\"subtitle1\">Additional important information</td> </tr> <tr> <td><strong>Acute coronary syndrome</strong></td> <td> <p>&#8226; Substernal/left-sided chest pressure or tightness is common</p> <p>&#8226; Onset is gradual</p> <p>&#8226; Pain radiating to shoulders or pain with exertion increases relative risk</p> <p>&#8226; \"Atypical\" symptoms (eg, dyspnea, weakness) more common in older adults, women, diabetics</p> <p>&#8226; Older adults can present with dyspnea, weakness, syncope, or &#916;MS alone</p> </td> <td> <p>&#8226; Nonspecific</p> <p>&#8226; May detect signs of HF</p> </td> <td> <p>&#8226; ST segment elevations, Q waves, new left bundle branch block are evidence of AMI</p> <p>&#8226; Single ECG is not sensitive for ACS</p> <p>&#8226; Prominent R waves with ST segment depressions in V<sub>1</sub> and V<sub>2</sub> strongly suggests posterior AMI</p> </td> <td> <p>&#8226; Nonspecific</p> <p>&#8226; May show evidence of HF</p> </td> <td> <p>&#8226; Troponin and/or CK-MB elevations diagnose AMI</p> <p>&#8226; Single set of biomarkers is not sufficiently sensitive to rule out AMI</p> </td> <td> <p>&#8226; Assume symptoms of ACS within days or a few weeks of PCI or CABG is from an occluded artery or graft</p> </td> </tr> <tr> <td><strong>Aortic dissection</strong></td> <td> <p>&#8226; Sudden onset of sharp, tearing, or ripping pain</p> <p>&#8226; Maximal severity at onset</p> <p>&#8226; Most often begins in chest, can begin in back</p> <p>&#8226; Can mimic stroke, ACS, mesenteric ischemia, kidney stone</p> </td> <td> <p>&#8226; Absent upper extremity or carotid pulse is suggestive</p> <p>&#8226; Discrepancy in systolic BP &#62;20 mmHg between right and left upper extremity is suggestive</p> <p>&#8226; Up to 30 percent with neurologic findings</p> <p>&#8226; Findings vary with arteries affected</p> </td> <td> <p>&#8226; Ischemic changes in 15 percent</p> <p>&#8226; Nonspecific ST and T changes in 30 percent</p> </td> <td> <p>&#8226; Wide mediastinum or loss of normal aortic knob contour is common (up to 76 percent)</p> <p>&#8226; 10 percent have normal CXR</p> </td> <td>&nbsp;</td> <td>&#8226; Can mimic many diseases depending on branch arteries involved (eg, AMI, stroke)</td> </tr> <tr> <td><strong>Pulmonary embolism</strong></td> <td> <p>&#8226; Many possible presentations, including pleuritic pain and painless dyspnea</p> <p>&#8226; Often sudden onset</p> <p>&#8226; Dyspnea often dominant feature</p> </td> <td> <p>&#8226; No finding is sensitive or specific</p> <p>&#8226; Extremity exam generally normal</p> <p>&#8226; Lung exam generally nonspecific; focal wheezing may be present; tachypnea is common</p> </td> <td> <p>&#8226; Usually abnormal but nonspecific</p> <p>&#8226; Signs of right heart strain suggestive (eg, RAD, RBBB, RAE)</p> </td> <td> <p>&#8226; Great majority are normal</p> <p>&#8226; May show atelectasis, elevated hemidiaphragm, pleural effusion</p> </td> <td>&#8226; A high-sensitivity D-dimer is useful to rule out PE only when negative in low-risk patients</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Tension pneumothorax</strong></td> <td> <p>&#8226; Often sudden onset</p> <p>&#8226; Initial pain often sharp and pleuritic</p> <p>&#8226; Dyspnea often dominant feature</p> </td> <td> <p>&#8226; Ipsilateral diminished or absent breath sounds</p> <p>&#8226; Subcutaneous emphysema is uncommon</p> </td> <td>&nbsp;</td> <td>&#8226; Demonstrates air in pleural space</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Pericardial tamponade</strong></td> <td> <p>&#8226; Pain from pericarditis is most often sharp anterior chest pain made worse by inspiration or lying supine and relieved by sitting forward</p> <p>&#8226; Dyspnea is common</p> </td> <td> <p>&#8226; Severe tamponade creates obstructive shock and causes jugular venous distension, pulsus paradoxus</p> <p>&#8226; Pericardial effusion can cause friction rub</p> </td> <td> <p>&#8226; Decreased voltage and electrical alternans can appear with significant effusions</p> <p>&#8226; Diffuse PR segment depressions and/or ST segment elevations can appear with acute pericarditis</p> </td> <td>&#8226; May reveal enlarged heart</td> <td>&#8226; Ultrasound reveals pericardial effusion with tamponade</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Mediastinitis (esophageal rupture)</strong></td> <td> <p>&#8226; Forceful vomiting often precedes esophageal rupture</p> <p>&#8226; Recent upper endoscopy or instrumentation increases risk of perforation</p> <p>&#8226; Odontogenic infection is possible cause</p> <p>&#8226; Coexistent respiratory and gastrointestinal complaints may occur</p> </td> <td> <p>&#8226; Ill-appearing; shock; fever</p> <p>&#8226; May hear (Hamman's) crunch over mediastinum</p> </td> <td>&nbsp;</td> <td>&#8226; Large majority have some abnormality: pneumomediastinum, pleural effusion, pneumothorax</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ΔMS: altered mental status; ACS: acute coronary syndrome; AMI: acute myocardial infarction; BP: blood pressure; CABG: coronary artery bypass graft; CK-MB: creatine kinase-MB; CXR: chest radiograph; ECG: electrocardiogram; HF: heart failure; PCI: percutaneous coronary intervention; PE: pulmonary embolism; RAD: right axis deviation; RAE: right atrial enlargement; RBBB: right bundle branch block.</div><div id=\"graphicVersion\">Graphic 54629 Version 3.0</div></div></div>"},"54630":{"type":"graphic_picture","displayName":"Lymphoma bone histology","title":"Primary lymphoma of bone","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Primary lymphoma of bone</div><div class=\"cntnt\"><img style=\"width:470px; height:355px;\" src=\"images/HEME/54630_Lymphoma_bone_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Specimen of bone from the right superior ilium of a 21-year-old female. An infiltrate of large lymphoid cells with prominent nucleoli is seen on histologic evaluation of this primary bone lesion.</div><div class=\"graphic_reference\">Courtesy of Heather Pacholke, MD.</div><div id=\"graphicVersion\">Graphic 54630 Version 1.0</div></div></div>"},"54631":{"type":"graphic_picture","displayName":"Skin in acute GVHD light","title":"Acute graft-versus-host disease skin biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute graft-versus-host disease skin biopsy</div><div class=\"cntnt\"><img style=\"width:377px; height:252px;\" src=\"images/HEME/54631_Skin_in_acute_GVHD_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy from a patient with cutaneous manifestations of acute graft-versus-host disease reveals an interface dermatitis.</div><div id=\"graphicVersion\">Graphic 54631 Version 3.0</div></div></div>"},"54634":{"type":"graphic_table","displayName":"Features giant cell arteritis","title":"Giant cell arteritis: clinical findings in 100 patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Giant cell arteritis: clinical findings in 100 patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Finding </td>\n<td class=\"subtitle1_single\">Number</td>\n</tr>\n<tr>\n<td>Sex (female/male) </td>\n<td> 69/31</td>\n</tr>\n<tr>\n<td>Duration of manifestations before diagnosis </td>\n<td>7*</td>\n</tr>\n<tr>\n<td>Onset (gradual/sudden) </td>\n<td>64/36</td>\n</tr>\n<tr>\n<td>Weight loss or anorexia </td>\n<td>50</td>\n</tr>\n<tr>\n<td>Malaise, fatigue, or weakness</td>\n<td>40</td>\n</tr>\n<tr>\n<td>Fever</td>\n<td>42</td>\n</tr>\n<tr>\n<td>Polymyalgia rheumatica </td>\n<td>39</td>\n</tr>\n<tr>\n<td>Other musculoskeletal pains </td>\n<td>30</td>\n</tr>\n<tr>\n<td>Synovitis </td>\n<td>15</td>\n</tr>\n<tr>\n<td>Sore throat</td>\n<td>9</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Symptoms related to arteries </td>\n<td class=\"sublist_other_start\">83</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Headache</td>\n<td class=\"sublist_other\">68</td>\n</tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\" class=\"sublist2\">Visual symptoms &nbsp;</td>\n\n</tr>\n<tr>\n<td class=\"sublist3\">Transient</td>\n<td class=\"sublist_other\">16</td>\n</tr>\n<tr>\n<td class=\"sublist3\">Fixed</td>\n<td class=\"sublist_other\">14</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Jaw claudication </td>\n<td class=\"sublist_other\">45</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Swallowing claudication or dysphagia </td>\n<td class=\"sublist_other\">8</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Tongue claudication </td>\n<td class=\"sublist_other\">6</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Limb claudication </td>\n<td class=\"sublist_other\">4</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Signs related to arteries </td>\n<td class=\"sublist_other_start\">66</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Artery tenderness </td>\n<td class=\"sublist_other\">27</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Decreased temporal artery pulsations</td>\n<td class=\"sublist_other\">46</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Erythematous, nodular, or swollen scalp arteries</td>\n<td class=\"sublist_other\">23</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Large artery bruits </td>\n<td class=\"sublist_other\">21</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Decreased large artery pulses </td>\n<td class=\"sublist_other\">7</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Visual loss </td>\n<td class=\"sublist_other\">14</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Ophthalmoscopic abnormalities </td>\n<td class=\"sublist_other\">18</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Extraocular muscle weakness </td>\n<td class=\"sublist_other\">2</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Raynaud's phenomenon </td>\n<td class=\"sublist_other\">3</td>\n</tr>\n<tr>\n<td>Central nervous system abnormalities </td>\n<td>15</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Range 1 to 48 months before diagnosis</div><div class=\"graphic_reference\">Adapted from: Calamia, KT, Hunder, GG. Clin Rheum Dis 1980; 6:389.</div><div id=\"graphicVersion\">Graphic 54634 Version 1.0</div></div></div>"},"54636":{"type":"graphic_diagnosticimage","displayName":"Fluoroscopic view of double balloon enteroscopy","title":"Fluoroscopic view of double balloon enteroscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fluoroscopic view of double balloon enteroscopy</div><div class=\"cntnt\"><img style=\"width:430px; height:562px;\" src=\"images/GAST/54636_Fluoroscopic_double_balloon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic image showing the concentric circles that are formed during double balloon enteroscopy as loops are reduced.</div><div class=\"graphic_reference\">Courtesy of Hiroto Kita, MD, PhD.</div><div id=\"graphicVersion\">Graphic 54636 Version 2.0</div></div></div>"},"54637":{"type":"graphic_figure","displayName":"Emergency pericardiocentesis parasternal approach","title":"Emergency pericardiocentesis parasternal approach","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Emergency pericardiocentesis parasternal approach</div><div class=\"cntnt\"><img style=\"width:521px; height:499px;\" src=\"images/EM/54637__Emergency-pericardiocentesis-parasternal-approach.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54637 Version 6.0</div></div></div>"},"54638":{"type":"graphic_table","displayName":"15year prost CA surv rising PSA","title":"10 and 15-year likelihood of prostate cancer-specific survival after biochemical (PSA) recurrence following radical prostatectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">10 and 15-year likelihood of prostate cancer-specific survival after biochemical (PSA) recurrence following radical prostatectomy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">PSADT, months</td>\n\n      <td rowspan=\"1\" colspan=\"4\" class=\"subtitle1\">Risk\nestimate, percent (95 percent confidence interval)</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2\">Recurrence\n&#62;3 years after surgery</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2\">Recurrence\n      &#8804;3 years after\nsurgery</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle3\">Gleason score &#60;8</td>\n\n      <td class=\"subtitle3\">Gleason score &#8805;8</td>\n\n      <td class=\"subtitle3\">Gleason score &#60;8</td>\n\n      <td class=\"subtitle3\">Gleason score &#8805;8</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">10-year\nestimate</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">&#8805;15.0\n      </td>\n\n      <td>98 (96-100)</td>\n\n      <td>96 (93-98)</td>\n\n      <td>93 (80-98)</td>\n\n      <td>86 (61-96)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">9.0-14.9</td>\n\n      <td>95 (75-99)</td>\n\n      <td>90 (58-98)</td>\n\n      <td>85 (49-97) </td>\n\n      <td>69 (30-92)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">3.0-8.9</td>\n\n      <td>84 (62-94)</td>\n\n      <td>68 (37-89)</td>\n\n      <td>55 (25-82) </td>\n\n      <td>26 (7-62) </td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">&#60;3.0</td>\n\n      <td>59 (29-83)</td>\n\n      <td>30 (10-63)</td>\n\n      <td>15 (3-53)</td>\n\n      <td>1 (&#60;1-55)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">15-year\nestimate</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">&#8805;15.0</td>\n\n      <td>94 (87-100)</td>\n\n      <td>87 (79-92)</td>\n\n      <td>81 (57-93)</td>\n\n      <td>62 (32-85)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">9.0-14.9</td>\n\n      <td>86 (57-97)</td>\n\n      <td>72 (35-92)</td>\n\n      <td>59 (24-87) </td>\n\n      <td>31 (7-72)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">3.0-8.9</td>\n\n      <td>59 (32-81)</td>\n\n      <td>30 (10-63) </td>\n\n      <td>16 (4-49)</td>\n\n      <td>1 (&#60;1-2)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">&#60;3.0</td>\n\n      <td>19 (5-51)</td>\n\n      <td>2 (&#60;1-38)</td>\n\n      <td>&#60;1 (&#60;1-26)</td>\n\n      <td>&#60;1 (&#60;1-2)</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">PSADT: prostate specific antigen doubling time.</div><div class=\"graphic_reference\">Data from Freedland, SJ, et al. JAMA 2005; 294:437.</div><div id=\"graphicVersion\">Graphic 54638 Version 1.0</div></div></div>"},"54640":{"type":"graphic_table","displayName":"Physiologic Rx Malnutrition B","title":"Physiologic basis for treatment of severe malnutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic basis for treatment of severe malnutrition</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Affected organ or system</td>\n\n      <td class=\"subtitle1\">Effects </td>\n\n      <td class=\"subtitle1\">Treatment</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Immune system</td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>All aspects of immunity are diminished</p><p>Lymph glands, tonsils and the thymus are atrophied</p><p>Cell-mediated (T-cell) immunity is severely depressed</p><p>IgA levels in secretions are reduced</p><p>Complement components are low</p><p>Phagocytes do not kill ingested bacteria efficiently</p><p>Tissue damage does not result in inflammation or migration of white cells to the affected area</p><p>Acute phase immune response is diminished</p><p>Typical signs of infection, such as an increased white cell count and fever, are frequently absent</p><p>Hypoglycaemia and hypothermia are both signs of severe infection and are usually associated with septic shock</p></td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>Treat all children with broad-spectrum antimicrobials</p><p>Because of the risk of transmission of infection, ensure that newly\nadmitted children are kept apart from children who are recovering from\ninfection</p></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    <tr>\n\n      <td>Endocrine system</td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>Insulin levels are reduced and the child has impaired glucose tolerance</p><p>Insulin growth factor 1 (IGF-1) levels are reduced, although growth hormone levels are increased</p><p>Cortisol levels are usually increased</p></td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>Give the child small, frequent feeds</p><p>Do not give steroids</p></td>\n\n    </tr>\n\n    \n\n\n    \n\n    <tr>\n\n      <td rowspan=\"2\">Circulatory system</td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>Basic metabolic rate is reduced by about 30 percent</p><p>Energy expenditure due to activity is very low</p></td>\n <td>Keep the child warm to prevent\nhypothermia; dry the child quickly and properly after washing and cover\nwith clothes and blankets, ensure that windows are kept closed at night\nand keep the temperature of the living environment at 25-30 &ordm;C</td></tr>\n\t\n<tr><td>\tBoth\nheat generation and heat loss are impaired; the child becomes\nhypothermic in a cold environment and hyperthermic in a hot environment\n</td>\n\n     <td>If a child has fever, cool the child by sponging with tepid (not cold) water (never alcohol rubs)</td>\n\n    </tr>\n\n    \n\n    \n\n\n\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &#169; 1999 World Health Organization.</div><div id=\"graphicVersion\">Graphic 54640 Version 1.0</div></div></div>"},"54641":{"type":"graphic_table","displayName":"Findings in children for evaluation of cancer","title":"Symptoms and signs in children suggestive of cancer that require immediate evaluation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs in children suggestive of cancer that require immediate evaluation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptoms/signs</td> <td class=\"subtitle1\">Laboratory, imaging studies, and consultations</td> <td class=\"subtitle1\">Major associated tumors</td> </tr> <tr> <td>Hypertension</td> <td>Labs-CXR, abdominal sonogram</td> <td>Renal or adrenal tumor, neuroblastoma</td> </tr> <tr> <td>Weight loss, sudden onset</td> <td>Labs-abdominal sonogram</td> <td>Any malignancy</td> </tr> <tr> <td>Petechiae</td> <td>CBC, plt, diff</td> <td>Leukemia, neuroblastoma</td> </tr> <tr> <td>Adenopathy unresponsive to antibiotics</td> <td>Surgical consultation, CXR, CBC, diff</td> <td>Leukemia, lymphoma</td> </tr> <tr> <td class=\"sublist1_start\">Endocrine abnormalities</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Growth failure</td> <td class=\"sublist_other\">Hormonal assays</td> <td class=\"sublist_other\">Pituitary tumors</td> </tr> <tr> <td class=\"sublist1\">Electrolyte disturbance</td> <td class=\"sublist_other\">CT hypothalamic area</td> <td class=\"sublist_other\">Hypothalamic tumors</td> </tr> <tr> <td class=\"sublist1\">Sexual abnormalities</td> <td class=\"sublist_other\">Abdominal CT</td> <td class=\"sublist_other\">Gonadal tumors</td> </tr> <tr> <td class=\"sublist1\">Cushing's syndrome</td> <td class=\"sublist_other\">Endocrine consultation</td> <td class=\"sublist_other\">Adrenal tumors</td> </tr> <tr> <td class=\"sublist1_start\">Brain</td> <td class=\"sublist_other_start\">Neurology or neurosurgery consultation followed by imaging studies</td> <td class=\"sublist_other_start\">Brain tumor</td> </tr> <tr> <td class=\"sublist1\">Headache, vomiting early am</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Cranial nerve palsy, ataxia</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Dilated pupil, papilledema</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Afebrile seizures</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hallucinations, aphasia</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Unilateral weakness, paralysis</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Eyes</td> <td class=\"sublist_other_start\">Ophthalmologist consultation</td> <td class=\"sublist_other_start\">Retinoblastoma, metastatic rhabdomyosarcoma, neuroblastoma</td> </tr> <tr> <td class=\"sublist1\">White spot, proptosis, blindness</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Wandering eye</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Intraorbital hemorrhage</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Ears</td> <td class=\"sublist_other_start\">CBC, diff, and imaging studies</td> <td class=\"sublist_other_start\">LCH, rhabdomyosarcoma</td> </tr> <tr> <td class=\"sublist1\">Bulging mass external canal</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Mastoid tenderness, swelling</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Puffy face and neck</td> <td class=\"sublist_other\">CBC, diff, and imaging studies</td> <td class=\"sublist_other\">Mediastinal tumors</td> </tr> <tr> <td class=\"sublist1\">Pharyngeal mass</td> <td class=\"sublist_other\">CBC, diff, and imaging studies</td> <td class=\"sublist_other\">Rhabdomyosarcoma, lymphoma, nasopharyngeal carcinoma</td> </tr> <tr> <td class=\"sublist1\">Periodontal mass, loose teeth</td> <td class=\"sublist_other\">Dental consultation, imaging studies</td> <td class=\"sublist_other\">LCH, Burkitt's lymphoma, neuroblastoma, osteosarcoma</td> </tr> <tr> <td class=\"sublist1_start\">Thorax</td> <td class=\"sublist_other_start\">CBC, diff, imaging studies</td> <td class=\"sublist_other_start\">Soft tissue sarcomas, mediastinal tumors, metastatic tumors</td> </tr> <tr> <td class=\"sublist1\">Mass</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Intrathoracic: coughing, SOB without fever or no history of asthma, allergies</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Abdomen/pelvis</td> <td class=\"sublist_other_start\">CBC, diff</td> <td class=\"sublist_other_start\">Wilms' tumor, soft tissue sarcoma, neuroblastoma, hepatoblastoma, hepatocarcinoma</td> </tr> <tr> <td class=\"sublist1\">Intraabdominal mass</td> <td class=\"sublist_other\">Labs, imaging studies</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Genitourinary</td> <td class=\"sublist_other_start\">UA, CBC, diff, sonogram of pelvis/abdomen</td> <td class=\"sublist_other_start\">Germ cell tumor, rhabdomyosarcoma, adrenal tumor</td> </tr> <tr> <td class=\"sublist1\">Testicular or vaginal mass</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Masculinization/feminization</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Musculoskeletal</td> <td class=\"sublist_other_start\">CBC, diff, imaging studies</td> <td class=\"sublist_other_start\">Osteosarcoma, Ewing's sarcoma, leukemia, neuroblastoma, soft tissue sarcoma</td> </tr> <tr> <td class=\"sublist1\">Soft tissue mass</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Musculoskeletal pain</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Signs and symptoms in children that require immediate evaluation that may include laboratory testing, imaging and/or consultation with pediatric subspecialists.</div><div class=\"graphic_footnotes\">CBC: complete blood cell count; CT: computerized tomography; CXR: chest x-ray; diff: differential; labs: laboratory studies, usually hepatic and renal function and electrolytes; LCH: Langerhans' cell histiocytosis; plt: platelet count; SOB: shortness of breath; UA: urinalysis.</div><div class=\"graphic_reference\">Reproduced with permission from: Kilburn LB, Siegel SE, Steuber CP. Clinical Assessment and Differential Diagnosis of the Child with Suspected Cancer. In: Principles and Practice of Pediatric Oncology, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 54641 Version 12.0</div></div></div>"},"54642":{"type":"graphic_table","displayName":"Commercially available stents","title":"Commercially-available airway stents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commercially-available airway stents</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Brand </td>\n\n      <td class=\"subtitle1\">Material </td>\n\n      <td class=\"subtitle1\">Shapes </td>\n\n      <td class=\"subtitle1\">Specific problems/complications</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dumon </td>\n\n      <td>Silicone </td>\n\n      <td>Straight, Y, J </td>\n\n      <td>Migration in benign disease (straight)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Orlowski </td>\n\n      <td>Silicone, armored with metal rings </td>\n\n      <td>Straight </td>\n\n      <td>Very stiff</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hood </td>\n\n      <td>Silicone </td>\n\n      <td>Straight, Y </td>\n\n      <td>Difficult to insert (Y)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Gianturco </td>\n\n      <td>Stainless steel, self-expandable </td>\n\n      <td>Straight </td>\n\n      <td>Stent fracture, airway perforation, fatal hemoptysis,\nocclusion by tissue growth</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Strecker </td>\n\n      <td>Tantalum, balloon-expandable </td>\n\n      <td>Straight </td>\n\n      <td>Stent collapse, occlusion by tissue growth</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Palmaz </td>\n\n      <td>Stainless steel, balloon-expandable </td>\n\n      <td>Straight </td>\n\n      <td>Stent collapse, occlusion by tissue growth</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wallstent </td>\n\n      <td>Cobalt-based alloy, uncovered, self-expandable</td>\n\n      <td>Straight </td>\n\n      <td>Granuloma, occlusion by tissue growth</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wallstent (Covered)</td>\n\n      <td>Cobalt-based alloy, polyurethane covering,\nself-expandable</td>\n\n      <td>Straight </td>\n\n      <td>Granuloma at stent ends, airway perforation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ultraflex </td>\n\n      <td>Nitinol, self-expandable covered and uncovered</td>\n\n      <td>Straight </td>\n\n      <td>Granuloma formation, stent fracture</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Polyflex </td>\n\n      <td>Polyester wire, silicone covering, self-expandable</td>\n\n      <td>Straight, Y, J </td>\n\n      <td>Migration (straight), difficult to insert (Y)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Screw-thread </td>\n\n      <td>Tygon </td>\n\n      <td>Straight </td>\n\n      <td>Only tracheal sizes, mucus retention</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dynamic </td>\n\n      <td>Silicone, metal hoops </td>\n\n      <td>Y </td>\n\n      <td>Difficult to insert</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Montgomery </td>\n\n      <td>Silicone </td>\n\n      <td>T-tube </td>\n\n      <td>Difficult to insert, tracheostomy necessary</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Manufacturer's details for all brands are as follows: Dumon: Endoxane&#174;, Novatech SA, Grasse, France; Orlowski: R&#252;sch AG, Kernen, Germany; Hood: Hood Laboratories, Pembroke, MA, USA; Gianturco: Cook, Bjaeverskov, Denmark; Strecker: Microvasive-Boston Scientific, Natick, MA, USA; Palmaz: Corning/Johnson and Johnson, Warren, NJ, USA; Wallstent and Covered Wallstent: Microvasive-Boston Scientific; Ultraflex: Microvasive-Boston Scientific; Polyflex: R&#252;sch AG; Screw-thread: Reynders Medical Supply, Lennik, Belgium; Dynamic: R&#252;sch AG; Montgomery: Boston Medical Products, Inc., Waltham, MA, USA.</div><div class=\"graphic_reference\">Reproduced with permission from: Bolliger, CT, Mathur, PN, Beamis, JF, et al. Eur Respir J 2002; 19:365. Copyright &#169; 2002 European Respiratory Society Journals Ltd.</div><div id=\"graphicVersion\">Graphic 54642 Version 1.0</div></div></div>"},"54643":{"type":"graphic_figure","displayName":"Muscle abnormalities in HF","title":"Skeletal muscle abnormalities in heart failure","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Skeletal muscle abnormalities in heart failure</div><div class=\"cntnt\"><img style=\"width:526px; height:305px;\" src=\"images/CARD/54643_MuscleabnormalitiesinHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skeletal muscle becomes fatigued with exercise due to a limited capacity for aerobic metabolism, causing a ventilatory response increase and breathlessness. These events result in ergoreflex activation, which in turn causes an activation of the sympathetic nervous system, an increase in vascular resistance and afterload, and a further reduction in cardiac function and blood flow to the periphery.</div><div class=\"graphic_reference\">Redrawn from: Clark AL, Poole-Wilson PA, Coats AJS, J Am Coll Cardiol 1996; 28:1092.</div><div id=\"graphicVersion\">Graphic 54643 Version 2.0</div></div></div>"},"54644":{"type":"graphic_picture","displayName":"Brugia malayi smear","title":"<em>Brugia malayi</em> smear","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\"><em>Brugia malayi</em> smear</div><div class=\"cntnt\"><img style=\"width:561px; height:309px;\" src=\"images/ID/54644_Brugia_malayi_smear_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Microfilaria of <em>B. malayi</em> in a thick blood smear, stained with Giemsa. The organism has a sheath (top yellow arrow) and two nuclei in its tail (bottom red arrows); body nuclei are dense.<br />(B) Microfilaria of <em>B. malayi</em> in a thin blood smear, stained with Giemsa.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Lymphatic filariasis. Available at: <a href=\"http://www.cdc.gov/dpdx/lymphaticFilariasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/lymphaticFilariasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 54644 Version 5.0</div></div></div>"},"54645":{"type":"graphic_algorithm","displayName":"Approach to the adult with weakness in the emergency department","title":"Approach to the adult with weakness in the emergency department","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Approach to the adult with weakness in the emergency department</div><div class=\"cntnt\"><img style=\"width:614px; height:792px;\" src=\"images/EM/54645_Acute_neuromusc_weak_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACS: acute coronary syndrome; CN: cranial nerve; GBS: Guillan-Barré syndrome; ICH: intracerebral hemorrhage; LE: lower extremities; LMN: lower motor neuron; MG: myasthenia gravis; NMJ: neuromuscular junction; UE: upper extremities; UMN: upper motor neuron.</div><div class=\"graphic_reference\">Data from: Asimos AW. Weakness: A systematic approach to acute, non-traumatic, neurologic and neuromuscular causes. Emerg Med Pract 2002; 4:1.</div><div id=\"graphicVersion\">Graphic 54645 Version 2.0</div></div></div>"},"54646":{"type":"graphic_table","displayName":"Equipment for central venous cannulation","title":"Equipment for central venous cannulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Equipment for central venous cannulation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>2 percent chlorhexidine skin preparation solution</td> </tr> <tr> <td>Sterile gown, gloves, face shield and cap</td> </tr> <tr> <td>Sterile gauze pads: 4\" x 4\"</td> </tr> <tr> <td>Sterile drapes</td> </tr> <tr> <td>1 percent lidocaine; 5cc</td> </tr> <tr> <td>25 Ga. needle with 3cc lock-tip syringe</td> </tr> <tr> <td>Seeker needle: 3.5 cm 22 Ga. needle with 5cc slip-tip syringe</td> </tr> <tr> <td>Introducer needle: 6 cm 18 Ga. large bore needle with 5cc slip-tip syringe</td> </tr> <tr> <td>J-tip guidewire</td> </tr> <tr> <td>Transduction catheter: 6 cm 18 Ga. catheter</td> </tr> <tr> <td>Transduction tubing</td> </tr> <tr> <td>Tissue dilator</td> </tr> <tr> <td>Sterile catheter flush solution</td> </tr> <tr> <td>Sheath</td> </tr> <tr> <td>Catheter or other device (eg, port, pulmonary catheter)</td> </tr> <tr> <td>Sterile sleeve for the catheter&nbsp;</td> </tr> <tr> <td>2-0 silk sutures</td> </tr> <tr> <td>Sterile dressing</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Equipment needed for central venous cannulation,&nbsp;in order of use during procedure. For certain procedures (eg, pulmonary artery catheter placement) additional supplies (drapes, gowns) or additional catheter sets (introducer, sheath, pulmonary catheter, other venous device) may be needed.</div><div id=\"graphicVersion\">Graphic 54646 Version 4.0</div></div></div>"},"54647":{"type":"graphic_table","displayName":"Clinical manifestations of hypercalcemia","title":"Clinical manifestations of hypercalcemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of hypercalcemia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Renal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Polyuria</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Polydipsia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nephrolithiasis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nephrocalcinosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Distal renal tubular acidosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nephrogenic diabetes insipidus</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute and chronic renal insufficiency</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Gastrointestinal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Anorexia, nausea, vomiting</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bowel hypomotility and constipation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pancreatitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Peptic ulcer disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Musculoskeletal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Muscle weakness</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bone pain</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Osteopenia/osteoporosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Neurologic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Decreased concentration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Confusion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Fatigue</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Stupor, coma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Cardiovascular\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Shortening of the QT interval</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bradycardia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hypertension</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 54647 Version 2.0</div></div></div>"},"54649":{"type":"graphic_figure","displayName":"Completion of cone excision","title":"Completion of cervical (uterine cervix) cone biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Completion of cervical (uterine cervix) cone biopsy</div><div class=\"cntnt\"><img style=\"width:413px; height:301px;\" src=\"images/OBGYN/54649_Completion_of_cone_excision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The specimen is excised by cutting across the endocervix.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 54649 Version 2.0</div></div></div>"},"54651":{"type":"graphic_diagnosticimage","displayName":"PAVM angiogram I","title":"Pulmonary arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:433px; height:309px;\" src=\"images/PULM/54651_PAVM_angiogram_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnified view of the left lower lung field from a digital subtraction angiogram in a patient with PAVM and HHT. The angiography catheter (c) is seen entering the feeding artery at the upper left corner. The angiogram shows a single feeding artery (a) which bifurcates to supply the&nbsp;two sacs of the bilobed PAVM. The draining vein (v) is seen as a faint vessel inferior to the feeding artery.</div><div class=\"graphic_footnotes\">PAVM: pulmonary arteriovenous malformation; HHT: hereditary hemorrhagic telangiectasia.</div><div class=\"graphic_reference\">Courtesy of James R Gossage, MD.</div><div id=\"graphicVersion\">Graphic 54651 Version 3.0</div></div></div>"},"54653":{"type":"graphic_table","displayName":"Risk score complications PCI","title":"Mayo clinic risk score to predict major complications after percutaneous coronary intervention","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mayo clinic risk score to predict major complications after percutaneous coronary intervention</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Risk factor</td>\n\n      <td class=\"subtitle1\">Integer score</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">Age</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">90 to 99 years</td>\n\n      <td class=\"sublist_other\">6</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">80 to 89 years</td>\n\n      <td class=\"sublist_other\">5</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">70 to 79 years</td>\n\n      <td class=\"sublist_other\">4</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">60 to 69 years</td>\n\n      <td class=\"sublist_other\">3</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">50 to 59 years</td>\n\n      <td class=\"sublist_other\">2</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">40 to 49 years</td>\n\n      <td class=\"sublist_other\">1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Preprocedural shock</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Left main coronary artery disease</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serum creatinine &#62;3 mg/dL (265 &#181;mol/L)</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>NYHA functional class III or IV heart failure</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Urgent or emergent PCI</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Multivessel disease</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thrombus on angiography</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Score</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">0 to 5 - very low\nrisk (&#8804;2 percent complications)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">6 to 8 - low risk\n(&#62;2 to 5 percent)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">9 to 11 -\nmoderate risk (&#8805;5 to 10 percent)\n      </td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">12 to 14 - high\nrisk (&#62;10 to 25 percent)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&#8805;15 - very high\nrisk (&#62;25 percent)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from Singh M, Lennon RJ, Holmes DR Jr, et al. J Am Coll Cardiol 2002; 40:387.</div><div id=\"graphicVersion\">Graphic 54653 Version 2.0</div></div></div>"},"54654":{"type":"graphic_figure","displayName":"Anatomy of the cervical esophagus - cross section","title":"Anatomy of the cervical esophagus - cross section","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Anatomy of the cervical esophagus - cross section</div><div class=\"cntnt\"><img style=\"width:523px; height:338px;\" src=\"images/SURG/54654_Anatomy_of_the_cervical_esophagus-cross_section_edit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54654 Version 4.0</div></div></div>"},"54655":{"type":"graphic_picture","displayName":"Portable hyperbaric chamber PI","title":"Portable hyperbaric chamber","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Portable hyperbaric chamber</div><div class=\"cntnt\"><img style=\"width:432px; height:260px;\" src=\"images/PI/54655_Portable_hyperbaric_chamber.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If you have severe altitude sickness and cannot get to a lower altitude, you might be put inside a special inflatable bag called a &quot;portable hyperbaric chamber.&quot; This bag zips shut and can be filled up with air that is similar to the air at lower altitudes.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 54655 Version 5.0</div></div></div>"},"54658":{"type":"graphic_figure","displayName":"Flank pain child PI","title":"Location of pain in pyelonephritis (kidney infection)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Location of pain in pyelonephritis (kidney infection)</div><div class=\"cntnt\"><img style=\"width:380px; height:587px;\" src=\"images/PI/54658_Flank_pain_child_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the area of the back and sides, called the flank, that can become painful in children with a kidney infection.</div><div id=\"graphicVersion\">Graphic 54658 Version 4.0</div></div></div>"},"54659":{"type":"graphic_figure","displayName":"Point prevalence back pain","title":"Back pain: Point prevalence in adolescents and adults","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Back pain: Point prevalence in adolescents and adults</div><div class=\"cntnt\"><img style=\"width:460px; height:338px;\" src=\"images/PEDS/54659_Point_prevalence_back_pain.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Point prevalence of low-back pain, individuals aged 12 to 41 years.</div><div class=\"graphic_reference\">Data from Leboeuf-Yde DC, Kyvik KO. At what age does low back pain become a common problem? A study of 29,424 individuals aged 12-41 years. Spine 1998; 23:228.</div><div id=\"graphicVersion\">Graphic 54659 Version 2.0</div></div></div>"},"54660":{"type":"graphic_figure","displayName":"Simple pneumothorax","title":"Simple pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Simple pneumothorax</div><div class=\"cntnt\"><img style=\"width:524px; height:410px;\" src=\"images/PEDS/54660_Simple_pneumothorax.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54660 Version 2.0</div></div></div>"},"54661":{"type":"graphic_picture","displayName":"Mediastinal seminoma II Low","title":"Cystic mediastinal seminoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic mediastinal seminoma</div><div class=\"cntnt\"><img style=\"width:371px; height:246px;\" src=\"images/PULM/54661_Mediastinal_seminoma_II_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows a multilocular thymic cyst containing tumor cells of seminoma in the cystic wall (hematoxylin and eosin, magnification 10x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 54661 Version 2.0</div></div></div>"},"54662":{"type":"graphic_figure","displayName":"Calcaneus CT","title":"Coronal computed tomograph of the calcaneus and its anatomic correlate","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Coronal computed tomograph of the calcaneus and its anatomic correlate</div><div class=\"cntnt\"><img style=\"width:545px; height:327px;\" src=\"images/EM/54662_CalcaneusCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomic correlation of anatomy with the coronal CT scan of the calcaneus. This is perhaps the most important view to assess the clinical reconstructability of the subtalar joint in displaced intra-articular fractures of the calcaneus.</div><div class=\"graphic_footnotes\">CT: computed tomography</div><div class=\"graphic_reference\">Reproduced with permission from: Crawford H. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54662 Version 12.0</div></div></div>"},"54663":{"type":"graphic_figure","displayName":"Foreign body removal","title":"Foreign body removal","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Foreign body removal</div><div class=\"cntnt\"><img style=\"width:497px; height:157px;\" src=\"images/EM/54663_Foreign_body_removal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When attempting to remove a foreign body, the clinician moves the device (eg, burr drill) tangential to the cornea. Remove only material that is easily scraped away.</div><div class=\"graphic_reference\">Reproduced with permission from: Knoop, K, Trott, A. Ophthalmologic procedures in the emergency department-Part III: Slit lamp use and foreign bodies. Acad Emerg Med 1995; 2:224. Copyright &#169;1995 Elsevier.</div><div id=\"graphicVersion\">Graphic 54663 Version 1.0</div></div></div>"},"54666":{"type":"graphic_figure","displayName":"Right ventricular EF outcome","title":"Right ventricular ejection fraction predicts outcome in HF","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Right ventricular ejection fraction predicts outcome in HF</div><div class=\"cntnt\"><img style=\"width:472px; height:302px;\" src=\"images/CARD/54666_Right_ventricular_EF_outcom.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 205 patients with class II or III heart failure (HF), the right ventricular ejection fraction (RVEF) correlated with two year survival free of cardiovascular mortality or urgent transplantation. The event-free survival rates for those with an RVEF &lt;25 percent, ≥25 to &lt;35 percent, and ≥35 percent were 59, 77, and 93 percent, respectively (p &lt;0.00001).</div><div class=\"graphic_reference\">Data from: De Groote P, Millaire A, Foucher-Hossein C, et al. J Am Coll Cardiol 1998; 32:948.</div><div id=\"graphicVersion\">Graphic 54666 Version 2.0</div></div></div>"},"54667":{"type":"graphic_table","displayName":"Histologic grading for neuroendocrine tumors","title":"Evolution of histologic grading for neuroendocrine tumors based upon mitotic count and Ki-67 labeling index, by classification and year","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evolution of histologic grading for neuroendocrine tumors based upon mitotic count and Ki-67 labeling index, by classification and year</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"8%\"></colgroup><colgroup width=\"4%\"></colgroup><colgroup span=\"7\" width=\"8%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle1\">Moran<sup>[1]</sup> (2000)</td> <td class=\"subtitle1\"> <p>WHO<sup>[2]</sup> (2004)</p> WHO<sup>[3]</sup> (2015)</td> <td class=\"subtitle1\">WHO<sup>[4]</sup> (2000)</td> <td class=\"subtitle1\"> <p>Hochwald<sup>[5]</sup> (2002)</p> AFIP<sup>[6]</sup> (2007)</td> <td class=\"subtitle1\">WHO<sup>[7]</sup> (2004)</td> <td class=\"subtitle1\"> <p>ENETS<sup>[8,9]</sup> (2006)</p> <p>AJCC<sup>[10]</sup> (2009)</p> WHO<sup>[11]</sup> (2010)</td> <td class=\"subtitle1\">WHO<sup>[12]</sup> (2017)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Organ system</strong></td> <td>Thymus</td> <td>Lung, thymus</td> <td>GI</td> <td>Pancreas</td> <td>Pancreas</td> <td>GI, pancreas</td> <td>Pancreas</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Mitotic index</strong></td> <td>G1</td> <td>&#60;3/10 HPF</td> <td>&#60;2/2 mm<sup>2</sup></td> <td>NA</td> <td>&#60;2/50 HPF</td> <td>&#60;2/2 mm<sup>2</sup></td> <td>&#60;2/2 mm<sup>2</sup></td> <td>&#60;2/2 mm<sup>2</sup></td> </tr> <tr> <td>G2</td> <td>4 to 9/10 HPF</td> <td>2 to 10/2 mm<sup>2</sup></td> <td>NA&nbsp;</td> <td>2 to 10/50 HPF</td> <td>2 to 10/2 mm<sup>2</sup></td> <td>2 to 20/2 mm<sup>2</sup></td> <td>2 to 20/2 mm<sup>2</sup></td> </tr> <tr class=\"divider_bottom\"> <td>G3</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>&#62;20/2 mm<sup>2</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Ki-67</strong></td> <td>G1</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>&#60;2%</td> <td>&#8804;2% (&#60;3%)</td> <td>&#60;3%</td> </tr> <tr> <td>G2</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>&#62;2%</td> <td>3 to 20%</td> <td>3 to 20%</td> </tr> <tr class=\"divider_bottom\"> <td>G3</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>&#62;20%</td> <td>&#62;20%</td> </tr> <tr> <td colspan=\"2\"><strong>Other parameters</strong></td> <td>Necrosis</td> <td>Necrosis</td> <td>Size, invasion, metastasis</td> <td>Necrosis</td> <td>Size, invasion, metastasis</td> <td>None</td> <td>G3 also considers morphology and marker expression</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">G1: Low grade, benign behavior, or typical carcinoid (lung and thymus).<br />G2: Intermediate grade, uncertain behavior, or atypical carcinoid (lung and thymus).<br />G3: High grade. In earlier classifications, G3 equated to poorly differentiated neuroendocrine carcinoma. The 2017 WHO classification of pancreatic neuroendocrine neoplasms first recognized G3 well-differentiated neuroendocrine tumors in addition to poorly differentiated neuroendocrine carcinoma. For well-differentiated pancreatic neuroendocrine tumors, G3 is diagnosed mostly&nbsp;based on Ki-67 labeling index, in correlation with well-differentiated morphology and aided by appropriate marker expression in difficult cases. The mitotic count in this new category generally is in the G2 range.</div><div class=\"graphic_footnotes\">WHO: World Health Organization; AFIP: Armed Forces Institute of Pathology; ENETS: European Neuroendocrine Tumour Society; AJCC: American Joint Committee on Cancer; GI: gastrointestinal; HPF: high-power field; NA: not applicable.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol 2000; 114:100.</LI>&#xD;&#xA;<LI>Travis WD. The concept of pulmonary neuroendocrine tumours. In: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, Travis WD, et al, Editors. IARC Press, Lyon, France, 2004, p.19.</LI>&#xD;&#xA;<LI>WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed, Travis WD, Brambilla E, Burke AP, et al (Eds), IARC Press, Lyon 2015.</LI>&#xD;&#xA;<LI>WHO Classification of Tumours of the Digestive System. Hamilton SR, Aaltonen LA, IARC Press, Lyon, 2000.</LI>&#xD;&#xA;<LI>Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002; 20:2633.</LI>&#xD;&#xA;<LI>Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. ARP/AFIP, Washington DC, 2007, p.422.</LI>&#xD;&#xA;<LI>Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014:13.</LI>&#xD;&#xA;<LI>Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395.</LI>&#xD;&#xA;<LI>Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451:757.</LI>&#xD;&#xA;<LI>Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed, Springer, New York, 2010.</LI>&#xD;&#xA;<LI>Bosman F, Carneiro F, Hruban R, et al, eds. WHO Classification of Tumours of the Digestive System. IARC Press, Lyon, France, 2010.</LI>&#xD;&#xA;<LI>WHO Classification of Tumours of Endocrine Organs, 4th ed, Lloyd RV, Osamura RY, Klöppel G, Rosai J (Eds), IARC Press, Lyon 2017.</LI></OL></div><div id=\"graphicVersion\">Graphic 54667 Version 5.0</div></div></div>"},"54668":{"type":"graphic_algorithm","displayName":"Suspected PE in pregnancy","title":"Diagnostic algorithm for suspected pulmonary embolism in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for suspected pulmonary embolism in pregnancy</div><div class=\"cntnt\"><img style=\"width:481px; height:337px;\" src=\"images/HEME/54668_SuspectedPEpregnancy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PE: pulmonary embolism; CUS: compression ultrasound; CXR: chest radiography; CTPA: computed-tomographic pulmonary angiography; V/Q: ventilation-perfusion.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright © 2011 American Thoracic Society. Leung AN, Bull TM, Jaeschke R, et al. An Official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline: Evaluation of Suspected Pulmonary Embolism In Pregnancy. Am J Respir Crit Care Med 2011; 184:1200. Official Journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 54668 Version 1.0</div></div></div>"},"54669":{"type":"graphic_table","displayName":"NIDA rx drug abusers ciminal justice","title":"NIDA principles of treatment for drug abusers in the criminal justice system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NIDA principles of treatment for drug abusers in the criminal justice system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Drug addiction is a brain disease that affects behavior</td> </tr> <tr> <td>Recovery from drug addiction requires effective treatment, followed by management of the problem over time</td> </tr> <tr> <td>Treatment must last long enough to produce stable behavioral change</td> </tr> <tr> <td>Assessment is the first step in treatment</td> </tr> <tr> <td>Tailoring services to fit the needs of the individual is an important part of effective drug abuse treatment for criminal justice populations</td> </tr> <tr> <td>Drug use during treatment should be carefully monitored</td> </tr> <tr> <td>Treatment should target factors that are associated with criminal behavior</td> </tr> <tr> <td>Criminal justice supervision should incorporate treatment planning for drug abusing offenders, and treatment providers should be aware of correctional supervision requirements</td> </tr> <tr> <td>Continuity of care is essential for drug abusers re-entering the community</td> </tr> <tr> <td>A balance of rewards and sanctions encourages prosocial behavior and treatment participation</td> </tr> <tr> <td>Offenders with co-occurring drug abuse and mental health problems often require an integrated treatment approach</td> </tr> <tr> <td>Medications are an important part of treatment for many drug abusing offenders</td> </tr> <tr> <td>Treatment planning for drug abusing offenders who are living in or re-entering the community should include strategies to prevent and treat serious, chronic medical conditions, such as HIV/AIDS, hepatitis B and C, and tuberculosis</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=99253&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">NIDA: National Institute on Drug Abuse; HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome.</div><div class=\"graphic_reference\">Information from: National Institute on Drug Abuse. InfoFacts: Treatment for Drug Abusers in the Criminal Justice System. National Institutes of Health 2006. Available at: <a href=\"http://www.drugabuse.gov/publications/infofacts/treatment-drug-abusers-in-criminal-justice-system\" target=\"_blank\">http://www.drugabuse.gov/publications/infofacts/treatment-drug-abusers-in-criminal-justice-system</a> (Accessed on January 18, 2012).</div><div id=\"graphicVersion\">Graphic 54669 Version 3.0</div></div></div>"},"54671":{"type":"graphic_picture","displayName":"Conjunctival scarring","title":"Cicatricial disease: Conjunctival scarring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cicatricial disease: Conjunctival scarring</div><div class=\"cntnt\"><img style=\"width:357px; height:385px;\" src=\"images/ID/54671_Conjunctival_scarring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) World Health Organization (WHO) grade TS (trachomatous conjunctival scarring). To make a diagnosis of TS, there must be evidence of scars on the tarsal conjunctiva. Initially thin discrete white lines appear to transverse the conjunctiva (as indicated by the arrows).<br />(B) Arlt's line. As scarring progresses, conjunctival tissue coalesces, forming a thick white band near the lid margin known as Arlt's line.</div><div id=\"graphicVersion\">Graphic 54671 Version 3.0</div></div></div>"},"54672":{"type":"graphic_picture","displayName":"Glycolipid inclusion bodies","title":"Plastic embedded renal tissue demonstrating glycolipid inclusion bodies in distal tubules, with relative sparing of proximal tubules, and interstitial fibrosis (toluidine blue stain, original magnification X80)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plastic embedded renal tissue demonstrating glycolipid inclusion bodies in distal tubules, with relative sparing of proximal tubules, and interstitial fibrosis (toluidine blue stain, original magnification X80)</div><div class=\"cntnt\"><img style=\"width:432px; height:366px;\" src=\"images/NEPH/54672_Glycolipidinclusionbodies.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 2002; 81:122. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54672 Version 7.0</div></div></div>"},"54674":{"type":"graphic_algorithm","displayName":"Algorithm breast mass under 30Y","title":"Diagnostic algorithm for palpable breast abnormalities in women less than 30 years of age","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for palpable breast abnormalities in women less than 30 years of age</div><div class=\"cntnt\"><img style=\"width:781px; height:1033px;\" src=\"images/ONC/54674_Algobreastmassunder30Y.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LCIS: lobular carcinoma in situ.<br />* If no cytologic expertise available, initial ultrasound preferred.<br />¶ If cytology indicates cancer, treat as appropriate. If nondiagnostic, indeterminate, or atypia, do ultrasound.</div><div class=\"graphic_reference\">Adapted from Esserman L, et al. Current Oncology Reports 2000; 2:572.</div><div id=\"graphicVersion\">Graphic 54674 Version 3.0</div></div></div>"},"54676":{"type":"graphic_picture","displayName":"Postop prim close exstrophy","title":"Postoperative picture of a male infant after complete primary bladder exstrophy repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postoperative picture of a male infant after complete primary bladder exstrophy repair</div><div class=\"cntnt\"><img style=\"width:405px; height:306px;\" src=\"images/PEDS/54676_Postop_prim_close_exstrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 54676 Version 3.0</div></div></div>"},"54677":{"type":"graphic_table","displayName":"Parenteral iron dose","title":"Calculation of parenteral iron dose for treatment of adults with iron deficiency anemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Calculation of parenteral iron dose for treatment of adults with iron deficiency anemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Required information</td> </tr> <tr> <td class=\"indent1\">Body weight (kilograms) = BW</td> </tr> <tr> <td class=\"indent2\">If patient is obese, use lean or ideal body weight*</td> </tr> <tr> <td class=\"indent1\">Hemoglobin concentration (g/dL) = Hgb</td> </tr> <tr> <td class=\"indent1\">Concentration of elemental iron in the parenteral product (mg/mL) = C<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Assumptions</td> </tr> <tr> <td class=\"indent1\">Blood volume is 65 mL per kilogram</td> </tr> <tr> <td class=\"indent1\">Hemoglobin concentration to be corrected to 14 g/dL</td> </tr> <tr> <td class=\"indent1\">Each gram of hemoglobin contains 3.3 mg of iron</td> </tr> <tr> <td class=\"indent1\">Addition of iron for repletion of body stores is optional</td> </tr> <tr> <td class=\"subtitle1_single\">Intermediate calculations</td> </tr> <tr> <td class=\"indent1\">Blood volume (dL) = 65 (mL/kg) x body weight (kg) &#247; 100 (mL/dL)</td> </tr> <tr> <td class=\"indent1\">Hemoglobin deficit (g/dL) = 14 - patient hemoglobin concentration</td> </tr> <tr> <td class=\"indent1\">Hemoglobin deficit (g) = hemoglobin deficit (g/dL) x blood volume (dL)</td> </tr> <tr> <td class=\"indent1\">Iron deficit (mg) = hemoglobin deficit (g) x 3.3 (mg Fe/g Hgb)</td> </tr> <tr> <td class=\"indent1\">Volume of parenteral iron product required (mL) = iron deficit (mg) &#247; C (mg/mL)</td> </tr> <tr> <td class=\"subtitle1_single\">Final calculations<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>Hemoglobin iron deficit (mg) = BW x (14 - Hgb) x (2.145) + iron to replenish stores if desired (mg)</strong></td> </tr> <tr> <td class=\"indent1\">Volume of product required (mL) = BW x (14 - Hgb) x (2.145) &#247; C (if no added iron for stores)</td> </tr> <tr> <td class=\"subtitle1_single\">Example</td> </tr> <tr> <td class=\"indent1\">60 kg woman with a hemoglobin concentration of 8 g/dL. Parenteral iron product is iron sucrose (C = 20 mg elemental iron/mL). No additional iron to replenish stores.</td> </tr> <tr> <td class=\"indent1\">Hemoglobin iron deficit = 60 x (14 - 8) x (2.145) = 772 mg iron</td> </tr> <tr> <td class=\"indent1\">Volume of iron sucrose needed = 60 x (14 - 8) x (2.145) &#247; 20 = 38.6 mL<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Calculators are available in UpToDate to determine ideal body weight and lean body weight.<br />&para; The concentration of elemental iron in the various products is, as follows: iron dextran: 50 mg/mL; iron sucrose: 20 mg/mL; ferric gluconate: 12.5 mg/mL; ferumoxytol: 30 mg/mL; ferric carboxymaltose: 50 mg/mL.<br />&Delta; These calculations are based upon the assumptions listed above. If correction is desired for a different blood volume, final hemoglobin concentration, or for additional iron for body stores, the intermediate calculations can be employed.<br /><span class=\"lozenge\">&loz;</span> The product information sheet should be consulted in order to determine the need for a test dose, proper dilution of the product and rate of infusion, as well as the maximal suggested dose per infusion session.</div><div id=\"graphicVersion\">Graphic 54677 Version 7.0</div></div></div>"},"54678":{"type":"graphic_figure","displayName":"Intralesional drug inject","title":"Intralesional drug injection","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Intralesional drug injection</div><div class=\"cntnt\"><img style=\"width:515px; height:629px;\" src=\"images/PC/54678_Intralesional_drug_inject.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intralesional drug injection in Peyronie's disease.</div><div id=\"graphicVersion\">Graphic 54678 Version 1.0</div></div></div>"},"54679":{"type":"graphic_figure","displayName":"LT inhibitors in asthma","title":"Benefit of leukotriene inhibitors in asthma","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Benefit of leukotriene inhibitors in asthma</div><div class=\"cntnt\"><img style=\"width:455px; height:304px;\" src=\"images/PULM/54679_LT_inhibitors_in_asthma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of the leukotriene synthesis inhibitor zileuton (A) and the LTD4 receptor antagonist zafirlukast (B) on FEV<SUB>1</SUB> in patients with mild to moderate asthma. Both drugs significantly improved the FEV<SUB>1</SUB> compared&nbsp;with placebo.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119:1059.</LI>&#xD;&#xA;<LI>Spector SL, Smith LJ, Glass M, et al. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994; 150:618.</LI></OL></div><div id=\"graphicVersion\">Graphic 54679 Version 2.0</div></div></div>"},"54680":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of abnormal fetal femur","title":"Ultrasound images of abnormal fetal femurs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound images of abnormal fetal femurs</div><div class=\"cntnt\"><img style=\"width:312px; height:453px;\" src=\"images/OBGYN/54680_US_abnormal_femur_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Mild shortening with bowing of the femur in a 20.2 week fetus with the diagnosis of asphyxiating thoracic dystrophy.<br> (B) Severe micromelia (entire limb shortening) of the lower extremity in a fetus at 24 weeks with the diagnosis of thanatophoric dysplasia type 2. Note surrounding thickened redundant soft tissues, which have grown relatively faster than the short long bones.</div><div id=\"graphicVersion\">Graphic 54680 Version 5.0</div></div></div>"},"54683":{"type":"graphic_figure","displayName":"Hematocolpos","title":"Diagram of agenesis of the lower vagina with normal uterus and cervix, and resulting blood-filled upper vagina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of agenesis of the lower vagina with normal uterus and cervix, and resulting blood-filled upper vagina</div><div class=\"cntnt\"><img style=\"width:391px; height:379px;\" src=\"images/OBGYN/54683_Hematocolposedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54683 Version 13.0</div></div></div>"},"54684":{"type":"graphic_figure","displayName":"Beta blocker MI COPD","title":"Beta blocker after MI is effective in patients with chronic lung disease","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Beta blocker after MI is effective in patients with chronic lung disease</div><div class=\"cntnt\"><img style=\"width:456px; height:298px;\" src=\"images/CARD/54684_Beta_blocker_MI_COPD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In an analysis of 201,752 patients with an acute myocardial infarction (MI), those with chronic obstructive pulmonary disease (COPD) who received a beta blocker had a significant increase in survival at two years compared to patients with COPD who did not receive this therapy (83.2 versus 72.2 percent).</div><div class=\"graphic_reference\">Data from Gottlieb SS, McCarter RJ, Vogel RA. N Engl J Med 1998; 339:489.</div><div id=\"graphicVersion\">Graphic 54684 Version 2.0</div></div></div>"},"54685":{"type":"graphic_figure","displayName":"Hemodynamic changes in normal pregnancy","title":"Hemodynamic changes in normal pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemodynamic changes in normal pregnancy</div><div class=\"cntnt\"><img style=\"width:429px; height:259px;\" src=\"images/NEPH/54685_Hemodynamics_in_pregnancy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal pregnancy is characterized by an increase in cardiac output, a reduction in systemic vascular resistance, and&nbsp;minimal change&nbsp;in mean blood pressure. These changes are associated with a 10- to 15-beat/minute increase in heart rate.</div><div class=\"graphic_footnotes\">BP: blood pressure; SVR: systemic vascular resistance.</div><div id=\"graphicVersion\">Graphic 54685 Version 6.0</div></div></div>"},"54686":{"type":"graphic_algorithm","displayName":"Treatment strategy for LEMS","title":"Treatment strategy for Lambert-Eaton myasthenic syndrome","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Treatment strategy for Lambert-Eaton myasthenic syndrome</div><div class=\"cntnt\"><img style=\"width:493px; height:653px;\" src=\"images/NEURO/54686_TreatmentstrategyLEMSedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended as a general guide to the treatment of LEMS. Sufficient benefit with treatment is achieved when the patient is satisfied with improvement in strength and function.</div><div class=\"graphic_footnotes\">3,4-DAP: 3,4-diaminopyridine; IVIG: intravenous immune globulin; LEMS: Lambert-Eaton myasthenic syndrome.<br />* Some experts are reluctant to use oral immunosuppressive agents such as azathioprine in patients with cancer because of concerns that such treatment may exacerbate the malignancy.<br />&para; Refer to UpToDate topic for details.</div><div id=\"graphicVersion\">Graphic 54686 Version 5.0</div></div></div>"},"54687":{"type":"graphic_table","displayName":"AC followed by TH regimen","title":"Doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) for HER2-positive* breast cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) for HER2-positive* breast cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> AC is given every 21 days for four cycles.<br /> Paclitaxel (T) and trastuzumab (H) are given every seven days of a 28 day cycle for three cycles (ie, weekly for 12 weeks). Following completion of T, H is given weekly for a total treatment duration of 52 weeks.<sup>&#182;</sup></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Doxorubicin</td> <td>60 mg/m<sup>2</sup> IV</td> <td>Dilute with normal saline (NS) to a final concentration of 2 mg/mL and administer as an IV bolus over three to five minutes into a free flowing IV infusion of NS or 5% dextrose in water (D5W). The presence of local erythematous streaking along the vein as well as facial flushing may be signs that administration is too rapid. If needed, doxorubicin can be further diluted after reconstitution in NS or D5W and given as a slow IV infusion administered over 15 to 60 minutes.<sup>[2]</sup></td> <td>Day 1</td> </tr> <tr> <td>Cyclophosphamide</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 to 500 mL NS or D5W and administer over 30 to 60 minutes. Rapid infusions may produce nasal burning or congestion that is relieved by slowing the rate.</td> <td>Day 1</td> </tr> <tr> <td colspan=\"4\"><strong>Following AC, administer:</strong></td> </tr> <tr> <td>Paclitaxel</td> <td>80 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL NS or D5W to a final concentration of 0.3 to 1.2 mg/mL and administer over one hour; special tubing needed.<sup>&#916;</sup></td> <td>Days 1, 8, 15, and 22<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Trastuzumab</td> <td>4 mg/kg IV loading dose, followed by 2 mg/kg</td> <td>Dilute in 250 mL NS and administer over 90 minutes for the loading dose and over 30 minutes for subsequent doses.<br /> <strong>DO NOT</strong> mix with D5W, and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Weekly for 52 weeks<sup>&#182;</sup></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Paclitaxel may cause severe hypersensitivity reactions. Premedication regimen should include dexamethasone (either 20 mg orally twelve and six hours before, or 20 mg IV 30 minutes before drug administration) plus both an H1 (diphenhydramine 25 to 50 mg IV) and an H2 receptor antagonist (ranitidine 50 mg or famotidine 20 mg IV) 30 to 60 minutes prior to paclitaxel administration. Severe infusion reactions (eg, skin rash, flushing, dyspnea, urticaria, back pain, hypotension, chest pain, tachycardia) occur primarily during the first and second infusions, typically within the first hour after the start of the infusion. Further information on infusion reactions, including management, is available. Trastuzumab may also cause infusion reactions. These can be severe, though most are mild; they typically occur during or within 24 hours of the first infusion. The most common symptoms are fever, chills, nausea, headache, abdominal pain, and dyspnea; less often are vomiting, dizziness, rash, rhinitis, or hypotension. Most clinicians do not routinely premedicate prior to the first trastuzumab dose.<br /> <strong>NOTE:</strong> Trastuzumab infusion should be discontinued for anaphylaxis (bronchospasm, hypotension, angioedema). Further information on infusion reactions and their management is available. </li> <li>Refer to UpToDate topics on \"Infusion reactions to systemic chemotherapy\" and \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is a vesicant and can cause significant tissue damage if an extravasation occurs. For peripheral infusions, the IV line should be recently placed into a large, intact vein, with good blood return established immediately prior to starting the infusion. The IV or catheter site should be continuously monitored throughout drug administration infusion. If extravasation occurs, apply ice to the site and consider use of dexrazoxane. Paclitaxel can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Not applicable. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustment is not necessary for doxorubicin or paclitaxel in renal impairment. The need for cyclophosphamide dose reduction in renal insufficiency is controversial. For patients with preexisting hepatic impairment, dose adjustments in doxorubicin, cyclophosphamide, and paclitaxel may be needed. The available data suggest that disposition of trastuzumab is not altered based on serum creatinine (&#8804;2 mg/dL). </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\". </li> <li>For patients with preexisting hepatic impairment, dose adjustments in doxorubicin, cyclophosphamide, and paclitaxel may be needed. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>A baseline assessment of LVEF is recommended, with periodic reassessment during therapy. The risk of doxorubicin-associated cardiac dysfunction is related to cumulative dose. The risk for cardiotoxicity is increased in patients with underlying heart disease, when anthracyclines are used concurrently with other cardiotoxic agents (including paclitaxel and trastuzumab) or radiation, and in patients previously treated with mediastinal or chest wall irradiation. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines.<sup>[2]</sup> Trastuzumab is associated with cardiotoxicity, and reassessment of LVEF prior to therapy (after completion of AC) is indicated. Information on use of trastuzumab according to baseline cardiac evaluation is available. </li> <li>Refer to UpToDate topics on \"Cardiotoxicity of anthracycline-like chemotherapy agents\" and \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary issues</strong></td> <td colspan=\"3\"> <ul> <li>Trastuzumab has been associated with serious pulmonary toxicity (including acute respiratory distress syndrome [ARDS] and interstitial pneumonitis) and should be used with caution in patients with preexisting pulmonary disease.<sup>[3]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment with AC and paclitaxel (or every three weeks if dosing paclitaxel every three weeks). </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes and liver and renal function tests prior to each treatment cycle of AC and paclitaxel. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment cycle of paclitaxel. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess cardiac function prior to AC and prior to initiation of trastuzumab. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess cardiac function prior to trastuzumab and at 3, 6, 9, 12, and 18 months after starting trastuzumab. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>During treatment with AC and paclitaxel, assess line site periodically during infusion of chemotherapy for signs and symptoms of extravasation. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Patients should be closely monitored for infusion reactions, especially during the first two courses of trastuzumab. Standing orders should be in place to allow immediate intervention without waiting for the physician to arrive. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Subsequent cycles should be delayed until the absolute neutrophil count is greater than 1000/microL and platelet count greater than 100,000/microL. If there is more than a three week delay in treatment, a dose reduction of 25% is recommended.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For patients who develop severe neuropathy (grade 3 or 4) that persists for a week or longer, the dose of paclitaxel should be reduced by 20% for subsequent courses of paclitaxel; hold if severe toxicity persists after dose reduction. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for hepatic or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Guidelines for managing doxorubicin, cyclophosphamide, and paclitaxel in patients who have changes in kidney or liver function during therapy are addressed in detail separately. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Guidelines for managing trastuzumab in patients with symptomatic cardiac dysfunction or asymptomatic changes in LVEF during therapy are addressed in detail separately. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Discontinue trastuzumab if patients develop ARDS, interstitial pneumonitis, or pulmonary fibrosis. </li> <li>Refer to UpToDate topics on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\" and \"Taxane-induced pulmonary toxicity\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; ARDS: acute respiratory distress syndrome; CBC: complete blood count.<br />* High levels of HER2 overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab. Refer to UpToDate topic on \"HER2 and predicting response to therapy in breast cancer\".<br />¶ Trastuzumab can also be administered as a 4 mg/kg loading dose week 1, then 2 mg/kg weekly (maintenance dose) for a total of 12 weeks (concurrent with paclitaxel), followed one week later by 6 mg/kg infused over 30 to 90 minutes every three weeks to complete a total 52 weeks of therapy. For patients who miss a dose by more than one week, the loading dose (weekly: 4 mg/kg; three weekly: 8 mg/kg) should be repeated before resuming the maintenance dose.<br />Δ Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.<br /><FONT class=lozenge>◊</FONT> Paclitaxel can be administered weekly (80 mg/m<SUP>2</SUP>) for 12 weeks, or it can be given as a dose of 175 mg/m<SUP>2</SUP> every 21 days for four cycles.<SUP>[1]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Romond EH, et al. N Engl J Med 2005; 353:1673.</LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</LI>&#xD;&#xA;<LI>Trastuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 54687 Version 23.0</div></div></div>"},"54690":{"type":"graphic_picture","displayName":"Heel to toe walk","title":"Balance exercises: Heel to toe walk","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balance exercises: Heel to toe walk</div><div class=\"cntnt\"><img style=\"width:369px; height:297px;\" src=\"images/PC/54690_Heel_to_toe_walk_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Having good balance is important for many everyday activities, such as going up and down stairs.   <OL>  <LI>Position the heel of one foot just in front of the toes of the other foot. Your heel and toes should touch or almost touch. </LI>  <LI>Choose a spot ahead of you and focus on it to keep you steady as you walk. </LI>  <LI>Take a step. Put your heel just in front of the toe of your other foot. </LI>  <LI>Repeat for 20 steps. </LI></OL></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 54690 Version 4.0</div></div></div>"},"54693":{"type":"graphic_picture","displayName":"Hashimotos thyroiditis FNA II","title":"Hashimoto's thyroiditis: Findings on fine needle aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hashimoto's thyroiditis: Findings on fine needle aspirate</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ENDO/54693_Hashimotos_thyroiditis_FN1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fine needle aspirate of the thyroid in Hashimoto's thyroiditis. Tearing of tissue lymphocytes is seen with scant follicular cells and colloid.</div><div id=\"graphicVersion\">Graphic 54693 Version 2.0</div></div></div>"},"54694":{"type":"graphic_figure","displayName":"Incidence HCV by risk factor","title":"Reported cases of acute hepatitis C by selected risk factors, United States, 1983-1998*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reported cases of acute hepatitis C by selected risk factors, United States, 1983-1998*</div><div class=\"cntnt\"><img style=\"width:445px; height:204px;\" src=\"images/GAST/54694_Incidence_HCV_by_risk_facto.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* 1983-1990 based on non-A, non-B hepatitis.</div><div class=\"graphic_reference\">Source: CDC Sentinel Counties Study.</div><div id=\"graphicVersion\">Graphic 54694 Version 1.0</div></div></div>"},"54695":{"type":"graphic_figure","displayName":"Preretinal hemorrhages","title":"Preretinal hemorrhages","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Preretinal hemorrhages</div><div class=\"cntnt\"><img style=\"width:418px; height:417px;\" src=\"images/PEDS/54695_Preretinal_hemorrhages.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A preretinal (subhyaloid) hemorrhage develops when blood escapes into the potential space between retina and vitreous. A preretinal hemorrhage typically is larger than other retinal hemorrhages. Because it is anterior to the retina, a preretinal hemorrhage obscures underlying retinal vessels. In an erect patient, red cells settle, creating a horizontal line of demarcation between plasma above and cells below.</div><div class=\"graphic_reference\">Reproduced with permission from: Bickley, LS and Szilagyi, P. Bates' Guide to Physical Examination and History Taking, 8th Ed. Philadelphia: Lippincott Williams &amp; Wilkins 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54695 Version 1.0</div></div></div>"},"54698":{"type":"graphic_diagnosticimage","displayName":"Postoperative hypotension PA","title":"Chest radiograph of patient with hypotension after pneumonectomy ","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of patient with hypotension after pneumonectomy </div><div class=\"cntnt\"><img style=\"width:332px; height:329px;\" src=\"images/PULM/54698_Postoperative_hypotension_P.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from pulmonary pearls II, Sahn SA, Heffner JE (Eds), Hanley &amp; Belfus, Inc. Philadelphia 1995.</div><div id=\"graphicVersion\">Graphic 54698 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"54699":{"type":"graphic_picture","displayName":"Sea urchin and resulting wound","title":"Sea urchin and resulting wound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sea urchin and resulting wound</div><div class=\"cntnt\"><img style=\"width:282px; height:370px;\" src=\"images/EM/54699_Sea_urchin_resulting_wound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Black sea urchin (<em>Echinometra locunter</em>).<br> (B) The presence of spines in a victim who stepped on the animal.</div><div class=\"graphic_reference\">Reproduced from: Haddad V, Lupi O, Lonza JP, Tyring SK. Tropical dermatology: marine and aquatic dermatology. J Am Acad Dermatol 2009; 61:733. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 54699 Version 1.0</div></div></div>"},"54700":{"type":"graphic_table","displayName":"Monitoring STI and OI in adolescents with HIV","title":"Screening for sexually transmitted and opportunistic infections in adolescents with HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening for sexually transmitted and opportunistic infections in adolescents with HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Coinfection or comorbidity</td> <td class=\"subtitle1\">Test(s) to perform</td> <td class=\"subtitle1\">Timing and follow-up</td> </tr> <tr class=\"divider_bottom\"> <td>Cytomegalovirus</td> <td>Anti-CMV IgG for patients other than MSM and injection drug users (who may be assumed to be seropositive)</td> <td>At initial diagnosis</td> </tr> <tr class=\"divider_bottom\"> <td>Gonorrhea, chlamydia*</td> <td>NAAT testing (preferred) or culture with sites based on exposure history (eg, urine, urethral, vaginal, cervical, rectal, oropharyngeal)</td> <td>At initial diagnosis and then at least every six months or more frequently if indicated. If positive, patient should be treated and retested in three months because of high reinfection rates.</td> </tr> <tr class=\"divider_bottom\"> <td>Syphilis</td> <td>RPR or VDRL. Confirm reactive tests with treponemal-specific antibody tests.</td> <td>At initial diagnosis and then at least yearly; in areas highly endemic for syphilis or high risk populations (ie, MSM) more frequently</td> </tr> <tr class=\"divider_bottom\"> <td>Latent <em>Toxoplasma gondii</em></td> <td>Anti-<em>Toxoplasma</em> IgG</td> <td>At initial diagnosis; also may be indicated in patients with initial negative serology if CD4 count drops below 100 cells/microL</td> </tr> <tr class=\"divider_bottom\"> <td>Latent <em>Mycobacterium tuberculosis</em></td> <td>Tuberculin skin test or IGRA. IGRA preferred if history of BCG vaccination or in patients with a low likelihood of returning to have their test read.</td> <td>At initial diagnosis and then annually. Those with positive test results should be treated for latent <em>M. tuberculosis</em> after active tuberculosis has been excluded.</td> </tr> <tr class=\"divider_bottom\"> <td>Varicella virus</td> <td>Anti-varicella IgG if no known history of chickenpox or shingles</td> <td>At initial diagnosis. If negative, then immunize if CD4 &#8805;200 cells/microL.</td> </tr> <tr class=\"divider_bottom\"> <td>Viral hepatitis</td> <td>HBsAg, HBsAb, anti-HBc, HCV antibody, HAV total or IgG antibody</td> <td>At initial diagnosis and annually. If HbsAg+, order HBV RNA level. If HCV Ab+, order HCV RNA level and HCV genotype. If HBsAb is negative, immunize for HBV. If HAV IgG is negative, immunize for HAV.</td> </tr> <tr class=\"divider_bottom\"> <td>Cervical cancer, anal cancer</td> <td>Cervical Pap test; anal Pap test if indicated<sup>&#182;</sup>. Abnormal results require follow-up with colposcopy and high-resolution anoscopy, respectively.</td> <td>At initial diagnosis<sup>&#916;</sup> then six months later. If result negative, then annually.</td> </tr> <tr> <td>Trichomoniasis</td> <td>HIV+ women should be screened with NAAT (preferred), microscopy, rapid antigen testing, or culture</td> <td>At initial diagnosis and then annually, more frequently if patient infected with other STIs. If positive, patient should be treated and retested in three months because of high reinfection rates.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; CMV: cytomegalovirus; IgG: immunoglobulin G; MSM: men who have sex with men; NAAT: nucleic acid amplification test; RPR: rapid plasma reagin; VDRL: Venereal Disease Research Laboratory; IGRA: interferon gamma release assay; BCG: Bacille Calmette-Gu&eacute;rin; HBsAg: hepatitis B surface antigen; HBsAb: hepatitis B surface antibody; anti-HBc: hepatitis B core antibody; HCV: hepatitis C virus; HAV: hepatitis A virus; HBV: hepatitis B virus; Pap test: Papanicolaou smear; STI: sexually transmitted infection.<br />* Testing should be performed among HIV positive adolescents who are sexually active; it is not necessary among HIV positive adolescents with vertical transmission until they become sexually active.<br />&para; Indicated in MSM, women with a history of receptive anal intercourse or abnormal cervical Pap test results, patients with genital warts.<br />&Delta; In contrast to the recommendations for healthy adolescents, sexually active HIV-infected female adolescents should undergo cervical cancer screening after the onset of sexual activity and not wait until 21 years of age.</div><div class=\"graphic_reference\">Adapted from: Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58:e1.</div><div id=\"graphicVersion\">Graphic 54700 Version 6.0</div></div></div>"},"54701":{"type":"graphic_table","displayName":"Case studies of FUO I","title":"Case studies of fever of unknown origin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Case studies of fever of unknown origin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Author</td> <td>Alt</td> <td>Petersdorf</td> <td>Vanderschueren</td> <td>Miller</td> <td>Knockaert</td> <td>Bleeker-Rovers</td> </tr> <tr> <td class=\"subtitle1_left\">Year</td> <td>1913 to 1930</td> <td>1952 to 1959</td> <td>1990 to 1999</td> <td>1989 to 1993</td> <td>1980 to1989</td> <td>2003 to 2005</td> </tr> <tr> <td class=\"subtitle1_left\">Location</td> <td>Boston, United States</td> <td>Seattle, United States</td> <td>Belgium</td> <td>London, United Kingdom</td> <td>Belgium</td> <td>Netherlands</td> </tr> <tr> <td class=\"subtitle1_left\">Subpopulation</td> <td>Adults</td> <td>Adults</td> <td>Adults</td> <td>AIDS</td> <td>Elderly</td> <td>Adults<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_left\">Case definition*</td> <td>1</td> <td>2</td> <td>2</td> <td>2</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"subtitle1_left\">Number of cases</td> <td>101</td> <td>100</td> <td>290</td> <td>79</td> <td>47</td> <td>73</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"7\">Diagnostic categories<sup>&#916;</sup></td> </tr> <tr> <td>Infections</td> <td>11</td> <td>36</td> <td>20</td> <td>80</td> <td>25</td> <td>16</td> </tr> <tr> <td>Neoplasms</td> <td>6</td> <td>19</td> <td>10</td> <td>8</td> <td>12</td> <td>7</td> </tr> <tr> <td>Multisystem<sup>&#9674;</sup></td> <td>0</td> <td>17</td> <td>24</td> <td>1</td> <td>31</td> <td>22</td> </tr> <tr> <td>Miscellaneous</td> <td>6</td> <td>21</td> <td>13</td> <td>2</td> <td>20</td> <td>4</td> </tr> <tr> <td>No diagnosis</td> <td>78</td> <td>7</td> <td>34</td> <td>9</td> <td>12</td> <td>51</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* 1: no diagnosis at time of hospital discharge; 2: temp &gt;101&deg;F (38.3&deg;C), duration &gt;3 weeks, undiagnosed &gt;1 week; 3 = temp &gt;101.3&deg;F (38.5&deg;C), duration &gt;2 weeks, undiagnosed.<br />&para; Includes collagen vascular disorders (eg, systemic lupus erythematosus, rheumatoid arthritis, and vasculitis), and granulomatous diseases (eg, sarcoidosis).<br />&Delta; Numbers represent percentages.<br /><span class=\"lozenge\">&loz;</span> Immunocompromised excluded.</div><div class=\"graphic_reference\">Alt H, et al. JAMA 1930; 94:1457. Petersdorf RG, et al. Medicine (Baltimore) 1961; 40:1. Vanderschueren S, et al. Arch Intern Med 2003; 163:1033. Miller RF, et al. Int J STD AIDS 1996; 7:170. Knockaert DC, et al. Clin Infect Dis 1994; 18:601. Bleeker-Rovers, CP, et al. Medicine (Baltimore) 2007; 86:26.</div><div id=\"graphicVersion\">Graphic 54701 Version 4.0</div></div></div>"},"54703":{"type":"graphic_waveform","displayName":"Basic case 3","title":"Basic case 3","html":"<div class=\"graphic normal\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Basic case 3</div><div class=\"cntnt\"><img style=\"width:531px; height:90px;\" src=\"images/CARD/54703_Basic_case_3.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54703 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"54705":{"type":"graphic_picture","displayName":"Interdigital scabies PI","title":"Scabies between the fingers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies between the fingers</div><div class=\"cntnt\"><img style=\"width:256px; height:400px;\" src=\"images/PI/54705_Interdigital_scabies_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scabies often affects the webs of the fingers.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 54705 Version 2.0</div></div></div>"},"54706":{"type":"graphic_picture","displayName":"Embryonal rhabdomyosarcoma","title":"Embryonal rhabdomyosarcoma","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Embryonal rhabdomyosarcoma</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/PEDS/54706_Embryonalrhabdomyosarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic embryonal rhabdomyosarcoma is composed of typical rhabdomyoblasts arranged in sheets and large nests, with infrequent intermixed fusiform cells. The typical rhabdomyoblast has moderate to deeply eosinophilic cytoplasm, representing poorly formed myofilaments (H&amp;E, 200x original magnification).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div id=\"graphicVersion\">Graphic 54706 Version 3.0</div></div></div>"},"54707":{"type":"graphic_picture","displayName":"Classic Kaposi sarcoma - nodules","title":"Classic Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54707_CKS_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple papules and nodules are present on the lower leg in this patient with classic Kaposi sarcoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54707 Version 5.0</div></div></div>"},"54708":{"type":"graphic_diagnosticimage","displayName":"Innominate artery stenosis","title":"Innominate artery stenosis","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Innominate artery stenosis</div><div class=\"cntnt\"><img style=\"width:550px; height:250px;\" src=\"images/SURG/54708_Innominate_artery_sten_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arteriogram demonstrates a stenosis of the proximal innominate artery.</div><div id=\"graphicVersion\">Graphic 54708 Version 1.0</div></div></div>"},"54709":{"type":"graphic_picture","displayName":"Linear corneal abrasion","title":"Linear corneal abrasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear corneal abrasion</div><div class=\"cntnt\"><img style=\"width:432px; height:272px;\" src=\"images/EM/54709_Linear_corneal_abrasion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows fluorescein uptake in a linear corneal abrasion, most likely from an edged foreign body. Note the sparing of the superior and inferior cornea as a result of the eyelids protecting the cornea. This is the classic \"exposure pattern.\"</div><div class=\"graphic_reference\">Courtesy of Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 54709 Version 4.0</div></div></div>"},"54710":{"type":"graphic_figure","displayName":"Human parathyroid hormone","title":"Parathyroid hormone","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Parathyroid hormone</div><div class=\"cntnt\"><img style=\"width:523px; height:387px;\" src=\"images/ENDO/54710_Human_parathyroid_hormone.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PTH is an 84-amino acid polypeptide secreted by the parathyroid glands. It has an N-terminal (H<SUB>2</SUB>N) and a C-terminal region (COOH). PTH 1-34 is shown in yellow; PTH 1-84 is the full-length polypeptide.</div><div class=\"graphic_reference\">PTH: parathyroid hormone.</div><div id=\"graphicVersion\">Graphic 54710 Version 3.0</div></div></div>"},"54711":{"type":"graphic_figure","displayName":"Anisotropic reentry","title":"Anisotropic reentry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anisotropic reentry</div><div class=\"cntnt\"><img style=\"width:343px; height:456px;\" src=\"images/CARD/54711_Anisotropic_reentry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A is an activation map of a single reentrant circuit at the epicardial border zone of a myocardial infarction. The large arrows represent the general activation pattern which occurs around a long line of block (blue arrow). Parallel isochrones 130 and 140 which are adjacent to the block suggest that activation is occurring across the block, resulting in a smaller circuit (shaded area) shown by the small black arrow. Panel B is an enlarged representation of this shaded area; the dark black rectangle represents an area of block around which there is a reentrant circuit (small arrows). Rapid activation occurs parallel to the long axis of the fiber orientation (isochrones 10-40 and 130-150), while in the transverse direction activation is slow (bunched isochrones 50-120).</div><div id=\"graphicVersion\">Graphic 54711 Version 1.0</div></div></div>"},"54712":{"type":"graphic_figure","displayName":"Imprinting--pedigree","title":"Example of a pedigree showing imprinting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of a pedigree showing imprinting</div><div class=\"cntnt\"><img style=\"width:444px; height:362px;\" src=\"images/PC/54712_Imprinting_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Imprinting. An example of a pedigree demonstrating genomic imprinting is presented. At this locus, the paternal allele is normally repressed and the maternal allele is normally expressed. Approximately 50% of offspring of affected women are themselves affected, whereas no offspring of affected men are affected. However, the grandchildren of affected males will be affected if the mutation is passed through a carrier (unaffected) daughter, but not if passed through a carrier son.</div><div id=\"graphicVersion\">Graphic 54712 Version 7.0</div></div></div>"},"54714":{"type":"graphic_table","displayName":"General functioning","title":"General Functioning Scale from the Family Assessment Device","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General Functioning Scale from the Family Assessment Device</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Planning family activities is difficult because we misunderstand each other.</td>\n   </tr>\n   <tr>\n   <td>In times of crisis we can turn to each other for support.</td>\n   </tr>\n   <tr>\n   <td>We cannot talk to each other about the sadness we feel.</td>\n   </tr>\n   <tr>\n   <td>Individuals are accepted for what they are.</td>\n   </tr>\n   <tr>\n   <td>We avoid discussing our fears and concerns.</td>\n   </tr>\n   <tr>\n   <td>We can express feelings to each other.</td>\n   </tr>\n   <tr>\n   <td>There are lots of bad feelings in the family.</td>\n   </tr>\n   <tr>\n   <td>We feel accepted for what we are.</td>\n   </tr>\n   <tr>\n   <td>Making decisions is a problem for our family.</td>\n   </tr>\n   <tr>\n   <td>We are able to make decisions about how to solve problems.</td>\n   </tr>\n   <tr>\n   <td>We don't get along well together.</td>\n   </tr>\n   <tr>\n   <td>We confide in each other.</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted from Epstein, NB, Baldwin, LM, Bishop, DS. The McMaster Family Assessment Device. Journal of Marital and Family Therapy 1983; 9:171.</div><div id=\"graphicVersion\">Graphic 54714 Version 1.0</div></div></div>"},"54715":{"type":"graphic_diagnosticimage","displayName":"Left lung RUL atelectasis","title":"Frontal chest radiograph shows complete atelectasis of the left lung and right upper lobe atelectasis due to right mainstem bronchus intubation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frontal chest radiograph shows complete atelectasis of the left lung and right upper lobe atelectasis due to right mainstem bronchus intubation</div><div class=\"cntnt\"><img style=\"width:432px; height:358px;\" src=\"images/PULM/54715_Left_lung_RUL_atelectasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked mediastinal shift to the left with hyperexpansion of the right middle and lower lobes is evident.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 54715 Version 2.0</div></div></div>"},"54716":{"type":"graphic_figure","displayName":"Foreleg and foot muscles","title":"Muscles of the anterior leg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Muscles of the anterior leg</div><div class=\"cntnt\"><img style=\"width:340px; height:600px;\" src=\"images/SM/54716_Foreleg_and_foot_muscles.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54716 Version 4.0</div></div></div>"},"54717":{"type":"graphic_picture","displayName":"Pathology of granuloma annulare - necrobiosis","title":"Pathology of granuloma annulare - necrobiosis (H&E 400x)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathology of granuloma annulare - necrobiosis (H&amp;E 400x)</div><div class=\"cntnt\"><img style=\"width:424px; height:313px;\" src=\"images/DERM/54717_Necrobiosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view at the edge of the focus of necrobiosis in the upper portion of this photomicrograph. The upper necrobiotic area shows faint basophilia representing mucinous degeneration between bundles of acellular fibrillary eosinophilic material. The rim shows numerous histiocytes and a few lymphocytes with complete mucinous degeneration of normal collagen (H&amp;E 400x).</div><div id=\"graphicVersion\">Graphic 54717 Version 2.0</div></div></div>"},"54720":{"type":"graphic_waveform","displayName":"Orthodromic AVRT tutorial","title":"Electrocardiogram (ECG) showing orthodromic atrioventricular reentrant tachycardia (AVRT)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing orthodromic atrioventricular reentrant tachycardia (AVRT)</div><div class=\"cntnt\"><img style=\"width:343px; height:92px;\" src=\"images/CARD/54720_AV_reentrant_tach_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrioventricular reentrant tachycardia (AVRT)&nbsp;is a supraventricular tachycardia associated with an accessory pathway connection between the atria and ventricles. The pathway may conduct antegrade only, retrograde only, or both antegrade and retrograde.&nbsp;AVRT is usually initiated by an atrial premature beat (arrow). The most common type of AVRT, termed orthodromic AVRT,&nbsp;uses the AV node and His Purkinje system (which has a relatively short refractory period) for antegrade conduction to the ventricles and the accessory AV pathway (which in these patients has a relatively long antegrade refractory period when compared to the node) for retrograde conduction. During orthodromic AVRT, QRS complexes are narrow. During sinus rhythm, however, wide and bizarre QRS complexes (indicative of the WPW pattern) are caused by conduction over both the accessory and normal pathways, resulting in a fusion beat. Since there is 1:1 retrograde activation of the atrium, a negative P wave may be present following the QRS complex.</div><div id=\"graphicVersion\">Graphic 54720 Version 5.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"54722":{"type":"graphic_table","displayName":"Chemo-associated nephrotoxicity","title":"Chemotherapeutic agents associated with nephrotoxicity and proposed mechanisms of renal damage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapeutic agents associated with nephrotoxicity and proposed mechanisms of renal damage</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug </td> <td class=\"subtitle1\">Renal toxicity (type) </td> <td class=\"subtitle1\">Mechanism </td> <td class=\"subtitle1\">Prevention </td> </tr> <tr> <td>Bevacizumab and orally active tyrosine kinase inhibitors targeting VEGF (axitinib, pazopanib, sorafenib, sunitinib)</td> <td>Proteinuria, nephrotic syndrome</td> <td>Renal thrombotic microangiopathy?</td> <td>&nbsp;</td> </tr> <tr> <td>Carboplatin</td> <td> <p>Rare</p> <p>Hypomagnesemia; recurrent salt wasting</p> </td> <td>Tubular injury (reversible)</td> <td>&nbsp;</td> </tr> <tr> <td>Cetuximab</td> <td>Hypomagnesemia</td> <td>Tubular injury</td> <td>&nbsp;</td> </tr> <tr> <td>Cisplatin</td> <td>Renal failure; renal tubular acidosis; hypomagnesemia (dose related and cumulative)</td> <td>Tubulointerstitial injury</td> <td> <p>Aggressive hydration</p> <p>Forced diuresis</p> <p>Cytoprotectants (eg, amifostine)</p> </td> </tr> <tr> <td>Cyclophosphamide</td> <td> <p>Hyponatremia</p> <p>Hemorrhagic cystitis</p> </td> <td>Direct effect on distal tubules</td> <td> <p>Use of mesna</p> <p>Adequate hydration</p> </td> </tr> <tr> <td>Gemcitabine</td> <td>Hemolytic uremic syndrome</td> <td>Microangiopathic lesions</td> <td>&nbsp;</td> </tr> <tr> <td>Ifosfamide</td> <td>Fanconi syndrome, renal tubular acidosis, nephrogenic diabetes insipidus; hemorrhagic cystitis</td> <td>Proximal tubular damage by acrolein and chloroacetic acid</td> <td> <p>Use of mesna</p> <p>Adequate hydration</p> <p>Electrolyte monitoring</p> </td> </tr> <tr> <td>Interferons</td> <td>Proteinuria; renal failure</td> <td>Minimal changes; ATN</td> <td>&nbsp;</td> </tr> <tr> <td>Interleukin-2</td> <td>Prerenal azotemia</td> <td>Renal hypoperfusion (capillary leak syndrome)</td> <td> <p>Strict patient selection</p> <p>Control volume and hemodynamic status</p> <p>Avoid other nephrotoxins</p> </td> </tr> <tr> <td rowspan=\"2\">Methotrexate </td> <td>Non-oliguric renal failure (high doses)</td> <td>Intratubular deposition of methotrexate</td> <td> <p>Aggressive hydration with normal saline</p> <p>Urine alkalinization</p> <p>Forced diuresis (3 L/day)</p> </td> </tr> <tr> <td>Hyponatremia</td> <td>SIADH</td> <td>&nbsp;</td> </tr> <tr> <td>Mitomycin C</td> <td>Hemolytic uremic syndrome (4 to 6%)</td> <td>Microangiopathic lesions</td> <td>&nbsp;</td> </tr> <tr> <td>Nitrosoureas</td> <td>Chronic interstitial nephritis with progressive renal failure</td> <td>Glomerular sclerosis tubular fibrosis</td> <td>Adequate hydration</td> </tr> <tr> <td>Panitumumab</td> <td>Hypomagnesemia</td> <td>Tubular injury</td> <td>&nbsp;</td> </tr> <tr> <td>Rituximab</td> <td>Acute renal failure</td> <td>Tumor lysis syndrome</td> <td>&nbsp;</td> </tr> <tr> <td>Sorafenib</td> <td>Proteinuria, nephrotic syndrome</td> <td>Renal thrombotic microangiopathy?</td> <td>&nbsp;</td> </tr> <tr> <td>Streptozocin</td> <td>Proteinuria common (65 to 75%); tubular syndromes</td> <td>Proximal tubular damage</td> <td>&nbsp;</td> </tr> <tr> <td>Sunitinib</td> <td>Proteinuria, nephrotic syndrome</td> <td>Renal thrombotic microangiopathy?</td> <td>&nbsp;</td> </tr> <tr> <td>Vinca alkaloids</td> <td>Hyponatremia</td> <td>SIADH</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VEGF: vascular endothelial growth factor; ATN: acute tubular necrosis; SIADH: syndrome of inappropriate secretion of antidiuretic hormone.</div><div id=\"graphicVersion\">Graphic 54722 Version 4.0</div></div></div>"},"54723":{"type":"graphic_form","displayName":"Asthma self assess PI","title":"Self-assessment form*","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Self-assessment form*</div><div class=\"cntnt\"><img style=\"width:591px; height:770px;\" src=\"images/PI/54723_Asthma_self_assess_PI.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* These questions are examples and do not represent a standardized assessment instrument. Other examples of asthma control questions: Asthma Control Questionnaire (Juniper); Asthma Therapy Assessment Questionnaire (Vollmer); Asthma Control Test (Nathan); Asthma Control Score (Boulet).</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood,and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 54723 Version 2.0</div></div></div>"},"54724":{"type":"graphic_picture","displayName":"GAVE argon plasma Rx Endosc","title":"Gastric antral vascular ectasia (watermelon stomach)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric antral vascular ectasia (watermelon stomach)</div><div class=\"cntnt\"><img style=\"width:353px; height:544px;\" src=\"images/GAST/54724_GAVE_argon_plasma_Rx_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serial endoscopic images of gastric antral vascular ectasia (\"watermelon stomach\"), that has been treated with argon plasma coagulation. The top row shows the original appearance of the lesions, and their appearance following initial treatment. The middle row shows the appearance following the first treatment session and after the second treatment session. The third row demonstrates the marked improvement following the first two treatment sessions, and the appearance after a third treatment session.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 54724 Version 2.0</div></div></div>"},"54726":{"type":"graphic_table","displayName":"Contraindications medication abortion","title":"Contraindications to medication abortion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to medication abortion</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass</td> </tr> <tr> <td>Intrauterine device in place</td> </tr> <tr> <td>Chronic adrenal failure</td> </tr> <tr> <td>Concurrent long-term corticosteroid therapy</td> </tr> <tr> <td>Hemorrhagic disorders or concurrent anticoagulant therapy</td> </tr> <tr> <td>Inherited porphyrias</td> </tr> <tr> <td>Inability to understand the effects of the treatment procedure or to comply with its regimen</td> </tr> <tr> <td>Lack of adequate access to medical facilities equipped to provide emergency treatment of incomplete abortion, blood transfusions, and emergency resuscitation during the period from the first visit until discharged by the administering physician</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Guidelines per manufacturer (Danco laboratories).</div><div id=\"graphicVersion\">Graphic 54726 Version 5.0</div></div></div>"},"54727":{"type":"graphic_diagnosticimage","displayName":"Long axis aortic root dilation","title":"Aortic root dilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic root dilation</div><div class=\"cntnt\"><img style=\"width:308px; height:259px;\" src=\"images/CARD/54727_Long_axis_aortic_root_dilat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal long axis view shows a greatly dilated aortic root (Ao), with a diameter of 6 cm; the etiology is aortoannular ectasia. In the Marfan syndrome this degree of dilation is considered an indication for prophylactic surgery.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; LA: left atrium; rPA: right pulmonary artery.</div><div id=\"graphicVersion\">Graphic 54727 Version 2.0</div></div></div>"},"54728":{"type":"graphic_picture","displayName":"Injection at mid trochanter","title":"Injection at the mid-trochanteric process","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Injection at the mid-trochanteric process</div><div class=\"cntnt\"><img style=\"width:495px; height:318px;\" src=\"images/EM/54728_Injection_at_mid_trochanter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A local anesthetic block placed below the gluteus medius tendon at the periosteum of the trochanteric process can confirm the presence of trochanteric bursitis. The patient is placed in the lateral decubitus position with the affected side up and the knees flexed to 90 degrees. The superior, posterior, and anterior edges of the trochanteric process are palpated and marked. The point of entry is directly over the center point of the trochanter, approximately 4 cm (1.5 in)&nbsp;below the superior trochanter. Alternatively, the point of entry is at the crown of the trochanter viewed tangentially. Topical anesthetic (eg, ethyl chloride) is&nbsp;applied to&nbsp;the skin. Local anesthetic is&nbsp;injected at the gluteus medius tissue plane (1 mL) and at the periosteum of the femur (0.5 to 1 mL). A 4 cm (1.5 in), 22-gauge or 22-gauge spinal needle is inserted perpendicular to the skin; the depth is 4 to&nbsp;7.5 cm (1.5 to 3 in)&nbsp;to the femur. The needle is held lightly and advanced through the low resistance of the subcutaneous fat to the firm, rubbery resistance of the gluteus medius tissue plane. Following anesthesia at this level, the needle is advanced with firm pressure approximately 1.3 cm (0.5 in)&nbsp;farther to the periosteum of the femur. The patient will usually experience sharp pain as the needle touches the periosteum. Injection at this deeper level requires firm pressure. The needle should be rotated 180 degrees&nbsp;or withdrawn slightly if excessive pressure is encountered. If the trochanter tenderness is significantly relieved with anesthetic injection, 1 mL of triamcinolone acetonide 40 mg/mL can be injected through the same needle.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 54728 Version 4.0</div></div></div>"},"54731":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of osteogenesis imperfecta type 2","title":"Ultrasound of osteogenesis imperfecta type 2","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Ultrasound of osteogenesis imperfecta type 2</div><div class=\"cntnt\"><img style=\"width:483px; height:311px;\" src=\"images/OBGYN/54731_US_osteogenesis_imperfecta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) 24 weeks of gestation: Two-dimensional ultrasound cross-section of the thorax demonstrates the \"bashed in\" appearance of the ribs at the lateral aspect of the thorax due to the elbows hitting the fragile rib bones resulting in fractures and angulation (arrows).<br />(B) Three-dimensional ultrasound sagittal image of the wavy irregular contour of the ribs due to multiple fractures. Note the ribs are short and do not encircle the thorax.</div><div id=\"graphicVersion\">Graphic 54731 Version 5.0</div></div></div>"},"54732":{"type":"graphic_figure","displayName":"Methimazole versus PTU","title":"Methimazole acts faster than PTU in Graves' hyperthyroidism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Methimazole acts faster than PTU in Graves' hyperthyroidism</div><div class=\"cntnt\"><img style=\"width:382px; height:261px;\" src=\"images/ENDO/54732_Methimazole_versus_PTU.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time required for patients with Graves' hyperthyroidism to become euthyroid (normal serum T4 and T3 concentrations) after therapy with methimazole (10 mg three times daily, n = 66) or PTU (100 mg three times daily, n = 17). The euthyroid state was achieved more quickly with methimazole (5.8 versus 16.8 weeks).</div><div class=\"graphic_footnotes\">PTU: propylthiouracil; T4: thyroxine; T3: triiodothyronine.</div><div class=\"graphic_reference\">Data from: Okamura K, Ikenoue H, Shiroozu A, et al. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1987; 65:719.</div><div id=\"graphicVersion\">Graphic 54732 Version 5.0</div></div></div>"},"54735":{"type":"graphic_table","displayName":"Tremor other than essential tremor","title":"Symptoms or signs suggestive of tremor other than essential tremor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms or signs suggestive of tremor other than essential tremor</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom or sign</td> <td class=\"subtitle1\">Likely differential diagnosis</td> </tr> <tr> <td>Unilateral tremor, leg tremor, rigidity, bradykinesia, rest tremor</td> <td>Parkinson disease</td> </tr> <tr> <td>Gait disturbance</td> <td>Parkinson disease; cerebellar tremor</td> </tr> <tr> <td>Irregular, jerky tremor</td> <td>Dystonic tremor</td> </tr> <tr> <td>Isolated head tremor with abnormal posture (head tilt or turning)</td> <td>Dystonic tremor</td> </tr> <tr> <td>Sudden or rapid onset</td> <td>Functional (psychogenic) tremor; toxic tremor</td> </tr> <tr> <td>Current drug treatment that may cause or exacerbate tremor</td> <td>Drug-induced or toxic tremor</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Bain P, Brin M, Deuschl G, et al. Criteria for the diagnosis of essential tremor. Neurology 2000; 54(11 Suppl 4):S7. Copyright © 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54735 Version 18.0</div></div></div>"},"54736":{"type":"graphic_table","displayName":"Complications in preeclampsia","title":"Complications of preeclampsia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of preeclampsia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Outcome measure</td>\n<td class=\"subtitle1\">Normal blood pressure, (percent)</td>\n<td class=\"subtitle1\">Mild preeclampsia (percent)</td>\n<td class=\"subtitle1\">Severe preeclampsia (percent)</td>\n</tr>\n<tr>\n<td colspan=\"4\" class=\"subtitle2_left\">Maternal</td>\n</tr>\n<tr>\n<td class=\"indent1\">Liver dysfunction</td>\n<td>0.2</td>\n<td>3.2</td>\n<td>20.2</td>\n</tr>\n<tr>\n<td class=\"indent1\">Kidney dysfunction</td>\n<td>0.3</td>\n<td>5.1</td>\n<td>12.8</td>\n</tr>\n<tr>\n<td class=\"indent1\">Placental abruption</td>\n<td>0.7</td>\n<td>0.5</td>\n<td>3.7</td>\n</tr>\n<tr>\n<td class=\"indent1\">Induced labor</td>\n<td>12.1</td>\n<td>41.5</td>\n<td>58.7</td>\n</tr>\n<tr>\n<td class=\"indent1\">Cesarean delivery</td>\n<td>13.3</td>\n<td>30.9</td>\n<td>34.9</td>\n</tr>\n<tr>\n<td class=\"indent1\">Delivery &#60;34 weeks</td>\n<td>3.2</td>\n<td>1.9</td>\n<td>18.5</td>\n</tr>\n<tr>\n<td colspan=\"4\" class=\"subtitle2_left\">Fetal or neonatal</td>\n</tr>\n<tr>\n<td class=\"indent1\">Growth restriction</td>\n<td>4.2</td>\n<td>10.2</td>\n<td>18.5</td>\n</tr>\n<tr>\n<td class=\"indent1\">Admission to NICU</td>\n<td>12.9</td>\n<td>27.3</td>\n<td>42.6</td>\n</tr>\n<tr>\n<td class=\"indent1\">Respiratory difficulty</td>\n<td>3.8</td>\n<td>3.2</td>\n<td>15.7</td>\n</tr>\n<tr>\n<td class=\"indent1\">Brain hemorrhage</td>\n<td>0.2</td>\n<td>0.5</td>\n<td>0</td>\n</tr>\n<tr>\n<td class=\"indent1\">Fetal death</td>\n<td>0.9</td>\n<td>0.5</td>\n<td>0.9</td>\n</tr>\n<tr>\n<td class=\"indent1\">Neonatal death</td>\n<td>0.5</td>\n<td>0.5</td>\n<td>0.9</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from data in Hauth, JC, Ewell, MG, Levine, RJ, et al. Obstet Gynecol 2000; 95:24.</div><div id=\"graphicVersion\">Graphic 54736 Version 1.0</div></div></div>"},"54737":{"type":"graphic_figure","displayName":"Uterine blood supply","title":"Uterine blood supply","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Uterine blood supply</div><div class=\"cntnt\"><img style=\"width:539px; height:495px;\" src=\"images/OBGYN/54737_Uterine_blood_supply.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54737 Version 2.0</div></div></div>"},"54738":{"type":"graphic_figure","displayName":"Cerebrospinal fluid manometry","title":"Cerebrospinal fluid (CSF) manometry","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Cerebrospinal fluid (CSF) manometry</div><div class=\"cntnt\"><img style=\"width:475px; height:363px;\" src=\"images/PEDS/54738_CSF_manometry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midsagittal section through lumbar spinal column showing positioning for measurement of CSF opening pressure. The manometer is attached to the spinal needle hub with a three-way stop-cock. CSF is permitted to enter the manometer; opening pressure is recorded at the highest level attained by the CSF in the manometer column. Pressure measurements should be taken with the patient recumbent.</div><div class=\"graphic_reference\">Adapted from Dieckmann RA, Fiser DH, Selbst SM, (Eds). Illustrated Textbook of Pediatric Emergency and Critical Care Procedures. Mosby, St. Louis, 1997.</div><div id=\"graphicVersion\">Graphic 54738 Version 4.0</div></div></div>"},"54739":{"type":"graphic_figure","displayName":"Ear infections PI","title":"Ear infection (otitis media)","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Ear infection (otitis media)</div><div class=\"cntnt\"><img style=\"width:474px; height:327px;\" src=\"images/PI/54739_OtitismediaPIedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ear on the left is normal and does not have an infection. The ear on the right shows what an infection can look like. The infected fluid in the middle ear causes the eardrum to bulge. Normally, fluid in the middle ear drains into the throat through a tube called the \"Eustachian tube.\" But during an infection, swelling blocks off the tube, so fluid builds up.</div><div id=\"graphicVersion\">Graphic 54739 Version 8.0</div></div></div>"},"54741":{"type":"graphic_picture","displayName":"Bakers cyst position for US","title":"Positions for aspiration of popliteal (Baker's) cyst with ultrasound guidance","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Positions for aspiration of popliteal (Baker's) cyst with ultrasound guidance</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/54741_Bakers_cyst_pos_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph showing how to aspirate a Baker's cyst in the popliteal fossa.</div><div class=\"graphic_reference\">Reproduced with permission from: George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 54741 Version 1.0</div></div></div>"},"54742":{"type":"graphic_diagnosticimage","displayName":"Jones fracture nonoperative healing","title":"Nonoperative healing of a Jones fracture in an adolescent","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Nonoperative healing of a Jones fracture in an adolescent</div><div class=\"cntnt\"><img style=\"width:514px; height:287px;\" src=\"images/EM/54742_Jonesfxnonoperative.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 13-year-old girl sustained a &quot;Jones&quot; fracture playing basketball and was treated nonoperatively. A) Initial x-ray shows minimal displacement. B) At 3 months, there is residual lucency, but the patient is asymptomatic. C) At 6 months, consolidation is still delayed but patient remains asymptomatic.</div><div class=\"graphic_reference\">Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54742 Version 12.0</div></div></div>"},"54743":{"type":"graphic_table","displayName":"Mechanisms of malabsorption","title":"Malabsorption: Examples of conditions causing malabsorption, categorized by the phase of absorption that is impaired","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Malabsorption: Examples of conditions causing malabsorption, categorized by the phase of absorption that is impaired</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Phase and nature of malabsorptive defect</td> <td class=\"subtitle1\">Example</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Luminal phase</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">A. Substrate hydrolysis</td> </tr> <tr> <td class=\"sublist1\">1. Digestive enzyme deficiency</td> <td class=\"sublist_other\">Chronic pancreatitis</td> </tr> <tr> <td class=\"sublist1\">2. Digestive enzyme inactivation</td> <td class=\"sublist_other\">Zollinger-Ellison syndrome</td> </tr> <tr> <td class=\"sublist1\">3. Dyssynchrony of enzyme release, inadequate mixing</td> <td class=\"sublist_other\">Post Billroth II procedure</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">B. Fat solubilization</td> </tr> <tr> <td class=\"sublist1\">1. Diminished bile salt synthesis</td> <td class=\"sublist_other\">Cirrhosis</td> </tr> <tr> <td class=\"sublist1\">2. Impaired bile secretion</td> <td class=\"sublist_other\">Chronic cholestasis</td> </tr> <tr> <td class=\"sublist1\">3. Bile salt de-conjugation</td> <td class=\"sublist_other\">Bacterial overgrowth</td> </tr> <tr> <td class=\"sublist1\">4. Increased bile salt loss</td> <td class=\"sublist_other\">Ileal disease or resection</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">C. Luminal availability of specific nutrients</td> </tr> <tr> <td class=\"sublist1\">1. Diminished gastric acid</td> <td class=\"sublist_other\">Atrophic gastritis - vitamin B12</td> </tr> <tr> <td class=\"sublist1\">2. Diminished intrinsic factor</td> <td class=\"sublist_other\">Pernicious anemia - vitamin B12</td> </tr> <tr> <td class=\"sublist1\">3. Bacterial consumption of nutrients</td> <td class=\"sublist_other\">Bacterial overgrowth - vitamin B12</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Mucosal (absorptive) phase</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">A. Brush border hydrolysis*</td> </tr> <tr> <td class=\"sublist1\">1. Congenital disaccharidase defect</td> <td class=\"sublist_other\">Sucrase-isomaltase deficiency</td> </tr> <tr> <td class=\"sublist1\">2. Acquired disaccharidase defect</td> <td class=\"sublist_other\">Lactase deficiency</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">B. Epithelial transport</td> </tr> <tr> <td class=\"sublist1\">1. Nutrient-specific defects in transport</td> <td class=\"sublist_other\">Hartnup's disease</td> </tr> <tr> <td class=\"sublist1\">2. Global defects in transport</td> <td class=\"sublist_other\">Celiac sprue</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Postabsorptive, processing phase</td> </tr> <tr> <td>A. Enterocyte processing</td> <td>Abetalipoproteinemia</td> </tr> <tr> <td>B. Lymphatic</td> <td>Intestinal lymphangiectasia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This process is sometimes considered as part of the luminal phase.</div><div class=\"graphic_reference\">Reproduced with permission from: Sleisenger MH, Fordtran JS (Eds), Gastrointestinal Diseases, 5th ed, 1993, W.B. Saunders, Philadelphia. p.1010. Copyright &#169; 1993 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 54743 Version 3.0</div></div></div>"},"54746":{"type":"graphic_table","displayName":"Susceptibility to TMP SMX","title":"Organisms susceptible to trimethoprim-sulfamethoxazole","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Organisms susceptible to trimethoprim-sulfamethoxazole</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Urinary tract pathogens</td> </tr> <tr> <td>Escherichia coli</td> </tr> <tr> <td>Klebsiella pneumonia</td> </tr> <tr> <td>Proteus mirabilis</td> </tr> <tr> <td>Enterobacter sp.</td> </tr> <tr> <td>Morganella morgani</td> </tr> <tr> <td class=\"subtitle1_single\">Respiratory tract pathogens</td> </tr> <tr> <td>Streptococcus pneumoniae</td> </tr> <tr> <td>Haemophilus influenzae</td> </tr> <tr> <td>Moraxella catarrhalis</td> </tr> <tr> <td>Pneumocystis jirovecii</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal pathogens</td> </tr> <tr> <td>Enterotoxigenic E. coli</td> </tr> <tr> <td>Shigella sp.</td> </tr> <tr> <td>Salmonella typhi (and other species)</td> </tr> <tr> <td>Vibrio cholerae</td> </tr> <tr> <td>Cyclospora cayetanensis</td> </tr> <tr> <td>Isospora belli</td> </tr> <tr> <td>Yersinia</td> </tr> <tr> <td class=\"subtitle1_single\">Other pathogens</td> </tr> <tr> <td>Nocardia sp.</td> </tr> <tr> <td>Listeria monocytogenes</td> </tr> <tr> <td>Mycobacterium marinum</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54746 Version 3.0</div></div></div>"},"54747":{"type":"graphic_algorithm","displayName":"Pathogenesis of abruption","title":"Conceptual model showing coagulation/thrombosis, infection, inflammation, angiogenesis, and collagen metabolism pathways to placental abruption","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Conceptual model showing coagulation/thrombosis, infection, inflammation, angiogenesis, and collagen metabolism pathways to placental abruption</div><div class=\"cntnt\"><img style=\"width:551px; height:310px;\" src=\"images/OBGYN/54747_Pathogenesis_of_abruption.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MMP = matrix metalloproteinases</div><div id=\"graphicVersion\">Graphic 54747 Version 2.0</div></div></div>"},"54748":{"type":"graphic_picture","displayName":"Vertical growth melanoma","title":"Vertical growth phase malignant melanoma","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Vertical growth phase malignant melanoma</div><div class=\"cntnt\"><img style=\"width:527px; height:566px;\" src=\"images/ONC/54748_Vertical_growth_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrographs of a nodular, vertical growth phase melanoma, characterized by the formation of an expansile nodule of melanoma cells in the dermis. Clinically, this results in a papule or nodule arising against the background of the flat radial growth phase. In the top figure (Panel A), the invasive melanoma has a polypoid growth pattern arising in a superficial spreading melanoma. The surface is ulcerated and the maximum depth of invasion is measured from the base of the ulcer to the deepest melanoma cell. In the bottom figure (Panel B), the invasive melanoma is forming large tumor nodules and has invaded the subcutis (black arrows).</div><div class=\"graphic_reference\">Courtesy of Roy King, MD.</div><div id=\"graphicVersion\">Graphic 54748 Version 1.0</div></div></div>"},"54749":{"type":"graphic_table","displayName":"Treatment plan for fecal incontinence","title":"Example of treatment plan for a 4-year-old child with fecal incontinence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of treatment plan for a 4-year-old&nbsp;child with fecal incontinence</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"> <p>A.&nbsp;Small fecal impaction</p> (oral medications)</td> <td class=\"subtitle1\"> <p>B. Large fecal impaction</p> (oral and rectal medication)</td> </tr> <tr> <td><strong>Day 1</strong></td> <td> <ul> <li>Educate family and caregiver about fecal impaction and overflow incontinence and the need for long term laxative therapy </li> <li>Start PEG (eg, Miralax, Glycolax, Pegalax),&nbsp;1 gram/kg&nbsp;once daily, given in the morning<sup>&#182;</sup> </li> </ul> </td> <td> <ul> <li>Educate family as in column A </li> <li>Start PEG&nbsp;1 to 1.5&nbsp;grams/kg&nbsp;daily, divided into two doses<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td><strong>Day 2 to 3</strong></td> <td> <ul> <li>Continue PEG&nbsp;once daily&nbsp; </li> </ul> </td> <td> <ul> <li>Continue&nbsp;PEG&nbsp;twice daily </li> </ul> </td> </tr> <tr> <td><strong>Day&nbsp;4 to 6</strong></td> <td> <ul> <li>If child is beginning to pass 1 to 2 soft to loose stools daily, continue above dose of PEG </li> <li>If child is not passing soft to loose stools, increase dose of PEG to 1.5 grams/kg, divided into two doses. Soiling should gradually decrease and stop. </li> <li>Establish regular toileting patterns by having&nbsp;the child sit on the toilet for 5 to 10 minutes, 2 to 3 times daily after meals </li> </ul> </td> <td> <ul> <li>If child has not passed a large amount of stool, give sodium phosphate enema<sup>&#916;</sup> (eg, Fleet enema), 33 to 66 mL, depending on the size of the child </li> <li>Continue twice daily dosing of PEG for up to six days total, until the child has passed a large amount of stool </li> <li>Once the child is having soft stools at least once daily, reduce PEG to&nbsp;1 gram/kg, given once daily in the morning). </li> <li>Establish regular toileting patterns (as described in column A) </li> </ul> </td> </tr> <tr> <td><strong>Day&nbsp;7 to 30</strong></td> <td colspan=\"2\"> <ul> <li>Be sure parent calls if not making progress, so further adjustments in PEG dose can be made. Occasionally it is necessary to increase PEG to twice daily dosing. </li> </ul> </td> </tr> <tr> <td><strong>1 month</strong></td> <td colspan=\"2\"> <ul> <li>Return office visit to evaluate progress and to reinforce need for regular laxative therapy </li> <li>Provide handout or references for fiber-rich diet and have family work to increase fiber content of diet, for long-term maintenance </li> </ul> </td> </tr> <tr> <td><strong>1 to 6 months</strong></td> <td colspan=\"2\"> <ul> <li>Return office visit every 1 to 2 months to reinforce therapy and adjust dose of laxative if necessary </li> </ul> </td> </tr> <tr> <td><strong>6 to 12 months (or longer)</strong></td> <td colspan=\"2\"> <ul> <li>Once the child is maintaining normal bowel movements without soiling for several months, consider gradually tapering laxative over 2 months </li> <li>Be sure patient is on a&nbsp;fiber-rich diet </li> <li>Some children require ongoing laxative treatment for one or more years </li> </ul> </td> </tr> <tr> <td><strong>Beyond 12 months</strong></td> <td colspan=\"2\"> <ul> <li>Follow as long as it takes for resolution. Can be months to several years before encopresis resolves completely. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This treatment plan describes the author's approach to a typical&nbsp;four-year old child* with constipation&nbsp;and&nbsp;fecal incontinence. Alternative regimens and considerations are described in the topic text.</div><div class=\"graphic_footnotes\">PEG: Polyethylene glycol-3350, which is also known as PEG without electrolytes and macrogol (eg, Miralax, Pegalax). Trade names shown are for over-the-counter products available in the United States and some other countries.<br />* Body weight 15 to 20 kg<br />¶ 1 packet or capful PEG = 17 grams = 3.5 teaspoons<br />Δ Sodium phosphate enemas or other phosphate-containing laxatives are rarely associated with severe electrolyte abnormalities and acute phosphate nephropathy. Avoid using these agents more than once daily, or in children who are dehydrated, aged &lt;2 years, or who have chronic kidney disease. </div><div class=\"graphic_reference\">Courtesy of Manu Sood, MD, with additional data from Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58:258.</div><div id=\"graphicVersion\">Graphic 54749 Version 9.0</div></div></div>"},"54750":{"type":"graphic_table","displayName":"Common fears in childhood and adolescence","title":"Common fears in childhood and adolescence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common fears in childhood and adolescence</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Age, years</td>\n\t\t\t\t\t<td class=\"subtitle1\">Common fears</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>1</td>\n\t\t\t\t\t<td>Separation, falling, animals/insects, toilet training, bath</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>2</td>\n\t\t\t\t\t<td>Separation, noises, toilet training, bath, bedtime</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>3</td>\n\t\t\t\t\t<td>Animals/insects, bedtime, monsters/ghosts, getting lost</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>5</td>\n\t\t\t\t\t<td>Animals/insects, monsters/ghosts, divorce, getting lost, loss of parent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>7</td>\n\t\t\t\t\t<td>Separation, noises, falling, bedtime</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>9</td>\n\t\t\t\t\t<td>Social rejection, war, new situations, adoption</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>12</td>\n\t\t\t\t\t<td>Falling, burglars</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>14</td>\n\t\t\t\t\t<td>Adoption, burglars, injections, sexual relations</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Schachter, R. When Your Child is Afraid. Simon and Schuster 1989.</div><div id=\"graphicVersion\">Graphic 54750 Version 2.0</div></div></div>"},"54751":{"type":"graphic_figure","displayName":"Port placement for TEP hernia repair","title":"Port placement for TEP hernia repair","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Port placement for TEP hernia repair</div><div class=\"cntnt\"><img style=\"width:486px; height:602px;\" src=\"images/SURG/54751_TEP_ports_A.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54751 Version 3.0</div></div></div>"},"54753":{"type":"graphic_picture","displayName":"Lentigo maligna melanoma 3","title":"Lentigo maligna melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/54753_Lentigo_malig_melan_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lentigo maligna melanoma with a nodule present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54753 Version 4.0</div></div></div>"},"54754":{"type":"graphic_picture","displayName":"Pterygium 2 and 3","title":"Examples of pterygium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examples of pterygium</div><div class=\"cntnt\"><img style=\"width:388px; height:583px;\" src=\"images/PC/54754_Pterygium_extending_iris.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image created by Christopher J. Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54754 Version 5.0</div></div></div>"},"54755":{"type":"graphic_table","displayName":"Graded prognostic assessment for brain metastases breast cancer","title":"Graded prognostic assessment for brain metastases from breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Graded prognostic assessment for brain metastases from breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Prognostic factor</td> <td class=\"subtitle1\" colspan=\"5\">GPA scoring criteria</td> <td class=\"subtitle1\" rowspan=\"2\">Patient score</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">0.5</td> <td class=\"subtitle2\">1.0</td> <td class=\"subtitle2\">1.5</td> <td class=\"subtitle2\">2.0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Breast cancer</td> </tr> <tr> <td class=\"indent1\">KPS</td> <td class=\"centered\">&#8804;50</td> <td class=\"centered\">60</td> <td class=\"centered\">70-80</td> <td class=\"centered\">90-100</td> <td class=\"centered\">N/A</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Subtype*</td> <td class=\"centered\">Basal</td> <td class=\"centered\">N/A</td> <td class=\"centered\">Luminal A</td> <td class=\"centered\">HER2</td> <td class=\"centered\">Luminal B</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Age, years</td> <td class=\"centered\">&#8805;60</td> <td class=\"centered\">&#60;60</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"6\" align=\"right\"><strong>Sum total:</strong></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Median survival (months) by GPA: 0-1.0 = 3.4; 1.5-2.0 = 7.7; 2.5-3.0 = 15.1; 3.5-4.0 = 25.3.</div><div class=\"graphic_footnotes\">GPA: graded prognostic assessment; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; KPS: Karnofsky performance score; PR: progesterone receptor.<br />* Basal: triple negative; Luminal A: ER/PR positive, HER2 negative; Luminal B: triple positive; HER2: ER/PR negative, HER2 positive.</div><div class=\"graphic_reference\">From: Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012: 30:419. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 54755 Version 5.0</div></div></div>"},"54757":{"type":"graphic_table","displayName":"Medications with plant origins","title":"Examples of conventional medications with plant origins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of conventional medications with plant origins</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Herb common name (Latin name)</td> </tr> <tr> <td>Atropine</td> <td>Belladona (<em>Atropa belladonna</em>)</td> </tr> <tr> <td>Codeine</td> <td>Poppy (<em>Papaver somniferum</em>)</td> </tr> <tr> <td>Colchicine</td> <td>Autumn crocus (<em>Colchicum autumnale</em>)</td> </tr> <tr> <td>Digoxin</td> <td>Foxglove (<em>Digitalis purpurea</em>)</td> </tr> <tr> <td>Ephedrine</td> <td>Ephedra (<em>Ephedra sinica</em>)</td> </tr> <tr> <td>Reserpine</td> <td>Rauwolfia (<em>Rauvolfia serpentine</em>)</td> </tr> <tr> <td>Salicylic acid</td> <td>Willow bark (<em>Salix purpurea</em>)</td> </tr> <tr> <td>Scopolamine</td> <td>Jimson weed (<em>Datura stramonium</em>)</td> </tr> <tr> <td>Taxol</td> <td>Pacific yew (<em>Taxus brevifolia</em>)</td> </tr> <tr> <td>Vincristine </td> <td>Madagascar periwinkle (<em>Catharanthus roseus</em>)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54757 Version 2.0</div></div></div>"},"54758":{"type":"graphic_figure","displayName":"LVEF survival LV dysfunction","title":"Mortality in heart failure is related to left ventricular function","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mortality in heart failure is related to left ventricular function</div><div class=\"cntnt\"><img style=\"width:397px; height:306px;\" src=\"images/CARD/54758_LVEF_survival_LV_dysfunctio.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival curves of 1172 patients in the SOLVD trials and registry show that a left ventricular ejection fraction (LVEF) &lt;35 percent is associated with an increased all-cause mortality (risk ratio 1.8 compared to a LVEF ≥35 percent, p = 0.012).</div><div class=\"graphic_reference\">Data from Quinones MA, Greenberg BH, Kopelen HA, et al, for the SOLVD Investigators. J Am Coll Cardiol 2000; 35:1237.</div><div id=\"graphicVersion\">Graphic 54758 Version 2.0</div></div></div>"},"54759":{"type":"graphic_table","displayName":"Preventing and managing smoking relapse","title":"Preventing and managing relapse in smokers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preventing and managing relapse in smokers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Technique</td> </tr> <tr> <td rowspan=\"5\"><strong>Relapse prevention</strong></td> <td>Every ex-tobacco user undergoing relapse prevention should receive congratulations on any success and strong encouragement to remain abstinent. When encountering a recent quitter, use open-ended questions designed to initiate patient problemsolving (eg, How has stopping tobacco use helped you?).</td> </tr> <tr> <td class=\"sublist1_start\">The clinician should encourage the patient's active discussion of the topics below:</td> </tr> <tr> <td class=\"sublist1\">The benefits, including potential health benefits, that the patient may derive from cessation</td> </tr> <tr> <td class=\"sublist1\">Any success the patient has had in quitting (duration of abstinence, reduction in withdrawal, etc)</td> </tr> <tr> <td class=\"sublist1\">The problems encountered or anticipated threats to maintaining abstinence (eg, depression, weight gain, alcohol, other tobacco users in the household)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Management of relapse</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Lack of support for cessation</td> <td>Schedule follow-up visits or telephone calls with the patient</td> </tr> <tr> <td>Help the patient identify sources of support within his or her environment</td> </tr> <tr> <td>Refer the patient to an appropriate organization that offers cessation counseling or support</td> </tr> <tr> <td class=\"indent1\">Negative mood or depression</td> <td>If significant, provide counseling, prescribe appropriate medications, or refer the patient to a specialist</td> </tr> <tr> <td class=\"indent1\">Strong or prolonged withdrawal symptoms</td> <td>If the patient reports prolonged craving or other withdrawal symptoms, consider extending the use of an approved pharmacotherapy or adding/combining pharmacologic medication to reduce strong withdrawal symptoms</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Weight gain</td> <td>Recommend starting or increasing physical activity; discourage strict dieting</td> </tr> <tr> <td>Reassure the patient that some weight gain after quitting is common and appears to be self-limiting</td> </tr> <tr> <td>Emphasize the importance of a healthy diet</td> </tr> <tr> <td>Maintain the patient on pharmacotherapy known to delay weight gain (eg, bupropion SR; nicotine-replacement pharmacotherapies, particularly nicotine gum)</td> </tr> <tr> <td>Refer the patient to a specialist or program</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Flagging motivation/feeling deprived</td> <td>Reassure the patient that these feelings are common</td> </tr> <tr> <td>Recommend rewarding activities</td> </tr> <tr> <td>Probe to ensure that the patient is not engaged in periodic tobacco use</td> </tr> <tr> <td>Emphasize that beginning to smoke (even a puff) will increase urges and make quitting more difficult</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Fiore MC, Jaen C, Baker T, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service. 2008.</div><div id=\"graphicVersion\">Graphic 54759 Version 7.0</div></div></div>"},"54760":{"type":"graphic_figure","displayName":"BOS after lung transplant","title":"Freedom from bronchiolitis obliterans syndrome in adult lung recipients","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Freedom from bronchiolitis obliterans syndrome in adult lung recipients</div><div class=\"cntnt\"><img style=\"width:489px; height:292px;\" src=\"images/PULM/54760_BOS_after_lung_transplant.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult lung transplant recipient freedom from bronchiolitis obliterans syndrome (BOS), conditional on survival to 14 days (transplant follow-up assessments: April 1994-June 2012).</div><div class=\"graphic_reference\">Reproduced from: Yusen RD, Christie JD, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth adult lung and heart-lung transplant report--2013; focus theme: age. J Heart Lung Transplant 2013; 32:965. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 54760 Version 3.0</div></div></div>"},"54762":{"type":"graphic_table","displayName":"Diagnosis of Behçet's syndrome","title":"Diagnostic criteria for Behçet's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for Behçet's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Criterion</td> <td class=\"subtitle1\">Required features</td> </tr> <tr> <td class=\"subtitle2_left\">Recurrent oral ulceration</td> <td>Aphthous (idiopathic) ulceration, observed by&nbsp;clinician&nbsp;or patient, with at least three episodes in any 12-month period</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Plus any two of the following:</td> </tr> <tr> <td class=\"indent1\">Recurrent genital ulceration</td> <td>Aphthous ulceration or scarring, observed by&nbsp;clinician or patient</td> </tr> <tr> <td class=\"indent1\">Eye lesions</td> <td>Anterior or posterior uveitis cells in vitreous in slit-lamp examination; or retinal vasculitis documented by ophthalmologist</td> </tr> <tr> <td class=\"indent1\">Skin lesions</td> <td>Erythema nodosum-like lesions observed by&nbsp;clinician or patient; papulopustular skin lesions or pseudofolliculitis with characteristic acneiform nodules observed by clinician</td> </tr> <tr> <td class=\"indent1\">Pathergy test</td> <td>Interpreted at 24 to 48 hours by clinician</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990; 335:1078.</div><div id=\"graphicVersion\">Graphic 54762 Version 5.0</div></div></div>"},"54763":{"type":"graphic_table","displayName":"Chest pain in ER","title":"Abbreviated list of causes of chest pain in patients presenting to the emergency department","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abbreviated list of causes of chest pain in patients presenting to the emergency department</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Cardiac\n   </td>\n   </tr>\n   <tr>\n   <td>Myocardial ischemia or infarction</td>\n   </tr>\n   <tr>\n   <td>Aortic dissection</td>\n   </tr>\n   <tr>\n   <td>Pericarditis</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Pulmonary\n   </td>\n   </tr>\n   <tr>\n   <td>Pulmonary embolus and other causes of pulmonary hypertension</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Chest wall trauma\n   </td>\n   </tr>\n   <tr>\n   <td>Myocardial or pericardial contusion</td>\n   </tr>\n   <tr>\n   <td>Traumatic valve injury</td>\n   </tr>\n   <tr>\n   <td>Aortic injury</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Noncardiac chest pain\n   </td>\n   </tr>\n   <tr>\n   <td>Gastrointestinal</td>\n   </tr>\n   <tr>\n   <td>Musculoskeletal</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 54763 Version 1.0</div></div></div>"},"54765":{"type":"graphic_waveform","displayName":"Echo MVG normal HHD","title":"Examples of echocardiographic transmitral flow patterns and myocardial velocity gradients","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examples of echocardiographic transmitral flow patterns and myocardial velocity gradients</div><div class=\"cntnt\"><img style=\"width:430px; height:352px;\" src=\"images/CARD/54765_EchoMVGnormalHHD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top panel (A) shows transmitral flow patterns ,and the bottom panel shows myocardial velocity gradients (MVGs) from normal subjects, patients with hypertensive heart disease (HHD), and patients with dilated cardiomyopathy (DCM). In HHD, there is a decrease in E and E/A and an increase in deceleration time of the early diastolic filling velocity (DcT). These variables were not altered in DCM compared&nbsp;with normals.&nbsp;By contrast, the peak MVGs were lower in HHD and DCM compared&nbsp;with normals.</div><div class=\"graphic_reference\">Reprinted with permission from Shimizu Y, Uematsu M, Shimizu H, et al. J Am Coll Cardiol 1998; 32:1418.</div><div id=\"graphicVersion\">Graphic 54765 Version 4.0</div></div></div>"},"54767":{"type":"graphic_table","displayName":"Wells criteria and modified Wells criteria","title":"Wells criteria and modified Wells criteria: clinical assessment for pulmonary embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Wells criteria and modified Wells criteria: clinical assessment for pulmonary embolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Clinical symptoms of DVT (leg swelling, pain with palpation)</td> <td>3.0</td> </tr> <tr> <td>Other diagnosis less likely than pulmonary embolism</td> <td>3.0</td> </tr> <tr> <td>Heart rate &#62;100</td> <td>1.5</td> </tr> <tr> <td>Immobilization (&#8805;3 days) or surgery in the previous four weeks</td> <td>1.5</td> </tr> <tr> <td>Previous DVT/PE</td> <td>1.5</td> </tr> <tr> <td>Hemoptysis</td> <td>1.0</td> </tr> <tr> <td>Malignancy</td> <td>1.0</td> </tr> <tr> <td class=\"subtitle1\">Probability </td> <td class=\"subtitle1\">Score </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Traditional clinical probability assessment (Wells criteria) </td> </tr> <tr> <td class=\"indent1\">High </td> <td>&#62;6.0</td> </tr> <tr> <td class=\"indent1\">Moderate </td> <td>2.0 to 6.0</td> </tr> <tr> <td class=\"indent1\">Low </td> <td>&#60;2.0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Simplified clinical probability assessment (Modified Wells criteria)</td> </tr> <tr> <td class=\"indent1\">PE likely </td> <td>&#62;4.0</td> </tr> <tr> <td class=\"indent1\">PE unlikely </td> <td>&#8804;4.0</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=66639&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">DVT: deep vein thrombosis; PE: pulmonary embolism.</div><div class=\"graphic_reference\">Data from van Belle A, Buller HR, Huisman MV,&nbsp;et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006; 295:172.</div><div id=\"graphicVersion\">Graphic 54767 Version 3.0</div></div></div>"},"54768":{"type":"graphic_figure","displayName":"Symptoms airway disease","title":"Symptoms of upper and lower airways disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Symptoms of upper and lower airways disease</div><div class=\"cntnt\"><img style=\"width:395px; height:366px;\" src=\"images/PULM/54768_Symptoms_airway_disease.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The symptoms of upper and lower airways disease can be directly or indirectly attributed to a dysregulation of airway nerves. See text for details.</div><div id=\"graphicVersion\">Graphic 54768 Version 1.0</div></div></div>"},"54769":{"type":"graphic_picture","displayName":"Brunsting-Perry pemphigoid","title":"Brunsting-Perry pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Brunsting-Perry pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/54769_Brunsting-Perry_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions leading to scarring on scalp skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54769 Version 4.0</div></div></div>"},"54770":{"type":"graphic_table","displayName":"Chronic eosinophilic leukemia WHO criteria","title":"WHO criteria: chronic eosinophilic leukemia and hypereosinophilic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO criteria: chronic eosinophilic leukemia and hypereosinophilic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Required </td> </tr> <tr> <td>Persistent peripheral blood eosinophilia (&#8805;1500/microL)</td> </tr> <tr> <td>Increased numbers of bone marrow eosinophils</td> </tr> <tr> <td>Myeloblasts &#60;20 percent in peripheral blood or bone marrow</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions to be excluded </td> </tr> <tr> <td class=\"subtitle2_single\">Reactive eosinophilia </td> </tr> <tr> <td class=\"indent1\">Allergy </td> </tr> <tr> <td class=\"indent1\">Parasitic diseases </td> </tr> <tr> <td class=\"indent1\">Infectious diseases </td> </tr> <tr> <td class=\"indent1\">Pulmonary disease (eg, hypersensitivity pneumonia, Loeffler's pneumonia) </td> </tr> <tr> <td class=\"indent1\">Collagen vascular disorders </td> </tr> <tr> <td class=\"subtitle2_single\">Neoplastic disorders with secondary reactive eosinophilia </td> </tr> <tr> <td class=\"indent1\">T cell lymphomas (eg, mycosis fungoides, S&#233;zary syndrome) </td> </tr> <tr> <td class=\"indent1\">Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Acute lymphoblastic leukemia </td> </tr> <tr> <td class=\"indent1\">Mastocytosis </td> </tr> <tr> <td class=\"subtitle2_single\">Neoplastic disorders in which eosinophils are part of the neoplastic clone </td> </tr> <tr> <td class=\"indent1\">Chronic myeloid leukemia (Ph1 + or BCR/ABL positive) </td> </tr> <tr> <td class=\"indent1\">Acute myeloid leukemia [eg, FAB M4Eo with inv(16), t(16;16)(p13;q22)] </td> </tr> <tr> <td class=\"indent1\">Other myeloproliferative disorders (eg, polycythemia vera, essential thrombocytosis, chronic idiopathic myelofibrosis) </td> </tr> <tr> <td class=\"subtitle2_single\">T cell population with aberrant phenotype and abnormal cytokine production </td> </tr> <tr> <td class=\"subtitle1_single\">Diagnosis </td> </tr> <tr> <td class=\"subtitle2_single\">Hypereosinophilic syndrome: </td> </tr> <tr> <td class=\"indent1\">This diagnosis is made if there is no demonstrable disease that could cause the eosinophilia, no abnormal T cell population, and no evidence for a clonal myeloid malignancy. </td> </tr> <tr> <td class=\"subtitle2_single\">Chronic eosinophilic leukemia: </td> </tr> <tr> <td class=\"indent1\">This diagnosis is made if all of the above exclusions have been met and if the myeloid cells demonstrate a clonal chromosomal abnormality, or are shown to be clonal by other means, or blast cells are present in the peripheral blood (&#62; 2 percent) or are increased in the bone marrow (&#62;5 to &#60;19 percent of nucleated cells). </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Bain B, et al. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2001. p.49. Permission granted from Harris NL and Vardiman JW.</div><div id=\"graphicVersion\">Graphic 54770 Version 3.0</div></div></div>"},"54771":{"type":"graphic_diagnosticimage","displayName":"Anterior chest pain bone scan","title":"Manubriosternal, sternoclavicular, and xyphisternal involvement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manubriosternal, sternoclavicular, and xyphisternal involvement</div><div class=\"cntnt\"><img style=\"width:246px; height:351px;\" src=\"images/RHEUM/54771_Anterior_chest_pain_bone_sc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An abnormal technetium labled pyrophosphate bone scan showing increased uptake at the xiphisternal, manubriosternal, and sternoclavicular articulations.</div><div class=\"graphic_reference\">Courtesy of Christopher Wise, MD.</div><div id=\"graphicVersion\">Graphic 54771 Version 2.0</div></div></div>"},"54772":{"type":"graphic_diagnosticimage","displayName":"CXR and chest CT scan showing pericardial and pleural effusions","title":"Chest radiograph (CXR, panel A) and computed tomography (CT, panel B) showing pericardial and pleural effusions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph (CXR, panel A) and computed tomography (CT, panel B) showing pericardial and pleural effusions</div><div class=\"cntnt\"><img style=\"width:323px; height:495px;\" src=\"images/CARD/54772_Pericardial_pleural_effus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Chest radiograph in a patient with concomitant malignant pericardial and malignant pleural effusions from metastatic breast cancer. B) CT scan of the chest in a patient with concomitant malignant pericardial and malignant pleural effusions from metastatic breast cancer.</div><div class=\"graphic_reference\">Courtesy of: DeCamp MM, Gangadharan SP.</div><div id=\"graphicVersion\">Graphic 54772 Version 4.0</div></div></div>"},"54773":{"type":"graphic_diagnosticimage","displayName":"Arteriovenous malformation I","title":"Pulmonary arteriovenous malformation in the right upper lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary arteriovenous malformation in the right upper lobe</div><div class=\"cntnt\"><img style=\"width:432px; height:335px;\" src=\"images/PULM/54773_Arteriovenous_malform_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal CT image with lung window settings shows a right upper lobe solitary pulmonary nodule with several tentacle-like extensions suspicious for an arteriovenous malformation. The enhancement of the nodule is identical to that of the central pulmonary arterial branches.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 54773 Version 3.0</div></div></div>"},"54774":{"type":"graphic_picture","displayName":"Fusarium cutaneous nodule","title":"Cutaneous nodule in a patient with disseminated fusariosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous nodule in a patient with disseminated fusariosis</div><div class=\"cntnt\"><img style=\"width:324px; height:273px;\" src=\"images/ID/54774_Fusarium_cutan_nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cutaneous nodule with central necrosis on the chest of a 15-year-old patient with aplastic anemia who had disseminated fusariosis.</div><div class=\"graphic_reference\">Reproduced from: Nucci M, Spector N, Lucena S, et al. Three cases of infection with Fusarium species in neutropenic patients. Eur J Clin Microbiol Infect Dis 1992; 11:1160, with kind permission from Springer Science and Business Media.</div><div id=\"graphicVersion\">Graphic 54774 Version 1.0</div></div></div>"},"54775":{"type":"graphic_figure","displayName":"Female pelvic and paraaortic lymph nodes","title":"Female pelvic and paraaortic lymph nodes","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Female pelvic and paraaortic lymph nodes</div><div class=\"cntnt\"><img style=\"width:465px; height:566px;\" src=\"images/OBGYN/54775_Pelv_paraaortic_lymph_nodes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pelvic and paraaortic lymph nodes and their relationship to the female pelvic organs and the major retroperitoneal blood vessels.</div><div class=\"graphic_reference\">Reproduced with permission from: Berek JS, Hacker NF. Practical Gynecologic Oncology, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54775 Version 2.0</div></div></div>"},"54776":{"type":"graphic_picture","displayName":"Nevus diffuse reticular pattern","title":"Dermoscopic image of a nevus with a diffuse reticular pattern","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nevus with a diffuse reticular pattern</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/54776_Nevus_diffuse_retic_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 54776 Version 5.0</div></div></div>"},"54777":{"type":"graphic_table","displayName":"Antimalarial ppx children","title":"Drug regimens for prophylaxis against malaria in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug regimens for prophylaxis against malaria in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug </td> <td class=\"subtitle1\">Tablet size </td> <td class=\"subtitle1\">Dose </td> <td class=\"subtitle1\">Frequency* </td> <td class=\"subtitle1\"> <p>Initiation</p> <p>(time before first exposure to malaria)</p> </td> <td class=\"subtitle1\"> <p>Discontinuation</p> <p>(time after last exposure)</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Areas with chloroquine-resistant <em>Plasmodium falciparum </em></td> </tr> <tr> <td class=\"indent1\">Atovaquone-proguanil (Malarone) </td> <td> <p>Pediatric tablet:</p> <p>62.5 mg atovaquone and 25 mg proguanil</p> <p>Adult tablet: </p> <p>250 mg atovaquone and 100 mg proguanil</p> </td> <td> <p>Body weight 5 to 8 kg, 1/2 pediatric tablet daily; </p> <p>Body weight 9 to 10 kg, 3/4 pediatric tablet daily; </p> <p>Body weight 11 to 20 kg, 1 pediatric tablet daily; </p> <p>Body weight 21 to 30 kg, 2 pediatric tablets daily; </p> <p>Body weight 31 to 40 kg, 3 pediatric tablets daily; </p> <p>Body weight &#8805;41 kg, 1 adult tablet daily</p> </td> <td>Once daily</td> <td>One to two days</td> <td>Seven&nbsp;days</td> </tr> <tr> <td class=\"indent1\">Mefloquine hydrochloride (Lariam and generic agents) </td> <td>250 mg salt (228 mg base)</td> <td> <p>Body weight &#8804;9 kg, 1/8 tablet or 5 mg salt per kg</p> <p>Body weight 10 to 19 kg, 1/4 tablet</p> <p>Body weight 20 to 30 kg, 1/2 tablet </p> <p>Body weight 31 to 45 kg, 3/4 tablet</p> <p>Body weight &#8805;46 kg, 1 tablet</p> </td> <td>Once weekly</td> <td>Three&nbsp;weeks preferable;&nbsp;two weeks acceptable</td> <td>Four&nbsp;weeks</td> </tr> <tr> <td class=\"indent1\">Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents) </td> <td>100 mg</td> <td>&#8805;8 years old, 2 mg per kg of body weight orally once daily (maximum dose 100 mg/day)</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Four&nbsp;weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Areas with chloroquine-sensitive <em>P. falciparum </em></td> </tr> <tr> <td class=\"indent1\">Chloroquine phosphate (Aralen and generic agents) </td> <td>500 mg salt (300 mg base)</td> <td>8.3 mg salt per kg of body weight (5 mg base per kg of body weight)</td> <td>Once weekly</td> <td>One to two&nbsp;weeks</td> <td>Four&nbsp;weeks</td> </tr> <tr> <td class=\"indent1\">Hydroxychloroquine sulfate (Plaquenil) </td> <td>400 mg salt (310 mg base)</td> <td>6.5 mg salt per kg of body weight (5 mg base per kg of body weight)</td> <td>Once weekly</td> <td>One to two&nbsp;weeks</td> <td>Four&nbsp;weeks</td> </tr> <tr> <td class=\"indent1\">Atovaquone-proguanil (Malarone) </td> <td>(as in 1st row above)</td> <td>(as in 1st row above)</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Seven&nbsp;days</td> </tr> <tr> <td class=\"indent1\">Mefloquine hydrochloride (Lariam and generic agents) </td> <td>250 mg salt (228 mg base)</td> <td>(as in 2nd row above)</td> <td>Once weekly</td> <td>Three&nbsp;weeks preferable;&nbsp;two weeks acceptable</td> <td>Four&nbsp;weeks</td> </tr> <tr> <td class=\"indent1\">Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents) </td> <td>100 mg</td> <td>&#8805;8 years old, 2 mg per kg of body weight orally once daily (maximum dose 100 mg/day)</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Four&nbsp;weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Areas with <em>Plasmodium vivax</em> </td> </tr> <tr> <td class=\"indent1\">Primaquine phosphate for primary prophylaxis (off-label use) </td> <td>26.3 mg salt (15 mg base)</td> <td>0.8 mg per kg of body weight salt (0.5 mg per kg of body weight base)</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Seven&nbsp;days</td> </tr> <tr> <td class=\"indent1\">Chloroquine phosphate (Aralen and generic agents) </td> <td>500 mg salt (300 mg base)</td> <td>8.3 mg salt per kg of body weight (5 mg base per kg of body weight)</td> <td>Once weekly</td> <td>One to two&nbsp;weeks</td> <td>Four&nbsp;weeks</td> </tr> <tr> <td class=\"indent1\">Hydroxychloroquine sulfate (Plaquenil) </td> <td>400 mg salt (310 mg base)</td> <td>6.5 mg salt per kg of body weight (5 mg base per kg of body weight)</td> <td>Once weekly</td> <td>One to two&nbsp;weeks</td> <td>Four&nbsp;weeks</td> </tr> <tr> <td class=\"indent1\">Atovaquone-proguanil (Malarone) </td> <td>(as in 1st row above)</td> <td>(as in 1st row above)</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Seven&nbsp;days</td> </tr> <tr> <td class=\"indent1\">Mefloquine hydrochloride (Lariam and generic agents) </td> <td>250 mg salt (228 mg base)</td> <td>(as in 2nd row above)</td> <td>Once weekly</td> <td>Three&nbsp;weeks preferable;&nbsp;two weeks acceptable</td> <td>Four&nbsp;weeks</td> </tr> <tr> <td class=\"indent1\">Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents) </td> <td>100 mg</td> <td>&#8805;8 years old, 2 mg per kg of body weight orally once daily (maximum dose 100 mg/day)</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Four&nbsp;weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Presumptive antirelapse therapy (to prevent relapse due to <em>P. vivax </em>or <em>P. ovale</em>) </td> </tr> <tr> <td class=\"indent1\">Primaquine phosphate </td> <td>26.3 mg salt (15 mg base)</td> <td>0.8 mg per kg of body weight salt (0.5 mg per kg of body weight base)</td> <td>Once daily</td> <td>As soon as possible following exposure for which another prophylactic drug taken</td> <td>14 days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Drugs administered once daily should be taken at the same time each day; drugs administered once weekly should be taken on the same day each week.</div><div class=\"graphic_reference\">1. Hill DR, Ericsson CD, Pearson RD, et al. The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.<br />2. Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 2008; 359:603.</div><div id=\"graphicVersion\">Graphic 54777 Version 4.0</div></div></div>"},"54778":{"type":"graphic_table","displayName":"Clinical criteria for staphylococcal toxic shock syndrome","title":"Clinical criteria for staphylococcal toxic shock syndrome (issued by the United States Centers for Disease Control and Prevention)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical criteria for staphylococcal toxic shock syndrome (issued by the United States&nbsp;Centers for Disease Control and Prevention)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Fever</td> </tr> <tr> <td>Temperature &#8805;38.9&#176;C (102.0&#176;F)</td> </tr> <tr> <td class=\"subtitle1_single\">Hypotension</td> </tr> <tr> <td>Systolic blood pressure &#8804;90 mmHg for adults or less than&nbsp;5<sup>th</sup>&nbsp;percentile by age for children &#60;16 years of age</td> </tr> <tr> <td class=\"subtitle1_single\">Rash</td> </tr> <tr> <td>Diffuse macular erythroderma</td> </tr> <tr> <td class=\"subtitle1_single\">Desquamation</td> </tr> <tr> <td>1 to 2 weeks after onset of illness, particularly involving palms and soles</td> </tr> <tr> <td class=\"subtitle1_single\">Multisystem involvement (3 or more of the following organ systems)</td> </tr> <tr> <td><strong>Gastrointestinal:</strong> Vomiting or diarrhea at onset of illness</td> </tr> <tr> <td><strong>Muscular:</strong> Severe myalgia or&nbsp;creatine phosphokinase elevation &#62;2 times the upper limit of normal</td> </tr> <tr> <td><strong>Mucous membranes:</strong> Vaginal, oropharyngeal, or conjunctival hyperemia</td> </tr> <tr> <td><strong>Renal:</strong> Blood urea nitrogen or serum creatinine &#62;2 times the&nbsp;upper limit of normal&nbsp;or pyuria (&#62;5 white blood count/high power field) in the absence of urinary tract infection</td> </tr> <tr> <td><strong>Hepatic:</strong> Bilirubin or transaminases &#62;2 times the upper limit of normal</td> </tr> <tr> <td><strong>Hematologic:</strong> Platelets &#60;100,000/microL</td> </tr> <tr> <td><strong>Central nervous system:</strong> Disorientation or alterations in consciousness without focal neurologic signs in the absence of fever and hypotension</td> </tr> <tr> <td class=\"subtitle1_single\">Negative results on the following tests, if obtained</td> </tr> <tr> <td>Blood or cerebrospinal fluid cultures for another pathogen (blood cultures may be positive for <em>Staphylococcus aureus</em>)</td> </tr> <tr> <td>Serologic tests for Rocky Mountain spotted fever, leptospirosis, or measles</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Criteria for a confirmed case include a patient with fever ≥38.9°C, hypotension, diffuse erythroderm, desquamation (unless the patient dies before desquamation can occur), and involvement of at least three organ systems. A probable case is a patient who is missing one of the characteristics of the confirmed case definition.</div><div class=\"graphic_reference\">Data from CDC:&nbsp;<br /><OL>&#xD;&#xA;<LI>Case definitions for public health surveillance. MMWR Morb Mortal Wkly Rep 1990; 39(RR-13):1. </LI>&#xD;&#xA;<LI>CDC: Case definitions for infectious conditions under public health surveillance. MMWR Morb Mortal Wkly Rep 1997; 46(RR-10):39.</LI>&#xD;&#xA;<LI>Toxic Shock Syndrome (other than streptococcal) (TSS) 2011 Case Definition. <A href=\"http://wwwn.cdc.gov/nndss/conditions/toxic-shock-syndrome-other-than-streptococcal/case-definition/2011/\">http://wwwn.cdc.gov/nndss/conditions/toxic-shock-syndrome-other-than-streptococcal/case-definition/2011/</A> (Accessed August 25, 2015).</LI></OL></div><div id=\"graphicVersion\">Graphic 54778 Version 7.0</div></div></div>"},"54780":{"type":"graphic_picture","displayName":"Micrograph MPNST","title":"Micrograph MPNST","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph MPNST</div><div class=\"cntnt\"><img style=\"width:256px; height:577px;\" src=\"images/NEURO/54780_MicrographMPNST.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low-power photomicrograph of a retroperitoneal, high-grade malignant peripheral nerve sheath tumor (MPNST). Note the dense cellularity of the neoplasm completely surrounding normal nerve fascicles (arrows). H&amp;E, x40. <br />(B) The tumor cells are spindle shaped, and mitoses are easily found on high power (arrows). H&amp;E, x400. <br />(C) MPNSTs can also have an epithelioid appearance, as seen in another retroperitoneal example. H&amp;E, x200.</div><div class=\"graphic_reference\">Courtesy of John E Donahue, MD.</div><div id=\"graphicVersion\">Graphic 54780 Version 3.0</div></div></div>"},"54781":{"type":"graphic_picture","displayName":"Normal optic disc 2","title":"Normal optic disc Grade 0","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal optic disc Grade 0</div><div class=\"cntnt\"><img style=\"width:450px; height:364px;\" src=\"images/NEURO/54781_Normal_optic_disc_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Michael Wall, MD.</div><div id=\"graphicVersion\">Graphic 54781 Version 1.0</div></div></div>"},"54782":{"type":"graphic_table","displayName":"Odds of Down syndrome after a positive screening test","title":"Odds of Down syndrome after a positive test result based on data from the SURUSS trial","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Odds of Down syndrome after a positive test result based on data from the SURUSS trial</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Test</td>\n<td class=\"subtitle1\">Odds</td>\n</tr>\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\">First plus second trimester</td>\n</tr>\n<tr>\n<td class=\"indent1\">Integrated</td>\n<td>1 in 5</td>\n</tr>\n<tr>\n<td class=\"indent1\">Serum integrated</td>\n<td>1 in 20</td>\n</tr>\n<tr>\n<td colspan=\"2\" class=\"subtitle2_left\">Second trimester</td>\n</tr>\n<tr>\n<td class=\"indent1\">Quadruple</td>\n<td>1 in 32</td>\n</tr>\n<tr>\n<td class=\"indent1\">Triple</td>\n<td>1 in 49</td>\n</tr>\n<tr>\n<td class=\"indent1\">Double</td>\n<td>1 in 68</td>\n</tr>\n<tr>\n<td colspan=\"2\" class=\"subtitle2_left\">First trimester</td>\n</tr>\n<tr>\n<td class=\"indent1\">Combined</td>\n<td>1 in 22</td>\n</tr>\n<tr>\n<td class=\"indent1\">NT</td>\n<td>1 in 94</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">These odds are obtained when each test is used to achieve an 85 percent detection rate.</div><div class=\"graphic_reference\">Adapted from: Wald, NJ, Rodeck, C, Hackshaw, AK, Rudnicka, A. BJOG 2004; 111:521.</div><div id=\"graphicVersion\">Graphic 54782 Version 2.0</div></div></div>"},"54783":{"type":"graphic_diagnosticimage","displayName":"Developing dominant follicle","title":"Developing dominant follicle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Developing dominant follicle</div><div class=\"cntnt\"><img style=\"width:392px; height:261px;\" src=\"images/ENDO/54783_Developing_dominant_follicl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonography of an ovary during the follicular phase of the menstrual cycle. The arrow points to the dominant follicle.</div><div class=\"graphic_reference\">Courtesy of Judith Adams, DMU.</div><div id=\"graphicVersion\">Graphic 54783 Version 3.0</div></div></div>"},"54784":{"type":"graphic_figure","displayName":"Exposing the upper vagina","title":"Vaginectomy: Exposing the upper vagina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vaginectomy: Exposing the upper vagina</div><div class=\"cntnt\"><img style=\"width:371px; height:370px;\" src=\"images/OBGYN/54784_Exposing_the_upper_vagina.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distal ureters and bladder are retracted while the proximal vagina is stretched up to facilitate further dissection prior to vaginectomy.</div><div id=\"graphicVersion\">Graphic 54784 Version 2.0</div></div></div>"},"54785":{"type":"graphic_table","displayName":"Features of NK LGL","title":"Clinical and biological features of CD3-negative NK-LGL leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and biological features of CD3-negative NK-LGL leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Clinical features</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Splenomegaly</td>\n\n      <td>90 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hepatomegaly</td>\n\n      <td>60 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lymphadenopathy</td>\n\n      <td>27 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Biologic features</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Marrow infiltration</td>\n\n      <td>100 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Neutropenia</td>\n\n      <td class=\"sublist_other_start\">50 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Severe neutropenia (ANC &#60;500/&#181;L)</td>\n\n      <td class=\"sublist_other\">18 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anemia</td>\n\n      <td>100 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thrombocytopenia</td>\n\n      <td>75 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperlymphocytosis (&#62;10,000/&#181;L)</td>\n\n      <td>70 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Rarely reported</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">Gastrointestinal infiltration</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">Central nervous system involvement</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">Ascites</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">Idiopathic thrombocytopenic purpura</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">Disseminated intravascular coagulation</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced by permission from Cancer Control: Journal of the Moffitt Cancer Center. Lamy, T, Loughran, TP Jr. Large granular lymphocyte leukemia. Cancer Control 1998; 5:25.</div><div id=\"graphicVersion\">Graphic 54785 Version 1.0</div></div></div>"},"54786":{"type":"graphic_picture","displayName":"Mycosis fungoides tumor","title":"Mycosis fungoides - tumor stage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides - tumor stage</div><div class=\"cntnt\"><img style=\"width:432px; height:314px;\" src=\"images/HEME/54786_Mycosis_fungoides_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, nodular lesion is present on the arm of the patient with tumor stage mycosis fungoides.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54786 Version 4.0</div></div></div>"},"54788":{"type":"graphic_figure","displayName":"Pleural fluid in pleurisy","title":"Pathways of pleural fluid accumulation in pleurisy","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Pathways of pleural fluid accumulation in pleurisy</div><div class=\"cntnt\"><img style=\"width:461px; height:298px;\" src=\"images/PULM/54788_Pleural_fluid_in_pleurisy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the pathways of pleural liquid accumulation in pleurisy. Direct involvement of pleural membranes by disease increases the formation of liquid from the intercostal and bronchial arteries (solid arrows) and interferes with parietal pleural lymphatic fluid removal (dashed open&nbsp;arrow).</div><div id=\"graphicVersion\">Graphic 54788 Version 2.0</div></div></div>"},"54790":{"type":"graphic_picture","displayName":"Arm sling","title":"Arm sling","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Arm sling</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/SURG/54790_Arm_sling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Elevation helps to reduce edema by improving venous and lymphatic drainage. The goal of elevation is to keep the hand above the level of the heart so that dependent drainage can occur. An arm sling, as shown here, does <strong>not</strong> provide adequate elevation to decrease edema.</div><div id=\"graphicVersion\">Graphic 54790 Version 3.0</div></div></div>"},"54791":{"type":"graphic_picture","displayName":"Esophageal coin erosion 2","title":"Ulceration at site of foreign body (coin) removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulceration at site of foreign body (coin) removal</div><div class=\"cntnt\"><img style=\"width:354px; height:315px;\" src=\"images/EM/54791_Coin_erosion_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 5-year-old child with three weeks of dysphagia with vomiting. A coin in the esophagus was discovered on upper GI radiograph. Both sides of the esophagus, particularly the right side, showed significant inflammation. Ulceration is evident at the site of coin removal.</div><div class=\"graphic_reference\">Courtesy of Karen Murray, MD.</div><div id=\"graphicVersion\">Graphic 54791 Version 2.0</div></div></div>"},"54792":{"type":"graphic_figure","displayName":"Vertebral extension teardrop fracture","title":"Extension teardrop fracture of the cervical spine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extension teardrop fracture of the cervical spine</div><div class=\"cntnt\"><img style=\"width:371px; height:441px;\" src=\"images/EM/54792_Verteb_ext_teardrop_fx.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54792 Version 4.0</div></div></div>"},"54793":{"type":"graphic_figure","displayName":"Acute HDV in chronic HBV","title":"Serum markers of an HDV superinfection of a chronic HBV carrier","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum markers of an HDV superinfection of a chronic HBV carrier</div><div class=\"cntnt\"><img style=\"width:329px; height:370px;\" src=\"images/GAST/54793_Acute_HDV_in_chronic_HBV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The serologic response to acute HDV superinfection in a chronic HBV carrier must be distinguished from acute HBV/HDV coinfection. HBsAg is present in both situations, but IgM anti-HBc should be negative in acute HDV superinfection. The diagnosis is made more difficult since HDV superinfection may cause transient suppression of HBV replication, transiently resulting in very low and rarely undetectable levels of HBsAg. As in patients with acute HBV/HDV coinfection, patients with acute HDV superinfection are usually positive for HDAg and/or HDV RNA in serum at the time of presentation. However, in contrast to acute coinfection, acute HDV superinfection is characterized by persistent detection of HDV RNA in serum and rapidly increasing titers of anti-HDV (total and IgM).</div><div id=\"graphicVersion\">Graphic 54793 Version 2.0</div></div></div>"},"54798":{"type":"graphic_picture","displayName":"Horners syndrome","title":"Horner's syndrome","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Horner's syndrome</div><div class=\"cntnt\"><img style=\"width:496px; height:209px;\" src=\"images/NEURO/54798_Horners_syndrome_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In dim light, the anisocoria is accentuated with the right pupil more miotic. The right upper lid is ptotic by 1.5 mm.</div><div class=\"graphic_reference\">Courtesy of Michael S Lee, MD.</div><div id=\"graphicVersion\">Graphic 54798 Version 2.0</div></div></div>"},"54799":{"type":"graphic_figure","displayName":"Thoracic inlet obstruction","title":"Variable obstruction at the thoracic inlet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variable obstruction at the thoracic inlet</div><div class=\"cntnt\"><img style=\"width:400px; height:168px;\" src=\"images/PULM/54799_Thoracic_inlet_obstruction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow volume loop in variable obstruction at the thoracic inlet showing a double hump in the the expiratory curve as the narrowing moves from an intrathoracic to a relative extrathoracic location toward the end of expiration</div><div id=\"graphicVersion\">Graphic 54799 Version 1.0</div></div></div>"},"54800":{"type":"graphic_picture","displayName":"Anterior anatomy of tibia and fibula","title":"Anterior anatomy of tibia and fibula","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Anterior anatomy of tibia and fibula</div><div class=\"cntnt\"><img style=\"width:504px; height:632px;\" src=\"images/EM/54800_Anatomy_tibia_fibula_anteri.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54800 Version 6.0</div></div></div>"},"54801":{"type":"graphic_figure","displayName":"ECG abnormalities outcome","title":"Abnormalities on baseline ECG predict outcome in asymptomatic persons","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abnormalities on baseline ECG predict outcome in asymptomatic persons</div><div class=\"cntnt\"><img style=\"width:446px; height:305px;\" src=\"images/CARD/54801_ECG_abnormalities_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 4797 men and 4320 women, age 25 to 74 years, who were initially free of angina, 8.4 percent of men and 10.6 percent of women had ischemic ECG changes, including abnormal Q waves, varying degrees of ST depression or T wave inversion, and left bundle branch block. The presence of ischemic ECG changes, particularly ST depression and T-wave inversion, were associated with increased cardiovascular mortality in both men and women (multivariately adjusted odds ratio 2.45 and 2.16, respectively).</div><div class=\"graphic_reference\">Data from: De Bacquer D, De Backer G, Kornitzer M, et al. J Am Coll Cardiol 1998; 32:680.</div><div id=\"graphicVersion\">Graphic 54801 Version 2.0</div></div></div>"},"54803":{"type":"graphic_figure","displayName":"Prostate anatomy","title":"Prostate anatomy","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Prostate anatomy</div><div class=\"cntnt\"><img style=\"width:658px; height:640px;\" src=\"images/ONC/54803_Prostateanatomyedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The prostate gland is a walnut-shaped structure located at the base of the urinary bladder. The prostate gland is composed of both glandular and muscular tissue. Secretions from the prostate, vas deferens and seminal vesicle empty into the prostatic urethra.</div><div id=\"graphicVersion\">Graphic 54803 Version 6.0</div></div></div>"},"54805":{"type":"graphic_picture","displayName":"Dysplastic kidney pathology","title":"Renal dysplasia: microscopic section","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal dysplasia: microscopic section</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/PEDS/54805_Dysplastic_kidney_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic section of a dysplastic kidney showing cartilage (arrows). Tubules (T) are poorly formed with cystic changes (C).</div><div id=\"graphicVersion\">Graphic 54805 Version 2.0</div></div></div>"},"54807":{"type":"graphic_diagnosticimage","displayName":"Adult TB case 2 PA view","title":"Classic adult tuberculosis posterior-anterior view case II","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Classic adult&nbsp;tuberculosis posterior-anterior view case II</div><div class=\"cntnt\"><img style=\"width:466px; height:416px;\" src=\"images/ID/54807_ClassicadultTBPAviewca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 40-year-old automobile mechanic from the Dominican Republic, in the United States eight years, presented to the urgent care clinic with four months of productive cough, fevers, progressive hoarseness, and a 40 pound weight loss. A chest radiograph (posterior-anterior view) demonstrates diffuse parenchymal disease with multiple cavities and bulla formation on the left. Sputum smear was positive for acid-fast bacilli.</div><div class=\"graphic_reference\">Courtesy of John Bernardo, MD.</div><div id=\"graphicVersion\">Graphic 54807 Version 4.0</div></div></div>"},"54809":{"type":"graphic_diagnosticimage","displayName":"MRI myotonic dystrophy","title":"Neuroimaging in myotonic dystrophy","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Neuroimaging in myotonic dystrophy</div><div class=\"cntnt\"><img style=\"width:505px; height:254px;\" src=\"images/NEURO/54809_MRI_myotonic_dystrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Axial fluid-attenuated inversion recovery image shows symmetric, confluent signal hyperintensity in the anterior temporal lobe white matter. B) Small basal angle (craniokyphosis), prominent frontal sinus, and diffuse thickening of the skull with ossification of the falx is noted on sagittal T1-weighted images.</div><div class=\"graphic_reference\">Reproduced with permission from: Donahue LA, Mangla R, Westesson PL. Neuroimaging in myotonic dystrophy type 1. Neurology 2009; 73:1931. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54809 Version 11.0</div></div></div>"},"54810":{"type":"graphic_table","displayName":"Brief fatigue inventory","title":"Components of a Brief Fatigue Inventory (BFI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of a Brief Fatigue Inventory (BFI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">1. Throughout our lives, most of us have times when we feel very tired or fatigued. Have you felt unusually tired or fatigued in the last week?</td> <td class=\"subtitle2_left\">Yes/No</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">2. Please answer the following questions by rating your fatigue (weariness, tiredness) on a scale from 0 to 10, with 0 representing \"no fatigue\" and 10 representing \"the worst fatigue you can imagine.\"</td> </tr> <tr> <td class=\"indent1\">A) Which number best represents your fatigue right <strong>now?</strong></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">B) Which number best describes your <strong>usual</strong> level of fatigue within the past 24 hours?</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">C) Which number best describes your <strong>worst</strong> level of fatigue within the past 24 hours?</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">3. Please use a scale from 0 to 10 to answer the following questions that describe how, during the past 24 hours, your fatigue has interfered with aspects of your life. 0 represents \"no interference\" and 10 represents \"complete interference.\"</td> </tr> <tr> <td class=\"indent1\">A) General activity</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">B) Mood</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">C) Walking ability</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">D) Normal work (including both work outside the home and daily chores)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">E) Relations with other people</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">F) Enjoyment of life</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from the University of Texas M. D. Anderson Cancer Center.</div><div id=\"graphicVersion\">Graphic 54810 Version 4.0</div></div></div>"},"54811":{"type":"graphic_table","displayName":"Historical classification of CMD","title":"Historical classification of congenital muscular dystrophy (CMD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Historical classification of congenital muscular dystrophy (CMD)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Classic CMD</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Merosin deficient CMD</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Primary merosin deficiency</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Secondary merosin deficiency</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Merosin positive CMD</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Classic CMD without distinguishing features</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Rigid spine syndrome</td>\n</tr>\n<tr>\n<td class=\"sublist1\">CMD with distal hyperextensibility (Ullrich type)</td>\n</tr>\n<tr>\n<td class=\"sublist1\">CMD with mental retardation or sensory abnormalities</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">CMD with central nervous system (CNS) abnormalities</td>\n</tr>\n<tr>\n<td>Fukuyama CMD</td>\n</tr>\n<tr>\n<td>Muscle-eye-brain disease</td>\n</tr>\n<tr>\n<td>Walker-Warburg syndrome</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Jones, K, North, K. The congenital muscular dystrophies. In: Neuromuscular Disorders of infancy, Childhood, and Adolescence: A Clinician's Approach, Jones, HR, De Vivo, DC, Darras, BT (Eds). Butterworth Heinemann, Philadelphia 2003. p.633. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 54811 Version 3.0</div></div></div>"},"54813":{"type":"graphic_figure","displayName":"Cervical esophagostomy","title":"Cervical esophagostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical esophagostomy</div><div class=\"cntnt\"><img style=\"width:356px; height:291px;\" src=\"images/SURG/54813_Cervical-esophagostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the suturing of the proximal portion of the cervical esophagus to the anterior chest wall. This procedure can be performed as a temporizing procedure for an esophageal perforation when a primary repair cannot be performed due to severe contamination of the mediastinum, large friable defect, or unstable condition of the patient.</div><div id=\"graphicVersion\">Graphic 54813 Version 2.0</div></div></div>"},"54814":{"type":"graphic_picture","displayName":"Poison ivy fruit","title":"Poison ivy fruit","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Poison ivy fruit</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/54814_Poisonivyfruit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cream-colored fruit of poison ivy.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54814 Version 4.0</div></div></div>"},"54816":{"type":"graphic_figure","displayName":"Acute insulin response","title":"Relative acute insulin response to IV glucose","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relative acute insulin response to IV glucose</div><div class=\"cntnt\"><img style=\"width:427px; height:341px;\" src=\"images/ENDO/54816_Acute_insulin_response.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous.</div><div class=\"graphic_reference\">Reproduced with permission from: Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42:222. http://jcem.endojournals.org. Copyright © 1976 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 54816 Version 7.0</div></div></div>"},"54818":{"type":"graphic_picture","displayName":"Healthy gingiva","title":"Healthy gingiva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Healthy gingiva</div><div class=\"cntnt\"><img style=\"width:432px; height:328px;\" src=\"images/PC/54818_Healthy_gingiva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pink and firm gingival tissues with no recession.</div><div id=\"graphicVersion\">Graphic 54818 Version 1.0</div></div></div>"},"54819":{"type":"graphic_table","displayName":"Causes of diffuse alveolar damage","title":"Causes of diffuse alveolar damage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of diffuse alveolar damage</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Acute respiratory distress syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute hypersensitivity pneumonitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Idiopathic acute interstitial pneumonia (Hamman Rich syndrome)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist1_start\">Drugs</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Chemotherapeutic agents</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Ethchlorvynol </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Aspirin</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Radiation therapy</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Oxygen toxicity</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Heroin</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Cocaine</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Toxic inhalants</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Chlorine gas</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Nitrogen dioxide</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Phosgene</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Smoke</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Ingestants</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Paraquat</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Kerosene</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Rapeseed oil-toxic oil syndrome</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Connective tissue disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Polymyositis&nbsp;</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Lupus pneumonitis</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Infections</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Legionella</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Mycoplasma</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Viral, including influenza and severe acute respiratory syndrome (SARS)</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54819 Version 2.0</div></div></div>"},"54821":{"type":"graphic_diagnosticimage","displayName":"Cartilage calcification (chondrocalcinosis) of knee","title":"Cartilage calcification (chondrocalcinosis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cartilage calcification (chondrocalcinosis)</div><div class=\"cntnt\"><img style=\"width:282px; height:322px;\" src=\"images/RHEUM/54821_Chondrocalcinosis_of_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph shows cartilage calcificationo (chondrocalcinosis) of the knee in a patient with hemochromatosis. There is calcification within the cartilage in the tibiofemoral joint space (arrows).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 54821 Version 3.0</div></div></div>"},"54824":{"type":"graphic_waveform","displayName":"AS continuous wave Doppler","title":"Aortic stenosis continuous wave","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic stenosis continuous wave</div><div class=\"cntnt\"><img style=\"width:273px; height:228px;\" src=\"images/CARD/54824_AS_continuous_wave_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Doppler shows a peak velocity across the aortic valve of 2.7 m/sec or a gradient of 30 mmHg, compatible with mild aortic stenosis. No aortic regurgitation is seen.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 54824 Version 3.0</div></div></div>"},"54825":{"type":"graphic_picture","displayName":"Ulceration mandibular vestibule","title":"Mouth ulceration in a child with Crohn's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mouth ulceration in a child with Crohn's disease</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/PEDS/54825_Ulcerationmandibularvesti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear ulceration deep in the mandibular vestibule (arrows) in a child with Crohn disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Hardy S, Fleming P, Rowland M, et al. A prospective study of the oral manefestations of Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:886. Copyright © 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 54825 Version 4.0</div></div></div>"},"54826":{"type":"graphic_table","displayName":"Lactose content","title":"Lactose content of dairy products","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lactose content of dairy products</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Product</td> <td class=\"subtitle1\">Lactose content (grams)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Milk (1 cup)</strong></td> </tr> <tr> <td class=\"indent1\">Whole, 2 percent, 1 percent, skim</td> <td>9-14</td> </tr> <tr> <td class=\"indent1\">Buttermilk</td> <td>9-12</td> </tr> <tr> <td class=\"indent1\">Evaporated milk</td> <td>24-28</td> </tr> <tr> <td class=\"indent1\">Sweetened condensed milk</td> <td>31-50</td> </tr> <tr> <td class=\"indent1\">Lactaid milk (lactose-reduced)</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Goat's milk</td> <td>11-12</td> </tr> <tr> <td class=\"indent1\">Acidophilus, skim</td> <td>11</td> </tr> <tr> <td><strong>Yogurt, low fat (1 cup)</strong></td> <td>4-17</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Cheese (1 ounce)</strong></td> </tr> <tr> <td class=\"indent1\">Cottage cheese (1/2 cup)</td> <td>0.7-4</td> </tr> <tr> <td class=\"indent1\">Cheddar (sharp)</td> <td>0.4-0.6</td> </tr> <tr> <td class=\"indent1\">Mozzarella (part skim, low moisture)</td> <td>0.08-0.9</td> </tr> <tr> <td class=\"indent1\">American (pasteurized, processed)</td> <td>0.5-4</td> </tr> <tr> <td class=\"indent1\">Ricotta (1/2 cup)</td> <td>0.3-6</td> </tr> <tr> <td class=\"indent1\">Cream cheese</td> <td>0.1-0.8</td> </tr> <tr> <td><strong>Butter (1 pat)</strong></td> <td>0.04-0.5</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Cream (1 tablespoon)</strong></td> </tr> <tr> <td class=\"indent1\">Light, whipping, sour</td> <td>0.4-0.6</td> </tr> <tr> <td><strong>Ice cream (1/2 cup)</strong></td> <td>2-6</td> </tr> <tr> <td><strong>Ice milk (1/2 cup)</strong></td> <td>5</td> </tr> <tr> <td><strong>Sherbet (1/2 cup)</strong></td> <td>0.6-2</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Scrimshaw NS, Murray EB. The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance. Am J Clin Nutr 1988; 48:1079. Copyright © 1988 American Society for Clinical Nutrition.</div><div id=\"graphicVersion\">Graphic 54826 Version 3.0</div></div></div>"},"54827":{"type":"graphic_table","displayName":"Organizations eating disorders","title":"National organizations for eating disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">National organizations for eating disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_single\">Academy for Eating Disorders</td> </tr> <tr> <td class=\"indent1\">111 Deer Lake Road, Suite 100</td> </tr> <tr> <td class=\"indent1\">Deerfield, IL 60015</td> </tr> <tr> <td class=\"indent1\">847-498-4274</td> </tr> <tr> <td class=\"indent1\">www.aedweb.org</td> </tr> <tr> <td class=\"subtitle2_single\">National Eating Disorders Association</td> </tr> <tr> <td class=\"indent1\">603 Steward Street, Suite 803</td> </tr> <tr> <td class=\"indent1\">Seattle, WA 98101</td> </tr> <tr> <td class=\"indent1\">206-382-3587; 800-931-2237</td> </tr> <tr> <td class=\"indent1\">www.nationaleatingdisorders.org</td> </tr> <tr> <td class=\"subtitle2_single\">Anorexia Nervosa and Related Eating Disorders, Inc</td> </tr> <tr> <td class=\"indent1\">P.O. box 5102</td> </tr> <tr> <td class=\"indent1\">Eugene, OR 97405</td> </tr> <tr> <td class=\"indent1\">541-344-1144</td> </tr> <tr> <td class=\"indent1\">www.anred.com</td> </tr> <tr> <td class=\"subtitle2_single\">National Association of Anorexia Nervosa and Associated Disorders</td> </tr> <tr> <td class=\"indent1\">P.O. box 7</td> </tr> <tr> <td class=\"indent1\">Highland Park, IL 60035</td> </tr> <tr> <td class=\"indent1\">847-831-3438</td> </tr> <tr> <td class=\"indent1\">www.anad.org</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54827 Version 2.0</div></div></div>"},"54828":{"type":"graphic_table","displayName":"ATS ERS Dx Criteria IPF without Bx","title":"ATS/ERS criteria for diagnosis of idiopathic pulmonary fibrosis in absence of surgical lung biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ATS/ERS criteria for diagnosis of idiopathic pulmonary fibrosis in absence of surgical lung biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major criteria</td> </tr> <tr> <td>Exclusion of other known causes of ILD such as certain drug toxicities, environmental exposures, and connective tissue diseases</td> </tr> <tr> <td>Abnormal pulmonary function studies that include evidence of restriction (reduced VC, often with an increased FEV1/FVC ratio) and impaired gas exchange [increased P(A-a)O<sub>2</sub>, decreased PaO<sub>2</sub> with rest or exercise or decreased DLco]</td> </tr> <tr> <td>Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT scans</td> </tr> <tr> <td>Transbronchial lung biopsy or BAL showing no features to support an alternative diagnosis</td> </tr> <tr> <td class=\"subtitle1_single\">Minor criteria</td> </tr> <tr> <td>Age &#62;50 years</td> </tr> <tr> <td>Insidious onset of otherwise unexplained dyspnea or exertion</td> </tr> <tr> <td>Duration of illness &#62;3 months</td> </tr> <tr> <td>Bibasilar, inspiratory crackles (dry or \"Velcro\"-type in quality)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">In the immunocompetent adult, the presence of all of the major diagnostic criteria as well as at least three of the four minor criteria increases the likelihood of a correct clinical diagnosis of IPF.<BR>BAL: bronchoalveolar lavage; DLco: diffusing capacity of the lung for CO; HRCT: high-resolution computerized tomography; ILD: interstitial lung disease; P(A-a)O<SUB>2</SUB>: alveolar-arterial pressure differences for O<SUB>2</SUB>; VC: vital capacity.</div><div id=\"graphicVersion\">Graphic 54828 Version 2.0</div></div></div>"},"54829":{"type":"graphic_picture","displayName":"Ear relapsing polychondritis","title":"Ear involvement in relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ear involvement in relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:305px; height:259px;\" src=\"images/RHEUM/54829_Earrelapspolychond.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal (contralateral) ear in a patient with relapsing polychondritis.<BR>(B) The affected ear in the same patient.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 54829 Version 3.0</div></div></div>"},"54830":{"type":"graphic_figure","displayName":"Continence mechanisms","title":"Mechanisms of preserving continence","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Mechanisms of preserving continence</div><div class=\"cntnt\"><img style=\"width:483px; height:419px;\" src=\"images/GAST/54830_Continence_mechanisms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomy of the anal canal, rectum, and distal colon illustrating the mechanisms for preserving continence.</div><div class=\"graphic_reference\">Reproduced with permission from Whitehead WE, Schuster MM. Gastrointestinal disorders: Behavioral and physiological basis for treatment. Academic, Orlando 1985.</div><div id=\"graphicVersion\">Graphic 54830 Version 2.0</div></div></div>"},"54831":{"type":"graphic_picture","displayName":"Clinodactyly","title":"Clinodactyly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinodactyly</div><div class=\"cntnt\"><img style=\"width:432px; height:285px;\" src=\"images/PEDS/54831_Clinodactyly_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inherited clinodactyly in a father (left) and son (right).</div><div class=\"graphic_reference\">Reproduced with permission from: Julie Boom, MD and Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54831 Version 2.0</div></div></div>"},"54832":{"type":"graphic_diagnosticimage","displayName":"TB chest radiograph 1","title":"Chest radiographs of tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Chest radiographs of tuberculosis</div><div class=\"cntnt\"><img style=\"width:512px; height:295px;\" src=\"images/ID/54832_TB_chest_radiograph_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiographs (posteroanterior and lateral views) demonstrating cavitary reactivation of latent tuberculosis infection in the posterior apical segment of the right upper lobe.</div><div class=\"graphic_reference\">Reproduced with permission from: Crapo JD, Glassroth J, Karlinsky JB, King TE. Baum's Textbook of Pulmonary Diseases, 7th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54832 Version 3.0</div></div></div>"},"54834":{"type":"graphic_waveform","displayName":"Doppler US vein","title":"Doppler waveform of the brachial vein with and without a tourniquet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler waveform of the brachial vein with and without a tourniquet</div><div class=\"cntnt\"><img style=\"width:344px; height:563px;\" src=\"images/EM/54834_Doppler_US_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal ultrasound images of the right arm with color and spectral Doppler shows normal venous waveforms in the brachial vein. The artery (deep to the vein) is the same color as the vein due to arterial pulsatility and the portion of the cardiac cycle captured. A) Without tourniquet, there is mild pulsality in the venous waveform reflecting right atrial pressures, but no sharp upstroke. B) When a tourniquet is applied, the waveform becomes flat.</div><div class=\"graphic_reference\">Courtesy of Lauren W Averill, MD.</div><div id=\"graphicVersion\">Graphic 54834 Version 2.0</div></div></div>"},"54835":{"type":"graphic_figure","displayName":"BHOB in prolonged fast","title":"Plasma beta-hydroxybutyrate concentrations after a prolonged fast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma beta-hydroxybutyrate concentrations after a prolonged fast</div><div class=\"cntnt\"><img style=\"width:291px; height:297px;\" src=\"images/ENDO/54835_B_OHB_in_prolonged_fast.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between plasma glucose and beta-hydroxybutyrate concentrations in normal subjects and patients with an insulinoma after a prolonged fast. In patients who become hypoglycemic, a plasma beta-hydroxybutyrate concentration below 2.7 mmol/L is suggestive of an insulinoma. To convert plasma glucose values to mmol/L, multiply by 0.056.</div><div class=\"graphic_reference\">Redrawn from Service FJ. Hypoglycemic disorders.&nbsp;N Engl J Med 1995; 332:1144.</div><div id=\"graphicVersion\">Graphic 54835 Version 2.0</div></div></div>"},"54836":{"type":"graphic_table","displayName":"Features of myxedema coma","title":"Clinical features of myxedema coma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of myxedema coma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Decreased mental status</td>\n</tr>\n<tr>\n<td>Hypothermia</td>\n</tr>\n<tr>\n<td>Bradycardia</td>\n</tr>\n<tr>\n<td>Hyponatremia</td>\n</tr>\n<tr>\n<td>Hypoglycemia</td>\n</tr>\n<tr>\n<td>Hypotension</td>\n</tr>\n<tr>\n<td>Precipitating illness</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54836 Version 1.0</div></div></div>"},"54840":{"type":"graphic_picture","displayName":"HUS vascular I","title":"Light microscopy showing thrombotic microangiopathy with subintimal fibrin deposition in an interlobular artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopy showing thrombotic microangiopathy with subintimal fibrin deposition in an interlobular artery</div><div class=\"cntnt\"><img style=\"width:378px; height:249px;\" src=\"images/NEPH/54840_HUS_Vascular_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subintimal fibrin deposition without inflammation (arrow) in an interlobular artery as can be seen acutely in any of the forms of the hemolytic uremic syndrome, including scleroderma. The marked narrowing of the vascular lumen will diminish distal perfusion, potentially leading to tissue necrosis if there is near total or total occlusion.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 54840 Version 5.0</div></div></div>"},"54842":{"type":"graphic_table","displayName":"Criteria diagnosis ARVD","title":"Criteria for the diagnosis of arrhythmogenic right ventricular dysplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the diagnosis of arrhythmogenic right ventricular dysplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Family history</td> </tr> <tr> <td class=\"subtitle2_single\">Major</td> </tr> <tr> <td class=\"indent1\">Familial disease confirmed at necropsy or surgery</td> </tr> <tr> <td class=\"subtitle2_single\">Minor</td> </tr> <tr> <td class=\"indent1\">Family history of premature sudden death (&#60;35 years) caused by suspected ARVD</td> </tr> <tr> <td class=\"indent1\">Family history (clinical diagnosis based on present criteria)</td> </tr> <tr> <td class=\"subtitle1_single\">ECG depolarization/conduction abnormalities</td> </tr> <tr> <td class=\"subtitle2_single\">Major</td> </tr> <tr> <td class=\"indent1\">Epsilon waves or localized prolongation (&#62;110 ms) of the QRS complex in the right precordial leads (V1 to V3)</td> </tr> <tr> <td class=\"subtitle2_single\">Minor</td> </tr> <tr> <td class=\"indent1\">Late potentials seen on signal averaged ECG</td> </tr> <tr> <td class=\"subtitle1_single\">Repolarization abnormalities</td> </tr> <tr> <td class=\"subtitle2_single\">Minor</td> </tr> <tr> <td class=\"indent1\">Inverted T waves in right precordial leads (V2 and V3) in people &#62;12 years and in the absence of right bundle branch block</td> </tr> <tr> <td class=\"subtitle1_single\">Tissue characterisation of walls</td> </tr> <tr> <td class=\"subtitle2_single\">Major</td> </tr> <tr> <td class=\"indent1\">Fibrofatty replacement of myocardium on endomyocardial biopsy</td> </tr> <tr> <td class=\"subtitle1_single\">Global and/or regional dysfunction and structural alterations</td> </tr> <tr> <td>(detected by echocardiography, angiography, magnetic resonance imaging, or radionuclide scintigraphy)</td> </tr> <tr> <td class=\"subtitle2_single\">Major</td> </tr> <tr> <td class=\"indent1\">Severe dilatation and reduction of right ventricular ejection fraction with no (or only mild) left ventricular impairment</td> </tr> <tr> <td class=\"indent1\">Localized right ventricular aneurysms (akinetic or dyskinetic areas with diastolic bulging)</td> </tr> <tr> <td class=\"indent1\">Severe segmental dilatation of the right ventricle</td> </tr> <tr> <td class=\"subtitle2_single\">Minor</td> </tr> <tr> <td class=\"indent1\">Mild global right ventricular dilatation and/or ejection fraction reduction with normal left ventricle</td> </tr> <tr> <td class=\"indent1\">Mild segmental dilatation of the right ventricle</td> </tr> <tr> <td class=\"indent1\">Regional right ventricular hypokinesia</td> </tr> <tr> <td class=\"subtitle1_single\">Arrhythmias</td> </tr> <tr> <td class=\"subtitle2_single\">Minor</td> </tr> <tr> <td class=\"indent1\">Left bundle branch block type ventricular tachycardia (sustained or nonsustained) documented on ECG, Holter monitoring, or during exercise testing</td> </tr> <tr> <td class=\"indent1\">Frequent ventricular extrasystoles (more than 1000/24 h) on Holter monitoring</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ARVD: arrhythmogenic right ventricular dysplasia; ECG: electrocardiogram.</div><div class=\"graphic_reference\">Data from: McKenna WJ, Thiene G, Nava A, et al. Br Heart J 1994; 71:215.</div><div id=\"graphicVersion\">Graphic 54842 Version 3.0</div></div></div>"},"54845":{"type":"graphic_figure","displayName":"Anatomy of the oral cavity","title":"Anatomy of the oral cavity - Primary structures in the oral cavity","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Anatomy of the oral cavity - Primary structures in the oral cavity</div><div class=\"cntnt\"><img style=\"width:523px; height:592px;\" src=\"images/ONC/54845_Anatomy_of_the_oral_cavity_edit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54845 Version 4.0</div></div></div>"},"54846":{"type":"graphic_table","displayName":"Staged treatment for childhood obesity","title":"Recommendations for treatment of childhood obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for treatment of childhood obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Staff and skills</td> <td class=\"subtitle1\">Nutrition goals</td> <td class=\"subtitle1\">Activity goals</td> <td class=\"subtitle1\">Behavior intervention</td> </tr> <tr> <td>1: Prevention plus</td> <td>Primary care provider</td> <td> <ul> <li>Encourage consumption of 5 or more servings of vegetables or fruit daily </li> <li>Minimize sugared beverages </li> <li>Eat breakfast every day </li> <li>Eat most meals at home and as a family </li> </ul> </td> <td> <ul> <li>Less than 2 hours of television or other screen time per day </li> <li>More than 1 hour of physical activity daily </li> </ul> </td> <td> <ul> <li>Reinforce goals at each health care visit, additional visits as tolerated </li> <li>Allow child to self-regulate, avoid overly strict eating regimens </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">2: Structured weight management</td> <td rowspan=\"2\">Primary care physician or provider with additional training in nutrition or behavioral counseling (eg, dietitian)</td> <td>Stage 1 plus:</td> <td>Stage 1 plus:</td> <td rowspan=\"2\"> <ul> <li>Monthly patient-provider contact </li> <li>Monitor eating and physical activities through logs </li> <li>Use positive reinforcement techniques (reward system) </li> <li>Strong parental involvement for school-aged children </li> </ul> </td> </tr> <tr> <td> <ul> <li>Daily eating plan, with scheduled meals and snacks </li> <li>Emphasize foods with low energy density </li> <li>Reduce frequency and quantity of foods with high energy density (eg, fried foods, baked goods, fats) </li> <li>Limit portion size </li> <li>Set explicit behavior goals </li> </ul> </td> <td> <ul> <li>Less than 1 hour of television or other screen time daily </li> <li>More than 1 hour of physical activity daily, supervised and structured </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">3: Comprehensive multidisciplinary intervention</td> <td rowspan=\"2\">Multidisciplinary team with childhood obesity expertise OR primary care-based program with counselor, dietitian, and use of structured outside activity program</td> <td>Stage 2 plus:</td> <td rowspan=\"2\">Similar to stage 2, supported by behavioral interventions</td> <td rowspan=\"2\"> <ul> <li>Weekly patient-provider contact (and/or phone) </li> <li>Similar, but with increased structure and accountability </li> <li>Parent training in behavioral techniques to improve home eating and activity environment </li> </ul> </td> </tr> <tr> <td> <ul> <li>Structured diet and physical activity designed for negative energy balance </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td>4: Tertiary care intervention</td> <td>Multidisciplinary team with childhood obesity expertise, including obesity medicine physician to rigorously assess comorbidities</td> <td colspan=\"3\">As guided by established protocols. Various modalities are available, including: highly structured diets, medications, or bariatric surgery.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Most children 2 years and older who are overweight or obese start at stage 1 (Prevention plus). Those who are older than 6 years progress to higher stages if there is no improvement in BMI percentile or trend after 3 to 6 months of treatment. Initiating treatment at higher stages of intervention is appropriate for children who are older, more severely obese (BMI &gt;99th percentile) and motivated.</div><div class=\"graphic_reference\">Based on information from: Spear BA, Barlow SE, Ervin C, et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics 2007; 120:S254.</div><div id=\"graphicVersion\">Graphic 54846 Version 8.0</div></div></div>"},"54848":{"type":"graphic_figure","displayName":"Ipodate versus PTU hyperthyroidism","title":"Efficacy of ipodate and PTU in hyperthyroidism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efficacy of ipodate and PTU in hyperthyroidism</div><div class=\"cntnt\"><img style=\"width:447px; height:242px;\" src=\"images/ENDO/54848_Ipodate_v_PTU_in_hyperthyro.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percent change from baseline in serum concentrations of T4 (left panel) and T3 (right panel) in patients with hyperthyroidism who were treated with ipodate (1 g/day) or propylthiouracil (200 mg three times daily). Ipodate produced more rapid correction of the hyperthyroidism.</div><div class=\"graphic_footnotes\">PTU: propylthiouracil; T4: thyroxine; T3: triiodothyronine.</div><div class=\"graphic_reference\">Data from: Wu SY, Shyh TP, Chopra IJ, et al. Comparison sodium ipodate (oragrafin) and propylthiouracil in early treatment of hyperthyroidism. J Clin Endocrinol Metab 1982; 54:630.</div><div id=\"graphicVersion\">Graphic 54848 Version 3.0</div></div></div>"},"54849":{"type":"graphic_algorithm","displayName":"Dx chronic diarrhea II","title":"Diagnostic approach to chronic diarrhea - part II","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to chronic diarrhea - part II</div><div class=\"cntnt\"><img style=\"width:610px; height:662px;\" src=\"images/GAST/54849_Dx_chronic_diarrhea_II_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted with permission from: Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.</div><div id=\"graphicVersion\">Graphic 54849 Version 4.0</div></div></div>"},"54850":{"type":"graphic_picture","displayName":"Biopsy incision bone tumor","title":"Biopsy incision for bone tumors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biopsy incision for bone tumors</div><div class=\"cntnt\"><img style=\"width:277px; height:369px;\" src=\"images/ONC/54850_Biopsy_incision_bone_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A properly performed incision is small and longitudinal.</div><div class=\"graphic_reference\">Courtesy of Francis Hornicek, MD, PhD.</div><div id=\"graphicVersion\">Graphic 54850 Version 1.0</div></div></div>"},"54853":{"type":"graphic_table","displayName":"Polyneuropathy systemic disease","title":"Polyneuropathy associated with systemic diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Polyneuropathy associated with systemic diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Systemic disease</td> <td class=\"subtitle1\">Axonal</td> <td class=\"subtitle1\">Demyelinating</td> <td class=\"subtitle1\">Additional comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Common</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> <td>Usually</td> <td>Sometimes</td> <td>Can be primary sensory, mixed sensorimotor, or, rarely, pure motor; autonomic involvement often present. Can be acute, subacute, or chronic.</td> </tr> <tr> <td class=\"indent1\">Critical illness</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensorimotor in most cases; can have superimposed myopathy that may add to motor phenotype.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Carcinoma</td> <td>Usually</td> <td>Sometimes</td> <td>Generally sensory&nbsp;greater than&nbsp;motor; autonomic involvement common as well; generally relatively rapidly progressive; sensory neuronopathy can occur. Can occur subacutely or chronically.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Less common</td> </tr> <tr> <td class=\"indent1\">Uremia</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensorimotor with autonomic component.</td> </tr> <tr> <td class=\"indent1\">Connective tissue disease</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensorimotor; chronic.</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia/acute correction of hyperglycemia</td> <td>Sometimes</td> <td>Rare if ever</td> <td>Primary sensory; autonomic component may be present; can occur acutely or subacutely.</td> </tr> <tr> <td class=\"indent1\">Vitamin deficiency (excluding B12)</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensorimotor; autonomic symptoms variably present.</td> </tr> <tr> <td class=\"indent1\">Vitamin B12 deficiency</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensory; generally subacute to chronic.</td> </tr> <tr> <td class=\"indent1\">Chronic liver disease</td> <td>Rare if ever</td> <td>Usually</td> <td>Generally sensory or sensorimotor; chronic.</td> </tr> <tr> <td class=\"indent1\">Malabsorption (sprue, celiac disease)</td> <td>Sometimes</td> <td>Rare if ever</td> <td>Sensory or sensorimotor with possible autonomic involvement; chronic.</td> </tr> <tr> <td class=\"indent1\">HIV infection</td> <td>Usually</td> <td>Rare if ever</td> <td>Primarily sensory; chronic.</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> <td>Sometimes</td> <td>Rare if ever</td> <td>Sensorimotor often with substantial radicular component; subacute to chronic.</td> </tr> <tr> <td class=\"indent1\">Lymphoma, including Hodgkin</td> <td>Sometimes</td> <td>Sometimes</td> <td>Sensory or sensorimotor; subacute or chronic.</td> </tr> <tr> <td class=\"indent1\">Multiple myeloma, osteosclerotic or solitary plasmacytoma type*</td> <td>Sometimes</td> <td>Usually</td> <td>Sensorimotor; can present subacute or more chronically.</td> </tr> <tr> <td class=\"indent1\">IgA</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensorimotor; chronic.</td> </tr> <tr> <td class=\"indent1\">IgG</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensorimotor; chronic.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IgM</td> <td>Rare if ever</td> <td>Usually</td> <td>Sensorimotor or pure sensory (as in the case of anti-myelin associated glycoprotein neuropathy); subacute or chronic.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Rare</td> </tr> <tr> <td class=\"indent1\">Porphyria (four types)</td> <td>Usually</td> <td>Rare if ever</td> <td>Primarily motor; limited sensory involvement; intermittent and acute or chronic.</td> </tr> <tr> <td class=\"indent1\">Primary biliary cholangitis</td> <td>Usually</td> <td>Rare if ever</td> <td>Primarily sensory; subacute to chronic.</td> </tr> <tr> <td class=\"indent1\">Primary systemic amyloidosis</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensorimotor with prominent autonomic involvement.</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensory; subacute.</td> </tr> <tr> <td class=\"indent1\">Chronic obstructive lung disease</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensory or sensorimotor; chronic.</td> </tr> <tr> <td class=\"indent1\">Acromegaly</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensory; chronic.</td> </tr> <tr> <td class=\"indent1\">Polycythemia vera</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensory; chronic.</td> </tr> <tr> <td class=\"indent1\">Cryoglobulinemia</td> <td>Usually</td> <td>Rare if ever</td> <td>Sensorimotor; subacute.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M.<br />* Some cases associated with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.</div><div class=\"graphic_reference\">Modified with data from: Fauci AS, Braunwald E, Isselbacher KJ, et al (Eds). Harrison's Principles of Internal Medicine, 14th ed, McGraw-Hill Company, Inc., New York 1998. p.2460.</div><div id=\"graphicVersion\">Graphic 54853 Version 6.0</div></div></div>"},"54855":{"type":"graphic_table","displayName":"Lung disease in IBD","title":"Pulmonary involvement in inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary involvement in inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"> <tbody>\n<tr> <td class=\"subtitle1\">Patterns of involvement</td>\n<td class=\"subtitle1\">Percent of total </td> </tr>\n<tr> <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Respiratory\ndisease</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis</td>\n<td>23</td> </tr> <tr> <td class=\"indent1\">Chronic\nbronchitis</td> <td>20</td> </tr> <tr>\n<td class=\"indent1\">Interstitial lung disease</td> <td>18</td>\n</tr> <tr> <td class=\"indent1\">Bronchiolitis\nobliterans with organizing pneumonia\n(BOOP)</td> <td>12</td> </tr> <tr> <td class=\"indent1\">Chronic bronchial suppuration</td> <td>8</td>\n</tr> <tr> <td class=\"indent1\">Subglottic\nstenosis</td> <td>7</td> </tr> <tr> <td class=\"indent1\">Necrobiotic nodules - neutrophilic\ninfiltrates</td> <td>6</td> </tr> <tr>\n<td class=\"indent1\">Chronic bronchiolitis</td> <td>3</td>\n</tr> <tr> <td class=\"indent1\">Pulmonary\ninfiltrates with eosinophilia</td> <td>3</td> </tr>\n<tr> <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Serositis</td> </tr> <tr> <td class=\"indent1\">Pericarditis</td> <td>36</td>\n</tr> <tr> <td class=\"indent1\">Pleuropericarditis</td>\n<td> 31</td> </tr> <tr> <td class=\"indent1\">Myocarditis</td> <td>24</td>\n</tr> <tr> <td class=\"indent1\">Pleural\neffusion</td> <td>9</td> </tr> </tbody>\n</table></div><div class=\"graphic_lgnd\">Patterns of lung disease in patients with inflammatory bowel disease: 89 patients had respiratory involvement and 42 patients had serosal disease.</div><div class=\"graphic_reference\">Data from Camus, P, Piard, F, Ashcroft, T, et al, Medicine 1993; 72:151.</div><div id=\"graphicVersion\">Graphic 54855 Version 1.0</div></div></div>"},"54856":{"type":"graphic_diagnosticimage","displayName":"Hepatoma invading major vessels","title":"Hepatoma invading major vessels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatoma invading major vessels</div><div class=\"cntnt\"><img style=\"width:365px; height:288px;\" src=\"images/GAST/54856_Hepatoma_invading_IVC_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A contrast-enhanced computed tomography&nbsp;(CT) scan demonstrates an ill-defined mass in the dome of the liver representing the region of the hepatoma (long arrow). A filling defect in the contrast filled inferior vena cava (IVC; arrowhead) reflects tumor thrombus extending from the primary tumor into the IVC.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 54856 Version 6.0</div></div></div>"},"54858":{"type":"graphic_table","displayName":"Clinical features fibrillary glomerulonephritis","title":"Demographics and presenting clinical features of 186 patients with fibrillary glomerulonephritis or immunotactoid glomerulonephropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Demographics and presenting clinical features of 186 patients with fibrillary glomerulonephritis or immunotactoid glomerulonephropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Clinical features</td> <td class=\"subtitle1\" colspan=\"2\">Fibrillary variant</td> <td class=\"subtitle1\" colspan=\"2\">Immunotactoid variant</td> </tr> <tr> <td class=\"subtitle2\">Fibril diameter*</td> <td class=\"subtitle2\">Fibril arrangement*</td> <td class=\"subtitle2\">Fibril diameter*</td> <td class=\"subtitle2\">Fibril arrangement*</td> </tr> <tr> <td>Number of patients<sup>&#182;</sup></td> <td>172</td> <td>164</td> <td>12</td> <td>22</td> </tr> <tr> <td>Male:female</td> <td>1.0:1.3</td> <td>1.0:1.3</td> <td>1.4:1.0</td> <td>2.6:1.0</td> </tr> <tr> <td>Age range</td> <td>10 to 81</td> <td>10 to 81</td> <td>12 to 68</td> <td>10 to 68</td> </tr> <tr> <td>Race (white:black)</td> <td>9:1 (n=70)</td> <td>9:1 (n=70)</td> <td>-&#916;</td> <td>-&#916;</td> </tr> <tr> <td>Hypertension</td> <td>85/126 (67%)</td> <td>81/118 (69%)</td> <td>5/11 (45%)</td> <td>11/13 (85%)</td> </tr> <tr> <td>Hematuria</td> <td>109/153 (71%)</td> <td>103/146 (70%)</td> <td>7/11 (64%)</td> <td>15/20 (75%)</td> </tr> <tr> <td>Proteinuria</td> <td>172/172 (100%)</td> <td>164/164 (100%)</td> <td>12/12 (100%)</td> <td>22/22 (100%)</td> </tr> <tr> <td>Nephrotic syndrome</td> <td>94/133 (71%)</td> <td>87/125 (70%)</td> <td>9/11 (82%)</td> <td>18/21 (86%)</td> </tr> <tr> <td>Renal insufficiency</td> <td>78/144 (54%)</td> <td>73/136 (54%)</td> <td>5/12 (42%)</td> <td>10/22 (45%)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* To determine whether the fibrillary (F) and immunotactoid (IT) variants have different clinical features, patients were subdivided according to the diameter (F ≤30 nm) or arrangement (F, random; IT, focally organized) of microfibrils and microtubules. In general, these different criteria identified the same subpopulations of patients (&gt;90 percent concordance).<br />¶ Fibril size was not reported in two patients. Study population consists of 25 patients presenting to the Brigham &amp; Women's Hospital and 161 patients reported previously in the literature.<br />Δ Insufficient data for interpretation.</div><div class=\"graphic_reference\">Adapted from Brady, HR. Kidney Int 1998; 53:1421.</div><div id=\"graphicVersion\">Graphic 54858 Version 3.0</div></div></div>"},"54862":{"type":"graphic_table","displayName":"TR knockout phenotype","title":"Summary of TR knockout phenotype","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of TR knockout phenotype</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">TR<sub>&#945;</sub>1/<sub>&#945;</sub>2</td> <td class=\"subtitle1\">TR<sub>&#945;</sub>1</td> <td class=\"subtitle1\">TR<sub>&#946;</sub>1/<sub>&#946;</sub>2</td> <td class=\"subtitle1\">TR<sub>&#945;</sub>1/<sub>&#945;</sub>2</td> </tr> <tr> <td>Thyroid</td> <td>Hypoplastic</td> <td>Normal</td> <td>&nbsp;</td> <td>Enlarged 2.5-fold</td> </tr> <tr> <td>Serum T4</td> <td>Low</td> <td>Low</td> <td>Elevated</td> <td>Markedly elevated</td> </tr> <tr> <td>TSH (serum/mRNA)</td> <td>Reduced</td> <td>Reduced</td> <td>Nonsuppressed</td> <td>Increased 10-fold</td> </tr> <tr> <td>Survival</td> <td>Neonatal lethal at&nbsp;four to&nbsp;six weeks</td> <td>Normal</td> <td>Normal</td> <td>Lethal at&nbsp;five weeks</td> </tr> <tr> <td>Bone</td> <td>Reduced longitudinal area, demineralized</td> <td>Normal</td> <td>Normal</td> <td>Abnormal growth, defective mineralization</td> </tr> <tr> <td>Brain</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td>Other</td> <td>Arrested maturation of small intestine</td> <td>Reduced heart rate, prolonged QT, reduced body temperature</td> <td>Functional cochlear defect</td> <td>Defective maturation of small intestine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T4: thyroxine; TR: thyroid hormone receptor; TSH: thyroid-stimulating hormone.</div><div class=\"graphic_reference\">Reproduced with permission from: Brent, GA. Tissue-specific actions of thyroid hormone: Insights from animal models. Reviews in Endocrine &amp; Metabolic Disorders 2000; 1:27. Copyright © 2000 Kluwer Academic Publishers.</div><div id=\"graphicVersion\">Graphic 54862 Version 2.0</div></div></div>"},"54863":{"type":"graphic_figure","displayName":"Cyclic versus chronic vomiting","title":"Differences between cyclic and chronic temporal patterns of vomiting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Differences between cyclic and chronic temporal patterns of vomiting</div><div class=\"cntnt\"><img style=\"width:370px; height:252px;\" src=\"images/GAST/54863_Cyclic_versus_chronic_vomit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Differences between cyclic and chronic temporal patterns of vomiting can be compared when the number of emeses is plotted over a two-month period. The chronic pattern (red line) is characterized by low-grade, nearly daily episodes whereas the cyclic pattern (black line) is marked by high-intensity episodes every several weeks.</div><div class=\"graphic_reference\">Adapted from: Li BU. New hope for children with cyclic vomiting syndrome. Contemp Pediatr 2002; 19:121.</div><div id=\"graphicVersion\">Graphic 54863 Version 3.0</div></div></div>"},"54865":{"type":"graphic_figure","displayName":"Coronal organ nasal view","title":"Coronal whole organ section through the nasal vestibule","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Coronal whole organ section through the nasal vestibule</div><div class=\"cntnt\"><img style=\"width:572px; height:286px;\" src=\"images/ONC/54865_Coronalorgannasalview.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lee N, Riaz N, Chen AM. General Principles and Management. In: Harrison LB, Kies M, Sessions RB (Eds). Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: Lippincott Williams &amp; Wilkins, 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54865 Version 11.0</div></div></div>"},"54866":{"type":"graphic_picture","displayName":"Vascular hemangioma of the buccal mucosa","title":"Vascular hemangioma of the buccal mucosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vascular hemangioma of the buccal mucosa</div><div class=\"cntnt\"><img style=\"width:289px; height:300px;\" src=\"images/PEDS/54866_Buccal_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Martha Ann Keels, DDS, PhD.</div><div id=\"graphicVersion\">Graphic 54866 Version 2.0</div></div></div>"},"54868":{"type":"graphic_picture","displayName":"TSC angiofibromas","title":"Tuberous sclerosis complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberous sclerosis complex</div><div class=\"cntnt\"><img style=\"width:392px; height:262px;\" src=\"images/PEDS/54868_TS_angiofibromas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiofibromas of the face presenting as erythematous papules in a child with tuberous sclerosis complex</div><div id=\"graphicVersion\">Graphic 54868 Version 4.0</div></div></div>"},"54870":{"type":"graphic_movie","displayName":"Supracristal VSD short axis 2D and color","title":"Supracristal VSD short axis 2D and color","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Supracristal VSD short axis 2D and color</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/54870_SupracristVSDshortmovie.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:545px; height:394px;\" src=\"images/CARD/54870_SupracristVSDshortposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The proximity of the defect to the pulmonary valve and the relationship to the tricuspid valve can be seen from this short axis window. As the imaging plane changes, the aortic valve leaflets come into view over the LVOT.</div><div class=\"graphic_footnotes\">RV: right ventricle; TV: tricuspid valve; LVOT: left ventricular outflow tract; PV: pulmonary valve; RA: right atrium; LA: left atrium; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 54870 Version 2.0</div></div></div>"},"54871":{"type":"graphic_figure","displayName":"HDV reinfection in liver TPL","title":"Hepatitis D virus reinfection alone after liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Hepatitis D virus reinfection alone after liver transplantation</div><div class=\"cntnt\"><img style=\"width:517px; height:438px;\" src=\"images/GAST/54871_HDV_reinfection_in_liver_TP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A patient who underwent transplantation for HDV cirrhosis became HBsAg negative while receiving HBIG immunoprophylaxis. Despite the absence of HBsAg from serum and liver, HDV-RNA was detected in serum and HDAg was detected in the graft for 15 months post- transplantation but not thereafter. Throughout the follow-up period, serum aminotransferases and graft histology remained normal, demonstrating the mild, benign course of isolated HDV reinfection. </div><div class=\"graphic_footnotes\">Arrows: liver biopsies; N: normal; ALT: alanine aminotransferase; hatched area: upper limit of normal for ALT. </div><div class=\"graphic_reference\">Data from Samuel, D, Zignego, AL, Reynes, M, et al, Hepatology 1995; 21:334</div><div id=\"graphicVersion\">Graphic 54871 Version 2.0</div></div></div>"},"54872":{"type":"graphic_table","displayName":"Identifiable causes of urticaria","title":"Identifiable causes of urticaria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Identifiable causes of urticaria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infections </td> </tr> <tr> <td>Viral</td> </tr> <tr> <td>Parasitic</td> </tr> <tr> <td>Bacterial</td> </tr> <tr> <td class=\"subtitle1_single\">IgE-mediated allergic cases </td> </tr> <tr> <td>Medications</td> </tr> <tr> <td class=\"sublist1_start\">Insects </td> </tr> <tr> <td class=\"sublist1\">Stinging (yellow jackets, bees, wasps, hornets, fire ants) </td> </tr> <tr> <td class=\"sublist1\">Biting (<em>Triatoma</em> [kissing bugs]) </td> </tr> <tr> <td>Foods</td> </tr> <tr> <td>Blood products (urticarial transfusion reaction)</td> </tr> <tr> <td>Latex (contact or inhaled)</td> </tr> <tr> <td>Contact allergens (animal saliva, raw foods)</td> </tr> <tr> <td>Aeroallergens (rare)</td> </tr> <tr> <td>Food additives</td> </tr> <tr> <td class=\"subtitle1_single\">Direct mast cell activation </td> </tr> <tr> <td>Narcotics/opiates</td> </tr> <tr> <td>Muscle relaxants (eg, succinylcholine)</td> </tr> <tr> <td>Radiocontrast agents</td> </tr> <tr> <td>Vancomycin</td> </tr> <tr> <td class=\"subtitle1_single\">Physical stimuli </td> </tr> <tr> <td>Dermatographism</td> </tr> <tr> <td>Delayed pressure</td> </tr> <tr> <td>Cold</td> </tr> <tr> <td>Cholinergic</td> </tr> <tr> <td>Vibratory</td> </tr> <tr> <td>Aquagenic</td> </tr> <tr> <td>Solar</td> </tr> <tr> <td>Exertion/exercise</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous mechanisms </td> </tr> <tr> <td>Nonsteroidal anti-inflammatory drugs</td> </tr> <tr> <td>Serum sickness</td> </tr> <tr> <td>Transfusion reactions (distinct from IgE-mediated reactions)</td> </tr> <tr> <td>Hormone-associated (progesterone)</td> </tr> <tr> <td>Stinging nettle</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 54872 Version 3.0</div></div></div>"},"54874":{"type":"graphic_diagnosticimage","displayName":"Renal hematoma CT","title":"Renal hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal hematoma</div><div class=\"cntnt\"><img style=\"width:359px; height:288px;\" src=\"images/NEPH/54874_Renal_hematoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows hemorrhage into the left perirenal and pararenal spaces following percutaneous biopsy of the left kidney. The hematoma has displaced the kidney anteriorly.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 54874 Version 3.0</div></div></div>"},"54876":{"type":"graphic_table","displayName":"Repeat bx HGPIN number cores","title":"Results of repeat prostate biopsy in men with high grade PIN, according to the number of cores sampled","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of repeat prostate biopsy in men with high grade PIN, according to the number of cores sampled</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Group</td>\n\n      <td class=\"subtitle1\">Number of cores, initial biopsy</td>\n\n      <td class=\"subtitle1\">Number of cores, rebiopsy</td>\n\n      <td class=\"subtitle1\">Number of cancers/total number of men</td>\n\n      <td class=\"subtitle1\">Risk of cancer, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1</td>\n\n      <td>Six or seven</td>\n\n      <td>Six or seven</td>\n\n      <td>49/295</td>\n\n      <td>17</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2</td>\n\n      <td>Six or seven</td>\n\n      <td>Eight or more</td>\n\n      <td>47/173</td>\n\n      <td>27</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3 </td>\n\n      <td>Eight or more</td>\n\n      <td>Eight or more</td>\n\n      <td>37/253</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4</td>\n\n      <td>Eight or more</td>\n\n      <td>Six or seven</td>\n\n      <td>6/70</td>\n\n      <td>9</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\">Overall</td>\n\n      \n\n      \n\n      <td>139/791</td>\n\n      <td>18</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">PIN: prostatic intraepithelial neoplasia.</div><div class=\"graphic_reference\">Data from Herawi, M, et al. J Urol 2006; 175:121.</div><div id=\"graphicVersion\">Graphic 54876 Version 1.0</div></div></div>"},"54877":{"type":"graphic_picture","displayName":"Urticarial vasculitis I","title":"Urticarial vasculitis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Urticarial vasculitis</div><div class=\"cntnt\"><img style=\"width:468px; height:309px;\" src=\"images/ALLRG/54877_UV_lesions_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urticarial patch with central ecchymosis.</div><div id=\"graphicVersion\">Graphic 54877 Version 3.0</div></div></div>"},"54878":{"type":"graphic_figure","displayName":"Vacuum constrictor device","title":"Vacuum constrictor device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vacuum constrictor device</div><div class=\"cntnt\"><img style=\"width:232px; height:276px;\" src=\"images/ENDO/54878_Vacuum_constrictor_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A vacuum-constrictor device causes an erection by creating a partial vacuum around the penis, which draws blood into the corpora cavernosa. Pictured here are the necessary components: (a) a plastic cylinder, which covers the penis; (b) a pump, which draws air out of the cylinder; and (c) an elastic ring, which, when fitted over the base of the penis, traps the blood and sustains the erection after the cylinder is removed.</div><div id=\"graphicVersion\">Graphic 54878 Version 1.0</div></div></div>"},"54879":{"type":"graphic_diagnosticimage","displayName":"Intraabdominal desmoid tumor in familial polyposis CT","title":"Intraabdominal desmoid tumor in familial polyposis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraabdominal desmoid tumor in familial polyposis</div><div class=\"cntnt\"><img style=\"width:347px; height:288px;\" src=\"images/GAST/54879_Desmoid_familial_polyposis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan through the mid-abdomen demonstrates a large well-circumscribed soft tissue mass arising in the mesentery (arrow); the mass represented a desmoid tumor (aggressive fibromatosis).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 54879 Version 5.0</div></div></div>"},"54882":{"type":"graphic_figure","displayName":"Fibroid embolization 2 PI","title":"Fibroid embolization 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibroid embolization 2</div><div class=\"cntnt\"><img style=\"width:323px; height:248px;\" src=\"images/PI/54882_Fibroid_embolization_2_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing embolic particles being released from the catheter and into the uterine arterial branches supplying the fibroid.</div><div id=\"graphicVersion\">Graphic 54882 Version 1.0</div></div></div>"},"54885":{"type":"graphic_diagnosticimage","displayName":"Pediatric Galeazzi fracture and dislocation","title":"Pediatric Galeazzi fracture and dislocation","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Pediatric Galeazzi fracture and dislocation</div><div class=\"cntnt\"><img style=\"width:584px; height:440px;\" src=\"images/EM/54885_PedGaleazzifracdisloc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) View of the entire forearm of an 11-year-old boy with a Galeazzi fracture-dislocation.<br />(B) Close-up of the distal forearm shows that there has been disruption of the distal radioulnar joint (arrows). The distal radial fragment is dorsally displaced (apex volar), making this a supination type of mechanism. Note that the distal ulna is volar to the distal radius.<br />(C) In this second patient, the anterior posterior view shows some shortening of the distal radius (arrowhead) in relation to the distal ulna, which has a small greenstick component.<br />(D) The pronation component (arrowhead) is better appreciated on this lateral view. The distal ulna lies dorsal to the distal radius (dashed arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Bae DS. Fractures of the distal radius and ulna. In: Rockwood and Wilkin's Fractures in Children, 7th Edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 54885 Version 11.0</div></div></div>"},"54886":{"type":"graphic_table","displayName":"Criteria for MMS","title":"Criteria for performing Mohs micrographic surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for performing Mohs micrographic surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Tumor characteristics</td> </tr> <tr> <td>Large tumor (&#62;2 cm)</td> </tr> <tr> <td>Poorly defined clinical borders</td> </tr> <tr> <td>Recurrent tumor</td> </tr> <tr> <td>Incompletely excised (positive margins)</td> </tr> <tr> <td class=\"sublist1_start\">Aggressive histologic features</td> </tr> <tr> <td class=\"sublist1\">Morpheaform, micronodular, infiltrative BCC</td> </tr> <tr> <td class=\"sublist1\">Basosquamous features</td> </tr> <tr> <td class=\"sublist1\">Poorly differentiated and deeply infiltrative SCC</td> </tr> <tr> <td class=\"sublist1\">Perineural invasion</td> </tr> <tr> <td>Chronic scar (Marjolin's ulcer)</td> </tr> <tr> <td class=\"subtitle1_single\">Patient characteristics</td> </tr> <tr> <td>Immunosuppressed</td> </tr> <tr> <td>Irradiated skin</td> </tr> <tr> <td>Genetic syndrome (eg, xeroderma pigmentosum, Gorlin or nevoid BCC)</td> </tr> <tr> <td class=\"subtitle1_single\">Anatomic location</td> </tr> <tr> <td class=\"sublist1_start\">Areas where tissue preservation is essential (including eyes, nose, hands/feet and genitalia)</td> </tr> <tr> <td>Embryonic fusion lines (preauricular, nasolabial fold, inner canthus and philtrum)</td> </tr> <tr> <td>\"Mask areas\" of face (central face, periorbital, nose, lips)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 54886 Version 1.0</div></div></div>"},"54887":{"type":"graphic_picture","displayName":"Lip-licking dermatitis","title":"Lip-licking dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lip-licking dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/54887_Lip_lick_dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lip-licking dermatitis is a chronic irritant contact dermatitis caused by repeated exposure to saliva of lips and perioral area. Erythema with hyperpigmentation, scaling, and fissures form a well-demarcated ring around the lips.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 54887 Version 4.0</div></div></div>"},"54888":{"type":"graphic_figure","displayName":"Mirizzi syndrome with compression of the common duct","title":"Mirizzi syndrome with compression of the common hepatic duct by an impacted stone","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Mirizzi syndrome with compression of the common hepatic duct by an impacted stone</div><div class=\"cntnt\"><img style=\"width:511px; height:426px;\" src=\"images/GAST/54888_Mirizzi-syndrome-compression-redo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of Mirizzi syndrome.<br> (Panel A) An impacted stone in the cystic duct or Hartmann's pouch of the gallbladder obstructs the common hepatic duct both by extrinsic compression and associated inflammation.<br> (Panel B) Treatment consists of cholecystectomy.</div><div id=\"graphicVersion\">Graphic 54888 Version 6.0</div></div></div>"},"54890":{"type":"graphic_table","displayName":"Labs organ donor","title":"Laboratory testing for the pediatric potential organ donor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory testing for the pediatric potential organ donor</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Basic lab tests - CBC, electrolytes, BUN, creatinine, AST, ALT, GGT, PT, PTT, urine analysis</td> </tr> <tr> <td>ABO blood group typing</td> </tr> <tr> <td class=\"sublist1_start\">Blood for HLA typing</td> </tr> <tr> <td class=\"sublist1\">In certain cases inguinal lymph nodes may be taken to facilitate tissue typing</td> </tr> <tr> <td class=\"sublist1_start\">Microbiological studies</td> </tr> <tr> <td class=\"sublist1\">Microscopy, culture and sensitivity of blood, urine and sputum samples</td> </tr> <tr> <td class=\"sublist1_start\">Viral serology</td> </tr> <tr> <td class=\"sublist1\">Epstein-Barr virus (EBV), cytomegalovirus (CMV), Human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV)</td> </tr> <tr> <td>Syphilis screening: VDRL or RPR</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Additional laboratory tests may be requested by the Organ Procurement Organization.</div><div class=\"graphic_footnotes\">CBC: complete blood count; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transpeptidase; PT: prothrombin time; PTT: partial thromboplastin time; HLA: human leukocyte antigens; VDRL: venereal disease research laboratory; RPR: rapid plasma reagin.</div><div id=\"graphicVersion\">Graphic 54890 Version 4.0</div></div></div>"},"54891":{"type":"graphic_picture","displayName":"Ulceration and hyperpigmentation following sclerotherapy","title":"Ulceration and hyperpigmentation following sclerotherapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulceration and hyperpigmentation following sclerotherapy</div><div class=\"cntnt\"><img style=\"width:360px; height:390px;\" src=\"images/PC/54891_Sclerotherapy_ulcers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulceration on the proximal right lower extremity with central skin necrosis. Scattered hyperpigmentation at bilateral injection sites.</div><div class=\"graphic_reference\">Reproduced with permission from: Zimmet, SE. Complications of Sclerotherapy. Available at: http://www.veindirectory.org/news/pdf/18.pdf.</div><div id=\"graphicVersion\">Graphic 54891 Version 2.0</div></div></div>"},"54892":{"type":"graphic_figure","displayName":"Exercise after LVRS or lung transplantation","title":"Exercise after lung volume reduction surgery (LVRS) or lung transplantation in emphysema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exercise after lung volume reduction surgery (LVRS) or lung transplantation in emphysema</div><div class=\"cntnt\"><img style=\"width:373px; height:230px;\" src=\"images/PULM/54892_Exercise_emphysema_lung_tra.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of six-minute walk distance before and after volume reduction (VR), single lung transplantation (SLT), and bilateral lung transplantation (BLT). The following differences were significantly different: VR greater than BLT (p &lt;0.05) at initial evaluation; VR less than BLT at six months (p &lt;0.001), and VR at evaluation versus six months (p &lt;0.001).</div><div class=\"graphic_reference\">Redrawn from Gaissert HA, Trulock EP, Cooper JD, et al, J Thorac Cardiovasc Surg 1996; 111:296.</div><div id=\"graphicVersion\">Graphic 54892 Version 2.0</div></div></div>"},"54894":{"type":"graphic_picture","displayName":"Proper knee position squat","title":"Proper knee position during a squat","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proper knee position during a squat</div><div class=\"cntnt\"><img style=\"width:284px; height:353px;\" src=\"images/RHEUM/54894_proper_knee_squat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The knee should not pass over the toes when squatting. This helps prevent placing excessive stress on the knee joint.</div><div class=\"graphic_reference\">Courtesy of Sharon Alzner, MPT.</div><div id=\"graphicVersion\">Graphic 54894 Version 1.0</div></div></div>"},"54895":{"type":"graphic_picture","displayName":"Slit lamp lock nut","title":"Slit lamp locking nut","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Slit lamp locking nut</div><div class=\"cntnt\"><img style=\"width:432px; height:327px;\" src=\"images/EM/54895_Slit_lamp_lock_nut.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loosen the locking nut on the slit lamp assembly to allow free movement.</div><div id=\"graphicVersion\">Graphic 54895 Version 2.0</div></div></div>"},"54897":{"type":"graphic_picture","displayName":"Lymphocytic colitis Light","title":"Lymphocytic colitis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocytic colitis</div><div class=\"cntnt\"><img style=\"width:436px; height:288px;\" src=\"images/GAST/54897_Lymphocytic_colitis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a colonic biopsy from a patient with lymphocytic colitis shows intraepithelial and lamina propria lymphocytic infiltrate.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 54897 Version 1.0</div></div><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Normal colon</div><div class=\"cntnt\"><img style=\"width:518px; height:172px;\" src=\"images/GAST/81083_Normal_colon_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 81083 Version 1.0</div></div></div>"},"54899":{"type":"graphic_waveform","displayName":"RA PA pressures pacing","title":"Pressure waveforms change with ventricular pacing","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Pressure waveforms change with ventricular pacing</div><div class=\"cntnt\"><img style=\"width:550px; height:159px;\" src=\"images/CARD/54899_RA_PA_pressures_pacing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure waveforms during pacing and sinus rhythm. Left panel: The rhythm initially is paced from the right ventricle and the right atrial (RA) pressure tracing demonstrates a significant &quot;v&quot; wave due to tricuspid regurgitation. Middle panel: In the presence of normal sinus rhythm in the last half of the tracing, the normal RA waveform is restored and the &quot;v&quot; wave is no longer seen. Right panel: The effect of the rhythm change on the pulmonary aretry (PA) pressure is depicted. During pacing, the PA pressure is higher and has a greater respiratory variation than during sinus rhythm.</div><div class=\"graphic_reference\">Courtesy of Morton Kern, MD.</div><div id=\"graphicVersion\">Graphic 54899 Version 2.0</div></div></div>"},"54900":{"type":"graphic_movie","displayName":"Posterior shoulder dislocation with blocked external rotation","title":"Posterior shoulder dislocation with blocked external rotation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior shoulder dislocation with blocked external rotation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/54900_Postblockedextrotation.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:432px; height:324px;\" src=\"images/EM/54900_Postblockedextrotat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Simon and Sherman, Emergency Orthopedics, 6th edition. DVD © Scott Sherman. All rights reserved.</div><div id=\"graphicVersion\">Graphic 54900 Version 3.0</div></div></div>"},"54902":{"type":"graphic_diagnosticimage","displayName":"Intraluminal obstruction after gastric bypass","title":"Intraluminal obstruction after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Intraluminal obstruction after gastric bypass</div><div class=\"cntnt\"><img style=\"width:540px; height:301px;\" src=\"images/SURG/54902_Intraluminal_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrows point to an intraluminal obstruction after gastric bypass. A feces sign is seen in the small bowel and distal bowel is collapsed. The patient presented with abdominal pain and was obstructed by steak. This obstruction resolved spontaneously.</div><div id=\"graphicVersion\">Graphic 54902 Version 7.0</div></div></div>"},"54904":{"type":"graphic_picture","displayName":"Strawberry gallbladder Gross","title":"Gallbladder cholesterolosis (strawberry gallbladder)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gallbladder cholesterolosis (strawberry gallbladder)</div><div class=\"cntnt\"><img style=\"width:425px; height:239px;\" src=\"images/GAST/54904_Strawberry_gallbladder_Gros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen from a patient with gallbladder cholesterolosis. The lipid accumulation on a background of hyperemic mucosa gives it the appearance of a strawberry.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 54904 Version 2.0</div></div></div>"},"54906":{"type":"graphic_picture","displayName":"Vacuolated uroepithelial cells","title":"Vacuolated uroepithelial cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vacuolated uroepithelial cells</div><div class=\"cntnt\"><img style=\"width:252px; height:429px;\" src=\"images/NEPH/54906_Vacuolated_uroepithelial_ce.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine showing vacuolated urinary epithelial cells (oval fat bodies) in a Fabry patient (Papanicolaou stain, original magnification X160).</div><div class=\"graphic_reference\">Reproduced with permission from: Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 2002; 81:122. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54906 Version 7.0</div></div></div>"},"54907":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound images of physiologic midgut herniation","title":"Prenatal ultrasound images of physiologic midgut herniation","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound images of physiologic midgut herniation</div><div class=\"cntnt\"><img style=\"width:578px; height:351px;\" src=\"images/OBGYN/54907_Physiol_midgut_hern_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional ultrasound of a fetus&nbsp;at 11 weeks and&nbsp;four days of gestation with physiologic midgut herniation (PMH). Arrows point to the PMH.<br />(A) Sagittal view of fetus with PMH.<br />(B) Transverse section at the level of the PMH.<br />(C) Coronal section.<br />(D) Three-dimensional rendering demonstrating the PMH.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 54907 Version 5.0</div></div></div>"},"54908":{"type":"graphic_table","displayName":"ESC Rx mechanical valve","title":"European College of Cardiology guideline summary: Antithrombotic therapy in patients with mechanical heart valves","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European College of Cardiology guideline summary: Antithrombotic therapy in patients with mechanical heart valves</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General principles</td> </tr> <tr> <td>Thromboembolic risk is related to two factors:</td> </tr> <tr> <td class=\"sublist1_start\">Thrombogenicity of the mechanical valve</td> </tr> <tr> <td class=\"sublist1\">1. Low - Medtronic Hall, St Jude Medical (without Silzone), CarboMedics AVR</td> </tr> <tr> <td class=\"sublist1\">2. Medium - Bileaflet valves with insufficient data, Bjork-Shiley</td> </tr> <tr> <td class=\"sublist1\">3. High - Lillehei Kaster, Omniscience, Starr Edwards</td> </tr> <tr> <td>Presence or absence of risk factors: atrial fibrillation, left atrial dimension &#62;50 mm, mitral valve gradient, left ventricular ejection fraction &#60;35 percent, spontaneous echo contrast, mitral, tricuspid, or pulmonary valve replacement, or a hypercoagulable state.</td> </tr> <tr> <td class=\"subtitle1_single\">Recommendations for anticoagulation</td> </tr> <tr> <td>&#8226;&nbsp; Until the INR is stable, intravenous unfractionated heparin (to achieve an activated partial thromboplastin time of 1.5 to 2.0) is probably safer than subcutaneous unfractionated heparin or low molecular weight heparin which, if used, should be accompanied by anti-factor Xa monitoring, particularly in patients with renal failure or obesity.</td> </tr> <tr> <td>&#8226;&nbsp; For low thrombogenicity valves, warfarin (or other vitamin K antagonist) to achieve a goal INR of 2.5 if no risk factors and 3.0 if risk factors.</td> </tr> <tr> <td>&#8226;&nbsp; For medium thrombogenicity valves, warfarin (or other vitamin K antagonist) to achieve a goal INR of 3.0 if no risk factors and 3.5 if risk factors.</td> </tr> <tr> <td>&#8226;&nbsp; For high thrombogenicity valves, warfarin (or other vitamin K antagonist) to achieve a goal INR of 3.5 if no risk factors and 4.0 if risk factors.</td> </tr> <tr> <td class=\"subtitle1_single\">Addition of antiplatelet therapy</td> </tr> <tr> <td class=\"sublist1_start\">&#8226;&nbsp; Relative indications</td> </tr> <tr> <td class=\"sublist1\">1. Concurrent arterial disease</td> </tr> <tr> <td class=\"sublist1\">2. Coronary artery stenting</td> </tr> <tr> <td class=\"sublist1\">3. Recurrent embolism, but only after treatment of risk factors and optimization of anticoagulation fail to abolish the problem</td> </tr> <tr> <td class=\"sublist1\">4. With caged ball valves, with dipyridamole being preferred to aspirin</td> </tr> <tr> <td class=\"sublist1_start\">&#8226;&nbsp; Relative contraindications</td> </tr> <tr> <td class=\"sublist1\">1. History of gastrointestinal bleeding, particularly associated with ulcer disease or angiodysplasia.</td> </tr> <tr> <td class=\"sublist1\">2. Hyperresponders to aspirin, with excessively prolonged bleeding time.</td> </tr> <tr> <td class=\"sublist1\">3. Poorly controlled hypertension, because of the risk of intracerebral hemorrhage.</td> </tr> <tr> <td class=\"sublist1\">4. Elderly patients, particularly women over age 75.</td> </tr> <tr> <td class=\"sublist1\">5. Patients who take multiple medications, require frequent courses of antibiotics, or have erratic INR control.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Butchart EG, Gohlke-Barwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26:2463.</div><div id=\"graphicVersion\">Graphic 54908 Version 3.0</div></div></div>"},"54909":{"type":"graphic_table","displayName":"Promotion of psychosocial skills","title":"Suggestions for enhancing a child's psychosocial skills before kindergarten entry","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggestions for enhancing a child's psychosocial skills before kindergarten entry</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Parents can promote psychosocial skill development in their children by: </td> </tr> <tr> <td>Modeling and encouraging the use of descriptive words to express feelings, rather than physical reactions. Label both positive and negative emotions.</td> </tr> <tr> <td>Practicing taking turns whenever possible (eg, in turning pages of a book being read to them, in describing what was seen or what activities were experienced on a family outing, when choosing games to play, etc).</td> </tr> <tr> <td>Talking to the child about social interactions witnessed in public or on television, noting what behaviors led to problems, what behaviors were helpful, how a situation might have ended differently if one behavior had been changed.</td> </tr> <tr> <td>Practicing listening and following simple directions (eg, \"put the ball behind the chair then take the book to the table, then sit down on the rug\"). Start with a single direction, then two-step directions, then three-step directions, etc, as the child demonstrates mastery.</td> </tr> <tr> <td>Reinforcing the child for sharing belongings with other individuals, taking turns, etc.</td> </tr> <tr> <td>Practicing sitting and working quietly at a table for a few moments, and gradually increasing the amount of time spent.</td> </tr> <tr> <td class=\"subtitle1_single\">Parents can increase their child's exposure to peers and help them to make lasting friendships by: </td> </tr> <tr> <td>Joining noncompetitive extracurricular activities such as scouting groups or activities/sports offered through local organizations (eg, sports clubs, museums)</td> </tr> <tr> <td>Inviting friends or neighborhood children to go on family outings to the park, movies, shopping, out to eat, etc.</td> </tr> <tr> <td>Inviting playmates over to the house on evenings and weekends where parents can monitor and model appropriate social skills and problem solving and to intervene if problems arise.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted in part from recommendations compiled by staff members of the Learning Support Center, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 54909 Version 4.0</div></div></div>"},"54910":{"type":"graphic_table","displayName":"Causes of elevated troponin","title":"Causes of elevated troponin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of elevated troponin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Myocardial ischemia</td> </tr> <tr> <td class=\"subtitle2_single\">Acute coronary syndrome</td> </tr> <tr> <td class=\"indent1\">STEMI</td> </tr> <tr> <td class=\"indent1\">NSTEMI</td> </tr> <tr> <td class=\"subtitle2_single\">Other coronary ischemia</td> </tr> <tr> <td class=\"indent1\">Arrhythmia: tachy- or brady-</td> </tr> <tr> <td class=\"indent1\">Cocaine/methamphetamine use</td> </tr> <tr> <td class=\"indent1\">Coronary intervention (PCI or cardiothoracic surgery)</td> </tr> <tr> <td class=\"indent1\">Coronary artery spasm (variant angina)</td> </tr> <tr> <td class=\"indent1\">Stable coronary atherosclerotic disease in setting of increased O<sup>2</sup> demand (eg, tachycardia)</td> </tr> <tr> <td class=\"indent1\">Severe hypertension</td> </tr> <tr> <td class=\"indent1\">Coronary embolus</td> </tr> <tr> <td class=\"indent1\">Aortic dissection</td> </tr> <tr> <td class=\"indent1\">Coronary artery vasculitis (SLE, Kawasaki)</td> </tr> <tr> <td class=\"subtitle2_single\">Non-coronary ischemia</td> </tr> <tr> <td class=\"indent1\">Shock (hypotension)</td> </tr> <tr> <td class=\"indent1\">Hypoxia</td> </tr> <tr> <td class=\"indent1\">Hypoperfusion</td> </tr> <tr> <td class=\"indent1\">Pulmonary embolism</td> </tr> <tr> <td class=\"indent1\">Global ischemia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">CT surgery</td> </tr> <tr> <td class=\"subtitle1_single\">Myocardial injury with no ischemia</td> </tr> <tr> <td class=\"subtitle2_single\">Comorbidities</td> </tr> <tr> <td class=\"indent1\">Renal failure</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> </tr> <tr> <td class=\"indent1\">Infiltrative diseases</td> </tr> <tr> <td class=\"indent1\">Acute respiratory failure</td> </tr> <tr> <td class=\"indent1\">Stroke</td> </tr> <tr> <td class=\"indent1\">Subarachnoid hemorrhage</td> </tr> <tr> <td class=\"subtitle2_single\">Specific identifiable precipitants</td> </tr> <tr> <td class=\"indent1\">Extreme exertion</td> </tr> <tr> <td class=\"indent1\">Cardiac contusion</td> </tr> <tr> <td class=\"indent1\">Burns &#62;30% BSA</td> </tr> <tr> <td class=\"indent1\">Cardiotoxic meds: anthracyclines, herceptin</td> </tr> <tr> <td class=\"indent1\">Electrical shock</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide exposure</td> </tr> <tr> <td class=\"subtitle2_single\">Other</td> </tr> <tr> <td class=\"indent1\">Apical ballooning (Takotsubo)</td> </tr> <tr> <td class=\"indent1\">Myocarditis</td> </tr> <tr> <td class=\"indent1\">Myopericarditis</td> </tr> <tr> <td class=\"indent1\">Rhabdomyolysis involving cardiac muscle</td> </tr> <tr> <td class=\"indent1\">Hypertrophic cardiomyopathy</td> </tr> <tr> <td class=\"indent1\">Peripartum cardiomyopathy</td> </tr> <tr> <td class=\"indent1\">Heart failure, malignancy, stress cardiomyopathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BSA: body surface area; CT: cardiothoracic; NSTEMI: non-ST elevation myocardial infarction; PCI: percutaneous coronary intervention; SLE: systemic lupus erythematosus; STEMI: ST elevation myocardial infarction.</div><div id=\"graphicVersion\">Graphic 54910 Version 11.0</div></div></div>"},"54912":{"type":"graphic_table","displayName":"Linear scanning echoendoscopes","title":"Linear scanning echoendoscopes currently available in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Linear scanning echoendoscopes currently available in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">GF-UC140-AL5</td> <td class=\"subtitle1\">GF-UCT140P-AL5</td> <td class=\"subtitle1\">EG-3630UR</td> <td class=\"subtitle1\">EG-3830UT</td> </tr> <tr> <td>US scanning orientation and range</td> <td>Electronic linear 180 degrees</td> <td>Electronic linear 180 degrees</td> <td>Electronic linear 120 degrees</td> <td>Electronic linear 120 degrees</td> </tr> <tr> <td>Endoscopic image</td> <td>Video oblique forward</td> <td>Video oblique forward</td> <td>Video oblique forward</td> <td>Video oblique forward</td> </tr> <tr> <td>Biopsy channel size</td> <td>2.8 mm</td> <td>3.7 mm</td> <td>2.4 mm</td> <td>3.8 mm</td> </tr> <tr> <td>Elevator</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Doppler/color Doppler</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>US scanning frequency (MHz)</td> <td>5, 6, 7.5, 10</td> <td>5, 6, 7.5, 10</td> <td>5, 7.5, 10</td> <td>5, 7.5, 10</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">6</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">8/24/99-au recieved print permission, sent back for electronic. 8/26/99-elec perm granted. 11/13-perm requested for 8.1. 12/16/99-perm granted for one year. 12/4/2000-perm granted for one year. 11/6/2001 -renewal request by email - jm; 1/10/2002 -re-emailed for status check -jm; 1/17/2002-left message in general mailbox for callback today -jm; 1/18/2002 -was informed all permissions is now done in england - emailed lindsay doyle -jm; 1/18/2002 pulled from 10.1 - jm; 2/11/2002 -per L.Doyle, refaxed request -jm; 4/2/2002-Sent reminder to L. Doyle. -kw 4/16/2002-Renewal granted. -kw 1/29/2003 renewal requested 3/11/2003 follow-up 4/8/2003 granted 1/30/2004 renewal requested 4/27/2004 faxed follow-up 5/12/2004 emailed another follow-up 5/14/2004 L wilson said she sent these out on Wednesday 5/25/2004 granted, but this should be free b/c Wiersema is the author of both -emailed L Wilson - yes, granted 2/2/2005 renewal requested 4/1/2005 resent this to L Wilson 6/3/2005 renewal reqeusted should be no fee 9/14/2005 checked in 1/10/2006 resent this to L Wilson 1/13/2006 checked in again 3/28/2006 bugged 5/11/2006 bugged 7/25/2006 renewal request 8/21/2006 bugged 8/24/2006renewal granted 8/6/2007 - renewal requst faxed.mn 9/24/2007 - granted.mn 7/7/2008--Removed 6203: EUS_FNA_Burkitt's_lymphoma and 6208: EUS_FNA_mediastinal_nodes from figure title field; removed from Gold, to Terrence to be removed and archived (JD). 8/8/2008--Requested renewal (JD). 9/10/2008--Renewal granted (JD). 8/7/2009--EUS_FNA_pancreatic_masses (6205) removed from Gold, to Terrence to be archived; permission expired with 17.2 (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=19552&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Courtesy of Maurits J. Wiersema, MD., with data from: Endoscopic ultrasound-guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography, Gress F, Bhattacharya I (Eds), Blackwell Science, Malden, MA 2001. p.136.</div><div id=\"graphicVersion\">Graphic 54912 Version 3.0</div></div></div>"},"54914":{"type":"graphic_figure","displayName":"Central dogma molecular biology","title":"Central dogma of molecular biology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central dogma of molecular biology</div><div class=\"cntnt\"><img style=\"width:396px; height:316px;\" src=\"images/PC/54914_Central_dogma_molecular_bio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">DNA codes for protein through the intermediary of RNA. For the longest time, it was believed that this flow was unidirectional. It is now clear that this is not entirely true. Nevertheless, this model frames the basics of our understanding of molecular biology, and while the study of genetics focuses on variation that originates in DNA, we must always be mindful that this variation has its action by eventually interfering with protein function. Refer to UpToDate topics on genetic variation for more information.</div><div id=\"graphicVersion\">Graphic 54914 Version 2.0</div></div></div>"},"54915":{"type":"graphic_diagnosticimage","displayName":"Chronic PE PA","title":"Chronic pulmonary embolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic pulmonary embolism</div><div class=\"cntnt\"><img style=\"width:351px; height:302px;\" src=\"images/PULM/54915_Chronic_PE_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows mosaic oligemia with localization of pulmonary blood flow to the lower lobes. This may be regarded as a Westermark's sign with oligemia affecting the subtended pulmonary parenchyma of the upper lobes.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 54915 Version 3.0</div></div></div>"},"54916":{"type":"graphic_picture","displayName":"EUS FNA sarcoidosis","title":"Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in sarcoidosis</div><div class=\"cntnt\"><img style=\"width:504px; height:364px;\" src=\"images/PULM/54916_EUS_FNA_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of a mediastinal lymph node from a patient with sarcoid.</div><div id=\"graphicVersion\">Graphic 54916 Version 3.0</div></div></div>"},"54917":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of the nuchal cord","title":"Ultrasound of the nuchal cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the nuchal cord</div><div class=\"cntnt\"><img style=\"width:432px; height:364px;\" src=\"images/OBGYN/54917_Ultrasound_nuchal_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Professor Josef Wisser, MD.</div><div id=\"graphicVersion\">Graphic 54917 Version 3.0</div></div></div>"},"54918":{"type":"graphic_diagnosticimage","displayName":"Benign metastasizing leiomyomas radiograph","title":"Benign metastasizing leiomyomas: Chest radiograph","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Benign metastasizing leiomyomas: Chest radiograph</div><div class=\"cntnt\"><img style=\"width:514px; height:275px;\" src=\"images/OBGYN/54918_Benignmetasleiomyoradio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Benign metastasizing leiomyoma in the lungs. Arrow points to small nodules in the lungs.<br> (B) Benign metastasizing leiomyoma in right upper lobe (RUL); cavitation as a result of secondary infection is demonstrated.</div><div class=\"graphic_reference\">Reproduced with permission from: Crapo JD, Glassroth J, Karlinsky JB, King TE, Jr. Baum's Textbook of Pulmonary Diseases, 7th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54918 Version 5.0</div></div></div>"},"54919":{"type":"graphic_picture","displayName":"Heterophyiasis adult worm","title":"Heterophyiasis adult worm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heterophyiasis adult worm</div><div class=\"cntnt\"><img style=\"width:435px; height:310px;\" src=\"images/ID/54919_Heterophyiasis_adul_worm_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult of&nbsp;<EM>Heterophyes heterophyes</EM>. In this figure, the following structures are labeled: oral sucker (OS), pharynx (PH), intestine (IN), ventral sucker, or acetabulum (AC), and eggs within the uterus (UT).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Heterophyiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/heterophyiasis/index.html\">http://www.cdc.gov/dpdx/heterophyiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 54919 Version 5.0</div></div></div>"},"54925":{"type":"graphic_picture","displayName":"Pos pressure urethroscopy","title":"Positive pressure urethroscopy of a large urethral diverticulum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Positive pressure urethroscopy of a large urethral diverticulum</div><div class=\"cntnt\"><img style=\"width:436px; height:217px;\" src=\"images/OBGYN/54925_Pos_pressure_urethroscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In figure A, the black arrow identifies the urethral lumen and the white arrow points to the large ostia of the diverticulum which is distended by fluid instillation. In figure B, the white arrow points to the ostia as exudate is expressed from the diverticulum using a vaginal examining finger.</div><div class=\"graphic_reference\">Courtesy of Robert E Gutman, MD.</div><div id=\"graphicVersion\">Graphic 54925 Version 1.0</div></div></div>"},"54926":{"type":"graphic_table","displayName":"Secondary causes osteoporosis","title":"Secondary causes of osteoporosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary causes of osteoporosis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td>Glucocorticoids</td> </tr> <tr> <td>Immunosuppressants (cyclosporine)</td> </tr> <tr> <td>Antiseizure medications (particularly phenobarbital and phenytoin)</td> </tr> <tr> <td>GnRH agonists and antagonists</td> </tr> <tr> <td>Heparin</td> </tr> <tr> <td>Cancer chemotherapy</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine disorders</td> </tr> <tr> <td>Acromegaly</td> </tr> <tr> <td>Adrenal insufficiency</td> </tr> <tr> <td>Cushing's syndrome</td> </tr> <tr> <td>Eating disorders</td> </tr> <tr> <td>Endometriosis</td> </tr> <tr> <td>Hyperparathyroidism</td> </tr> <tr> <td>Hyperprolactinemia</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Hypogonadism (primary or secondary)</td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal disease/nutritional disorders</td> </tr> <tr> <td>Alcohol-related liver disease</td> </tr> <tr> <td>Celiac disease</td> </tr> <tr> <td>Chronic active hepatitis</td> </tr> <tr> <td>Chronic cholestatic disease</td> </tr> <tr> <td>Gastrectomy</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Jejunoileal bypass</td> </tr> <tr> <td>Malabsorption syndromes</td> </tr> <tr> <td>Pancreatic insufficiency</td> </tr> <tr> <td>Parenteral nutrition</td> </tr> <tr> <td>Primary biliary cholangitis</td> </tr> <tr> <td>Severe liver disease</td> </tr> <tr> <td>Vitamin D and/or calcium deficiency</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Marrow-related disorders</td> </tr> <tr> <td>Amyloidosis</td> </tr> <tr> <td>Hemochromatosis</td> </tr> <tr> <td>Hemophilia</td> </tr> <tr> <td>Leukemia</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Mastocytosis</td> </tr> <tr> <td>Multiple myeloma</td> </tr> <tr> <td>Pernicious anemia</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Sickle cell anemia</td> </tr> <tr> <td>Thalassemia</td> </tr> <tr> <td class=\"subtitle1_single\">Organ transplantation</td> </tr> <tr> <td>Bone marrow</td> </tr> <tr> <td>Heart</td> </tr> <tr> <td>Kidney</td> </tr> <tr> <td>Liver</td> </tr> <tr> <td>Lung</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous causes</td> </tr> <tr> <td>Ankylosing spondylitis</td> </tr> <tr> <td>Chronic obstructive pulmonary disease</td> </tr> <tr> <td>Congenital porphyria</td> </tr> <tr> <td>Epidermolysis bullosa</td> </tr> <tr> <td>Hemophilia</td> </tr> <tr> <td>Idiopathic hypercalciuria</td> </tr> <tr> <td>Idiopathic scoliosis</td> </tr> <tr> <td>Multiple sclerosis</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic disorders</td> </tr> <tr> <td>Hypophosphatasia</td> </tr> <tr> <td>Osteogenesis imperfecta</td> </tr> <tr> <td>Homocystinuria due to cystathionine deficiency</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc 2002; 77:453. Copyright © 2002 Mayo Foundation.</div><div id=\"graphicVersion\">Graphic 54926 Version 7.0</div></div></div>"},"54928":{"type":"graphic_diagnosticimage","displayName":"Arteriovenous malformation","title":"Arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:346px; height:258px;\" src=\"images/OBGYN/54928_Arteriovenous_malformation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right uterine angiography on a 42-year-old woman who presented with sudden uterine bleeding. Angiogram shows very dilated uterine artery and veins with nidus of dilated tangled blood vessels within the uterine wall consistent with arteriovenous malformation (AVM).</div><div id=\"graphicVersion\">Graphic 54928 Version 2.0</div></div></div>"},"54929":{"type":"graphic_figure","displayName":"Control of iron absorption","title":"Control of iron absorption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Control of iron absorption</div><div class=\"cntnt\"><img style=\"width:442px; height:324px;\" src=\"images/HEME/54929_Control_of_iron_absorption.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathways of iron absorption and excretion in an intestinal mucosal cell in the normal state, in iron deficiency, and in an iron- loaded state. Normal iron absorption is 1 mg/day with a total daily intake of 10 mg. Iron absorption is appropriately enhanced in iron deficiency, and diminished with loss by cell sloughing into the intestinal lumen with iron overload.</div><div class=\"graphic_reference\">Adapted from Scientific American Medicine, Scientific American, New York, 1995.</div><div id=\"graphicVersion\">Graphic 54929 Version 1.0</div></div></div>"},"54932":{"type":"graphic_figure","displayName":"Transabdominal CVS PI","title":"Technique for transabdominal chorionic villus sampling (CVS)","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Technique for transabdominal chorionic villus sampling (CVS)</div><div class=\"cntnt\"><img style=\"width:534px; height:494px;\" src=\"images/PI/54932_Transabdominal_CVS_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the transabdominal CVS technique, the physician guides a needle from the patient's abdomen into the placenta under ultrasound guidance.</div><div id=\"graphicVersion\">Graphic 54932 Version 2.0</div></div></div>"},"54933":{"type":"graphic_picture","displayName":"Gross path bronchogenic cyst","title":"Gross pathology specimen of a bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross pathology specimen of a bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:447px; height:288px;\" src=\"images/PEDS/54933_Gross_path_bronchogenic_cys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cyst is intraparenchymal and unilocular. The incision shows the smooth interior.</div><div class=\"graphic_reference\">Courtesy of Christopher Oermann, MD and Claire Langston, MD</div><div id=\"graphicVersion\">Graphic 54933 Version 2.0</div></div></div>"},"54935":{"type":"graphic_figure","displayName":"FEV1 and age in females","title":"FEV1 and age in healthy women","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">FEV1 and age in healthy women</div><div class=\"cntnt\"><img style=\"width:414px; height:308px;\" src=\"images/PULM/54935_FEV1_and_age_in_females.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Growth and decline of lung function in healthy females. Actual values are shown in the top panel and growth velocity in the bottom panel.</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Redrawn from: Sherrill DL, Camilli A, Lebowitz MD. Am Rev Respir Dis 1989; 140:638.</div><div id=\"graphicVersion\">Graphic 54935 Version 2.0</div></div></div>"},"54936":{"type":"graphic_waveform","displayName":"ECG type II sinoatrial block","title":"Single-lead electrocardiogram (ECG) showing lead V5 in type II sinoatrial block","html":"<div class=\"graphic normal\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing lead V5 in type II sinoatrial block</div><div class=\"cntnt\"><img style=\"width:466px; height:87px;\" src=\"images/CARD/54936_Type_II_sinoatrial_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a 3:2 SA block, resulting in group beating of pairs of sinus beats. The P-P interval during the pause has a duration (1840 msec) that is approximately equal to two P-P cycles (920 msec); this finding distinguishes this arrhythmia from type I SA block in which the pause duration is less than that of two P-P cycles. There may be some sinus variability, as in this case, due to sinus arrhythmia and possibly to baroreceptor responses to varying diastolic filling intervals.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 54936 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"54942":{"type":"graphic_table","displayName":"Phases of tonic clonic seizures","title":"Phases of tonic-clonic seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phases of tonic-clonic seizures</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_left\">Aura (None)</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Tonic phase (10 to 20 seconds)</td>\n\n</tr>\n<tr>\n<td>Sudden loss of consciousness</td>\n\n</tr>\n<tr>\n<td>Loss of posture with high risk of self injury depending on activity</td>\n\n</tr>\n<tr>\n<td>Brief flexion of arms, eyes deviated upward</td>\n\n</tr>\n<tr>\n<td>Extension of back, neck, arms, and legs</td>\n\n</tr>\n<tr>\n<td>Involuntary crying out from contraction of respiratory muscles</td>\n\n</tr>\n<tr>\n<td>Shallow respiration, cyanosis may occur</td>\n\n</tr>\n<tr>\n<td>Ends with tremors which gradually slow and merge with clonic phase</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Clonic phase (30 to 90 seconds)</td>\n\n</tr>\n<tr>\n<td>Brief, violent, generalized flexor contractions alternating with progressively longer muscle relaxation</td>\n\n</tr>\n<tr>\n<td>Cyanosis</td>\n\n</tr>\n<tr>\n<td>Possible cheek or tongue biting</td>\n\n</tr>\n<tr>\n<td>Foamy salivation</td>\n\n</tr>\n<tr>\n<td>Possible loss of bowel or bladder control</td>\n\n</tr>\n<tr>\n<td>Ends with deep inspiration, sustained muscle relaxation</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Postictal phase (Minutes to several hours)</td>\n\n</tr>\n<tr>\n<td>Headache, mild confusion</td>\n\n</tr>\n<tr>\n<td>Muscles sore</td>\n\n</tr>\n<tr>\n<td>Fatigue, patient may sleep and awake refreshed</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Other features</td>\n\n</tr>\n<tr>\n<td>Fast heart rate</td>\n\n</tr>\n<tr>\n<td>Elevated blood pressure</td>\n\n</tr>\n<tr>\n<td>Respiratory and metabolic acidosis</td>\n\n</tr>\n<tr>\n<td>Dilated pupils</td>\n\n</tr>\n<tr>\n<td>Risk of vertebral fracture, pneumonia</td>\n\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 54942 Version 1.0</div></div></div>"},"54943":{"type":"graphic_waveform","displayName":"Wandering atrial pacer tutorial","title":"Wandering atrial pacemaker","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wandering atrial pacemaker</div><div class=\"cntnt\"><img style=\"width:393px; height:104px;\" src=\"images/CARD/54943_Wandering_atrial_pacer_tuto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wandering atrial pacemaker is present when there are multiple ectopic foci within the atrial myocardium that serve as dominant pacemakers. There is a changing vector of atrial activation which causes a changing P wave morphology and PR interval duration. The QRS intervals have very variable cycle lengths since the ectopic foci have differences of automaticity and rates of impulse generation. The rhythm is therefore irregularly irregular. QRS morphology is not altered from that seen during sinus rhythm, since activation of the ventricular myocardium occurs normally via the His-Purkinje system.</div><div id=\"graphicVersion\">Graphic 54943 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"54944":{"type":"graphic_table","displayName":"DDx BPLL path","title":"Differential diagnosis of B cell prolymphocytic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of B cell prolymphocytic leukemia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Entity\n   </td>\n   <td  class=\"subtitle1\">\n   Histology\n   </td>\n   <td  class=\"subtitle1\">\n   Immunophenotype\n   </td>\n   <td  class=\"subtitle1\">\n   Genetic features/Other\n   </td>\n   </tr>\n   <tr>\n   <td>B cell prolymphocytic leukemia</td>\n   <td>\t<p>&#62;55 percent (and usually &#62;90 percent) of circulating white cells are \"prolymphocytes\": medium-sized cells with moderately abundant, slightly basophilic cytoplasm; a round or oval nucleus with moderately condensed chromatin; and a single, prominent nucleolus.</p>\n\t<p>The bone marrow is infiltrated in an interstitial or nodular pattern by similar cells.</p>\n</td>\n   <td>\t<p>Express bright surface IgM +/- IgD and bright CD20 as well as other B-cell antigens (CD19, CD22, CD79a, FMC7).</p>\n\t<p>CD5 and CD23 expression is usually weak or absent. CD11c, CD103, CD10, CD25, and cyclin D1 are not expressed.</p>\n</td>\n   <td>\t<p>t(11;14) must be excluded.</p>\n\t<p>No associated paraproteinemia.</p>\n</td>\n   </tr>\n   <tr>\n   <td>Chronic lymphocytic leukemia/Small lymphocytic lymphoma</td>\n   <td>\t<p>\"Typical\" CLL cells are small mature appearing lymphocytes with a dense nucleus, partially aggregated chromatin, no discernible nucleoli, and a narrow border of clear to slightly basophilic cytoplasm.</p>\n\t<p>\"Prolymphocytes\" may be present, but are &#60;55 percent of circulating cells.</p>\n</td>\n   <td>Typically express CD5 and CD23. Expression of CD20 and surface immunoglobulin is dim.</td>\n   <td>Trisomy 12, deletions of 6q, 11q, 13q, and 17p</td>\n   </tr>\n   <tr>\n   <td>T cell prolymphocytic leukemia</td>\n   <td>Similar morphologic appearance to B-PLL.</td>\n   <td>Expresses pan-T cell antigens (CD2, CD3, CD5, CD7).</td>\n   <td>inv(14q)</td>\n   </tr>\n   <tr>\n   <td>Mantle cell lymphoma</td>\n   <td>Can have a leukemic phase that mimics B-PLL morphologically.</td>\n   <td>\t<p>Typically CD20 and CD5 positive and CD23 negative.</p>\n\t<p>Express cyclin D1.</p>\n</td>\n   <td>t(11;14)</td>\n   </tr>\n   <tr>\n   <td>Follicular lymphoma</td>\n   <td>Circulating centrocytes have highly irregular or cleaved nuclear contours.</td>\n   <td>Typically expresses CD10.</td>\n   <td>t(14;18)</td>\n   </tr>\n   <tr>\n   <td>Lymphoplasmacytic lymphoma</td>\n   <td>Occasionally associated with circulating malignant cells with a plasmacytoid appearance.</td>\n   <td>&nbsp;</td>\n   <td>Often associated with a paraproteinemia.</td>\n   </tr>\n   <tr>\n   <td>Hairy cell leukemia</td>\n   <td>Variant has circulating tumor cells with morphology intermediate between hairy cells and prolymphocytes.</td>\n   <td>Unlike B-PLL, most cases of HCL express CD11c, CD103, CD123, cyclin D1, and/or annexin A1. Express the interleukin-2 receptor beta chain, but not the alpha chain (CD25).</td>\n   <td>&nbsp;</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=25164&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>DDx_BPLL_path.htm</title></head></div><div id=\"graphicVersion\">Graphic 54944 Version 1.0</div></div></div>"},"54945":{"type":"graphic_table","displayName":"RBC changes HS splenectomy","title":"Red blood cell abnormalities in hereditary spherocytosis: role of the spleen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Red blood cell abnormalities in hereditary spherocytosis: role of the spleen</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">RBC property</td> <td class=\"subtitle1\">Controls</td> <td class=\"subtitle1\">HS</td> <td class=\"subtitle1\">HS-Splenect</td> </tr> <tr> <td>Number of subjects</td> <td>37</td> <td>25</td> <td>23</td> </tr> <tr> <td>Hemoglobin (g/dL)</td> <td>13.9&#177;1.0*</td> <td>12.2&#177;1.5</td> <td>15.2&#177;1.3</td> </tr> <tr> <td>Reticulocytes (percent)</td> <td>1.0&#177;0.3</td> <td>6.7&#177;3.5</td> <td>2.1&#177;1.0</td> </tr> <tr> <td>MCHC reticulocytes (g/dL)</td> <td>26.6&#177;1.3</td> <td>30.2&#177;2.5</td> <td>31.2&#177;1.2</td> </tr> <tr> <td>MCHC mature RBC (g/dL)</td> <td>32.2&#177;0.7</td> <td>36.1&#177;1.6</td> <td>36.1&#177;0.8</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RBC: red blood cells; HS: hereditary spherocytosis; HS-Splenect: splenectomized patients with HS; MCHC: mean corpuscular hemoglobin concentration. <br />* Values are mean ±1 standard deviation. <br />Note that splenectomy corrected the anemia and reduced the reticulocyte percentage almost to normal in patients with HS, but did not alter the spherocytic changes, as reflected by the increased values for MCHC, either in the reticulocytes or the mature red cells.</div><div class=\"graphic_reference\">Data from: Da Costa L, Mohandas N, Sorette M, et al. Temporal differences in membrane loss lead to distinct reticulocyte features in hereditary spherocytosis and in immune hemolytic anemia. Blood 2001; 98:2894.</div><div id=\"graphicVersion\">Graphic 54945 Version 3.0</div></div></div>"},"54946":{"type":"graphic_picture","displayName":"Ulnarhumeral range of motion","title":"Range of motion of the ulnarhumeral joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Range of motion of the ulnarhumeral joint</div><div class=\"cntnt\"><img style=\"width:434px; height:368px;\" src=\"images/EM/54946_Ulnarhumeral_range_of_motio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Full arm flexion and extension are compared side to side. Loss of full extension with end-point stiffness suggests the presence of a small effusion or mild arthritis, while loss of full extension and flexion is consistent with a large effusion or moderate to severe arthritis.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 54946 Version 2.0</div></div></div>"},"54948":{"type":"graphic_picture","displayName":"MTX hepatotoxicity light","title":"Histologic findings in methotrexate hepatotoxicity","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Histologic findings in methotrexate hepatotoxicity</div><div class=\"cntnt\"><img style=\"width:542px; height:379px;\" src=\"images/RHEUM/54948_MTX_hepatotoxicity_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spectrum of histologic changes in methotrexate hepatotoxicity includes steatosis (top left), stellate (Ito) cell hypertrophy (top right), anisonucleosis (nuclei of varying sizes, bottom left), and, on Masson stain, hepatic fibrosis (bottom right).</div><div class=\"graphic_reference\">Courtesy of Joel M Kremer, MD.</div><div id=\"graphicVersion\">Graphic 54948 Version 2.0</div></div></div>"},"54949":{"type":"graphic_table","displayName":"Standardized allergens - Effective doses","title":"United States standardized extracts: Effective and ineffective doses and major allergen content","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">United States standardized extracts: Effective and ineffective doses and major allergen content</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Allergen</td> <td class=\"subtitle1\">Effective doses*</td> <td class=\"subtitle1\">Ineffective doses*</td> <td class=\"subtitle1\">Labeling of United States standardized extracts</td> <td class=\"subtitle1\">Average major allergen content<sup>&#182;</sup></td> </tr> <tr> <td>Short ragweed</td> <td>4 to 24 mcg Amb a 1</td> <td>0.6 and 2 mcg Amb a 1</td> <td>1:10 w/v (100,000 AU/mL)</td> <td>520 mcg/mL Amb a 1</td> </tr> <tr> <td><em>Dermatophagoides pteronyssinus</em></td> <td>3.25 to 12 mcg Der p 1</td> <td>0.7 mcg Der p 1</td> <td>10,000 AU/mL</td> <td>67 mcg/mL Der p 1</td> </tr> <tr> <td><em>Dermatophagoides farinae</em></td> <td>10 mcg Der f 1</td> <td>Not determined</td> <td>10,000 AU/mL</td> <td>65 mcg/mL Der f 1</td> </tr> <tr> <td>Timothy grass</td> <td>15 and 20 mcg Phl p 5</td> <td>2 mcg Phl p 5</td> <td>100,000 BAU/mL</td> <td>660 mcg/mL Phl p 5</td> </tr> <tr> <td>Bermuda grass</td> <td>Not determined</td> <td>Not determined</td> <td>10,000 BAU/mL</td> <td>225 mcg/mL Cyn d 1</td> </tr> <tr> <td>Cat hair or pelt</td> <td>11 to 17 mcg Fel d 1</td> <td>3 mcg Fel d 1</td> <td>10,000 BAU/mL</td> <td>40 mcg/mL Fel d 1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">w/v: weight/volume; AU: allergy unit; BAU: bioequivalent allergy unit.<br />* Effective and ineffective doses are based upon double-blind, placebo-controlled studies.<br />¶&nbsp;Mean values. Individual lots of extracts may vary considerably from these values.</div><div id=\"graphicVersion\">Graphic 54949 Version 9.0</div></div></div>"},"54950":{"type":"graphic_figure","displayName":"Open angle glaucoma","title":"Open angle glaucoma","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Open angle glaucoma</div><div class=\"cntnt\"><img style=\"width:512px; height:397px;\" src=\"images/PC/54950_Open-angle-glaucoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exact pathophysiology of open angle glaucoma is not known but may be related to decreased aqueous outflow and/or increased aqueous production.</div><div id=\"graphicVersion\">Graphic 54950 Version 9.0</div></div></div>"},"54954":{"type":"graphic_table","displayName":"IHC stain Merkel cell carcinoma","title":"Immunocytochemical differential diagnosis of Merkel cell carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunocytochemical differential diagnosis of Merkel cell carcinoma</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Tumour\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   CK20\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   CK7\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   NSE\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   NFP\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   S100\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   LCA\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   CD99\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   TTF1\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Merkel cell carcinoma</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>Rarely + (cytoplasmic)</td>\r\n  \r\n   <td>_</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Small cell carcinoma</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+/-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>Rarely + (cytoplasmic)</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lymphoma</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Primitive neuroectodermal tumour</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>Rarely +</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+ (membranous)</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Small-cell melanoma</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=46514&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>IHC_stain_Merkel_cell_carci.htm</title></head></div><div class=\"graphic_footnotes\">CK20: cytokeratin 20; CK7: cytokeratin 7; NSE: neuron-specific enolase; NFP: neurofilament protein; S100: S100 protein; LCA: leucocyte common antigen; CD99: cluster-of-differentiation antigen 99; TTF1: thyroid transcription factor 1; +: positive stain; -: negative stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Poulsen M. Merkel-cell carcinoma of the skin. Lancet Oncol 2004; 5:593. Copyright© 2004 The Lancet.</div><div id=\"graphicVersion\">Graphic 54954 Version 2.0</div></div></div>"},"54955":{"type":"graphic_table","displayName":"Pathogens cystitis in children","title":"Urinary tract pathogens in acute cystitis in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urinary tract pathogens in acute cystitis in children and adolescents</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Bacteria</td> </tr> <tr> <td class=\"subtitle2_single\">Gram-negative bacilli</td> </tr> <tr> <td class=\"indent1\"><em>Escherichia coli</em></td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> </tr> <tr> <td class=\"indent1\"><em>Klebsiella</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Enterobacter cloacae</em></td> </tr> <tr> <td class=\"indent1\"><em>Enterobacter aerogenes</em></td> </tr> <tr> <td class=\"indent1\"><em>Morganella morganii</em></td> </tr> <tr> <td class=\"indent1\"><em>Proteus mirabilis</em></td> </tr> <tr> <td class=\"indent1\"><em>Providencia stuartii</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Serratia</em> spp</td> </tr> <tr> <td class=\"subtitle2_single\">Gram-negative cocci</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Neisseria gonorrhoeae</em>*</td> </tr> <tr> <td class=\"subtitle2_single\">Gram-positive cocci</td> </tr> <tr> <td class=\"indent1\"><em>Enterococcus</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus</em> group B</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus</em> group D</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus epidermidis</em><sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Staphylococcus saprophyticus</em></td> </tr> <tr> <td class=\"subtitle2_single\">Other bacterial pathogens</td> </tr> <tr> <td class=\"indent1\"><em>Chlamydia trachomatis</em>*</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Fungi</td> </tr> <tr> <td class=\"indent1\"><em>Candida</em> spp<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\"><em>Trichosporon</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Aspergillus</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Microsporidia</em> spp</td> </tr> <tr> <td class=\"subtitle1_single\">Viruses</td> </tr> <tr> <td class=\"indent1\">Adenovirus</td> </tr> <tr> <td class=\"sublist2_start\">Polyomaviruses</td> </tr> <tr> <td class=\"sublist2\">BK virus<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist2\">JC virus<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus*</td> </tr> <tr> <td class=\"subtitle1_single\">Parasites</td> </tr> <tr> <td class=\"indent1\"><em>Schistosoma</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Trichomonas vaginalis</em></td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Associated with sexually transmitted disease.<br />¶ Most often in patients with an indwelling catheter.<br />Δ Most often in immunocompromised hosts.</div><div id=\"graphicVersion\">Graphic 54955 Version 8.0</div></div></div>"},"54956":{"type":"graphic_waveform","displayName":"Intermediate case 14","title":"Intermediate case 14","html":"<div class=\"graphic normal\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Intermediate case 14</div><div class=\"cntnt\"><img style=\"width:505px; height:211px;\" src=\"images/CARD/54956_Intermediate_case_14.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 54956 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"54957":{"type":"graphic_picture","displayName":"Periodontal destruction","title":"Necrotizing periodontal disease","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Necrotizing periodontal disease</div><div class=\"cntnt\"><img style=\"width:535px; height:432px;\" src=\"images/PC/54957_Periodontal_destruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HIV-positive individual. Pre-treatment and after treatment showing the sequela of severe periodontal destruction.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 54957 Version 2.0</div></div></div>"},"54959":{"type":"graphic_table","displayName":"Gemcitabine plus carboplatin for non-small cell lung cancer","title":"Gemcitabine plus carboplatin for non-small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine plus carboplatin for non-small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Every 21 days for a maximum of four cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Gemcitabine</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS (concentration no more than 40 mg/mL) and administer over 30 to 60 minutes.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_bottom\"> <td>Carboplatin</td> <td>AUC* = 5 mg/mL &times; min IV</td> <td>Dilute in 250 mL normal saline (NS)<sup>&#182;</sup> and administer over 30 minutes.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE on day 1 and<br /> LOW on day 8. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Carboplatin is an irritant. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The incidence of neutropenic infections was reported to be 9% but may be higher in patients 75 years of age or older.<sup>[1]</sup> Decisions about primary prophylaxis with hematopoietic growth factors should be individualized according to current guidelines. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.* A lower starting dose of gemcitabine may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count on days 1 and 8 of each cycle during treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Electrolytes, renal, and liver function on day 1 of each cycle. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Chemotherapy should be delayed for one week if the ANC is &#60;1000 cells/microL and/or the platelet count is &#60;75,000/microL prior to the start of each cycle. Doses for subsequent cycles are reduced by 25% if the ANC is 1000 to 1499 cells/microL or platelets are 75,000 to 99,000/microL on day 22 after the preceding cycle, or if the nadir ANC was &#60;500 cells/microL. A 50% dose reduction should be considered if the platelet nadir is &#60;50,000/microL. Consider discontinuing therapy if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days. </li> <li>Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed and are based upon the same criteria as on day 1. Dose reductions should be maintained for subsequent cycles.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[3]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other nonhematologic toxicity</strong><sup>&#9674;</sup></td> <td colspan=\"3\"> <ul> <li>Creatinine clearance should be &#8805;45 mL/min and grade 3 or 4 toxicities should be resolved prior to beginning therapy. A delay in therapy by one week should be considered if toxicities are not resolved or the creatinine clearance &#8804;45 mL/min. It is recommended that subsequent cycles be dose reduced by 25% if the patient has grade 3 or 4 toxicity (excluding grade 3 or 4 mucositis, in which a 50% dose reduction is warranted) and discontinued if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days. </li> <li>Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed. Dose reductions should be maintained for subsequent cycles.<sup>[1]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count; GFR: glomerular filtration rate.<br />* AUC (area under the concentration × time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) × (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Δ Dose adjustments in the study may differ slightly from that recommended by the manufacturer. The manufacturer's recommendations can be found in the United States Prescribing Information.<SUP>[2,3]</SUP><br /><FONT class=lozenge>◊</FONT> Toxicity was graded using the Common Terminology Criteria of Adverse Events version 3.0.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gronberg BH, et al. J Clin Oncol. 2009; 27:3217.</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 54959 Version 23.0</div></div></div>"},"54960":{"type":"graphic_picture","displayName":"Duodenal ulcer with visible vessel","title":"Duodenal ulcer with visible vessel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duodenal ulcer with visible vessel</div><div class=\"cntnt\"><img style=\"width:450px; height:385px;\" src=\"images/GAST/54960_Duodenalulcervisvessel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing a duodenal ulcer with a nonbleeding visible vessel (arrow)&nbsp;in a large circumferential ulcer&nbsp;(Forrest classification IIa).</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha.</div><div id=\"graphicVersion\">Graphic 54960 Version 4.0</div></div></div>"},"54961":{"type":"graphic_figure","displayName":"Anatomy of the chest wall and axilla","title":"Anatomy of the chest wall and axilla","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Anatomy of the chest wall and axilla</div><div class=\"cntnt\"><img style=\"width:590px; height:495px;\" src=\"images/SURG/54961_Anatomychestwallaxilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Topographic anatomic depiction of levels I, II, and III of the axillary contents with relation to the neurovascular bundle, pectoralis minor, latissimus dorsi, posterior axillary space, and chest wall. Level I comprises three principal axillary nodal groups: the external mammary group, the subscapular group, and the axillary vein (lateral) group. Level II, the central nodal group, is centrally placed immediately beneath the pectoralis minor muscle. The subclavicular (apical) group is designated level III nodes and is superomedial to the pectoralis minor muscle.</div><div class=\"graphic_reference\">Reproduced with permission from: Bland KI. Modified radical mastectomy and total (simple) mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54961 Version 8.0</div></div></div>"},"54962":{"type":"graphic_diagnosticimage","displayName":"TEE left upper pulmonary vein","title":"Left upper pulmonary vein on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Left upper pulmonary vein on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:494px; height:225px;\" src=\"images/CARD/54962_TEE_left_upper_pulmonary_ve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Horizontal (0º) imaging shows the left upper pulmonary vein (LUPV, panel A). Note the position of the pulsed Doppler sample volume obtained from the proximal portion of the vein (red arrow). Panel B shows the normal pulsed Doppler spectra of pulmonary venous flow; there is a biphasic pattern with a predominance of pulmonary venous flow during ventricular systole (*). There is also mild flow reversal in the pulmonary vein related to atrial systole (+).</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 54962 Version 2.0</div></div></div>"},"54963":{"type":"graphic_algorithm","displayName":"NHLBI pediatric risk stratification associated with CVD","title":"Risk stratification and management for children with conditions predisposing to accelerated atherosclerosis and early cardiovascular disease from the 2011 NHLBI Expert Panel","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Risk stratification and management for children with conditions predisposing to accelerated atherosclerosis and early cardiovascular disease from the 2011 NHLBI Expert Panel</div><div class=\"cntnt\"><img style=\"width:547px; height:855px;\" src=\"images/PEDS/54963_NHLBIpedriskstratCVD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NHLBI: National Heart, Lung, and Blood Institute; HIV: human immunodeficiency virus; CV: cardiovascular; RF: risk factor; CVD: cardiovascular disease; BP: blood pressure; BMI: body mass index; FG: fasting glucose; LDL-C: low density lipoprotein cholesterol; TG: triglycerides; HDL-C: high density lipoprotein cholesterol; HgbA1c: hemoglobin A1c.<br />* Though not included in the 2011 NHLBI recommendations, a 2015 American Heart Association statement advocates including major depressive disorder and bipolar disorder in adolescents as moderate risk conditions for premature CVD.<br />&para; For details of management of hypertension, dyslipidemia, and other specific conditions listed in this algorithm, refer to separate UpToDate content on these conditions in children.</div><div class=\"graphic_reference\">Modified from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at: http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf.</li>&#xD;&#xA;    <li>Goldstein BI, Carnethon MR, Matthews KA, et al. Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2015; 132:965.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 54963 Version 8.0</div></div></div>"},"54964":{"type":"graphic_waveform","displayName":"ECG ventriculophasic sinus arrhythmia","title":"Electrocardiographic (ECG) rhythm strip demonstrating ventriculophasic sinus arrhythmia","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Electrocardiographic (ECG) rhythm strip demonstrating ventriculophasic sinus arrhythmia</div><div class=\"cntnt\"><img style=\"width:518px; height:113px;\" src=\"images/CARD/54964_Ventriculophasic_sinus_arrh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complete atrioventricular (AV) block is seen as evidenced by the AV dissociation. A junctional escape rhythm sets the ventricular rate at 45 bpm. The PP intervals vary because of ventriculophasic sinus arrhythmia; this is defined when the PP interval that includes a QRS is shorter than a PP interval that excludes a QRS. The QRS generates a strong enough pulse to activate the carotid sinus mechanism which slows the subsequent PP interval. With permission of Dr. Frank Yanowitz, University of Utah, from the Alan E. Lindsey ECG Learning Center in Cyberspace (http://medstat.med.utah.edu/kw/ecg).</div><div id=\"graphicVersion\">Graphic 54964 Version 5.0</div></div></div>"},"54965":{"type":"graphic_table","displayName":"Clinical features of bleomycin lung injury ","title":"Clinical presentation of bleomycin-induced lung injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical presentation of bleomycin-induced lung injury</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Symptoms</td> </tr> <tr> <td>Dyspnea (75 to 90%)</td> </tr> <tr> <td>Nonproductive cough (50 to 93%)</td> </tr> <tr> <td>Chest discomfort</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Signs</td> </tr> <tr> <td>Fever</td> </tr> <tr> <td>Tachypnea</td> </tr> <tr> <td>Crackles</td> </tr> <tr> <td>Cyanosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Laboratory</td> </tr> <tr> <td>PFTs show reduced lung volumes and DLCO</td> </tr> <tr> <td>Oximetry shows decreased oxygen saturation (at rest or on exertion); ABGs show increased alveolar-arterial oxygen gradient</td> </tr> <tr> <td>No peripheral blood eosinophilia (except possibly in hypersensitivity-like reaction)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ABGs: arterial blood gases.</div><div id=\"graphicVersion\">Graphic 54965 Version 2.0</div></div></div>"},"54967":{"type":"graphic_table","displayName":"Pulm drug complication I","title":"Pulmonary complications of cardiovascular drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary complications of cardiovascular drugs</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Agent</td>\n\n      <td class=\"subtitle1\">Syndrome</td>\n\n      <td class=\"subtitle1\">Frequency</td>\n\n      <td class=\"subtitle1\">Potential mechanism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Procainamide</td>\n\n      <td>SLE-like syndrome</td>\n\n      <td>50 to 90 percent of patients have positive ANA test; 10\nto 20 percent become symptomatic; pleuritis, pleural effusion, and\nparenchymal infiltrates are common</td>\n\n      <td>Autoantibodies against histone H2A-H2B complex,\npotentially induced by interaction of drug\nmetabolites with DNA, or drug-induced alteration in T-cell DNA\nmethylation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Quinidine</td>\n\n      <td>SLE-like syndrome</td>\n\n      <td>Rare; pleuritis and pleural effusions are most common\npulmonary signs; parenchymal infiltrates uncommon</td>\n\n      <td>Autoantibodies against histone H2A-H2B complex,\npotentially induced by interaction of drug\nmetabolites with DNA, or drug-induced alteration in T-cell DNA\nmethylation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tocainide</td>\n\n      <td>Pneumonitis/fibrosis</td>\n\n      <td>Incidence is about 0.3 percent</td>\n\n      <td>Unknown</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Flecainide</td>\n\n      <td>Pneumonitis/fibrosis</td>\n\n      <td>Rare</td>\n\n      <td>Unknown</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mexiletine</td>\n\n      <td>Pneumonitis/fibrosis</td>\n\n      <td>Rare</td>\n\n      <td>Unknown; interferes with theophylline metabolism and\ncan cause toxic elevations\nin theophylline levels in serum</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">ACE inhibitors</td>\n\n      <td>Cough</td>\n\n      <td>Incidence is 5 to 15 percent; occurs with all ACE\ninhibitors; whether these agents precipitate bronchospasm in patients\nwith asthma is controversial</td>\n\n      <td>Decreased degradation of irritant and\nbronchoconstrictive mediators (bradykinin and\nsubstance P); direct increase in sensitivity to irritant-induced\ncough; genetic predisposition (based on differences in ACE gene).</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Angioneurotic edema</td>\n\n      <td>Rare; can lead to respiratory failure</td>\n\n      <td>Unknown</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sotalol</td>\n\n      <td>Bronchospasm</td>\n\n      <td>Occurs in 2 percent of patients</td>\n\n      <td>Direct blockage of &#946;2-receptors</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Adenosine</td>\n\n      <td>Bronchospasm</td>\n\n      <td>Occurs with rapid infusion in 5 to 10 percent of\npatients; may trigger acute bronchospasm in patients with asthma or\nCOPD. Reversible with aminophylline</td>\n\n      <td>Induction of mast cell mediator release</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Redrawn from Zitnik, RJ, J Respir Dis 1996; 17:254; and Zitnik, RJ, J Respir Dis 1996; 17:293.</div><div id=\"graphicVersion\">Graphic 54967 Version 1.0</div></div></div>"},"54968":{"type":"graphic_table","displayName":"Signs and symptoms of rejection","title":"Clinical findings of acute lung transplant rejection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings of acute lung transplant rejection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>No symptoms</td> </tr> <tr> <td>Fever</td> </tr> <tr> <td>Nonproductive cough</td> </tr> <tr> <td>Dyspnea on exertion</td> </tr> <tr> <td>Decline in oximetry (with exercise)</td> </tr> <tr> <td>Decline in spirometry (&#62;10 percent)</td> </tr> <tr> <td>Chest x-ray: Diffuse opacities or normal</td> </tr> <tr> <td>Leukocytosis</td> </tr> <tr> <td>Crackles on physical examination</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Clinical findings alone are not sufficient to separate infection from acute rejection.</div><div id=\"graphicVersion\">Graphic 54968 Version 2.0</div></div></div>"},"54969":{"type":"graphic_diagnosticimage","displayName":"MRI of a sacral insufficiency fracture","title":"MRI of a sacral insufficiency fracture","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">MRI of a sacral insufficiency fracture</div><div class=\"cntnt\"><img style=\"width:787px; height:270px;\" src=\"images/RADIOL/54969_Sacral_stress_fracture_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sacral insufficiency fracture. Pelvic MR axial T1-weighted (A) and T2-weighted (B) images of the pelvis demonstrates the sacroiliac joints and an insufficiency fracture (arrow) through the right sacral ala seen as dark T1 and bright T2 linear signal.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Doug Brown, MD.</div><div id=\"graphicVersion\">Graphic 54969 Version 4.0</div></div></div>"},"54972":{"type":"graphic_figure","displayName":"Incidence of CKD after nonrenal organ TPL","title":"Graph showing incidence of chronic kidney disease following nonrenal solid organ transplantation","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Graph showing incidence of chronic kidney disease following nonrenal solid organ transplantation</div><div class=\"cntnt\"><img style=\"width:541px; height:293px;\" src=\"images/NEPH/54972_CRF_after_nonrenal_organ_TP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence of chronic renal failure (CRF), defined as an estimated glomerular filtration rate ≤29 mL/min/1.73 m<SUP>2</SUP>, among 69,321 people who received nonrenal solid organ transplants in the United States between January 1, 1990 and December 31, 2000. Cyclosporine was given to 60 percent and tacrolimus to 28 percent. Measurements of renal function were obtained at six-month intervals during the first year and annually thereafter.</div><div class=\"graphic_footnotes\">CRF: chronic renal failure.</div><div class=\"graphic_reference\">Data from Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ.&nbsp;N Engl J Med 2003; 349:931.</div><div id=\"graphicVersion\">Graphic 54972 Version 3.0</div></div></div>"},"54973":{"type":"graphic_table","displayName":"Causes of fetal death","title":"Causes of fetal death","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes&nbsp;of fetal death</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Perinatal infection</td> </tr> <tr> <td class=\"sublist1_start\">Bacterial</td> </tr> <tr> <td class=\"sublist1\">Group B <em>Streptococcus</em></td> </tr> <tr> <td class=\"sublist1\"><em>Escherichia coli</em></td> </tr> <tr> <td class=\"sublist1\"><em>Listeria monocytogenes</em></td> </tr> <tr> <td class=\"sublist1\">Spirochaetal</td> </tr> <tr> <td class=\"sublist1\">Other bacterial</td> </tr> <tr> <td class=\"sublist1_start\">Viral</td> </tr> <tr> <td class=\"sublist1\">Cytomegalovirus</td> </tr> <tr> <td class=\"sublist1\">Parvovirus</td> </tr> <tr> <td class=\"sublist1\">Herpes simplex virus</td> </tr> <tr> <td class=\"sublist1\">Rubella virus</td> </tr> <tr> <td class=\"sublist1\">Other viral</td> </tr> <tr> <td>Protozoal, eg, <em>Toxoplasma</em></td> </tr> <tr> <td>Fungal</td> </tr> <tr> <td>Other specified organism</td> </tr> <tr> <td class=\"subtitle1_single\">Hypertension or preeclampsia</td> </tr> <tr> <td class=\"subtitle1_single\">Antepartum hemorrhage</td> </tr> <tr> <td>Placental abruption</td> </tr> <tr> <td>Placenta previa</td> </tr> <tr> <td>Vasa previa</td> </tr> <tr> <td>Other</td> </tr> <tr> <td class=\"subtitle1_single\">Maternal conditions</td> </tr> <tr> <td>Termination of pregnancy</td> </tr> <tr> <td>Diabetes/gestational diabetes</td> </tr> <tr> <td class=\"sublist1_start\">Maternal injury</td> </tr> <tr> <td class=\"sublist1\">Accidental</td> </tr> <tr> <td class=\"sublist1\">Nonaccidental</td> </tr> <tr> <td>Maternal sepsis</td> </tr> <tr> <td>Systemic lupus erythematosis</td> </tr> <tr> <td>Obstetric cholestasis</td> </tr> <tr> <td>Other</td> </tr> <tr> <td class=\"subtitle1_single\">Perinatal conditions</td> </tr> <tr> <td>Twin-twin transfusion</td> </tr> <tr> <td>Fetomaternal hemorrhage</td> </tr> <tr> <td>Antepartum cord complications</td> </tr> <tr> <td>Uterine abnormalities</td> </tr> <tr> <td>Birth trauma</td> </tr> <tr> <td>Alloimmune disease</td> </tr> <tr> <td>Nonimmune fetal hydrops</td> </tr> <tr> <td>Other</td> </tr> <tr> <td class=\"subtitle1_single\">Hypoxic peripartum death</td> </tr> <tr> <td class=\"sublist1_start\">With intrapartum complications</td> </tr> <tr> <td class=\"sublist1\">Uterine rupture</td> </tr> <tr> <td class=\"sublist1\">Cord prolapse</td> </tr> <tr> <td class=\"sublist1\">Shoulder dystocia</td> </tr> <tr> <td class=\"sublist1\">Other</td> </tr> <tr> <td>Evidence of nonreassuring fetal status in a normally grown infant</td> </tr> <tr> <td>No intrapartum complications and no evidence of nonreassuring fetal status</td> </tr> <tr> <td class=\"subtitle1_single\">Fetal growth restriction </td> </tr> <tr> <td>Unspecified or not known whether placenta examined</td> </tr> <tr> <td class=\"subtitle1_single\">Spontaneous preterm birth</td> </tr> <tr> <td>Intact membranes</td> </tr> <tr> <td>Ruptured membranes</td> </tr> <tr> <td class=\"subtitle1_single\">Unexplained antepartum death</td> </tr> <tr> <td>With evidence of reduced vascular perfusion on Doppler studies and/or placental histopathology (eg, significant infarction, acute atherosis, maternal and/or fetal vascular thrombosis, or maternal floor infarction)</td> </tr> <tr> <td>With chronic villitis</td> </tr> <tr> <td>No placental pathology</td> </tr> <tr> <td>Other specified placental pathology</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Chan A, King JF, Flenad V, et al. Classification of perinatal deaths: Development of the Australian and New Zealand classifications. J Paediatr Child Health 2004; 40:340.</div><div id=\"graphicVersion\">Graphic 54973 Version 6.0</div></div></div>"},"54974":{"type":"graphic_figure","displayName":"Surv resect marg status","title":"Survival according to resection margin status (n = 111)","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Survival according to resection margin status (n = 111)</div><div class=\"cntnt\"><img style=\"width:523px; height:354px;\" src=\"images/ONC/54974_Surv_resect_marg_status.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cha C, Antonescu CR, Quan ML, et al. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004; 239:903. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54974 Version 8.0</div></div></div>"},"54975":{"type":"graphic_table","displayName":"Differential diagnosis of HFpEF","title":"Differential diagnosis of heart failure with preserved ejection fraction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of heart failure with preserved ejection fraction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Heart failure with preserved ejection fraction (HFpEF)</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HFpEF (contributing factors include hypertension, aging, coronary heart disease, diabetes mellitus, sleep-disordered breathing, chronic kidney disease, and obesity)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Cardiomyopathies with preserved ejection fraction</strong></td> </tr> <tr> <td class=\"indent1\">Restrictive cardiomyopathy</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Familial causes include sarcomeric gene mutations, familial amyloidosis (TTR or apolipoprotein mutation), unknown gene mutation, familial causes of iron overload (hereditary hemochromatosis, hereditary anemias), Fabry disease, glycogen storage disease, desminopathy, and pseudoxanthoma elasticum </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Non-familial causes include amyloid (AL or wild-type TTR), systemic sclerosis, endomyocardial fibrosis (idiopathic, caused by hypereosinophilic syndrome, or drugs), carcinoid heart disease, metastatic cancer, radiation, non-familial iron overload (eg, acquired iron-loading anemia, high-dietary intake), and drug toxicity (anthracycline) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hypertrophic cardiomyopathy</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Familial causes in addition to sarcomere gene mutations include unknown mutations, glycogen storage disease, lysosomal storage disease (including Fabry disease), syndromic hypertrophic cardiomyopathy (eg, Noonan's syndrome, LEOPARD syndrome, Friedreich's ataxia), and familial amyloidosis (TTR or apolipoprotein mutation) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Non-familial causes include non-familial amyloidosis (AL or wild-type TTR) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Noncompaction cardiomyopathy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Valvular heart disease</strong></td> </tr> <tr> <td class=\"indent1\">Valvular stenosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Valvular regurgitation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Right heart failure</strong></td> </tr> <tr> <td class=\"indent1\">Pulmonary hypertension</td> </tr> <tr> <td class=\"indent1\">Right ventricular infarction</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Arrhythmogenic right ventricular cardiomyopathy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Pericardial disease</strong></td> </tr> <tr> <td class=\"indent1\">Cardiac tamponade</td> </tr> <tr> <td class=\"indent1\">Constrictive pericarditis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Effusive-constrictive pericardial disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Obstructive lesion in heart or great vessel</strong></td> </tr> <tr> <td class=\"indent1\">Atrial myxoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pulmonary vein stenosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>High-output heart failure</strong></td> </tr> <tr> <td class=\"highlight_gray_text\"><strong>Transient left ventricular systolic dysfunction</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 2006; 47:500.</div><div id=\"graphicVersion\">Graphic 54975 Version 10.0</div></div></div>"},"54976":{"type":"graphic_table","displayName":"Clues RD 2nd grade and up","title":"Clues to dyslexia from second grade on","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clues to dyslexia from second grade on</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Problems in speaking\n   </td>\n   </tr>\n   <tr>\n   <td>Mispronunciation of long, unfamiliar, or complicated words; the <em> fracturing </em> of words--leaving out parts of words or confusing the order of the parts of words; for example <em> aluminum </em> becomes <em> amulium </em></td>\n   </tr>\n   <tr>\n   <td>Speech that is not fluent--pausing or hesitating often when speaking, lots of <em> um's </em> during speech, no glibness</td>\n   </tr>\n   <tr>\n   <td>The use of imprecise language, such as vague references to <em> stuff </em> or <em> things </em> instead of the proper name of an object</td>\n   </tr>\n   <tr>\n   <td>Not being able to find the exact word, such as confusing words that sound alike: saying <em> tornado </em> instead of <em> volcano, </em> substituting <em> lotion </em> for <em> ocean, </em> or <em> humanity </em> for <em> humidity </em></td>\n   </tr>\n   <tr>\n   <td>The need for time to summon an oral response or the inability to come up with a verbal response quickly when questioned</td>\n   </tr>\n   <tr>\n   <td>Difficulty in remembering isolated pieces of verbal information (rote memory)--trouble remembering dates, names, telephone numbers, random lists</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Problems in reading\n   </td>\n   </tr>\n   <tr>\n   <td>Very slow progress in acquiring reading skills</td>\n   </tr>\n   <tr>\n   <td>The lack of a strategy to read new words</td>\n   </tr>\n   <tr>\n   <td>Trouble reading <em> unknown </em> (new, unfamiliar) words that must be sounded out; making wild stabs or guesses at reading a word; failure to systematically sound out words</td>\n   </tr>\n   <tr>\n   <td>The inability to read small \"function\" words, such as <em> that, </em><em> an, </em><em> in </em></td>\n   </tr>\n   <tr>\n   <td>Stumbling on reading multisyllable words, or the failure to come close to sounding out the full word</td>\n   </tr>\n   <tr>\n   <td>Omitting parts of words when reading; the failure to decode parts within a word, as if someone had chewed a hole in the middle of the word, such as <em> conible </em> for <em> convertible </em></td>\n   </tr>\n   <tr>\n   <td>A terrific fear of reading out loud; the avoidance of oral reading</td>\n   </tr>\n   <tr>\n   <td>Oral reading filled with substitutions, omissions, and mispronunciations</td>\n   </tr>\n   <tr>\n   <td>Oral reading that is choppy and labored, not smooth or fluent</td>\n   </tr>\n   <tr>\n   <td>Oral reading that lacks inflection and sounds like the reading of a foreign language</td>\n   </tr>\n   <tr>\n   <td>A reliance on context to discern the meaning of what is read</td>\n   </tr>\n   <tr>\n   <td>A better ability to understand words <em> in context </em> than to read <em> isolated </em> single words</td>\n   </tr>\n   <tr>\n   <td>Disproportionately poor performance on multiple-choice tests</td>\n   </tr>\n   <tr>\n   <td>The inability to finish tests on time</td>\n   </tr>\n   <tr>\n   <td>The substitution of words with the same meaning for words in the text he can't pronounce, such as <em> car </em> for <em> automobile </em></td>\n   </tr>\n   <tr>\n   <td>Disastrous spelling, with words not resembling true spelling; some spellings may be missed by spell check</td>\n   </tr>\n   <tr>\n   <td>Trouble reading mathematics word problems</td>\n   </tr>\n   <tr>\n   <td>Reading that is very slow and tiring</td>\n   </tr>\n   <tr>\n   <td>Homework that never seems to end, or with parents often recruited as readers</td>\n   </tr>\n   <tr>\n   <td>Messy handwriting despite what may be an excellent facility at word processing--nimble fingers</td>\n   </tr>\n   <tr>\n   <td>Extreme difficulty learning a foreign language</td>\n   </tr>\n   <tr>\n   <td>A lack of enjoyment of reading, and the avoidance of reading books or even a sentence</td>\n   </tr>\n   <tr>\n   <td>The avoidance of reading for pleasure, which seems too exhausting</td>\n   </tr>\n   <tr>\n   <td>Reading whose accuracy improves over time, though it continues to lack fluency and is laborious</td>\n   </tr>\n   <tr>\n   <td>Lowered self-esteem, with pain that is not always visible to others</td>\n   </tr>\n   <tr>\n   <td>A history of reading, spelling, and foreign language problems in family members</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">2/26/2008 - Fax permission request\r\n10/10/2008--Permission granted for a 5-year period; figures to Terrence, invoices to Susan (JD).\r\n\r\n The total fee of $&amp;quot;110.00&amp;quot;was originally charged to\r\nClues_RD_early_childhood\r\nClues_RD_2nd_grade_and_up\r\nClues_RD_young_adult</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51020&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Clues_RD_2nd_grade_and_up.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Shaywitz S. Overcoming Dyslexia: A New and Complete Science-Based Program for Reading Problems at Any Level. Copyright © 2003 by Sally Shaywitz, MD. Used with permission of Alfred A. Knopf, a division of Random House, Inc. For online information about other Random House, Inc. books and authors, see the internet website at www.randomhouse.com.</div><div id=\"graphicVersion\">Graphic 54976 Version 4.0</div></div></div>"},"54977":{"type":"graphic_picture","displayName":"Actinic purpura","title":"Actinic (solar) purpura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Actinic (solar) purpura</div><div class=\"cntnt\"><img style=\"width:380px; height:190px;\" src=\"images/DERM/54977_Actinicpurpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ecchymoses are present on the dorsal forearms in an older adult.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54977 Version 2.0</div></div></div>"},"54978":{"type":"graphic_table","displayName":"Medications for emergency treatment of opioid withdrawal adults","title":"Medications used in management of opioid withdrawal for adults in emergency setting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications used in management of opioid withdrawal for adults in emergency setting</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Initial dose (adult)</td> <td class=\"subtitle1\">Indication</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Opioid</td> </tr> <tr> <td class=\"indent1\">Methadone</td> <td>10 mg intramuscularly or 20 mg orally</td> <td> <p>Naturally occurring withdrawal</p> Not recommended for management of acute withdrawal triggered by an antagonist (naloxone, naltrexone)</td> </tr> <tr> <td class=\"indent1\">Buprenorphine&nbsp;</td> <td> <p>0.3 to 0.9 mg IV or intramuscularly</p> <p>Slow IV administration&nbsp;(eg, over 20 to 30 minutes)&nbsp;is preferred because it decreases risk of transient overdose&nbsp;</p> <p>&nbsp;</p> </td> <td> <p>Symptoms of withdrawal in a patient who takes buprenorphine and has missed doses.</p> <p>Buprenorphine is a partial agonist and<strong> not</strong> recommended for management of acute&nbsp;opioid withdrawal other than buprenorphine.&nbsp;</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Non-opioid adjunctive medications*</td> </tr> <tr> <td class=\"indent1\">Clonidine</td> <td>0.1&nbsp;to 0.3 mg orally every hour with monitoring of blood pressure and heart rate (0.7 mg maximum total daily dose). Check blood pressure prior to each dose and hold the dose if hypotension is present.</td> <td>Anxiety, restlessness, dysphoria with elevated or normal blood pressure and heart rate</td> </tr> <tr> <td class=\"indent1\">Diazepam</td> <td>1 to 10 mg orally, IV or intramuscularly</td> <td>Anxiety, restlessness, dysphoria, insomnia, muscle cramping</td> </tr> <tr> <td class=\"indent1\">Promethazine</td> <td>25 to 50 mg intramuscularly (preferred) or IV (venous irritant)</td> <td rowspan=\"3\">Nausea, vomiting, restlessness, insomnia<br /> </td> </tr> <tr> <td class=\"indent1\">Diphenhydramine</td> <td>50 mg IV, intramuscularly or orally</td> </tr> <tr> <td class=\"indent1\">Hydroxyzine</td> <td>50 to 100 mg intramuscularly or orally</td> </tr> <tr> <td class=\"indent1\">Loperamide</td> <td>4 mg orally, followed by 2 mg every loose stool</td> <td rowspan=\"3\">Diarrhea, stomach cramps<br /> </td> </tr> <tr> <td class=\"indent1\">Octreotide</td> <td>50 micrograms subcutaneously every 6 hours</td> </tr> <tr> <td class=\"indent1\">Bismuth subsalicylate</td> <td>524 mg orally</td> </tr> <tr> <td class=\"indent1\">Acetaminophen</td> <td>650 mg orally</td> <td rowspan=\"2\">Pain, myalgia</td> </tr> <tr> <td class=\"indent1\">Ibuprofen</td> <td>600 mg orally</td> </tr> <tr> <td class=\"indent1\">Baclofen</td> <td>5 to 10 mg orally</td> <td>Muscle cramping</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For additional information on managing symptoms of withdrawal in patients cared for in a non-emergency setting, refer to topic on Opioid detoxification during treatment for addiction.</div><div class=\"graphic_footnotes\">* If withdrawal is naturally-occurring, the physician may opt to manage the patient with either opioid or non-opioid adjunctive medication. If withdrawal is triggered by an antagonist, only non-opioid adjunctive medications should be used to manage emergent withdrawal. Refer to UpToDate topics on opioid withdrawal in adults.</div><div id=\"graphicVersion\">Graphic 54978 Version 11.0</div></div></div>"},"54979":{"type":"graphic_picture","displayName":"Endosc resect and RFA HALO","title":"Endoscopic and histological images of long-segment Barrett's esophagus with early cancer treated with a combination of endoscopic resection and radiofrequency ablation using the Barrx system","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Endoscopic and histological images of long-segment Barrett's esophagus with early cancer treated with a combination of endoscopic resection and radiofrequency ablation using the Barrx system</div><div class=\"cntnt\"><img style=\"width:586px; height:255px;\" src=\"images/GAST/54979_Endosc_resect_and_RFA_HALO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>(A)</STRONG> Antegrade view of Barrett's esophagus.<BR><STRONG>(B)</STRONG> A lesion suspicious for early cancer is noted from the 2 to 4 o'clock positions.<BR><STRONG>(C)</STRONG> View of the esophagus after endoscopic resection of the lesion in two pieces.<BR><STRONG>(D)</STRONG> Histopathological evaluation of the specimens showed a radically resected adenocarcinoma infiltrating the muscularis mucosae (T1m3).<BR><STRONG>(E)</STRONG> Same area six weeks after the endoscopic resection showing that the wound has healed completely with scarring.<BR><STRONG>(F)</STRONG> Esophagus after primary circumferential ablation using the Barrx360 system (two applications at 12 J/cm2).<BR><STRONG>(G)</STRONG> Residual Barrett's mucosa six weeks after prior circumferential ablation.<BR><STRONG>(H)</STRONG> After additional focal ablation of the residual islands of Barrett's mucosa, complete ablation of the Barrett's segment was achieved.</div><div class=\"graphic_reference\">Reproduced with permission of www.endosurgery.eu. Copyright © 2010 Esophageal Research Foundation Amsterdam.</div><div id=\"graphicVersion\">Graphic 54979 Version 2.0</div></div></div>"},"54980":{"type":"graphic_table","displayName":"ACC AHA HRS congenital HD","title":"ACC/AHA/HRS guideline summary: Indications for permanent pacing in children, adolescents, and patients with congenital heart disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/HRS guideline summary: Indications for permanent pacing in children, adolescents, and patients with congenital heart disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class I - There is evidence and/or general agreement that permanent pacing should be performed in children, adolescents, and patients with congenital heart disease in the following settings:</td> </tr> <tr> <td class=\"indent1\">&#8226; Advanced second- or third-degree atrioventricular (AV) block that is associated with symptomatic bradycardia, ventricular dysfunction, or a low cardiac output. (Level of Evidence C)</td> </tr> <tr> <td class=\"indent1\">&#8226; Sinus node dysfunction with correlation of symptoms during age-inappropriate bradycardia. The definition of bradycardia varies with the patient's age and expected heart rate. (Level of Evidence B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Postoperative advanced second- or third-degree AV block that is not expected to resolve or that persists for at least 7 days after cardiac surgery. (Level of Evidence B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Congenital third-degree AV block with a wide QRS escape rhythm, complex ventricular ectopy, or ventricular dysfunction. (Level of Evidence B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Congenital third-degree AV block in the infant with a ventricular rate less than 55 bpm or with congenital heart disease and a ventricular rate less than 70 bpm. (Level of Evidence C)</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIa - Based upon the weight of evidence or opinion, it is reasonable to perform permanent pacing in children, adolescents, and patients with congenital heart disease in the following settings:</td> </tr> <tr> <td class=\"indent1\">&#8226; Sinus bradycardia for the prevention of recurrent episodes of intra-atrial reentrant tachycardia;&nbsp;sinus node dysfunction&nbsp;may be intrinsic or secondary to antiarrhythmic treatment. (Level of Evidence: C)</td> </tr> <tr> <td class=\"indent1\">&#8226; Congenital third-degree AV block beyond the first year of life with an average heart rate less than 50 bpm, abrupt pauses in ventricular rate that are two or three times the basic cycle length, or symptoms due to chronotropic incompetence. (Level of Evidence: B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Sinus bradycardia with complex congenital heart disease with a resting heart rate less than 40 bpm or pauses in ventricular rate lasting longer than three seconds. (Level of Evidence: C)</td> </tr> <tr> <td class=\"indent1\">&#8226; Impaired hemodynamics due to sinus bradycardia or loss of AV synchrony. (Level of Evidence: C)</td> </tr> <tr> <td class=\"indent1\">&#8226; Unexplained syncope in the patient with prior congenital heart surgery complicated by transient complete heart block with residual fascicular block after a careful evaluation to exclude other causes of syncope. (Level of Evidence: B)</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIb - The weight of evidence or opinion is less well established, permanent pacing may be considered in children, adolescents, and patients with congenital heart disease in the following settings:</td> </tr> <tr> <td class=\"indent1\">&#8226; Transient postoperative third-degree AV block that reverts to sinus rhythm with residual bifascicular block. (Level of Evidence: C)</td> </tr> <tr> <td class=\"indent1\">&#8226; Congenital third-degree AV block in asymptomatic children or adolescents with an acceptable rate, a narrow QRS complex, and normal ventricular function. (Level of Evidence: B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Asymptomatic sinus bradycardia after biventricular repair of congenital heart disease with a resting heart rate less than 40 bpm or pauses in ventricular rate longer than&nbsp;three seconds. (Level of Evidence: C)</td> </tr> <tr> <td class=\"subtitle1_single\">Class III - There is evidence and/or general agreement that permanent pacing should not be performed in children, adolescents, and patients with congenital heart disease in the following settings:</td> </tr> <tr> <td class=\"indent1\">&#8226; Transient postoperative AV block with return of normal AV conduction in the otherwise asymptomatic patient. (Level of Evidence: B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Asymptomatic bifascicular block with or without first-degree AV block after surgery for congenital heart disease in the absence of prior transient complete AV block. (Level of Evidence: C)</td> </tr> <tr> <td class=\"indent1\">&#8226; Asymptomatic type I second-degree AV block. (Level of Evidence: C)</td> </tr> <tr> <td class=\"indent1\">&#8226; Asymptomatic sinus bradycardia if the longest relative risk interval less than three seconds and a minimum heart rate more than 40 bpm. (Level of Evidence: C)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51:e1.</div><div id=\"graphicVersion\">Graphic 54980 Version 4.0</div></div></div>"},"54982":{"type":"graphic_picture","displayName":"Toxocariasis eye findings","title":"Toxocariasis eye findings","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Toxocariasis eye findings</div><div class=\"cntnt\"><img style=\"width:514px; height:217px;\" src=\"images/PEDS/54982_Toxocariasis_eye_findings.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Twelve-year-old boy who noted poor vision in the left eye over the preceding two months. His visual acuity measured 20/20 RE and 20/100 LE. Toxocara serum titer (ELISA) was positive at 1:4. Ophthalmoscopic photograph, left eye. Note the deep, subretinal white mass with surrounding hemorrhage, lipid, and retinal edema.<br />(B) Eight-year-old girl with a Toxocara lesion adjacent to the optic disk with overlying vitreal inflammation. Visual acuity measured 20/25 RE and 20/100 LE. Ophthalmoscopic photograph, left eye. There is a white mass over the optic nerve head. Also, note the significant vitritis associated with the mass. White, fingerlike projections from the white mass extend into the peripheral retina.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 54982 Version 3.0</div></div></div>"},"54984":{"type":"graphic_picture","displayName":"Rheumatic subcutaneous nodules","title":"Rheumatic subcutaneous nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatic subcutaneous nodules</div><div class=\"cntnt\"><img style=\"width:400px; height:530px;\" src=\"images/RHEUM/54984_Rheumatic_subcutaneous_nodu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rheumatic subcutaneous nodules are usually located near tendons or over a bony surface or prominence (see arrows). The overlying skin is not inflamed and typically can be moved over the nodules. The diameter varies from a few millimeters to 1 to 2 centimeters.</div><div class=\"graphic_reference\">Courtesy of Robert Sidbury, MD.</div><div id=\"graphicVersion\">Graphic 54984 Version 3.0</div></div></div>"},"54985":{"type":"graphic_diagnosticimage","displayName":"Influenza pneumonia CXR","title":"Influenza pneumonia with progression over one week","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Influenza pneumonia with progression over one week</div><div class=\"cntnt\"><img style=\"width:288px; height:533px;\" src=\"images/ID/54985_Influenzapneumonia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior chest radiograph (A) shows poorly defined nodular opacities and small areas of consolidation in the right middle and lower lung zones. Chest radiograph one week later (B) demonstrates extensive bilateral consolidation and poorly defined nodular opacities. Also noted are an endotracheal tube and a central venous line. The patient was a 44-year-old man with influenza pneumonia.</div><div class=\"graphic_reference\">Reproduced with permission from: Muller NL, Franquet T, Lee KS, Silva CIS. Viruses, Mycoplasma, and Chlamydia. In: Imaging of Pulmonary Infections, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 54985 Version 11.0</div></div></div>"},"54986":{"type":"graphic_picture","displayName":"Eccentric hamstring strength testing","title":"Eccentric hamstring strength testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eccentric hamstring strength testing</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/EM/54986_Eccen_hamstr_strength_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eccentric strength testing of the hamstring is begun with the knee bent between 15 and 30 degrees.</div><div class=\"graphic_reference\">Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.</div><div id=\"graphicVersion\">Graphic 54986 Version 1.0</div></div></div>"},"54987":{"type":"graphic_figure","displayName":"Construction of a loop colostomy - circumferential incision","title":"Construction of a loop colostomy - circumferential incision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of a loop colostomy - circumferential incision</div><div class=\"cntnt\"><img style=\"width:364px; height:316px;\" src=\"images/SURG/54987_Loop-colostomy-incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts constructing a loop colostomy with a defunctionalized distal llimb. An 80 percent&#160;circumferential incision is made in the distal portion of the loop.</div><div id=\"graphicVersion\">Graphic 54987 Version 1.0</div></div></div>"},"54988":{"type":"graphic_figure","displayName":"Health care worker HIV cases since 1985","title":"Confirmed cases of occupationally acquired HIV infection among health care personnel in the United States, 1985 to 2013","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Confirmed cases of occupationally acquired HIV infection among health care personnel in the United States, 1985 to 2013</div><div class=\"cntnt\"><img style=\"width:517px; height:351px;\" src=\"images/ID/54988_HCWHIVcasessnc1985.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure above is a bar chart showing the number of confirmed cases (n = 58) of occupationally acquired HIV infection among health care workers in the United States reported to CDC&nbsp;from 1985 to 2013. During that time frame, 58 confirmed and 150 possible cases of occupationally acquired HIV infection among health care workers were reported.</div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention.</div><div class=\"graphic_reference\">Reproduced from: Joyce MP, Kuhar D, Brooks JT. Notes from the field: occupationally acquired HIV infection among health care workers - United States, 1985-2013. MMWR Morb Mortal Wkly Rep 2015; 63:1245.</div><div id=\"graphicVersion\">Graphic 54988 Version 3.0</div></div></div>"},"54992":{"type":"graphic_picture","displayName":"Discolored amniotic fluid","title":"Samples of amniotic fluid taken during genetic amniocentesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Samples of amniotic fluid taken during genetic amniocentesis</div><div class=\"cntnt\"><img style=\"width:280px; height:378px;\" src=\"images/OBGYN/54992_Discolored_amniotic_fluid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal amniotic fluid (left) is clear bright yellow. Dark green or brown amniotic fluid (right) indicates blood degradation products caused by prior bleeding. latter sample was obtained from patient in figure 3. Level of alpha-fetoprotein in amniotic fluid may be elevated as a result of bleeding.</div><div class=\"graphic_reference\">Reproduced with permission from: Trop, I, Levine, D. Hemorrage During Pregnancy: Sonography and MR Imaging. AJR Am J Roentgenol 2001; 176:607. Copyright 2001 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 54992 Version 1.0</div></div></div>"},"54994":{"type":"graphic_table","displayName":"Exclusions organ donation","title":"Exclusions for organ donation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Exclusions for organ donation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Severe untreated systemic sepsis</td> </tr> <tr> <td>Acquired immunodeficiency syndrome</td> </tr> <tr> <td>Active viral hepatitis B or C, cytomegalovirus</td> </tr> <tr> <td>Viral encephalitis</td> </tr> <tr> <td>Active extracranial malignancy</td> </tr> <tr> <td>Risk of rare viral or prion protein illness,&nbsp;such as&nbsp;Creutzfeldt-Jakob disease</td> </tr> <tr> <td>Recipients of cadaver human pituitary growth hormone</td> </tr> <tr> <td>Undiagnosed acute or progressive neurological disorder with or without dementia</td> </tr> <tr> <td>Active West Nile virus or rabies</td> </tr> <tr> <td>Active disseminated tuberculosis</td> </tr> <tr> <td>Zika virus infection or relevant epidemiologic&nbsp;exposure within six months*&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Typical exclusion criteria are listed here. No assumptions about donor suitability should be made prior to consultation with the Organ Procurement Organization.</div><div class=\"graphic_footnotes\">* Relevant environmental exposure to Zika virus includes residence in or travel to an area where mosquito-borne transmission of Zika virus infection has been reported, or unprotected sexual contact with a person who meets these criteria.<SUP>[1]</SUP></div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>US Food and Drug Administration. Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products: Guidance for Industry, March 2016. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM488582.pdf (Accessed on March 07, 2016). </LI></OL></div><div id=\"graphicVersion\">Graphic 54994 Version 3.0</div></div></div>"},"54996":{"type":"graphic_algorithm","displayName":"Diagnostic approach to upper airway obstruction in children","title":"Diagnostic approach to upper airway obstruction in children","html":"<div class=\"graphic\"><div style=\"width: 937px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to upper airway obstruction in children</div><div class=\"cntnt\"><img style=\"width:917px; height:1014px;\" src=\"images/EM/54996_Severe_upper_airway_obstruc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The following findings suggest upper airway obstruction:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Inspiratory stridor, wheezing, or stertor</li>&#xD;&#xA;    <li>Suprasternal or supraclavicular retractions</li>&#xD;&#xA;    <li>Prolonged inspiratory phase</li>&#xD;&#xA;    <li>Oral mucosa or tongue swelling</li>&#xD;&#xA;    <li>Drooling</li>&#xD;&#xA;    <li>Dysphagia</li>&#xD;&#xA;</ul>&#xD;&#xA;&nbsp;&nbsp;Positions of comfort to help maintain airway patency in patients with severe obstruction:&#xD;&#xA;<ul>&#xD;&#xA;    <li>\"Sniffing\" position (neck is mildly flexed and head is mildly extended)</li>&#xD;&#xA;    <li>Tripod position (leaning forward while bracing on the arms with neck hyperextended and chin thrust forward)</li>&#xD;&#xA;</ul>&#xD;&#xA;&para; Given the risk of sudden decompensation, patients with significant laryngotracheal injury, thermal or chemical epiglottitis, or symptomatic upper airway obstruction warrant emergency consultation with an anesthesiologist or pediatric intensivist and an otolaryngologist to help secure the airway.</div><div id=\"graphicVersion\">Graphic 54996 Version 3.0</div></div></div>"},"54997":{"type":"graphic_table","displayName":"Rome criteria for IBS","title":"Rome III diagnostic criteria* for irritable bowel syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rome III diagnostic criteria* for irritable bowel syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Recurrent abdominal pain or discomfort<sup>&#182;</sup> at least&nbsp;three days per month in the last&nbsp;three months associated with&nbsp;two or more of the following:</td> </tr> <tr> <td>(1) Improvement with defecation</td> </tr> <tr> <td>(2) Onset associated with a change in frequency of stool</td> </tr> <tr> <td>(3) Onset associated with a change in form (appearance) of stool</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Criteria fulfilled for the last&nbsp;three months with symptom onset at least&nbsp;six months prior to diagnosis.<br />¶&nbsp;Discomfort means an uncomfortable sensation not described as pain. In pathophysiology research and clinical trials, a pain/discomfort frequency of at least&nbsp;two days a week during screening evaluation for subject eligibility.</div><div class=\"graphic_reference\">Reproduced with permission from: Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130:1480.</div><div id=\"graphicVersion\">Graphic 54997 Version 6.0</div></div></div>"},"54998":{"type":"graphic_picture","displayName":"Defibulation 1","title":"Defibulation (reversal of female genital infibulation)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Defibulation (reversal of female genital infibulation)</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/OBGYN/54998_Defibulation_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Step 1: Insert a Kelly clamp under the scar.</div><div id=\"graphicVersion\">Graphic 54998 Version 2.0</div></div></div>"},"54999":{"type":"graphic_diagnosticimage","displayName":"2D TTE Apical five-chamber view","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the apical five-chamber view","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the apical five-chamber view</div><div class=\"cntnt\"><img style=\"width:522px; height:171px;\" src=\"images/CARD/54999_Apical_5_chamber_TTE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical five-chamber view from a transthoracic echocardiogram shows the right (RV) and left (LV) ventricles, right (RA) and left (LA) atria, and the aorta (Ao).</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 54999 Version 4.0</div></div></div>"}};